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Summary 
 
The burden of non-communicable diseases, including cancer, is growing globally. 
Epidemiological studies have shown that lifestyle factors can increase the risk of these 
diseases. Colorectal cancer represents the third most common cancer for men and 
women in the UK. This thesis investigated the relationships between three classic 
lifestyle risk factors - alcohol intake, adiposity and smoking - and colorectal cancer in 
the UK Biobank cohort. 
 
UK Biobank is a cohort of 500,000 men and women aged 40-69 recruited between 
2006-2010. Participants were followed-up for cancer and death registrations until 31
st
 
March 2014 through linkage with national datasets. Cox proportional hazards models 
were used to analyse these data. 
 
This thesis found that alcohol intake was associated with colorectal cancer for men but 
not for women. For men, there was a dose-response relationship between alcohol intake 
and colorectal cancer. Results were similar using non-drinkers or never drinkers as the 
reference group. 
 
Body mass index (BMI), waist circumference (WC) and waist to hip ratio (WHR) were 
each strongly associated with colon cancer for men but there was only slight evidence 
for an association with WC and WHR for women. Modelling BMI and WC/WHR 
together, the associations for WC/WHR remained while the association for BMI was 
attenuated, indicating that WC/WHR may be more directly associated with colorectal 
cancer risk than BMI. 
 
While former cigarette smokers had an increased risk of colorectal cancer compared to 
never smokers, there was no clear evidence of an increased risk for current cigarette 
smokers. Furthermore, former cigarette smokers with ≥40 years smoking duration had a 
higher risk than current cigarette smokers with ≥40 years duration. 
 
In conclusion, this thesis found that alcohol intake, adiposity and smoking are each 
associated with colorectal cancer risk. The prevalence of these risk factors should be 
minimised in order to prevent disease.  
Contents 
Chapter 1 Introduction ......................................................................... 1 
1.1 Colorectal Cancer Epidemiology ........................................................................... 1 
1.1.1 Risk Factors for Colorectal Cancer ................................................................. 4 
1.2 Alcohol Intake, Adiposity and Smoking ............................................................... 5 
1.3 Alcohol Intake and Colorectal Cancer .................................................................. 6 
1.4 Adiposity and Colorectal Cancer........................................................................... 7 
1.5 Smoking and Colorectal Cancer ............................................................................ 8 
1.6 Limitations of Existing Studies and the Need for Further Research ................. 8 
1.7 UK Biobank ............................................................................................................. 9 
1.8 Summary ................................................................................................................ 10 
Chapter 2 Literature Reviews ............................................................ 11 
2.1 Overall Search Strategy........................................................................................ 11 
2.2 Alcohol Intake and Colorectal Cancer Literature Review................................ 12 
2.2.1 Search Strategy ............................................................................................. 12 
2.2.2 Alcohol Intake .............................................................................................. 14 
2.2.3 Effect Modifiers ............................................................................................ 19 
2.2.4 Reference Groups ......................................................................................... 22 
2.2.5 Mechanisms .................................................................................................. 23 
2.2.6 Summary ....................................................................................................... 24 
2.3 Adiposity and Colorectal Cancer Literature Review ........................................ 34 
2.3.1 Search Strategy ............................................................................................. 34 
2.3.2 Body Mass Index .......................................................................................... 37 
2.3.3 Waist Circumference and Waist to Hip Ratio .............................................. 45 
2.3.4 Early Adulthood Adiposity ........................................................................... 49 
2.3.5 Weight Change ............................................................................................. 51 
2.3.6 Effect Modifiers ............................................................................................ 52 
2.3.7 Mechanisms .................................................................................................. 56 
2.3.8 Summary ....................................................................................................... 56 
 
 
2.4 Smoking and Colorectal Cancer Literature Review .......................................... 78 
2.4.1 Search Strategy ............................................................................................. 78 
2.4.2 Smoking Status ............................................................................................. 80 
2.4.3 Smoking Duration ......................................................................................... 88 
2.4.4 Smoking Intensity ......................................................................................... 90 
2.4.5 Pack-years ..................................................................................................... 92 
2.4.6 Age at initiation ............................................................................................ 93 
2.4.7 Smoking Cessation ....................................................................................... 95 
2.4.8 Effect Modifiers ............................................................................................ 97 
2.4.9 Colorectal Adenomas .................................................................................... 98 
2.4.10 Molecular Subtypes .................................................................................. 100 
2.4.11 Mechanisms .............................................................................................. 102 
2.4.12 Summary ................................................................................................... 103 
2.5 Thesis Objectives ................................................................................................. 119 
Chapter 3 UK Biobank ..................................................................... 120 
3.1 Initiation ............................................................................................................... 121 
3.2 Pilot Studies ......................................................................................................... 122 
3.3 Main Recruitment ............................................................................................... 124 
3.3.1 Identification and Invitation........................................................................ 124 
3.3.2 Assessment Centres .................................................................................... 125 
3.3.3 Assessment.................................................................................................. 126 
3.4 Response ............................................................................................................... 128 
3.5 Representativeness .............................................................................................. 129 
3.6 Further Measurements ....................................................................................... 131 
3.7 Follow-up ............................................................................................................. 132 
3.8 Characteristics of UK Biobank Cohort ............................................................. 133 
Chapter 4 Methods ............................................................................ 139 
4.1 Alcohol Data ........................................................................................................ 139 
4.1.1 Measuring Alcohol Intake .......................................................................... 139 
4.1.2 Alcohol Reference Group ........................................................................... 142 
4.1.3 UK Biobank Questionnaire ......................................................................... 145 
4.1.4 Alcohol Analysis Variable .......................................................................... 150 
4.2 Adiposity Data ..................................................................................................... 157 
4.3 Smoking Data ...................................................................................................... 165 
4.3.1 Measuring Smoking Exposure .................................................................... 165 
4.3.2 UK Biobank Questionnaire ......................................................................... 168 
4.3.3 Smoking Analysis Variables ....................................................................... 174 
4.4 Other Analysis Variables.................................................................................... 180 
4.4.1 Confounder Variables ................................................................................. 180 
4.4.2 Other Variables ........................................................................................... 185 
4.5 Outcome Data on Cancers and Deaths ............................................................. 191 
4.5.1 Data Sources ............................................................................................... 191 
4.5.2 Death Data .................................................................................................. 192 
4.5.3 Cancer Data ................................................................................................ 192 
4.5.4 Outcome Definition .................................................................................... 193 
4.6 Statistical Methods .............................................................................................. 196 
4.6.1 Cox Proportional Hazards Models .............................................................. 196 
4.6.2 Proportional Hazards Assumption .............................................................. 197 
4.6.3 Fractional Polynomials ............................................................................... 201 
4.6.4 Population Attributable Fraction ................................................................ 202 
4.6.5 Multiple Imputation .................................................................................... 204 
Chapter 5 Alcohol Intake and Colorectal Cancer .......................... 215 
5.1 Data Summary..................................................................................................... 215 
5.2 Results .................................................................................................................. 223 
5.2.1 Main Results ............................................................................................... 223 
5.2.2 Continuous Alcohol Intake Variable .......................................................... 232 
5.2.3 Alternative Reference Group ...................................................................... 233 
5.2.4 Effect Modifiers .......................................................................................... 239 
5.2.5 Multiple Imputation .................................................................................... 240 
5.3 Discussion ............................................................................................................. 245 
 
 
5.3.1 Alcohol Intake and Colorectal Cancer ........................................................ 245 
5.3.2 Sex .............................................................................................................. 245 
5.3.3 Continuous Alcohol Intake Variable .......................................................... 248 
5.3.4 Colorectal Cancer Subsites ......................................................................... 248 
5.3.5 Reference Group ......................................................................................... 249 
5.3.6 Pattern of Drinking ..................................................................................... 253 
5.3.7 Effect Modifiers .......................................................................................... 254 
5.3.8 Multiple Imputation .................................................................................... 256 
5.3.9 Summary ..................................................................................................... 257 
Chapter 6 Adiposity and Colorectal Cancer .................................. 258 
6.1 Results .................................................................................................................. 258 
6.1.1 Body Mass Index ........................................................................................ 259 
6.1.2 Waist Circumference and Waist to Hip Ratio ............................................ 265 
6.1.3 Waist to Height Ratio ................................................................................. 272 
6.1.4 Percent Body Fat ......................................................................................... 272 
6.1.5 Effect Modifiers .......................................................................................... 273 
6.2 Discussion ............................................................................................................. 275 
6.2.1 Body Mass Index ........................................................................................ 275 
6.2.2 Waist Circumference and Waist to Hip Ratio ............................................ 278 
6.2.3 Waist to Height Ratio ................................................................................. 281 
6.2.4 Percent Body Fat ......................................................................................... 281 
6.2.5 Menopause .................................................................................................. 282 
6.2.6 Physical Activity ......................................................................................... 283 
6.2.7 Summary ..................................................................................................... 287 
Chapter 7 Smoking and Colorectal Cancer .................................... 288 
7.1 Results .................................................................................................................. 288 
7.1.1 Main Results ............................................................................................... 288 
7.1.2 Smoking Duration and Intensity ................................................................. 295 
7.1.3 Smoking Initiation ...................................................................................... 298 
7.1.4 Smoking Cessation ..................................................................................... 299 
7.1.5 Effect Modifiers .......................................................................................... 301 
7.2 Discussion ............................................................................................................. 302 
7.2.1 Smoking Status and Colorectal Cancer ...................................................... 302 
7.2.2 Colorectal Cancer Subsites ......................................................................... 304 
7.2.3 Smoking Duration and Intensity ................................................................. 306 
7.2.4 Smoking Initiation ...................................................................................... 309 
7.2.5 Smoking Cessation ..................................................................................... 310 
7.2.6 Smoking and Body Mass Index .................................................................. 312 
7.2.7 Former and Current Smokers ...................................................................... 313 
7.2.8 Summary ..................................................................................................... 315 
7.3 Population Attributable Fractions .................................................................... 316 
Chapter 8 Discussion ......................................................................... 318 
8.1 Alcohol Intake and Colorectal Cancer .............................................................. 318 
8.2 Adiposity and Colorectal Cancer....................................................................... 320 
8.3 Smoking and Colorectal Cancer ........................................................................ 321 
8.4 Strengths and Limitations .................................................................................. 322 
8.5 Further Research ................................................................................................ 327 
8.6 Awareness of the Effects of Lifestyle on Cancer .............................................. 329 
8.7 Public Health and the Prevention of NCDs ...................................................... 330 
Appendix ................................................................................................ 332 
References .............................................................................................. 346 
 
  
Chapter 1 | Introduction 
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Chapter 1 Introduction 
 
There has been a dramatic shift worldwide in disease patterns as non-communicable 
diseases (NCDs) (which mainly affect adults in later life) have replaced communicable 
diseases (which mainly affect infants and children) as the predominant causes of 
morbidity and mortality.
1, 2
 NCDs now represent the leading cause of death globally, 
responsible for 68% of all deaths in 2012.
3
 The global population is predicted to reach 
8.5 billion by 2030 with the population aged 60 or over growing fastest.
4
 Thus, the 
burden of NCDs will continue to grow worldwide. Whilst the burden of NCDs has 
increased as a result of more people surviving to later adulthood, it is clear that a 
significant proportion of NCDs are preventable.
3
 
 
Cancer represents one of the leading NCDs and a major cause of morbidity and 
mortality globally. In 2012, there were an estimated 14.1 million new cancer cases and 
8.2 million cancer deaths.
5
 By 2030, the annual incidence of new cancer cases is 
expected to increase by more than 50%, to 22 million.
6
 In the UK, it is predicted that 1 
in 2 people born after 1960 will be diagnosed with some form of cancer in their 
lifetime.
7
 
 
1.1 Colorectal Cancer Epidemiology 
 
Worldwide, there were an estimated 1.4 million cases of colorectal (or bowel) cancer in 
2012.
5
 In the UK, 22,957 men and 18,155 women were diagnosed with colorectal 
cancer in 2013, making it the third most common type of cancer for both men and 
women.
8
 The predicted lifetime risk of colorectal cancer is 7.3% for men and 5.5% for 
women.
8
 
 
Trends of colorectal cancer in Great Britain show that the number of people diagnosed 
with colorectal cancer has increased in recent decades. From 1979-1981 to 2011-2013, 
the crude incidence rate of colorectal cancer (i.e. the proportion of people diagnosed 
with colorectal cancer) per year in Great Britain increased by 56.7% for men and 14.8% 
for women (Figure 1.1.1). This increase was largely due to the increase in the age of the 
population during this time and age standardised incidence rates showed more moderate 
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trends; nevertheless, the age standardised incidence rate increased by 17.0% for men 
and 3.2% for women from 1979-1981 to 2011-2013. 
 
Figure 1.1.1 Colorectal Cancer Incidence Rates in Great Britain between 1979 and 
2013
8
 
 
Blue circles represent crude incidence rates of colorectal cancer for men. Red circles represent crude 
incidence rates of colorectal cancer for women. Blue squares represent age standardised incidence rates 
for men. Red squares represent age standardised incidence rates for women. The dotted line represents the 
introduction of the bowel screening programme in England. 
 
Cancer sites are classified according to the International Classification of Diseases for 
Oncology (published by the World Health Organisation (WHO)).
9
 Colon cancer is 
defined as cancer diagnosed in the appendix through to the sigmoid colon and rectal 
cancer is defined as cancer diagnosed in the rectosigmoid junction and rectum (see 
Figure 1.1.2 for the anatomy of the large bowel). 61% of colorectal cancers diagnosed 
in men and 70% of colorectal cancers diagnosed in women are located in the colon. 
Proximal colon is usually defined as the appendix to the splenic flexure and distal colon 
is usually defined as the descending colon and sigmoid colon. 
 
Colorectal cancer also represents the third most common cause of cancer death for both 
men and women in the UK with 16,187 deaths attributable to colorectal cancer in 2012.
8
 
However, the age-standardised mortality rate has decreased dramatically since 1971 
(Figure 1.1.3) and the 10-year survival rate for men and women diagnosed with 
colorectal cancer has increased from 22% in 1971-1972 to 56% in 2010-2011.
8
 The 
increase in survival is a result of improved treatment as well as earlier detection. 
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Survival for colorectal cancer is strongly related to the stage of disease at diagnosis; 
there is a much higher chance of survival associated with earlier stage of disease 
diagnosis.
8, 10, 11
 
 
Figure 1.1.2 Anatomy of the Large Bowel and Distribution of Colorectal Cancers
8
 
 
Anatomy of the large bowel. Blue and pink circles show the percentage of colorectal cancer cases 
diagnosed by anatomical subsite for men and women, respectively. 
 
Figure 1.1.3 Colorectal Cancer Mortality Rates in UK between 1971 and 2012
8
 
 
Blue circles represent age standardised mortality rates of colorectal cancer for men. Red circles represent 
age standardised mortality rates of colorectal cancer for women. The dotted line represents the 
introduction of the bowel screening programme in England. 
 
The importance of early detection for survival led to the introduction of colorectal 
screening programmes which have been shown to reduce colorectal cancer incidence 
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and mortality.
12-14
 In the UK, colorectal screening began in 2006, 2007 and 2008 in 
England, Scotland and Wales respectively.
15-17
 All men and women aged 60-74 (50-74 
in Scotland) are invited to complete a guaiac faecal occult blood test at home every two 
years. People with a positive test are then offered colonoscopy to identify any polyps or 
cancers. However, the uptake of colorectal screening remains disappointingly low with 
only 55% uptake.
15
 Also, colorectal screening is not recommended in less developed 
countries where resources are lower and the incidence of colorectal cancer is not yet 
sufficiently high.
18
 
 
Most cases of colorectal cancer develop from a small growth called a polyp or adenoma. 
It is predicted that the progression from adenoma to cancer takes approximately 10-20 
years though not all adenomas will develop into cancers.
19, 20
 Hence, colorectal 
incidence and mortality can be reduced by detecting and treating colorectal polyps at an 
early stage.
21
 
 
1.1.1 Risk Factors for Colorectal Cancer 
 
The incidence rate of colorectal cancer varies greatly between countries; the highest 
age-standardised incidence rates are in Australia/New Zealand, Europe and North 
America and the lowest rates are in Africa and South-Central Asia.
5, 22
 The incidence of 
colorectal cancer is also increasing in many countries, particularly economically 
transitioning countries.
22, 23
 Migrant studies also show that the incidence of colorectal 
cancer increases rapidly among migrants after moving from areas with low rates of 
colorectal cancer to areas with high rates.
19, 24
 
 
These data suggest an important role of lifestyle for the risk of colorectal cancer. Over 
the last few decades numerous epidemiological studies have investigated the 
relationship between a number of lifestyle factors and colorectal cancer risk and there is 
currently convincing evidence that alcohol intake, adiposity, smoking, physical 
inactivity, red meat consumption and processed meat consumption can increase the risk 
of colorectal cancer.
25-29
 Therefore, many cases of colorectal cancer may be prevented 
by people adopting healthier lifestyles. It was estimated that 54% of colorectal cancers 
in the UK in 2010 were preventable.
30
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Genetics and hereditary factors are also known to influence an individual’s risk of 
colorectal cancer and it is estimated that inherited factors are important in 15-35% of 
cases.
31
 People with inherited syndromes, such as Lynch syndrome (LS) and familial 
adenomatous polyposis (FAP), have a particularly high risk of colorectal cancer. The 
lifetime risk of colorectal cancer is 50-80% for individuals with LS and virtually 100% 
for those with FAP.
32, 33
 However, these syndromes are only estimated to be responsible 
for approximately 5% of colorectal cancer.
31, 33
 Other genetic factors increasing the risk 
of colorectal cancer are less well understood. 
 
1.2 Alcohol Intake, Adiposity and Smoking 
 
This thesis focused on alcohol intake, adiposity and smoking since they represent three 
of the most important modifiable lifestyle factors for the reduction of disease burden 
worldwide.
3
 Alcohol consumption is causally related to more than 200 health conditions 
and in 2012, approximately 3.3 million (6%) of all global deaths were attributable to 
alcohol consumption.
34
 Wide variation in alcohol consumption exists between countries 
with the highest levels found in Europe, Australia/New Zealand and North America.
34
 
In 2013, 34% of men and 26% of women in Great Britain reported drinking above the 
recommended guidelines (four units for men and three units for women) on at least one 
occasion in the previous week and 19% of men and 12% of women reported binge 
drinking (more than eight units for men and six units for women) on at least one 
occasion in the previous week.
35
 
 
The rising prevalence of obesity worldwide has been described as a global obesity 
pandemic.
36
 In the past 30 years obesity has risen in practically all countries.
37
 The 
prevalence of obesity has more than doubled since 1980 and, in 2014, more than 1.9 
billion (39%) adults aged 18 or older were overweight or obese and 600 million (13%) 
were obese.
38
 Overweight and obesity were estimated to cause 3.4 million deaths in 
2010.
39
 In England, 67.1% of men and 57.2% of women aged 16 and over are 
overweight or obese. Between 1993 and 2013, the prevalence of obesity in England 
increased from 13.2% in 1993 to 26.0% in men and from 16.4% to 23.8% in women.
40
 
 
Six million people die each year worldwide as a result of tobacco smoking and this is 
increasing.
41
 At least half of lifelong smokers are killed by smoking and, on average, 
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lifelong smokers lose at least ten years of life.
42
 Though the prevalence of smoking has 
decreased in many high-income countries, it is increasing in many low- and middle-
income countries. It is estimated that one billion people will die as a result of smoking 
in the current century (compared to 100 million in the previous century) with the large 
majority occurring in low- and middle-income countries unless there is widespread 
cessation.
43
 In 2013, 19% of people in Great Britain were cigarette smokers.
44
 This has 
decreased from 46% in 1974 due to greater awareness of the health risks as well as a 
wide range of public health interventions. However, smoking remains the leading cause 
of preventable death in Great Britain.
44
 
 
Thus, alcohol intake, adiposity and smoking represent three of the most important risk 
factors for reducing the burden of disease worldwide. Furthermore, epidemiological 
studies have shown that alcohol intake, adiposity and smoking can increase an 
individual’s risk of colorectal cancer. Based on the existing evidence for the 
associations between these risk factors and colorectal cancer risk, it was predicted that 
11.6, 13.0 and 8.1% of colorectal cancer cases diagnosed in the UK in 2010 were 
attributable to alcohol intake, adiposity and smoking, respectively.
30
 However, there are 
inconsistent results between studies and there remain many important questions about 
these relationships. 
 
1.3 Alcohol Intake and Colorectal Cancer 
 
Both the World Cancer Research Fund and the International Agency for Research on 
Cancer concluded that there is convincing evidence from numerous cohort studies that 
alcohol intake is causally related to colorectal cancer.
25, 26
 Both organisations also 
highlighted a potential threshold with an increased risk only for intake above 30 grams 
of alcohol (approximately equal to three small glasses of wine or half pints of beer) per 
day. This conclusion was largely based on a study which pooled results from eight 
separate cohort studies.
45
 However, few other studies have so far been able to analyse 
the association in similar detail. Thus, more studies are required to investigate the shape 
of the relationship between alcohol and colorectal cancer risk and whether lower levels 
of intake are associated with an increased risk. 
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It is also unclear whether alcohol increases the risk of colorectal cancer equally for both 
men and women. The World Cancer Research Fund concluded that alcohol was a 
convincing cause of colorectal cancer only for men.
25
 Overall, the evidence that alcohol 
intake increases the risks of colorectal cancer is clearer for men than for women, but this 
may simply be a result of studies of men including a much higher proportion of heavy 
drinkers than studies of women.  
 
Furthermore, many studies of alcohol intake and colorectal cancer use non-drinkers as 
the reference group i.e. both former drinkers and never drinkers. However, there is 
much debate about the reference group used for analyses of alcohol intake and the 
inclusion of former drinkers in the reference group may lead to underestimated risks in 
current drinkers.
46
 
 
1.4 Adiposity and Colorectal Cancer 
 
Body mass index (BMI), defined as the weight in kilograms divided by the square of 
height in metres, is the most common measure used to assess adiposity. There is 
consistent evidence that BMI is more strongly related to colon cancer than rectal 
cancer.
25
 Studies have also found that the association between BMI and colorectal 
cancer is stronger for men than for women though the reason for this difference is not 
known.
25
 
 
Waist circumference (WC) and waist to hip ratio (WHR) are also associated with 
colorectal cancer risk.
25
 WC and WHR provide alternative measures of adiposity that 
focus on abdominal adiposity. There is evidence from one cohort study that suggests 
WC and WHR are more important measures of adiposity for colorectal cancer risk and 
thus the different results observed for men and women for the association between BMI 
and colorectal cancer may be due to the different body fat distributions of men and 
women though this needs to be confirmed in further analyses.
47
 
 
Many studies have relied on self-reported data to measure adiposity. However, self-
reported measures of adiposity are likely to underestimate actual adiposity. For 
example, people tend to underestimate their weight and overestimate their height, 
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resulting in underestimated measures of BMI.
48
 This may lead to overestimation of the 
associations with colorectal cancer risk. 
 
1.5 Smoking and Colorectal Cancer 
 
Both former smokers and current smokers have an increased risk of colorectal cancer in 
comparison to never smokers. A recent meta-analysis found that, compared to never 
smokers, the pooled relative risk and 95% confidence interval was 1.20 (1.10–1.30) for 
current smokers and 1.18 (1.12–1.25) for former smokers.49 It remains unclear exactly 
why current smokers and former smokers appear to experience a similar level of risk 
though it may indicate that smoking mainly affects early stages of colorectal cancer and 
so the effects of smoking persist for many years, even after cessation. 
 
Studies have also analysed more detailed measures of smoking exposure such as 
smoking intensity and smoking duration.
26, 29, 50
 Most studies found that these measures 
are positively associated with colorectal cancer. However, most studies combine former 
and current smokers when analysing intensity or duration which may lead to misleading 
results and few studies have investigated the effects of intensity and duration together. 
 
It is also important to investigate how the risk of colorectal cancer differs according to 
smoking cessation at different times. Although former smokers have a similar level of 
risk to current smokers, studies have generally found that the risk of colorectal cancer 
decreases with earlier cessation.
26, 29
 Furthermore, it remains unclear whether the 
reduced risk is due to earlier cessation or shorter duration of smoking. 
 
1.6 Limitations of Existing Studies and the Need for Further Research 
 
In summary, while it is known that alcohol intake, adiposity and smoking are related to 
colorectal cancer risk, there are a number of important questions that remain about these 
associations and many existing studies have a number of limitations. For example, 
alcohol intake, adiposity and smoking represent three complex risk factors, yet many 
studies include only very basic information about these risk factors. Studies also often 
include limited information on other important risk factors. Consideration of 
confounders is essential in observational studies since many aspects of lifestyle are 
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correlated in the general population. The quality of data in existing studies is also very 
variable and there is a need for more high quality studies with detailed information on a 
wide range of risk factors. 
It may also be important to consider how associations are modified by exposure to other 
risk factors. Different levels of exposure to effect modifiers could contribute to 
differences in results between different studies. For example, the association between 
alcohol intake and colorectal cancer risk may be modified by levels of BMI.
45
 However, 
in general, there is a lack of evidence for effect modifiers from existing studies. 
 
Furthermore, though generally analysed as a single disease, colorectal cancer actually 
represents a heterogeneous group of diseases
51, 52
 and studies have found different 
associations according to different colorectal subsites. Therefore, more research is 
needed based on large cohort studies that are able to investigate the subsites separately. 
 
Thus, there is a clear need to investigate the associations between alcohol intake, 
adiposity and smoking and colorectal cancer in greater detail. A greater understanding 
of these associations may provide insight into why some studies find contrasting results 
and lead to a greater understanding of the mechanisms linking these risk factors to 
colorectal cancer and thus to greater opportunities for prevention. To achieve this, it is 
necessary to employ cohort studies with detailed information on a wide range of risk 
factors on a large number of people. 
 
1.7 UK Biobank 
 
Data from UK Biobank were used in this thesis to investigate the associations between 
alcohol intake, adiposity and smoking and colorectal cancer. UK Biobank is a 
prospective cohort study of half a million men and women mostly aged 40-69 recruited 
from the general population in England, Scotland and Wales.
53
 UK Biobank was 
established by the Medical Research Council and the Wellcome Trust with the aim to 
provide insights into the complex interplay of lifestyle, environment and genetics in 
promoting a wide range of diseases. Men and women were invited to an assessment 
centre where they gave very detailed information on health and lifestyle factors, 
completed physical measures and gave biological samples. Recruitment of participants 
finished in 2010. Follow-up data on participants for outcomes was ascertained through 
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linkage with national datasets.
53
 Data from UK Biobank is available to all bona fide 
researchers undertaking health-related research that is in the public good. The large size 
of UK Biobank, combined with the detailed information on a wide range of health and 
lifestyle factors, makes it ideal to contribute to a better understanding of how alcohol 
intake, adiposity and smoking are associated with colorectal cancer risk. Further 
information on the UK Biobank cohort is provided in Chapter 3. 
 
1.8 Summary 
 
In summary, the burden of cancer is rising dramatically worldwide, representing a major 
challenge for health services. The prevention of disease is vital in efforts to alleviate the 
burden of cancer. Colorectal cancer is the third most commonly diagnosed cancer in 
males and the second in females worldwide.
5
 The risk of colorectal cancer is strongly 
associated with lifestyle factors, including alcohol intake, adiposity and smoking, three 
classic causes of disease. However, many important questions remain about the 
relationships between these risk factors and colorectal cancer. 
 
The aim of this thesis is to investigate the relationships between alcohol intake, 
adiposity and smoking and colorectal cancer risk in detail using data from the UK 
Biobank cohort in order to contribute to a greater understanding of how these risk 
factors contribute to the risk of colorectal cancer. 
 
The first objective of this thesis is to conduct detailed literature reviews in order to 
identify and summarise the existing evidence for the relationships between alcohol 
intake, adiposity and smoking and colorectal cancer. Following these literature reviews, 
more specific objectives will be described for this thesis. 
 
These literature reviews and thesis objectives are included in Chapter 2. Chapter 3 
provides further information on the UK Biobank cohort. The methods used in the 
analyses of this thesis are described in Chapter 4. The main results for the associations 
between alcohol intake, adiposity and smoking and colorectal cancer are presented in 
Chapters 5, 6 and 7. Chapter 8 details the final discussion of this thesis. 
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Chapter 2 Literature Reviews 
 
The aim of this chapter is to review the existing literature and summarise the evidence 
for the effects of alcohol intake, adiposity and smoking in relation to colorectal cancer 
risk. Three separate literature reviews were conducted, one for each risk factor. The 
general methodology used to complete the three literature reviews was similar across 
the reviews and is described below. 
 
2.1 Overall Search Strategy 
 
Alcohol intake, adiposity and smoking represent three of the most important modifiable 
lifestyle factors for long-term health and disease prevention
3, 39
 and have been 
extensively investigated in relation to a wide range of diseases including colorectal 
cancer. This means that there exist a large number of studies investigating these 
relationships and numerous reviews and meta-analyses have previously attempted to 
identify the relevant literature for each risk factor. These reviews and meta-analyses 
were used as a starting point to identify the relevant literature for these reviews. 
 
Literature searches were also conducted for each risk factor using PubMed in order to 
identify the most recent literature not included in previous reviews or meta-analyses, 
using similar search criteria to the previous reviews and meta-analyses. The literature 
searches overlapped in time with the existing reviews/meta-analyses to ensure that no 
articles were missed (and to verify that the literature searches identified similar articles). 
References of identified articles were carefully searched for further relevant articles. 
The specific search strategy used for each risk factor is described within each literature 
review. 
 
These literature reviews focused on evidence from prospective cohort studies. 
Prospective cohort studies are generally considered to be of greater quality than 
retrospective case-control studies since case-control studies may be more prone to 
selection bias and are unable to preclude potential recall bias.
54, 55
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2.2 Alcohol Intake and Colorectal Cancer Literature Review 
 
In this section, the existing evidence for an association between alcohol intake and 
colorectal cancer risk is reviewed. The relationship between alcohol intake and 
colorectal cancer has been investigated in numerous prospective cohort studies and the 
World Cancer Research Fund (WCRF) and the International Agency for Research on 
Cancer (IARC) have both concluded that alcohol intake is causally related to colorectal 
cancer risk.
26, 56
 Questionnaires are usually employed to assess individuals’ average 
intake of different alcoholic beverages. The most common measurement of alcohol 
intake in the literature is grams of alcohol. In the UK, the alcoholic content of beverages 
is usually measured in units with one unit being approximately equal to eight grams of 
alcohol.
57, 58
 
 
2.2.1 Search Strategy 
 
The WCRF published reports in 2007 and 2011 and the IARC published reports in 2010 
and 2012 summarising the evidence from prospective cohort studies for an association 
between alcohol intake and colorectal cancer.
25, 26, 56, 59
 The most recent report from the 
WCRF searched the Medline database for articles published up to May 2010.
56
 Details 
on the literature search were not provided in the IARC reports though the most recent 
report included articles published in 2009.
26
 Recent meta-analyses
60-63
 and review 
articles
64
 were also searched for relevant articles. 
 
To complement the articles identified by these reports and meta-analyses, PubMed was 
searched for articles reporting human studies, written in English, and published between 
1
st
 January 2008 and 31
st
 March 2015, using the MeSH terms “Colorectal Neoplasms” 
and at least one of “Ethanol”, “Alcohol Drinking” or “Alcoholic Beverages”. 196 
articles were retrieved. 
 
Articles were selected for inclusion in this review if they (i) were based on prospective 
cohort studies (including nested case-control studies), (ii) analysed total alcohol intake 
in relation to colorectal cancer incidence (or colorectal subsites) in the general 
population and (iii) reported risk estimates (hazard ratios (HR), relative risks (RR), odds 
ratios (OR)) and confidence intervals (CI). Analyses that reported results only by other 
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factors were not included. Analyses based on fewer than 30 cases were excluded. 
References of included articles were carefully examined for additional articles. 
 
Figure 2.2.1 shows a flow diagram of the literature search process, illustrating the 
numbers of articles identified from the different sources. Overall, 54 articles, based on 
28 independent cohorts, met the inclusion criteria for this literature review. 
 
Figure 2.2.1 Flowchart of Literature Search Process for Alcohol Intake and Colorectal 
Cancer 
 
WCRF = World Cancer Research Fund, IARC = International Agency for Research and Cancer 
 
Table 2.2.1, presented at the end of this review, provides more details on the articles 
(identified in the literature search) mentioned in this review. Where necessary, more 
than one article from the same cohort is included in Table 2.2.1. At least one article 
from each cohort identified in the literature search is included (normally the article with 
the largest number of cases). Results are included for the highest vs lowest exposure 
comparison and separate results are included for colorectal cancer, colon cancer and 
rectal cancer where possible. Articles are ordered by publication year. 
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2.2.2 Alcohol Intake 
 
The evidence is fairly consistent that alcohol intake is associated with an elevated risk 
of colorectal cancer, particularly alcohol intake above 30 g/day. A potential threshold 
effect was first suggested by a pooled analysis of data from eight cohort studies in five 
countries in North America and Europe, including 490,000 men and women and 4,700 
cases of colorectal cancer. This analysis by Cho et al. found that an increased risk of 
colorectal cancer was restricted to people drinking at least 30 g/d.
45
 Compared with non-
drinkers, the RRs and 95% CIs for people drinking >0-<5, 5-<15, 15-<30, 30-<45 and 
≥45 g/d were 0.94 (0.86-1.03), 0.97 (0.88-1.06), 1.01 (0.86-1.18), 1.16 (0.99-1.36) and 
1.41 (1.16-1.72). 
 
Analyses of the individual cohorts (with longer follow-up) also provided support for a 
threshold at 30 g/d. The Netherlands Cohort Study and the Health Professionals Follow-
up Study both found evidence of an increased risk of colorectal cancer only for people 
drinking above 30 g/d.
65, 66
 Two studies of women (the Iowa Women’s Health Study 
and the Canadian National Breast Screening Study) did not find evidence for an 
increased risk of colorectal cancer for women drinking ≥30 g/d67, 68 but there was 
evidence of an increased risk in the Nurses’ Health Study of women.66  
 
Data from two large cohorts also suggested that there is a threshold for the association 
between alcohol intake and colorectal cancer. The European Prospective Investigation 
into Cancer and Nutrition (EPIC), which included almost 500,000 men and women and 
1,833 cases of colorectal cancer, found an increased risk only above 30 g/d; the HRs 
and 95% CIs comparing 4.9-14.9, 15-29.9, 30-59.9 and ≥60 g/d with 0.1-4.9 g/d were 
1.05 (0.92-1.19), 1.03 (0.88-1.20), 1.26 (1.06-1.49) and 1.64 (1.29-2.08).
69
 The Million 
Women Study included over 4,000 cases of colon cancer and over 2,000 cases of rectal 
cancer. Women mainly reported low to moderate alcohol intake. No association was 
observed between alcohol intake and colon cancer but drinking ≥15 drinks per week 
(approximately ≥20 g/d) was associated with an increased risk of rectal cancer (HR, 
1.25; 95% CI, 1.06-1.49).
70
 
 
Mizoue et al. also conducted a pooled analysis, this time of five cohort studies in Japan, 
including 1,724 cases for men.
71
 Results from this analysis did not seem to suggest a 
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threshold for the effects of alcohol intake. Compared with non-drinkers, the RRs and 
95% CIs for men drinking 0.1-<23, 23-<46, 46-<69, 69-<92 and ≥92 g/d were 1.22 
(0.92-1.61), 1.42 (1.21-1.66), 1.95 (1.53-2.49), 2.15 (1.74-2.64) and 2.96 (2.27-3.86). 
There seemed to be a particularly strong association between alcohol intake and 
colorectal cancer for Japanese men compared to other studies in Western populations 
although this study analysed a much wider range of alcohol intake than other studies. 
However, re-analysing the data using the same categories as the Western pooled 
analysis by Cho et al.,
45
 alcohol intake still appeared to be more strongly associated 
with colorectal cancer among Japanese men compared to Western men.
71
 
 
In general, other studies have not been able to investigate the relationship between 
alcohol intake and colorectal cancer in such a precise manner. A number of studies still 
found evidence for an increased risk of colorectal cancer with increased alcohol 
intake.
72-76
 The Singapore Chinese Health Study found that drinking at least seven 
drinks/week increased the risk of colorectal cancer compared with non-drinkers (HR, 
1.58; 95% CI, 1.23-2.04).
72
 Results from a study of Danish men and women by 
Pedersen et al. indicated a dose-response association between alcohol and rectal cancer 
but no association with colon cancer.
73
 One study of Japanese American men in Hawaii 
found that drinking ≥22.35 g/d increased the risk of colon cancer (HR, 1.39; 95% CI, 
1.05-1.83) and rectal cancer (HR, 2.30; 95% CI, 1.43-4.69) compared with non-
drinkers.
74
 
 
Overall, the evidence seems consistent that a high intake of alcohol (particularly above 
30 g/d) increases a person’s risk of colorectal cancer. It is less clear whether more 
moderate alcohol intake increases the risk. Figure 2.2.2 shows the pattern of results for 
the association between alcohol intake and colorectal cancer from different prospective 
cohort studies. 
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Figure 2.2.2 Results from Prospective Cohort Studies for the Association between 
Alcohol Intake and Colorectal Cancer 
 
Results show the comparison between the highest intake category and the reference group from 
prospective cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. 
 
Sex 
 
There is some uncertainty about whether the effects of alcohol intake on colorectal 
cancer risk are consistent for men and women. Results from meta-analyses
60, 62
 have 
shown stronger associations between alcohol intake and colorectal cancer for men than 
for women and the WCRF stated that alcohol is a cause of colorectal cancer for men but 
only a probable cause for women.
56
 However, rather than a true difference in the 
association for men and women, this could simply reflect the fact that on average men 
are heavier drinkers than women and so the stronger associations may be due to higher 
levels of intake being analysed among men. For example, the highest category of intake 
in the Japanese pooled analysis of men was ≥92 g/d. Mizoue et al. also performed a 
pooled analysis for Japanese women and the highest category of intake was ≥23 g/d.71 
However, these differences are not reflected in meta-analyses which simply pool highest 
vs lowest results. A further possibility is that there are different patterns of confounding 
for men and women or perhaps even a difference in the accuracy of reporting. 
 
In contrast to the stronger effect for men suggested by meta-analyses, no individual 
studies have found evidence for a different effect for men and women.
45, 65, 66, 69, 73, 77
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These studies have the advantage (compared with meta-analyses) of being able to take 
into account alcohol consumption more precisely when comparing results for men and 
women. For example, the RRs (95% CIs) from the Western pooled analysis comparing 
≥45 g/d with non-drinkers were 1.41 (1.11-1.79) for men and 1.41 (0.98-2.02) for 
women.
45
 Comparing ≥30 g/d with non-drinkers in the Netherlands Cohort Study, the 
HRs (95% CIs) for colorectal cancer risk were 1.61 (1.17-2.20) for men and 1.82 (1.06-
3.11) for women.
65
 The risk of colorectal cancer was also similar for men (HR, 1.38; 
95% CI, 1.00-1.69 for ≥30 g/d vs non-drinkers) and women (HR, 1.38; 95% CI, 1.11-
1.72 for ≥30 g/d vs non-drinkers) in the Health Professionals Follow-up Study and the 
Nurses’ Health Study.66 The risk of colon and rectal cancer associated with a 15 g/day 
increase was similar for men and women in the EPIC study.
69
 Thus, there is no strong 
evidence that the effects of alcohol intake on colorectal cancer risk are different for men 
and women. 
 
Colorectal Subsites 
 
It seems clear that alcohol intake increases the risk of both colon and rectal cancer 
though the association may be slightly stronger for rectal cancer. One meta-analysis 
which pooled results for the highest vs. lowest categories of intake from cohort studies 
found RRs (95% CIs) of 1.50 (1.25-1.79) for colon cancer and 1.63 (1.35-1.97) for 
rectal cancer.
60
 Another meta-analysis pooled results from case-control and cohort 
studies of both incidence and mortality using a “dose-response” approach.62 The RRs 
for colon and rectal cancer were 1.15 (1.06-1.24) and 1.23 (1.13-1.35) for moderate 
drinking (12.6-49.9 g/day) and 1.43 (1.23-1.67) and 1.59 (1.18-2.15) for heavy drinking 
(≥50 g/day). 
 
The majority of studies (including the EPIC study and the Netherlands Cohort Study) 
showed stronger associations for rectal cancer than colon cancer.
65, 69, 74, 75, 78, 79
 Also, 
the Million Women Study and the Danish study by Pedersen et al. found that alcohol 
intake was associated only with rectal cancer and not with colon cancer.
70, 73
 However, 
the results were similar for colon and rectal cancer in the Western pooled analysis
45
 and 
among the men of the Japanese pooled analysis (results were stronger for rectal cancer 
for Japanese women).
71
 The Singapore Chinese Health Study found a stronger 
association for colon cancer
77
 and the Health Professionals Follow-up Study found an 
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association only for colon cancer.
80
 Figure 2.2.3 shows the association between alcohol 
and colon and rectal cancer from different cohorts. Only cohorts which presented results 
for both colon and rectal cancer are included. 
 
Figure 2.2.3 Results from Prospective Cohort Studies for the Association between 
Alcohol Intake and Colon Cancer and Rectal Cancer 
 
Results show the comparison between the highest intake category and the reference group from 
prospective cohort studies which presented results for colon cancer and rectal cancer. Squares represent 
HRs/RRs. Bars represent 95% CIs. Black squares represent results for colon cancer and white squares 
represent results for rectal cancer. 
 
The proximal and distal colon differ in terms of anatomy, incidence rates and embryonic 
origins
51, 81
 and thus the effects of alcohol intake on cancer risk may differ for the 
proximal and distal colon. All studies seem to agree that there is a stronger association 
between alcohol intake and distal colon cancer than between alcohol intake and 
proximal colon cancer
45, 65, 69, 80, 82
 except for Pedersen et al. which found null results for 
colon cancer overall as well as for proximal and distal colon cancer.
73
 In the Western 
pooled analysis the results for proximal and distal colon cancer were 1.35 (0.97-1.89) 
and 1.66 (1.17-2.36) comparing ≥45 g/d with non-drinkers.45 The results were 0.92 
(0.51-1.66) and 1.68 (1.08-2.62) for >60 vs 0.1-4.9 g/d in the EPIC study.
69
 Meta-
Chapter 2 | Literature Reviews 
19 
analysis results for heavy drinking (≥50 g/day) were 1.38 (0.96-1.98) for proximal colon 
cancer and 2.46 (1.38-4.40) for distal colon cancer.
62
 
 
Beverage Types 
 
The increased risk of colorectal cancer due to alcohol intake does not appear to differ by 
beverage type. Different studies have employed slightly different methods when 
investigating whether certain beverages are more strongly related to colorectal cancer 
though there seems to be general agreement amongst studies that the increased risk is 
due to overall alcohol intake rather than specific beverages.
45, 65, 69, 70, 73, 77, 80
 
 
Summary 
 
Alcohol intake is positively associated with colorectal cancer risk. It is possible that 
there exists a threshold for increased risk at 30 g/d. Alcohol intake seems to have a 
similar effect on cancer risk for both men and women. Alcohol intake increases the risk 
of both colon and rectal cancer though alcohol intake seems to have a slightly stronger 
effect on rectal cancer. The effect seems to be stronger for distal colon cancer than 
proximal colon cancer. 
 
2.2.3 Effect Modifiers 
 
It is important to consider if there are any important effect modifiers such that certain 
groups of people are at a particularly elevated risk due to alcohol intake. Investigating 
effect modifiers may explain why studies find different results and may contribute to the 
understanding of underlying mechanisms. A number of studies have investigated 
different factors as possible modifiers of the relationship between alcohol intake and 
colorectal cancer. 
 
Alcohol Intake and BMI 
 
Analysing the effect of alcohol intake on colorectal cancer risk by BMI, the Western 
pooled analysis found evidence for a stronger effect of alcohol amongst leaner people; 
the HRs (95% CIs) comparing ≥30 g/d with non-drinkers were 1.84 (1.27-2.67), 1.23 
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(0.91-1.65) and 1.08 (0.88-2.33) for people with BMI <22, 22-<25 and ≥25 kg/m2.45 
The same pattern was found for men in the Japanese pooled study using the same BMI 
categories; the results for ≥69 g/d vs non-drinkers were 3.25 (2.12-4.99), 2.12 (1.57-
2.87) and 1.83 (1.26-2.67) for men with BMI <22, 22-<25 and ≥25 kg/m2.71 
 
These two large pooled analyses of subjects in different populations provide fairly 
strong evidence for an effect modification of BMI on the relationship between alcohol 
intake and colorectal cancer yet there is a dearth of evidence from other studies. The 
Norfolk arm of the EPIC cohort found no association between alcohol intake and 
colorectal cancer for people with BMI <25, 25-30 or >30 kg/m
2
 however the analysis 
included few cases and only analysed drinking ≥8 g/d compared with non-drinkers.83 
One case-control study actually found the opposite effect i.e. alcohol intake was 
associated with colorectal cancer among people with BMI ≥30 kg/m2 but not among 
people with BMI ≤30 kg/m2.84 
 
Folate 
 
Folate is a B vitamin found in foods such as leafy green vegetables, asparagus, broccoli 
and liver. Folate intake is thought to be protective against colorectal cancer risk
85-87
 and 
alcohol is known to inhibit the bioavailability and metabolism of folate.
88, 89
 Thus, it is 
hypothesised that alcohol intake is more strongly related to colorectal cancer among 
people with low folate intake. 
 
However, the evidence for an association between folate intake and colorectal cancer 
risk from cohort studies is not clear. While some studies indicate an inverse association 
between folate intake and colorectal cancer risk,
72, 90-94
 other studies do not find clear 
evidence for an association.
68, 95-101
 One reason contributing to the conflicting results is 
that different study populations will have different distributions of folate intake and 
different studies have considered very different comparisons of folate intake. Another 
reason for the conflicting results could be measurement error. Accurately measuring 
folate intake using questionnaires presents a real challenge and error in measuring folate 
intake will bias associations towards the null.
102
 Given the difficulties in accurately 
measuring folate intake using questionnaires, measures of circulating folate may 
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provide a more accurate reflection of average folate intake however studies of 
circulating folate also provide conflicting results.
103-106
 
 
While evidence from cohort studies may indicate an inverse association between folate 
intake and colorectal cancer, randomised controlled trials (RCTs) of folic acid have 
generally failed to show an effect on colorectal adenoma recurrence
107-111
 or 
incidence.
112
 RCTs are often considered to be the gold standard of epidemiological 
studies for evaluating the effectiveness of a treatment since randomisation should 
minimise differences between the treatment groups.
113
 Associations between other 
nutrients or dietary factors and cancer observed in observational studies have also not 
been confirmed in RCTs.
114-116
 This difference may be because a collection of dietary 
(and possibly lifestyle) factors might work together to prevent cancer but it is very 
difficult to disentangle the separate effects in cohort studies. However, there are other 
differences that could possibly explain the difference. For example, the RCTs 
considered colorectal adenoma as the outcome compared to colorectal cancer in the 
cohort studies and most of the RCTs were conducted among people with a history of 
adenoma. Also, the RCTs only considered relatively short periods of treatment and 
follow-up; cancer has a long latency period and folate intake in cohort studies may more 
accurately reflect long-term intake. 
 
Alcohol Intake and Folate 
 
A number of cohort studies of alcohol intake and colorectal cancer have investigated a 
possible interaction by folate intake though results are conflicting. Neither of the two 
large pooled analyses found important differences in the association between alcohol 
intake and colorectal cancer according to tertiles of folate intake.
45, 71
 The Netherlands 
Cohort Study also found no evidence for an interaction between alcohol intake and 
folate intake.
65
 In contrast, the EPIC study found that the effect of alcohol intake on 
colorectal cancer risk was modified by folate intake; the HRs and 95% CIs for an 
increase of 15 g/day of alcohol for low, middle and high tertiles of folate intake were 
1.13 (1.06-1.20), 1.09 (1.03-1.15) and 1.03 (0.98-1.09).
69
 
 
Analyses of folate intake and colorectal cancer have also investigated whether the 
association varies by alcohol intake and also find conflicting results. Though some 
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studies have found a stronger inverse association between folate intake and colorectal 
cancer among people with higher alcohol intake,
91, 93
 other studies do not support such 
an interaction.
68, 90, 96-98, 117-119
 
 
Alcohol Intake and Smoking 
 
Few cohort studies have investigated the possible interaction between alcohol intake 
and smoking status though results seem to suggest that the association between alcohol 
intake and colorectal cancer may be stronger for people with greater smoking exposure. 
Comparing an intake of ≥30 g/d with non-drinkers for never, former and current 
smokers, the results from the Western pooled analysis were 1.17 (0.84-1.63), 1.26 
(1.00-1.58) and 1.42 (1.11-1.83).
45
 Similarly, in the EPIC study, an increase of 15 g/d 
was associated with a greater risk among current smokers (HR, 1.23; 95% CI, 1.12-
1.36) than among never (HR, 1.15; 95% CI, 1.03-1.28) or former smokers (HR, 1.11; 
95% CI, 0.97-1.28).
69
 The Singapore Chinese Health Study suggested a stronger effect 
of alcohol intake for ever smokers than for never smokers for colon cancer but not for 
rectal cancer.
77
 Two smaller Japanese studies did not find strong evidence for an 
interaction.
82, 120
 
 
Summary 
 
Two large pooled analyses in different populations support a stronger association 
between alcohol intake and colorectal cancer risk for people with lower BMI. However, 
there is an absence of evidence from other studies and one case-control study found 
evidence for an opposite interaction between alcohol intake and BMI. An interaction 
between alcohol intake and folate intake has been investigated in a number of studies 
but the results are conflicting and equivocal. Few studies have investigated an 
interaction between alcohol intake and smoking for the risk of colorectal cancer though 
the evidence so far seems to suggest a synergistic effect of alcohol intake and smoking. 
 
2.2.4 Reference Groups 
 
The choice of reference group is an important consideration in analyses of alcohol 
intake. There are a number of advantages and disadvantages for different choices of 
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reference group (see section 4.1.2 for a more detailed discussion on the choice of 
reference groups) and different choices could lead to very different results. Many 
studies of alcohol intake and colorectal cancer, including the two pooled analyses,
45, 71
 
have used non-drinkers as the reference group (i.e. never drinkers and former drinkers 
combined). Using non-drinkers as the reference group could possibly underestimate the 
association between alcohol intake and colorectal cancer (compared to results using 
never drinkers) since former drinkers may have an increased risk of colorectal cancer 
compared to never drinkers. Few studies have analysed alcohol intake and colorectal 
cancer using never drinkers as the reference group, perhaps because it was not possible 
to separately identify former and never drinkers or because never drinkers represented a 
small group. Other studies, including EPIC and the Million Women Study have used 
some definition of light drinkers as the reference group.
69, 70
 
  
Very few studies have compared results using different reference groups. The two 
pooled analyses did include sensitivity analyses to assess the effect of including former 
drinkers in the reference group (though data from the Western pooled analysis was very 
limited).
45, 71
 Four of the cohorts in the Western pooled analysis had data on alcohol 
intake five to ten years before baseline. Restricting the analysis to these cohorts, the 
results were similar when past drinkers (in the last five or ten years) were included (RR, 
1.56; 95% CI, 1.20-2.04 for ≥45 g/d vs non-drinkers) and excluded (RR, 1.65; 95% CI, 
1.24-2.21 for ≥45 g/d vs never drinkers) from the reference group.45 The Japanese 
pooled analysis also found similar results when former drinkers were excluded from the 
reference group.
71
 
 
2.2.5 Mechanisms 
 
Colorectal cancer is a complex disease and it remains unclear exactly how alcohol 
intake increases the risk of colorectal cancer. It seems likely that acetaldehyde, the first 
metabolite of ethanol and a known carcinogen in animals, plays a key role in colorectal 
carcinogenesis.
26, 121
 Alcohol is absorbed into the blood from the stomach and small 
intestine and is circulated around the body. Alcohol is primarily metabolised in a two-
step process. First alcohol dehydrogenase (ADH) enzymes oxidise ethanol to 
acetaldehyde which is then oxidised to acetate by aldehyde dehydrogenase (ALDH) 
enzymes. 
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These dehydrogenase enzymes exist in different variants with different levels of 
activity.
122-124
 For example, the ALDH2*2 allele, relatively common in East Asian 
populations but essentially absent in Europeans, is virtually inactive. This causes 
acetaldehyde to accumulate in the body which results in facial flushing and other 
adverse effects. These effects are particularly severe for homozygous carriers who 
generally become abstainers whereas heterozygous carriers may tolerate alcohol 
consumption. 
 
Hence, polymorphisms of these enzymes should be associated with different levels of 
colorectal cancer risk since these polymorphisms will lead to different levels of 
acetaldehyde as a result of alcohol intake. However, since the different polymorphisms 
may be predictive of alcohol use, it is important that the actual alcohol intake is also 
considered at the same time. Studies of alcohol intake and colorectal cancer 
investigating dehydrogenase enzymes do not provide strong evidence that the 
association between alcohol intake and colorectal cancer is modified by any of these 
polymorphisms.
125-137
 Most of these studies included a relatively small number of cases 
and the confounding adjustment was quite poor in a number of studies. 
 
2.2.6 Summary 
 
Numerous studies have shown that high alcohol intake is associated with an increased 
risk of colorectal cancer and both the WCRF and the IARC declared in their most recent 
reports that alcohol intake is a cause of colorectal cancer.
25, 26, 56, 59
 Alcohol intake is 
associated with both colon and rectal cancer. The association may be slightly stronger 
for rectal cancer and seems to be stronger for distal colon cancer than proximal colon 
cancer (though few studies have investigated colon subsites). The largest studies 
indicate that an increased risk of colorectal cancer may be limited to people drinking 
above 30 g/d. It is less clear whether lower levels of alcohol intake increase colorectal 
cancer risk. The association appears to be similar for men and women. The risk does not 
seem to differ by beverage type and whether the risk differs according to other factors is 
unclear. 
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Table 2.2.1 Prospective Cohort Studies of Alcohol Intake and Colorectal Cancer 
Ref. 
Author, 
year 
Study name, location Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex 
Number 
of subjects 
Exposure Site 
Number 
of cases 
RR (95% CI) 
66
 Nan 2013 Nurses’ Health Study 
Health Professionals 
Follow-up Study, USA 
Nurses 
Health 
professionals 
1980 - 2008 
(28 yrs) 
1986 - 2008 
(22 yrs) 
34-59 
40-75 
B 134,730 ≥30 g/d vs non-
drinkers 
CRC 2,793 1.35 (1.14-1.59) 
            
67
 Razzak 
2011 
Iowa Women’s Health 
Study, USA 
General 
population 
1986 - 2002 
(17 yrs) 
55-69 F 38,001 >30 g/d vs non-
drinkers 
CRC 1,255 1.00 (0.71-1.40) 
            
138
 Shin 2011 Korea General 
population 
1996 - 2003 30-80 M 869,725 >1 bottle of 
Korean distilled 
spirits vs non-
drinkers 
PCC 536 1.2 (0.9-1.6) 
DCC 751 1.5 (1.2-2.0) 
RC 1,535 1.2 (1.0-1.4) 
F 395,501 >1 bottle of 
Korean distilled 
spirits vs non-
drinkers 
PCC 236 1.6 (0.7-3.5) 
DCC 225 0.5 (0.1-1.9) 
RC 551 1.7 (1.0-2.8) 
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Ref. 
Author, 
year 
Study name, location Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex 
Number 
of subjects 
Exposure Site 
Number 
of cases 
RR (95% CI) 
139
 Park 2010 EPIC-Norfolk 
EPIC-Oxford 
Guernsey Study 
Oxford Vegetarian 
Study 
MRC National Survey 
of Health and 
Development 
UK Women’s Cohort 
Study 
Whitehall II, UK 
General 
population 
 40-77 
32-84 
39-78 
26-79 
43 
44-78 
41-62 
B 1,734* ≥30 vs >0-<5 
g/d 
CRC 458 1.30 (0.86-1.95) 
CC 308 1.47 (0.89-2.43) 
RC 150 1.01 (0.48-2.11) 
            
70
 Allen 2009 Million Women Study, 
UK 
General 
population 
1996 - 2006 
(7.2 yrs) 
50-64 F 1,280,296 ≥15 vs >0-2 
drinks/week 
CC 4,169 1.00 (0.87-1.15) 
RC 2,129 1.25 (1.06-1.49) 
            
140
 Le 
Marchand 
2009 
Multiethnic Cohort 
Study, USA 
General 
population 
2001 - 2006 53-88 B 411* >16.4 g/d vs 
non-drinkers 
CRC 224 1.37 (0.81-2.31) 
            
83
 Park 2009 European Prospective 
Investigation into 
Cancer and Nutrition-
Norfolk, UK 
General 
population 
1993 - 2006 
(11 yrs) 
40-79 B 24,244 ≥21 units/week 
vs non-drinkers 
CRC  386 0.70 (0.44-1.13) 
CC 256 0.59 (0.32-1.09) 
RC 122 0.94 (0.43-2.09) 
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65
 Bongaerts 
2008 
Netherlands Cohort 
Study, Netherlands 
General 
population 
1986 - 1999 
(13.3 yrs) 
55-69 B 4,118† ≥30 g/d vs non-
drinkers 
CRC 2,323 1.32 (1.06-1.65) 
CC 1,573 1.24 (0.96-1.59) 
RC 532 1.50 (1.05-2.16) 
            
72
 Butler 2008 Singapore Chinese 
Health Study, 
Singapore 
General 
population 
1993 - 2005 
(9.8 yrs) 
45-74 B 61,321 ≥7 drinks/week 
vs non-drinker 
CRC 961 1.58 (1.23-2.04) 
            
68
 Kabat 2008 
 
Canadian National 
Breast Screening 
Study, Canada 
General 
population 
1980 - 2000 
(16.4 yrs) 
40-59 F 49,654 ≥30 g/d vs non-
drinkers 
CRC 617 1.02 (0.72-1.44) 
            
71
 Mizoue 
2008 
Japan Public Health 
Center-based 
Prospective Study I 
Japan Public Health 
Center-based 
Prospective Study II 
Japan Collaborative 
Cohort Study 
Miyagi Cohort Study 
Takayama Study, 
Japan 
General 
population 
1990 - 2004 
1993 - 2004 
1988 - 2001 
1990 - 2001 
1992 - 1999 
40-59 
40-69 
40-79 
40-64 
≥35 
M 98,265 ≥92 g/d vs non-
drinkers 
 
CRC 1,724 2.96 (2.27-3.86) 
CC 1,093 3.44 (2.50-4.72) 
RC 629 2.10 (1.16-3.83) 
F 111,498 ≥23 g/d vs non-
drinkers 
CRC 1,078 1.57 (1.11-2.21) 
CC 736 1.66 (1.12-2.46) 
RC 338 2.39 (1.18-4.88) 
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80
 Thygesen 
2008 
Health Professionals 
Follow-up Study, USA 
Health 
professionals 
1986 - 2002 
(16 yrs) 
40-75 M 47,432 >45 g/d vs non-
drinkers 
CRC 868 1.75 (1.21-2.52) 
            
141
 Toriola 
2008 
Findrink Study, 
Finland 
General 
population 
1984 - 2005 
(16.7 yrs) 
42-60 M 2,627 >115.3 vs <3.3 
g/week 
CRC 59 3.5 (1.2-9.8) 
            
82
 Akhter 2007 Miyagi Cohort Study, 
Japan 
General 
population 
1990 - 2001 
(11 yrs) 
40-64 B 21,199 ≥45.6 g/d vs 
never drinkers 
CRC 307 1.91 (1.32-2.78) 
CC 179 2.03 (1.23-3.33) 
RC 131 1.84 (1.05-3.21) 
            
69
 Ferrari 2007 European Prospective 
Investigation into 
Cancer and Nutrition, 
Europe 
General 
population 
1992 - 2002 
(6.2 yrs) 
35-70 B 478,732 ≥60 vs 0.1-4.9 
g/d 
CRC 1,833 1.64 (1.29-2.08) 
CC 1,183 1.43 (1.04-1.97) 
RC 649 1.93 (1.35-2.78) 
            
77
 Tsong 2007 Singapore Chinese 
Health Study, 
Singapore 
General 
population 
1993 - 2004 
(8.9 yrs) 
45-74 B 61,321 ≥7 drinks/week 
vs non-drinker 
CRC 845 1.84 (1.31-2.58) 
CC 516 1.84 (1.31-2.35) 
RC 329 1.59 (1.07-2.35) 
            
142
 Yeh 2006 Taiwan General 
population 
1990 - 2001 
(10 yrs) 
30-65 M 10,923 Drinkers vs 
non-drinkers 
CRC 68 1.23 (0.71-2.16) 
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79
 Chen 2005 China General 
population 
1990 - 2001 
(10.6 yrs) 
≥30 B 64,100 Daily vs never 
drinkers 
CRC 242 1.11 (0.74-1.67) 
CC 107 0.97 (0.52-1.78) 
RC 135 1.24 (0.71-2.14) 
            
143
 Wakai 2005 Japan Collaborative 
Cohort Study, Japan 
General 
population 
1988 - 1997 
(7.6 yrs) 
40-79 M 23,708 ≥66 g/d vs never 
drinkers 
CC 220 2.40 (1.31-4.40) 
RC 150 1.32 (0.67-2.63) 
F 34,028 ≥22 g/d vs never 
drinkers 
CC 198 1.22 (0.49-3.03) 
RC 61 1.53 (0.36-6.47) 
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45
 Cho 2004 Alpha-Tocopherol 
Beta-Carotene Cancer 
Prevention Study, 
Finland 
Canadian National 
Breast Screening 
Study, Canada 
Health Professionals 
Follow-up Study, USA 
Iowa Women’s Health 
Study, USA 
Netherlands Cohort 
Study, Netherlands 
New York State 
Cohort, USA 
Nurses’ Health Study, 
USA 
Sweden 
Mammography 
Cohort, Sweden 
General 
population 
1985 - 1995 
1980 - 1993 
1986 - 1996 
1986 - 1998 
1986 - 1993 
1980 - 1987 
1980 - 1996 
1987 - 1998 
50-69 
40-59 
40-75 
55-69 
55-69 
15-
107 
34-59 
40-76 
B 489,979 ≥45 g/d vs non-
drinkers 
CRC 4,687 1.41 (1.16-1.72) 
CC 3,291 1.45 (1.14-1.83) 
RC 1,370 1.49 (1.04-2.12) 
            
144
 Sanjoaquin 
2004 
Oxford Vegetarian 
Study, UK 
Vegetarians and 
non-vegetarians 
1980 - 1999 
(17 yrs) 
16-89 B 10,998 >7 vs <1 
units/week 
CRC 95 1.53 (0.87-2.69) 
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145
 Su 2004 National Health and 
Nutrition Examination 
Survey I 
Epidemiologic Follow-
Up Study, USA 
General 
population 
1982 - 1993 36-87 B 10,418 ≥1 drink/day vs 
non-drinkers 
CC 111 1.69 (1.03-2.79) 
            
78
 Wei 2004 
 
Nurses’ Health Study 
Health Professionals 
Follow-up Study, USA 
Nurses 
Health 
professionals 
1980 - 2000 
(20 yrs) 
1986 - 2000 
(14 yrs) 
34-59 
40-75 
B 134,365 ≥20 g/d vs non-
drinkers 
CC 1,139 1.27 (1.03-1.56) 
RC 339 1.26 (0.85-1.87) 
            
120
 Otani 2003 Japan Public Health 
Center-based 
Prospective Study, 
Japan 
General 
population 
1990 - 1999 40-69 M 42,540 ≥42.9 g/d vs 
non-drinkers 
CRC 447 2.1 (1.6-2.7) 
CC 299 1.9 (1.4-2.7) 
RC 148 2.4 (1.5-4.0) 
F 47,464 ≥1 vs <1/week  CRC 259 0.7 (0.4-1.1) 
            
73
 Pedersen 
2003 
Copenhagen Centre for 
Prospective Population 
Studies, Denmark 
General 
population 
1964/70/76- 
1999 
(14.7 yrs) 
23-95 B 29,132 ≥41 vs <1 
drinks/week 
CC 411 0.8 (0.5-1.5) 
RC 202 2.2 (1.0-4.6) 
            
146
 Shimizu 
2003 
Takayama Study, 
Japan 
General 
population 
1993 - 2000 ≥35 M 13,392 >36.7 g/d vs 
non-drinkers 
CC 108 2.67 (1.06-6.76) 
RC 59 1.17 (0.50-2.73) 
F 15,659 >3.75 g/d vs 
non-drinkers 
CC 94 1.78 (1.00-3.18) 
RC 41 1.80 (0.70-4.62) 
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98
 Flood 2002 Breast Cancer 
Detection 
Demonstration Project 
Follow-up Study, USA 
General 
population 
1987 - 1998 
(8.5 yrs) 
40-93 F 45,264 >2 servings/day 
vs non-drinkers 
CRC 490 1.16 (0.63-2.14) 
            
135
 Chen 2001 
 
Physicians’ Health 
Study, USA 
Physicians 1982 - 1995 40-84 M 1,113* ≥5 vs ≤1 
drinks/week 
CRC 211 1.25 (0.85-1.84) 
            
147
 Singh 1998 Adventist Health 
Study, USA 
Seventh-day 
Adventists 
1977 - 1982 
(6 yrs) 
≥25 B 32,051 ≥1 vs <1/week CC 157 2.05 (1.00-4.23) 
            
74
 Chyou 1996 Honolulu Heart 
Program, Hawaii 
General 
population 
1965 - 1995 
(16.2 yrs) 
45-65 M 7,945 ≥24 oz/month 
vs non-drinkers 
CC 328 1.39 (1.05-1.83) 
RC 123 2.30 (1.43-3.69) 
            
148
 Glynn 1996 Alpha-Tocopherol 
Beta-Carotene Cancer 
Prevention Study, 
Finland 
Smokers 1985 - 1993 50-69 M 27,109 >25.6 vs ≤2.6 
g/d 
CRC 140 1.3 (0.8-2.1) 
149
 Kreger 1992 Framingham Study, 
USA 
General 
population 
1948 - 1988 30-62 M 2,336 Per 1oz/week CC 56 1.00 (0.97-1.04) 
F 2,873 Per 1oz/week CC 66 0.95 (0.87-1.04) 
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75
 Klatsky 
1988 
Kaiser Permanente 
Study, USA 
General 
population 
1978 - 1984  B 10,303* ≥3 drinks/day vs 
non-drinkers 
CRC 268 1.94 (1.14-3.31) 
CC 203 1.71 (0.92-3.19) 
RC 66 3.17 (1.05-9.57) 
            
76
 Wu 1987 USA Retirement 
community 
1981 - 1985  B 11,644 >30 ml/day vs 
non-daily 
drinkers 
CRC 126 1.9 (1.3-2.9) 
M = males, F = females, CRC = colorectal cancer, CC = colon cancer, PCC = proximal colon cancer, DCC = distal colon cancer, RC = rectal cancer 
*Number of controls in a nested case-control study 
†Number of non-cases in case-cohort analysis 
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2.3 Adiposity and Colorectal Cancer Literature Review 
 
This section reviews the existing evidence for an association between adiposity and 
colorectal cancer, focusing on body mass index, waist circumference and waist to hip 
ratio. BMI is widely used in epidemiological studies to assess adiposity. A large number 
of studies have presented results for BMI and colorectal cancer and the WCRF 
concluded that there is convincing evidence that BMI is causally related to colorectal 
cancer.
25
 Fewer studies have investigated WC and WHR though the WCRF also 
concluded that there was convincing evidence that WC and WHR are causally related to 
colorectal cancer.
25
 This review first discusses the evidence for the association between 
BMI and colorectal cancer. The evidence for WC and WHR is then discussed. Other 
measures such as adiposity in early adulthood and weight change are also considered in 
this review. Possible effect modifiers and potential mechanisms are then described. 
 
2.3.1 Search Strategy 
 
The WCRF published reports in 2007 and 2011 summarising the evidence from cohort 
studies for an association between adiposity (specifically BMI, WC and WHR) and 
colorectal cancer.
25, 56
 The WCRF searched the Medline database for articles published 
up to December 2009. There were a number of recent meta-analyses of adiposity and 
colorectal cancer that were also searched for relevant studies.
150-156
 These meta-analyses 
are summarised in Table 2.3.1. Review articles were also searched for relevant 
studies.
157, 158
 
 
To complement the articles identified by these reports and meta-analyses, PubMed was 
searched for articles reporting human studies, written in English, and published between 
1
st
 January 2008 and 31
st
 March 2015, using the MeSH terms “Colorectal Neoplasms” 
and at least one of “Body Mass Index”, “Body Weight”, “Waist Circumference” or 
“Waist-Hip Ratio”. 748 articles were retrieved. 
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Table 2.3.1 Meta-analyses of Adiposity and Colorectal Cancer 
Ref. 
Author, 
Year 
Search 
Date 
Adiposity 
Measure 
Number 
of 
Studies 
Main Results 
Comparison RR (95% CI) 
150
 Ma 2013 01/2012 BMI 41* P Highest vs 
lowest category 
 
M CC 1.55 (1.47-1.63) 
M RC 1.24 (1.11-1.38) 
F CC 1.23 (1.10-1.37) 
F RC 1.07 (1.01-1.14) 
    
WC 13 P Highest vs 
lowest category 
 
M CC 1.81 (1.46-2.42) 
M RC 1.28 (0.99-1.66) 
F CC 1.50 (1.25-1.79) 
F RC 1.50 (1.03-2.18) 
       
151
 Robsahm 
2013 
12/2010 BMI 17 P Highest vs 
lowest category 
 
B PCC 1.24 (1.08-1.42) 
B DCC 1.59 (1.34-1.89) 
B RC 1.23 (1.02-1.48) 
       
152
 Ning 
2010 
02/2008 BMI 44† P 
14 R 
 
≥30 vs <23.0 
kg/m
2 
M CC 1.60 (1.53-1.69) 
M RC 1.30 (1.17-1.43) 
F CC 1.25 (1.12-1.39) 
F RC 1.14 (1.02-1.27) 
       
153
 Harriss 
2009 
12/2007 BMI 28 P 5 kg/m
2
 increase M CC 1.24 (1.20-1.28) 
M RC 1.09 (1.06-1.12) 
F CC 1.09 (1.04-1.14) 
F RC 1.02 (0.99-1.04) 
       
154
 Larsson 
2007 
04/2007 BMI 31† P 5 kg/m2 increase M CC 1.30 (1.25-1.35) 
M RC 1.12 (1.09-1.16) 
F CC 1.12 (1.07-1.18) 
F RC 1.03 (0.99-1.08) 
    
WC 6 P 10 cm increase M CC 1.33 (1.19-1.49) 
M RC 1.12 (1.03-1.22) 
F CC 1.16 (1.09-1.23) 
F RC 1.09 (0.99-1.20) 
    
WHR 7 P 0.1 increase M CC 1.43 (1.19-1.71) 
M RC 1.22 (0.81-1.83) 
F CC 1.20 (1.08-1.33) 
F RC 1.15 (0.95-1.39) 
       
155
 Moghadd
am 2007 
04/2007 BMI 23 P 
8 R 
≥30 vs <25.0 
kg/m
2
 
M CC 1.51 (1.42-1.61) 
M RC 1.29 (1.19-1.40) 
F CC 1.16 (1.01-1.34) 
F RC 1.08 (0.92-1.26) 
    
WC 10 P Highest vs 
lowest category 
B CRC 1.50 (1.35-1.67) 
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Ref. 
Author, 
Year 
Search 
Date 
Adiposity 
Measure 
Number 
of 
Studies 
Main Results 
Comparison RR (95% CI) 
156
 Dai 2007 01/2007 BMI 15 P ≥30 vs 18.5-24.9 
kg/m
2
 
M CC 1.71 (1.33-2.19) 
M RC 1.75 (1.17-2.62) 
F CC 1.10 (0.92-1.32) 
F RC 1.12 (0.84-1.49) 
    
WC 6 P Highest vs 
lowest category 
M CC 1.68 (1.36-2.08) 
M RC 1.26 (0.90-1.77) 
F CC 1.48 (1.19-1.84) 
F RC 1.23 (0.81-1.86) 
    
WHR 6 P Highest vs 
lowest category 
M CC 1.91 (1.46-2.49) 
M RC 1.93 (1.19-3.13) 
F CC 1.49 (1.23-1.81) 
F RC 1.20 (0.81-1.78) 
*Some studies included more than once. 
†Included 5 studies of cancer mortality. 
BMI, body mass index; WC, waist circumference; WHR, waist to hip ratio; P, prospective studies; R, 
retrospective studies; M, males; F females; B, both males and females; CRC, colorectal cancer; CC, colon 
cancer; PCC, proximal colon cancer; DCC, distal colon cancer; RC, rectal cancer. 
 
Articles were selected for inclusion in this review if they (i) were prospective cohort 
studies (including nested case-control studies and historical cohort studies), (ii) analysed 
measures of current adiposity (BMI, WC or WHR) assessed at baseline in relation to 
colorectal cancer incidence (or colorectal subsites) in the general population at least 18 
years old and (iii) reported risk estimates (HRs, RRs, ORs) and CIs. Analyses that 
reported results by other factors were not included. Analyses based on fewer than 30 
cases were ignored. References of included articles were carefully examined for 
additional articles. 
 
Figure 2.3.1 shows a flow diagram of the literature search process, illustrating the 
number of articles identified from the different sources. Overall, 87 articles met the 
inclusion criteria for this literature review. These 87 articles were based on 53 
independent cohorts. 
 
Table 2.3.6, presented at the end of this review, shows the key characteristics of the 
articles (identified in the literature search) mentioned in this review. Results are shown 
for BMI, WC and WHR and results are presented separately for colon and rectal cancer 
and men and women where possible. At least one article from each cohort identified in 
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the literature search is included. More than one article from the same cohort is included 
if they include analyses of different measures of adiposity. 
 
Figure 2.3.1 Flowchart of Literature Search Process for Adiposity and Colorectal 
Cancer 
 
WCRF = World Cancer Research Fund 
 
2.3.2 Body Mass Index 
 
The most common measure of adiposity is BMI, defined as the weight in kilograms 
divided by the square of the height in metres (kg/m
2
). The WHO has defined categories 
of BMI which are widely used in epidemiological studies of adiposity. BMI below 18.5 
kg/m
2
 is defined as underweight, BMI between 18.5-<25.0 kg/m
2
 is defined as normal 
weight, BMI ≥25.0 kg/m2 is defined as overweight and BMI ≥30.0 kg/m2 is defined as 
obese.
159
 
 
Prospective cohort studies have consistently found an increased risk of colon cancer 
associated with excess body weight as measured by BMI. BMI is also associated with 
rectal cancer risk though the evidence is less clear. The associations between BMI and 
colon and rectal cancer are stronger for men than for women.
150, 152, 153
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The NIH-AARP Diet and Health Study recruited 307,708 men and 209,436 women 
aged 50-71 years old in 1995-1996 who were followed-up until 2000.
160
 The results for 
the association between BMI and colon and rectal cancer for men and women are shown 
in Table 2.3.2. There was strong evidence for an association between BMI and colon 
cancer risk for men with increasing levels of BMI associated with greater risk. BMI was 
also associated with colon cancer risk for women but the evidence was weaker. There 
was no clear evidence for an increased risk of rectal cancer for men or women. 
 
Table 2.3.2 Body Mass Index and the Risk of Colon Cancer and Rectal Cancer in the 
NIH-AARP Diet and Health Study
160
 
 Colon cancer   Rectal cancer 
BMI, kg/m
2 
Cases HR (95% CI)  BMI, kg/m
2 
Cases HR (95% CI) 
Men    Men   
18.5-<23 136 1.00  18.5-<23 74 1.00 
23-<25 260 1.11 (0.90-1.37)  23-<25 101 0.78 (0.58-1.06) 
25-<27.5 479 1.22 (1.01-1.48)  25-<27.5 218 1.01 (0.77-1.31) 
27.5-<30 367 1.44 (1.18-1.76)  27.5-<30 135 0.96 (0.72-1.28) 
30-<32.5 219 1.53 (1.23-1.90)  30-<32.5 74 0.94 (0.68-1.30) 
32.5-<35 110 1.57 (1.22-2.03)  32.5-<35 42 1.10 (0.75-1.61) 
35-<40 76 1.71 (1.29-2.27)  ≥35 33 1.00 (0.68-1.58) 
≥40 29 2.39 (1.59-3.58)     
Women    Women   
18.5-<23 151 1.00  18.5-<23 60 1.00 
23-<25 141 1.20 (0.95-1.51)  23-<25 49 1.05 (0.72-1.53) 
25-<27.5 172 1.29 (1.03-1.60)  25-<27.5 60 1.13 (0.79-1.63) 
27.5-<30 106 1.31 (1.01-1.68)  27.5-<30 37 1.16 (0.76-1.76) 
30-<32.5 77 1.28 (0.97-1.69)  30-<32.5 26 1.09 (0.68-1.75) 
32.5-<35 42 1.13 (0.80-1.60)  32.5-<35 14 0.95 (0.52-1.71) 
35-<40 52 1.46 (1.06-2.02)  ≥35 32 1.44 (0.92-2.25) 
≥40 28 1.49 (0.98-2.25)     
 
In the Nurses’ Health Study and Health Professionals Follow-up Study, 87,733 female 
nurses and 46,632 male health professionals were followed-up from 1980 and 1986, 
respectively, until 2000 with repeat questionnaires on weight (and other variables) every 
two years.
78
 Similar results to the NIH-AARP Diet and Health Study were seen for 
colon cancer with a strong, dose-response association for men and a weaker association 
for women (Table 2.3.3). There was no evidence for an association with rectal cancer 
for men but BMI appeared to be more strongly related to rectal cancer than colon cancer 
for women (though the CIs were wide). 
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Table 2.3.3 Body Mass Index and the Risk of Colon Cancer and Rectal Cancer in the 
Health Professionals Follow-up Study and the Nurses’ Health Study78 
 Colon cancer   Rectal cancer 
BMI, kg/m
2 
Cases RR (95% CI)  Cases RR (95% CI) 
Men      
<23 57 1.00  24 1.00 
23-<25 119 1.33 (0.97-1.83)  42 1.16 (0.70-1.94) 
25-<30 225 1.54 (1.15-2.07)  55 0.93 (0.57-1.53) 
≥30 51 1.85 (1.26-2.72)  11 1.03 (0.49-2.14) 
Women      
<23 210 1.00  56 1.00 
23-<25 141 1.10 (0.88-1.36)  46 1.37 (0.92-2.02) 
25-<30 207 1.11 (0.91-1.35)  68 1.40 (0.98-2.01) 
≥30 113 1.28 (1.10-1.62)  34 1.56 (1.01-2.42) 
 
The EPIC study analysed the risk of colon cancer and rectal cancer among 129,731 men 
and 238,546 women recruited from ten European countries.
47
 Results were presented 
according to sex-specific quintiles of BMI (Table 2.3.4). There was only evidence for an 
increased risk of colon cancer for men in the highest quintile of BMI; there was no 
evidence for an association for colon cancer for women or for rectal cancer for men or 
women. 
 
Table 2.3.4 Body Mass Index and the Risk of Colon Cancer and Rectal Cancer in the 
European Investigation into Cancer and Nutrition
47
 
 Colon cancer   Rectal cancer 
BMI, kg/m
2 
Cases HR (95% CI)  Cases HR (95% CI) 
Men      
<23.6  64 1.00  52 1.00 
23.6-25.3 85 1.18 (0.85-1.63)  52 0.88 (0.60-1.30) 
25.4-27.0 74 1.00 (0.71-1.41)  58 0.96 (0.66-1.40) 
27.1-29.3 88 1.19 (0.85-1.66)  69 1.11 (0.77-1.62) 
≥29.4 110 1.55 (1.12-2.15)  64 1.05 (0.72-1.55) 
Women      
<21.7 87 1.00  47 1.00 
21.7-23.5 96 0.92 (0.68-1.23)  44 0.78 (0.51-1.18) 
23.6-25.7 120 1.02 (0.77-1.35)  72 1.14 (0.78-1.66) 
25.8-28.8 137 1.09 (0.83-1.45)  63 0.95 (0.65-1.41) 
≥28.9 123 1.04 (0.79-1.42)  65 1.06 (0.78-1.51) 
 
Bhaskaran et al. utilised primary care data on over five million UK adults to analyse the 
relationship between BMI and colorectal cancer.
161
 During the defined follow-up 
period, over 13,000 cases of colon cancer and 6,000 cases of rectal cancer were 
identified. Besides measured height and weight, data on smoking status, alcohol use, 
diabetes and deprivation were also available. For men there was a piecewise linear 
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relationship between BMI and colon cancer such that there was an association only for 
men with BMI 22-34 kg/m
2
 (which included the large majority of men). The HR and 
99% CI for a 5 kg/m
2
 increase for BMI <22, 22-34 and >34 kg/m
2
 was 0.92 (0.69-1.23), 
1.23 (1.17-1.30) and 0.97 (0.81-1.15). For women, the increased risk was more modest 
with no evidence for non-linearity (HR, 1.05; 99% CI, 1.01-1.08 for 5 kg/m
2
 increase). 
For rectal cancer there was no evidence for effect modification by gender or a non-
linear relationship (HR, 1.04; 99% CI, 1.00-1.08 for 5 kg/m
2
 increase for men and 
women). 
 
The large majority of studies investigating adiposity and colorectal cancer risk have 
been carried out in Western countries. For the same level of BMI, Asian people 
generally have a higher percentage of body fat than white people and a greater risk of 
type 2 diabetes and cardiovascular disease.
162
 Thus, it is possible that BMI represents a 
stronger risk factor for colorectal cancer in Asian populations. 
 
One study pooled data from eight Japanese cohorts including almost 5,000 cases of 
colorectal cancer.
163
 Compared to men and women with BMI 23-<25 kg/m
2
, men and 
women with BMI ≥30 kg/m2 had an increased risk of colon cancer (Table 2.3.5). There 
was also slight evidence of a decreased risk of colon cancer for men and women with 
BMI <19 kg/m
2
. For rectal cancer, there was evidence of an increased risk only for men 
with BMI ≥30 kg/m2. 
 
In a study of Chinese men and women, men (but not women) in the highest quintile of 
BMI had an increased risk of colon cancer but there was no clear evidence of an 
association with rectal cancer for men or women.
164
 Jee et al. analysed data from over 
one million Korean men and women who completed a medical examination as part of 
the national health system, identifying 8,703 cases of colorectal cancer for men and 
3,640 cases for women.
165
 Compared with men with BMI 23.0-24.9 kg/m
2
, men with 
BMI ≥30 kg/m2 had an increased risk of colon cancer but not rectal cancer. Men with 
BMI <20.0 and 20.0-22.9 kg/m
2
 had a decreased risk of colon cancer and rectal cancer. 
For women, there was no evidence for an increased risk of colon or rectal cancer for 
women with BMI ≥30 kg/m2 but there was evidence for a decreased risk of colon cancer 
for women with BMI <20.0 and 20.0-22.9 kg/m
2
. There was also slight evidence of a 
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decreased risk of rectal cancer for women with BMI <20.0 kg/m
2
. (Results were 
adjusted only for age and smoking status). 
 
Table 2.3.5 Body Mass Index and the Risk of Colon Cancer and Rectal Cancer in the 
Pooled Analysis of Japanese Studies
163
 
 Colon cancer   Rectal cancer 
BMI, kg/m
2 
Cases HR (95% CI)  Cases HR (95% CI) 
Men      
<19 98 0.84 (0.67-1.04)  59 0.92 (0.69-1.23) 
19-<21 317 0.94 (0.81-1.08)  179 0.95 (0.79-1.15) 
21-<23 473 0.86 (0.76-0.97)  325 1.09 (0.93-1.28) 
23-<25 512 1.00  284 1.00 
25-<27 319 1.16 (1.01-1.34)  158 1.04 (0.86-1.27) 
27-<30 168 1.27 (1.07-1.52)  80 1.17 (0.91-1.52) 
≥30 32 1.37 (0.96-1.98)  26 1.85 (1.23-2.78) 
Women      
<19 76 0.80 (0.61-1.04)  53 1.31 (0.95-1.81) 
19-<21 215 1.00 (0.83-1.20)  97 0.98 (0.76-1.27) 
21-<23 330 1.03 (0.88-1.21)  147 0.94 (0.74-1.18) 
23-<25 512 1.00  284 1.00 
25-<27 217 1.18 (0.99-1.41)  80 0.88 (0.66-1.17) 
27-<30 136 1.22 (0.99-1.51)  54 0.92 (0.67-1.27) 
≥30 48 1.39 (1.02-1.90)  20 1.33 (0.82-2.15) 
 
Figure 2.3.2 and Figure 2.3.3 show the pattern of results by sex across the individual 
cohorts included in this review for the association between BMI and colon cancer and 
rectal cancer. Only one set of results is included for each cohort. 
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Figure 2.3.2 Results from Prospective Cohort Studies for the Association between 
Body Mass Index and Colon Cancer Risk 
 
Results show the comparison between the highest BMI category and the reference group from prospective 
cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. Black squares represent results for 
men and white squares represent results for women. 
*Separate results presented for different age groups. 
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Figure 2.3.3 Results from Prospective Cohort Studies for the Association between 
Body Mass Index and Rectal Cancer Risk 
 
Results show the comparison between the highest BMI category and the reference group from prospective 
cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. Black squares represent results for 
men and white squares represent results for women. 
 
Proximal Colon Cancer and Distal Colon Cancer 
 
Studies have also investigated the associations with proximal colon and distal colon 
cancer.
138, 163, 166-180
 In the NIH-AARP Diet and Health Study, results were similar for 
proximal and distal colon cancer for men (HR, 1.57; 95% CI, 1.09-2.25 and HR, 1.68; 
95% CI, 1.05-2.68, comparing ≥35 vs 18.5-21.9 kg/m2) and women (HR, 1.15; 95% CI, 
0.82-1.63 and HR, 1.35; 95% CI, 0.81-2.25).
167
 Comparing highest and lowest quintiles 
of BMI in the Netherlands Cohort Study, results were also similar for proximal and 
distal colon cancer for men (HR, 1.35; 95% CI, 0.93-1.98 and HR, 1.38; 95% CI, 0.95-
1.98) and women (HR, 0.91; 95% CI, 0.65-1.28 and HR, 1.04; 95% CI, 0.72-1.50).
168
 
The pooled Japanese study also found similar results for proximal and distal colon 
cancer, for men and women, though the CIs were very wide.
163
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In contrast, however, some studies have found evidence for a stronger association for 
distal colon cancer. For example, the HRs and 95% CIs from a Norwegian cohort study 
comparing BMI ≥30 vs 18.5-<23.0 kg/m2 were 1.17 (0.68-2.00) for proximal colon 
cancer and 3.26 (1.79-5.95) for distal colon cancer for men.
169
 Results for women were 
1.48 (1.09-2.02) and 1.65 (1.01-2.70). The Nurses’ Health Study also found a stronger 
association for distal colon cancer (RR, 1.96; 95% CI, 1.18-3.25 for ≥29 vs <21 kg/m2) 
than proximal colon cancer (RR, 1.26; 95% CI, 0.71-2.23).
180
 Two other studies found 
slight evidence for a stronger association for proximal colon cancer.
174, 175
 
 
Meta-analysis results support a stronger association for distal colon cancer.
150, 151, 153
 
Pooling highest vs lowest results from prospective cohort studies, the RRs and 95% CIs 
were 1.24 (1.08-1.42) for proximal colon cancer and 1.59 (1.34-1.89) for distal colon 
cancer.
151
 
 
Differences between Studies 
 
It remains unclear if there are reasons why different studies have found different results. 
Meta-analyses found that associations were stronger from studies with self-reported 
height and weight than from studies that measured height and weight.
152-154
 For 
example, one meta-analysis found that the RR (95% CI) for a 5 kg⁄m2 increase in BMI 
in relation to colon cancer for men was 1.32 (1.21-1.44) for studies using self-reported 
data and 1.22 (1.19-1.26) for studies using measured data.
153
 There is expected to be 
measurement error when asking participants to report height and weight data. However, 
random measurement error would attenuate associations towards the null.
102
 Thus, since 
analysing self-reported height and weight results in stronger associations, it seems that 
BMI tends to be underestimated in these studies. 
 
In fact, it has been shown in numerous studies that both men and women tend to 
overestimate height and underestimate weight, resulting in underestimated BMI.
48
 Also, 
although studies generally find high correlations between self-reported and measured 
BMI, there is large variation at the individual level with the extent of underestimation 
increasing with increasing BMI and increasing age for both men and women.
181-183
 It 
was estimated in one study that 41% of obese men and 27% of obese women were 
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misclassified into a lower BMI category using self-reported measures of height and 
weight.
181
 
 
It is possible that other aspects of study design or analysis may also contribute to the 
differences in results observed between studies. Studies have adjusted for different sets 
of confounders and the quality of the measurement of these confounders will vary 
between studies. Another possibility is that the different results are due to the 
differences in study populations. The distributions of different lifestyle factors will 
differ between studies. If any of these factors influence the association between BMI 
and colorectal cancer, this would result in different studies finding different results. 
  
For example, the Million Women Study (including 4,008 cases of colorectal cancer) 
found a null association between BMI and colorectal cancer risk overall.
184
 However, 
stratifying the analysis by menopausal status, BMI was associated with an increased risk 
of colorectal cancer among premenopausal women (HR, 1.61; 95% CI, 1.05-2.48 per 10 
kg/m
2
 increase) but not postmenopausal women who were never users of hormone 
replacement therapy (HR, 0.99; 95% CI, 0.88-1.12 per 10 kg/m
2
 increase). Thus, this 
could mean that the association between BMI and colorectal cancer for women depends 
on the proportions of pre- and post-menopausal women. The potential effects of 
menopause and other risk factors on the association between BMI and colorectal cancer 
are described in section 2.3.6. 
 
Summary 
 
There is convincing evidence for an association between BMI and colon cancer. The 
evidence for the relationship between BMI and rectal cancer is less consistent. 
Associations are stronger for men than for women. The association appears to be 
stronger for the distal colon than the proximal colon. Studies relying on self-reported 
height and weight may overestimate results. 
 
2.3.3 Waist Circumference and Waist to Hip Ratio 
 
BMI is the most commonly studied measure of adiposity since it is very straightforward 
to assess in large populations; almost all cohorts include data on height and weight 
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(whether measured or self-reported). This has resulted in a multitude of studies relating 
BMI to colorectal cancer, albeit with varying quality.
150, 152
 As described above, BMI is 
strongly associated with colon cancer risk for men with a weaker association for 
women. The exact reasons for the discrepancy in results between men and women 
remain unclear. 
 
One potential explanation is that men and women have different body compositions. 
BMI is a rather crude measure of weight adjusted for height; it does not discriminate fat 
mass from lean mass and ignores fat distribution. Men tend to store excess weight 
centrally (abdominal adiposity) whereas women are more likely to store excess weight 
in the thighs and buttocks (gluteofemoral adiposity).
185
 Also, visceral adipose tissue 
(stored within the abdominal cavity) is more metabolically active and secretes greater 
levels of cytokines and hormones compared to subcutaneous adipose tissue (stored just 
below the skin).
185
 Hence, visceral adiposity is thought to be of particular importance 
for colorectal cancer
157, 158
 and it has been hypothesised that measures of abdominal 
adiposity such as WC and WHR may be more directly associated with colorectal cancer 
risk for both men and women.
47
 
 
Results from the EPIC study provided strong support for the hypothesis that measures 
of central adiposity are more important than BMI for assessing colorectal cancer risk. 
As described in the previous section, BMI was associated with an increased risk of 
colon cancer for men but not women.
47
 In contrast, WC and WHR were associated with 
an increased risk of colon cancer for both men (HR, 1.39; 95% CI, 1.01-1.93 for highest 
vs lowest quintile of WC and HR, 1.51; 95% CI, 1.06-2.15 for highest vs lowest quintile 
of WHR) and women (HR, 1.48; 95% CI, 1.08-2.03 for highest vs lowest quintile of 
WC and HR, 1.52; 95% CI, 1.12-2.05 for highest vs lowest quintile of WHR). 
Furthermore, WC and WHR were still associated with colon cancer risk for women 
after further adjustment for weight (as well as height) (HR, 1.44; 95% CI, 0.92-2.26 and 
HR, 1.46; 95% CI, 1.06-2.00).
47
 However, there was no longer evidence for an 
association with WC or WHR for men (HR, 1.01; 95% CI, 0.62-1.65 and HR, 1.18; 
95% CI, 0.79-1.76). Hence, these results suggest that WC and WHR convey important 
information about colon cancer risk beyond BMI for women. 
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Results from the Melbourne Collaborative Cohort Study followed a similar pattern. 
BMI (HR, 1.7; 95% CI, 1.1-2.8 for highest vs lowest quartile), WC (HR, 2.1; 95% CI, 
1.3-3.5) and WHR (HR, 2.1; 95% CI, 1.3-3.4) were all associated with colon cancer risk 
for men.
173
 Women in the highest tertile of BMI were not at an increased risk of colon 
cancer (HR, 1.0; 95% CI, 0.7-1.4) but there was evidence of an increased risk for 
women in the highest tertiles of WC (HR, 1.4; 95% CI, 1.0-1.9) and WHR (HR, 1.7; 
95% CI, 1.1-2.4).
172
 
 
Other studies, however, do not provide such clear support. Results from the NIH-AARP 
Diet and Health Study were in complete contrast to those from the EPIC study. BMI, 
WC and WHR were each associated with an increased risk of colon cancer for men but 
there was no association for women for any of these measures.
186
 The HRs and 95% CIs 
comparing the highest and lowest quintiles for BMI, WC and WHR for men were 1.42 
(1.19-1.68), 1.45 (1.16-1.82) and 1.29 (1.10-1.52). The corresponding results for 
women were 0.96 (0.74-1.23), 0.90 (0.63-1.27) and 0.90 (0.70-1.15). After adjusting for 
BMI, results were attenuated but WC (HR, 1.32; 95% CI, 1.03-1.70) and WHR (HR, 
1.17; 95% CI, 0.99-1.38) were both still associated with colon cancer for men, 
suggesting WC/WHR may provide important information beyond BMI for colon cancer 
risk for men. 
 
One study found that both BMI (HR, 1.93; 95% CI, 1.14-3.28 for ≥35.0 vs 18.5-24.9 
kg⁄m2) and WC (HR, 2.05; 95% CI, 1.29-2.35 for ≥120 vs <95 cm) were strongly 
associated with colon cancer risk for men.
187
 The associations were weaker for women 
(HR, 1.40; 95% CI, 0.84-2.36 for ≥35.0 vs 18.5-24.9 kg⁄m2 and HR, 1.54; 95% CI, 1.00-
2.37 for ≥110 vs <85 cm). Mutually adjusting for BMI and WC, the associations with 
WC seemed to remain for men and women while the associations with BMI were 
attenuated (though the CIs were very wide). 
 
The Iowa Women’s Health Study found a similar increased risk of colorectal cancer 
comparing high and low quartiles of BMI (HR, 1.29; 95% CI, 1.10-1.51), WC (HR, 
1.32; 95% CI, 1.11-1.56) and WHR (HR, 1.28; 95% CI, 1.08-1.50).
188
 A cohort of 
Chinese men and women found a strong association between BMI and colon cancer for 
men (HR, 2.15; 95% CI, 1.35-3.43 for highest vs lowest quintile) but no association for 
women (HR, 1.00; 95% CI, 0.70-1.43).
164
 WC and WHR were also strongly associated 
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with colon cancer risk for men (HR, 2.00; 95% CI, 1.21-3.29 for WC and HR, 1.97; 
95% CI, 1.19-3.24 for WHR) but there was no association for women (HR, 1.34; 95% 
CI, 0.89-2.00 for WC and HR, 0.96; 95% CI, 0.69-1.34 for WHR). 
 
Hence, it is unclear whether WC or WHR represent more accurate predictors of colon 
cancer risk and whether the stronger association between BMI and colon cancer for men 
than for women is due to different body compositions. Though the EPIC study found 
similar associations between WC/WHR and colon cancer for men and women, most 
studies find a stronger association for men.
150, 154
 
 
Figure 2.3.4 and Figure 2.3.5 show the results by sex from different cohorts for the 
association between WC and colon cancer and rectal cancer. Only one set of results is 
included for each cohort. 
 
Figure 2.3.4 Results from Prospective Cohort Studies for the Association between 
Waist Circumference and Colon Cancer Risk 
 
Results show the comparison between the highest WC category and the reference group from prospective 
cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. Black squares represent results for 
men and white squares represent results for women. 
*Separate results presented for different age groups. 
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Figure 2.3.5 Results from Prospective Cohort Studies for the Association between 
Waist Circumference and Rectal Cancer Risk 
 
Results show the comparison between the highest WC category and the reference group from prospective 
cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. Black squares represent results for 
men and white squares represent results for women. 
 
Summary 
 
BMI is predominantly used to measure adiposity due to its simplicity. However, BMI 
may be limited as a measure of adiposity since it ignores fat distribution. Measures of 
central adiposity such as WC and WHR are also associated with colon cancer risk, 
particularly for men. Results are conflicting for women. It remains unclear whether WC 
or WHR may be more directly associated with colorectal cancer risk than BMI, for men 
or women. 
 
2.3.4 Early Adulthood Adiposity 
 
Another question that remains about the relationship between adiposity and colorectal 
cancer is how adiposity throughout life influences lifetime risk. Adiposity during early 
adulthood and weight change throughout life may be just as important as attained 
weight for determining colorectal cancer risk. People with similar levels of excess 
weight at baseline (i.e. cohort initiation) may have had very different trajectories of 
weight gain and this may result in different levels of risk. 
 
Few studies have included contemporaneous measures of early adulthood adiposity.
189-
192
 All of these studies were historical cohort studies, relying on existing data on 
exposure and follow-up. The main disadvantage of historical cohort studies is that, since 
data were collected for other purposes, the quality of data can be poor. For example, the 
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data on confounders were very limited in these studies. Results from these studies do 
suggest that excess weight in early adulthood is associated with colon cancer risk for 
men (none of these studies included results for women).
189, 191, 192
 The largest study 
included measured height and weight data (recorded as part of an examination for 
military service) for over a million Jewish Israeli men aged 16-19 from 1967 to 2005 
who were followed up for cancer incidence until the end of 2006.
189
 The HR (95% CI) 
for colon cancer comparing men above with men below the 85
th
 percentile of BMI 
(25.14 kg⁄m2) was 1.53 (1.17-2.00).189 
 
Other studies have relied on participant recall in order to analyse the effects of early 
adiposity on later colorectal cancer risk. Since self-reported current weight involves 
significant measurement error, there should be even greater concern about the accuracy 
of recalled weight. Studies comparing measured weight during early adulthood and 
recalled weight many years later show that people tend to underestimate their previous 
weight and also that people’s recall is influenced by current BMI.193-195 
 
Overall, studies that used participants’ recall to analyse early adulthood BMI do not 
provide strong evidence that early adulthood BMI increases the risk of colorectal 
cancer.
164, 167, 168, 188, 196-198
 However, Zhang et al. did find that BMI at age 18 was 
associated with an increased risk of colorectal cancer for women in the Nurses’ Health 
Study (HR, 1.71; 95% CI, 1.16-2.51 for ≥30 vs <18.5 kg⁄m2) though there was no 
association for BMI at age 21 for men in the Health Professionals Follow-up Study 
(HR, 1.11; 95% CI, 0.70-1.76 for ≥30 vs <18.5 kg⁄m2).198 Two other studies also found 
slight evidence for an increased risk of colon cancer with BMI at age 18/20 for men but 
no evidence for women.
167, 168
 
 
There are two main issues concerning the analysis of early adiposity with colorectal 
cancer risk. The first issue is that there is a much narrower range of BMI during early 
adulthood, meaning that many studies will lack sufficient statistical power to evaluate 
the risk due to excess BMI during early adulthood. The second issue is that people with 
higher BMI during early adulthood will be more likely to have higher BMI later in life. 
Thus, it is very difficult to identify whether early adulthood adiposity is associated with 
an increased risk of colorectal cancer independent of later adiposity. Zhang et al. was 
the only study that considered adult BMI when investigating the effect of early 
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adulthood BMI on colorectal cancer risk and actually found evidence to support an 
independent effect of early adulthood BMI.
198
 Adjusting for adult BMI, early adulthood 
BMI was still associated with colon cancer risk among women (HR, 1.44; 95% CI, 
1.06-1.95). 
 
Summary 
 
Adiposity during early adulthood may increase the risk of colorectal cancer later in life. 
Crucially, however, it is unknown whether early adiposity is related to colorectal cancer 
risk independent of adiposity in later life. 
 
2.3.5 Weight Change 
 
A number of studies have analysed the relationship between weight change and 
colorectal cancer risk. Weight change may represent a useful measure of adiposity since 
adult weight gain generally occurs through accumulating fat mass and also because 
adult weight gain tends to accumulate centrally and central adiposity may be of 
particular importance for colorectal cancer risk, as described above.
199
 Also, weight gain 
is simple for the general public to understand. 
  
Most studies have analysed weight change from early adulthood to baseline, relying on 
self-reported weight during early adulthood.
164, 167, 168, 171, 188, 196, 197, 200, 201
 In general, 
these studies have found that weight change is associated with colorectal cancer risk. 
For example, weight gain ≥20 kg from age 18/21 to baseline was associated with an 
increased risk of colorectal cancer compared to weight change <2 kg for men in the 
Health Professionals Study and women in the Nurse’s Health Study.200 Weight gain ≥20 
kg compared to weight change <2 kg from age 20 to baseline was also associated with 
an increased risk of colorectal cancer in the EPIC study.
201
 
 
The main issue with weight change from early adulthood is that it is unclear what the 
effect of weight change may be, independent of later attained weight. On average, 
individuals with the largest weight gain since early adulthood will have the highest 
weight at baseline. Also, many individuals who maintained a stable weight since early 
adulthood will have a normal BMI at baseline since there is a much narrower range of 
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BMI during early adulthood (compared to later adulthood). Only two studies presented 
results attempting to separate the effects of weight change since early adulthood from 
the effects of attained adiposity later in life.
188, 201
 
 
Other studies have analysed weight change during later adulthood using data from 
prospective repeat assessments.
169, 200, 202, 203
 None of these studies have found strong 
evidence for a relationship between weight change and colorectal cancer for men or 
women though one study found an increased risk for men (but not women) who gained 
≥10 kg when restricting the analysis to men with BMI ≥25 kg/m2 at baseline.169 
 
Most studies investigating weight change have also included separate categories for 
weight loss. However, it is unclear whether weight loss is associated with a decreased 
risk of colorectal cancer. This is partly because the reference group in these analyses 
was people who maintain a stable weight which will include many people with a low 
BMI. Studies should focus on people with excess weight at baseline to investigate 
whether intentional weight loss reduces the excess risk of cancer due to excess weight. 
There is currently a lack of evidence for the effects of intentional weight loss on the risk 
of cancer.
204
 Hence, given the current prevalence of obesity in many countries,
36
 this 
represents an important research question. 
 
Summary 
 
Weight gain from early adulthood is associated with an increased risk of colorectal 
cancer. Similar to the relationship with BMI, weight gain from early adulthood is 
primarily associated with an increased risk of colon cancer and the association appears 
to be stronger for men than women.
199, 205
 However, the effect of weight gain 
independent of attained weight in later adulthood is unknown. 
 
2.3.6 Effect Modifiers 
 
As mentioned above, it is unclear why different studies find contrasting results. One 
possible explanation is that the relationship between adiposity and colorectal cancer is 
modified by other risk factors. Study populations may have very different distributions 
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of other risk factors and if these risk factors modify the relationship between adiposity 
and colorectal cancer risk, this will lead to different results. 
 
Adiposity and Menopause and Hormone Replacement Therapy Use 
 
Early studies of BMI and colorectal cancer found that the association was stronger 
among younger women,
178, 206
 suggesting that the relationship between BMI and 
colorectal cancer could be modified by changes due to menopause. Another study was 
able to stratify by menopausal status at baseline and found evidence for an association 
for premenopausal women (HR, 1.88; 95% CI, 1.24-2.86 for ≥30 vs <25 kg⁄m2) but no 
association for postmenopausal women (HR, 0.73; 95% CI, 0.48-1.10).
177
 This finding 
was supported by the Million Women Study which also found an association only for 
pre-menopausal women (described above).
184
 Meta-analysis results have also indicated 
a greater effect of BMI on colorectal cancer risk for pre-menopausal women than post-
menopausal women.
152
 
 
Oestrogen may be protective against colorectal cancer. A number of prospective cohort 
studies found evidence for an inverse association between hormone replacement therapy 
(HRT) use and colorectal cancer risk.
64
 Furthermore, the Women’s Health Initiative 
(WHI), an RCT of HRT use, found a 44% decreased risk (HR, 0.56; 95% CI, 0.38-0.81) 
of colorectal cancer among post-menopausal women given oestrogen plus progestin 
versus placebo.
207
 However, there is some doubt about this result since cancers in the 
treatment group were diagnosed at a more advanced stage
207
 and there was no evidence 
for a lower colorectal cancer mortality in the treatment group.
208
 Also, a separate RCT 
within the WHI found no decreased risk of colorectal cancer for women given oestrogen 
only (though this was based on few cases).
209
 
 
Recent prospective studies
210-214
 (though not all)
215
 have generally shown that HRT use 
is associated with a decreased colorectal cancer risk and a recent meta-analysis of 
RCTs, cohort studies and case-control studies found that both combined and oestrogen 
only HRT use were associated with lower colorectal cancer risk.
216
  
  
Some studies have investigated the relationship between endogenous oestrogen levels 
and colorectal cancer risk for post-menopausal women though the results are 
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inconsistent.
217-220
 One study did find inverse associations between oestrogen levels and 
colorectal cancer risk
220
 though another study indicated a positive association.
217
 
 
After menopause, oestrogen levels decrease and adipose tissue becomes the main source 
of endogenous oestrogens. Consequently, BMI is positively associated with circulating 
oestrogen levels in post-menopausal women.
221, 222
 Thus, this may explain why there is 
a stronger association between BMI and colorectal cancer for pre-menopausal women. 
It is hypothesised that, for post-menopausal women, the higher risk of colorectal cancer 
for women with greater adiposity is counterbalanced by the beneficial effect of excess 
adiposity on oestrogen levels. 
 
However, the evidence for the effect modification by menopause status is not entirely 
consistent. Two cohort studies of post-menopausal women found a strong association 
between BMI and colorectal cancer risk
188, 223
 and another study found a positive 
association for post-menopausal women (HR, 1.76; 95% CI, 1.13-2.74 for ≥30 vs 18.5-
22.9 kg⁄m2) but no association for pre-menopausal women (HR, 0.79; 95% CI, 0.30-
2.10).
169
 In the NIH-AARP Diet and Health Study, BMI was associated with colon 
cancer risk for women aged 50-62 and 63-66 at baseline (though there was no 
association for women aged 67-71).
160
 
 
Studies have also investigated how hormone replacement therapy (HRT) use may affect 
the relationship between adiposity and colorectal cancer risk. The hypothesis described 
above would predict a stronger relationship for current users of hormone replacement 
therapy.
206
 Evidence by HRT use is fairly scarce and not all studies support this 
prediction. The NIH-AARP Diet and Health Study did find that BMI was positively 
associated with colorectal cancer risk for current HRT users (HR, 1.13; 95% CI, 1.01-
1.26 for 5 kg⁄m2 increase) but was unrelated to cancer risk among former HRT users 
(HR, 1.02; 95% CI, 0.83-1.26) and never HRT users (HR, 0.97; 95% CI, 0.89-1.06).
167
 
Another study also found slight evidence for an interaction; there seemed to be a 
positive association between BMI and colorectal cancer for ever users but an inverse 
association for never users.
166
 However, BMI was not associated with colon cancer risk 
for HRT users or non-users in the EPIC study and WC and WHR were both associated 
with colon cancer risk among HRT non-users only.
47
 Two further studies did not find 
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clear evidence that the association between BMI and colorectal cancer risk differed by 
HRT use.
174, 224
 
 
Adiposity and Physical Activity 
 
Physical activity is inversely associated with colon cancer.
225
 Given the strong relation 
between physical activity and adiposity, it is surprising that more studies have not 
investigated a possible interaction between these two factors.
168, 170, 175, 192
 In a study of 
Swedish men, the risk of colorectal cancer was analysed according to categories of BMI 
and physical activity. Compared to men with the highest BMI and the least amount of 
physical activity, men with the lowest BMI and the most physical activity had the 
lowest cancer risk though there was no clear evidence for an interaction.
170
 A similar 
analysis was performed in the Netherlands Cohort Study with WC and physical activity 
but there was no clear pattern, for men or women.
168
 
 
A recent meta-analysis actually found that there was a slightly stronger association 
between BMI and colorectal cancer risk among studies that adjusted for physical 
activity.
152
 Since BMI is associated with physical activity, adjusting for physical activity 
should result in a weaker association. It is unclear what may explain this result. The 
authors hypothesised that including data on physical activity could be indicative of 
greater study quality but is not clear how this could relate to results. For example, 
greater study quality could mean that BMI was measured with greater accuracy. 
However, since people tend to underestimate BMI,
48
 results using self-reported data 
would overestimate the association between BMI and colorectal cancer, meaning that 
greater study quality would produce lower results. Greater study quality could also 
mean that studies included more confounders and/or that confounders were more 
accurately measured but this would also likely lead to lower results. 
 
Adiposity and Smoking 
 
Cigarette smoking is another risk factor that is associated with both colorectal cancer 
and BMI.
226, 227
 Again, few studies have explored a potential interaction between these 
two risk factors. In a study of Singapore Chinese men and women, BMI was associated 
with colon cancer risk among never smokers but not ever smokers.
228
 Another study 
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similarly found stronger results when restricting to never smokers
171
 but Bhaskaran et 
al. found similar associations for BMI and colon and rectal cancer, both overall and 
restricting to never smokers.
161
 
 
Summary 
 
BMI seems to have a stronger effect on colorectal cancer risk among pre-menopausal 
women than among post-menopausal women. This may be explained by a protective 
effect of oestrogen on colorectal cancer since adipose tissue becomes an important 
source of endogenous oestrogen after menopause. The results according to hormone 
therapy use are equivocal. Evidence for interactions with physical activity and smoking 
are insufficient. 
 
2.3.7 Mechanisms 
 
The exact mechanisms relating adiposity and excess weight with increased colorectal 
cancer risk remain unclear. Insulin resistance, a condition where the body uses insulin 
less effectively and which results in elevated levels of insulin (and also insulin-like 
growth factor (IGF)-1), may be the most important factor relating adiposity to colorectal 
cancer development. Adiposity is strongly associated with insulin resistance and insulin 
and IGF-1 have been shown to promote cell proliferation and inhibit apoptosis.
157, 158, 
185, 229
 The role of insulin resistance is also supported by the evidence of an increased 
risk of colorectal cancer for men and women with type 2 diabetes.
230
 Adipose tissue also 
produces various hormones and cytokines, known collectively as adipokines or 
adipocytokines, which have been related to cancer development.
158, 185
 Another possible 
mechanism relates to inflammation, supported by evidence that individuals with chronic 
inflammatory bowel disease have a higher risk of colorectal cancer and that aspirin and 
other anti-inflammatory drugs are associated with a lower risk.
157
 
 
2.3.8 Summary 
 
Substantial evidence indicates an association between BMI and colorectal cancer risk. 
The evidence is strongest for colon cancer and for men. The mechanisms underlying the 
stronger association for men remain unclear. BMI is a simple measure of weight 
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adjusted for height but does not take into account fat distribution. WC and WHR are 
also associated with increased colorectal cancer risk though it remains unclear what the 
most appropriate measure of adiposity is for predicting colorectal cancer risk. Early 
adulthood adiposity and weight gain may both be associated with increased colorectal 
cancer risk but their effects independent of attained adiposity are unknown. The effect 
of BMI on colorectal cancer risk may be stronger among pre-menopausal women than 
post-menopausal women. 
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8 Table 2.3.6 Prospective Cohort Studies of Adiposity and Colorectal Cancer 
Ref. 
Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
161
 Bhaskaran 
2014 
UK General 
population 
M 1987 - 2012 ≥16 B 5,243,978 BMI, ≥35.0 vs 
18.5-24.9 kg/m
2
 
CC 13,465 1.36 (1.23-1.51)* 
RC 6,123 1.18 (1.01-1.38)* 
             
197
 Han 2014 Atherosclerosis 
Risk in 
Communities, 
USA 
General 
population 
M 1987 - 2006 45-64 M 6,332 BMI, ≥30 vs 
18.5-<25.0 kg/m
2
 
CRC 151 1.14 (0.91-1.44) 
 F 7,569 BMI, ≥30 vs 
18.5-<25.0 kg/m
2
 
CRC 147 1.01 (0.80-1.26) 
             
202
 Steins 
Bisschop 
2014 
European 
Prospective 
Investigation into 
Cancer–Physical 
Activity, 
Nutrition, 
Alcohol, 
Cessation of 
Smoking, Eating 
Study, Europe 
General 
population 
S 1992 - 2008 
(6.8 yrs) 
25-70 M 91,231 BMI, >30 vs <25 
kg/m
2
 
CC 480 1.49 (1.13-1.97) 
RC 354 1.13 (0.81-1.58) 
F 237,550 BMI, >30 vs <25 
kg/m
2
 
CC 781 1.24 (0.99-1.56) 
RC 393 1.09 (0.78-1.51) 
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Ref. 
Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
186
 
 
 
 
Keimling 
2013 
NIH-AARP Diet 
& Health Study, 
USA 
Membership 
organisation 
of over 50s 
S 1996 - 2006 
(10 yrs) 
50-72 M 124,208 BMI, Q5 vs Q1 CC 1,463 1.42 (1.19-1.68) 
RC 536 0.90 (0.68-1.19) 
WC, ≥106.5 vs 
<89.5 cm 
CC 1,463 1.45 (1.16-1.82) 
RC 536 0.97 (0.67-1.38) 
WHR, Q5 vs Q1 CC 1,463 1.29 (1.10-1.52) 
RC 536 1.08 (0.82-1.43) 
F 78,969 BMI, Q5 vs Q1 CC 680 0.96 (0.74-1.23) 
RC 190 1.26 (0.79-2.01) 
WC, ≥94.5 vs 
<73.6 cm 
CC 680 0.90 (0.63-1.27) 
RC 190 1.01 (0.53-1.94) 
WHR, Q5 vs Q1 CC 680 0.90 (0.70-1.15) 
RC 190 1.13 (0.69-1.86) 
             
166
 Kitahara 
2013 
Prostate, Lung, 
Colorectal, and 
Ovarian Cancer 
Screening Trial, 
USA 
General 
population 
S 1993 - 2009 
(11.9 yrs) 
55-74 M 36,912 BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
PCC 275 1.48 (1.05-2.09) 
DCC 131 1.48 (0.90-2.42) 
RC 134 1.38 (0.83-2.27) 
F 37,562 BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
PCC 254 1.23 (0.89-1.69) 
DCC 88 0.66 (0.36-1.21) 
RC 66 0.95 (0.50-1.79)  
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Ref. 
Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
164
 Li 2013 Shanghai Men’s 
Health Study, 
China 
General 
population 
M 2002 - 2009 
(5.5 yrs) 
40-74 M 61,283 BMI, ≥26.2 vs 
<21.1 kg/m
2
 
CC 180 2.15 (1.35-3.43) 
RC 133 1.20 (0.69-2.10) 
WC, ≥92 vs <78 
cm 
CC 180 2.00 (1.21-3.29) 
RC 133 0.88 (0.52-1.49) 
WHR, ≥0.95 vs 
<0.85 
CC 180 1.97 (1.19-3.24) 
RC 133 1.24 (0.69-2.26) 
Shanghai 
Women’s Health 
Study, China 
General 
population 
M 1997 - 2009 
(11.0 yrs) 
40-70 F 72,972 BMI, ≥26.7 vs 
<21.1 kg/m
2
 
CC 382 1.00 (0.70-1.43) 
RC 240 1.22 (0.78-1.90) 
WC, ≥85 vs <70 
cm 
CC 382 1.34 (0.89-2.00) 
RC 240 1.17 (0.73-1.88) 
WHR, ≥0.85 vs 
<0.77 
CC 382 0.96 (0.69-1.34) 
RC 240 1.11 (0.74-1.66) 
             
167
 Renehan 
2012 
NIH-AARP Diet 
& Health Study, 
USA 
Membership 
organisation 
of over 50s 
S 1996 - 2006 
(10 yrs) 
50-72 M 168,294 BMI, ≥35 vs 
18.5-21.9 kg/m
2
 
CC 2,070 1.53 (1.16-2.03) 
RC 762 1.43 (0.90-2.28) 
F 105,385 BMI, ≥35 vs 
18.5-21.9 kg/m
2
 
CC 962 1.23 (0.93-1.64) 
RC 282 1.28 (0.76-2.16) 
             
             
             
             
             
             
  
6
1 
C
h
a
p
te
r 2
 | L
iteratu
re R
ev
iew
s 
Ref. 
Author, 
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Study name, 
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method
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period 
(average 
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Age Sex
b 
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of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
168
 Hughes 
2011 
Netherlands 
Cohort Study, 
Netherlands 
General 
population 
S 1986 - 2002 
(16.3 yrs) 
55-69 M 1,365† BMI, ≥27.1 vs 
<23.0 kg/m
2
 
PCC 327 1.35 (0.90-1.98) 
DCC 427 1.38 (0.95-1.98) 
RC 299 1.01 (0.67-1.51) 
WC, Q5 vs Q1 PCC 327 1.32 (0.81-2.15) 
DCC 427 2.56 (1.55-4.24) 
RC 299 1.33 (0.77-1.29) 
F 1,832† BMI, ≥27.6 vs 
<22.1 kg/m
2
 
PCC 459 0.91 (0.65-1.28) 
DCC 327 1.04 (0.72-1.50) 
RC 205 1.07 (0.67-1.60) 
WC, Q5 vs Q1 PCC 459 1.46 (0.98-2.18) 
DCC 327 1.15 (0.74-1.80) 
RC 205 1.07 (0.59-1.93) 
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method
a 
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period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
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c 
Site
d Number 
of cases 
HR/RR (95% CI) 
163
 Matsuo 
2011 
Japan Public 
Health Center-
based 
Prospective 
Study I 
Japan Public 
Health Center-
based 
Prospective 
Study II 
Japan 
Collaborative 
Cohort Study 
Miyagi Cohort 
Study-I 
Miyagi Cohort 
Study-II 
Aichi Cohort 
Study 
Ohsaki Cohort 
Study 
Takayama Study, 
Japan, Japan 
General 
population 
S 1990 - 2006 
1993 - 2006 
1988 - 2001 
1990 - 2003 
1984 - 1992 
1985 - 2000 
1992 - 1999 
1994 - 2003 
40-59 
40-69 
40-79 
40-64 
≥40 
40-103 
≥35 
40-79 
M 157,927 BMI, ≥30 vs 23-
<25 kg/m
2
 
CC 1,919 1.37 (0.96–1.98) 
RC 1,111 1.85 (1.23–2.78) 
F 183,457 BMI, ≥30 vs 23-
<25 kg/m
2
 
CC 1,534 1.39 (1.02–1.90) 
RC 735 1.33 (0.82–2.15) 
             
228
 Odegaard 
2011 
Singapore 
Chinese Health 
Study, Singapore 
General 
population 
S 1993 - 2007 
(11.5 yrs) 
45-74 B 51,251 BMI, ≥27.5 vs 
21.5-24.4 kg/m
2
 
CC 596 1.48 (1.13-1.92) 
RC 384 0.93 (0.64-1.36) 
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Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
138
 Shin 2011 Korea General 
population 
M 1996 - 2003 30-80 M 869,725 BMI, ≥25 vs 
18.5-22.9 kg/m
2
 
PCC 536 1.1 (0.9-1.4) 
DCC 751 1.6 (1.4-2.0) 
RC 1,535 1.1 (1.0-1.3) 
F 395,501 BMI, ≥25 vs 
18.5-22.9 kg/m
2
 
PCC 236 1.5 (1.1-2.0) 
DCC 225 1.3 (0.9-1.8) 
RC 451 1.1 (0.9-1.3) 
             
196
 Bassett 
2010 
Melbourne 
Collaborative 
Cohort 
Study, Australia 
General 
population 
M 1990 - 2007 
(14.0 yrs) 
27-80 M 16,188 BMI, ≥30 vs 23-
<25 kg/m
2
 
CC 277 1.51 (1.00-2.28) 
F 23,438 BMI, ≥30 vs 23-
<25 kg/m
2
 
CC 292 1.00 (0.70-1.44) 
             
190
 Burton 
2010 
Glasgow Alumni 
Cohort, Scotland 
University 
students 
M 1948 - 2008 
(47.5 yrs) 
<30 B 12,206 BMI, >25 vs 19-
23 kg/m
2
 
CC 71 1.12 (0.44–2.82) 
RC 41 1.46 (0.51–4.61) 
             
169
 Laake 
2010 
Norwegian 
Counties Study, 
Norway 
General 
population 
M 1974 - 2005 
(23.2 yrs) 
20-49 M 38,822 BMI, ≥30 vs 
18.5-<23 kg/m
2
 
CC 450 1.80 (1.25-2.59) 
F 37,357 BMI, ≥30 vs 
18.5-<23 kg/m
2
 
CC 419 1.48 (1.09-2.02) 
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Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
Site
d Number 
of cases 
HR/RR (95% CI) 
188
 Oxentenko 
2010 
Iowa Women’s 
Health Study, 
USA 
General 
population 
S 1986 - 2005 55-69 F 36,941 BMI, ≥40 vs 
18.5–24.9 kg/m2  
CRC 1,464 1.56 (1.10-2.22) 
WC, ≥96.53 vs 
≤77.15 cm 
CRC 1,464 1.32 (1.11-1.56) 
WHR, ≥0.90 vs 
≤0.78 
CRC 1,464 1.28 (1.08-1.50) 
             
231
 Cnattingiu
s 2009 
Sweden Twins S 1973 - 2006 15-47 B 23,337 BMI, ≥25.0 vs 
18.5-24.9 kg/m
2
 
CRC 210 1.60 (1.15-2.23) 
             
217
 Gunter 
2008 
Women’s 
Health Initiative 
Observational 
Study, USA 
General 
population 
M 1993 - 2004 
(6.4 yrs) 
50-79 F 809† BMI, ≥30 vs 
18.5-<25.0 kg/m
2
 
CRC 438 1.55 (1.13–2.13) 
WC, ≥93.0 vs 
75.0 cm 
CRC 438 1.47 (1.04–2.09) 
WHR, ≥0.85 vs 
<0.75 
CRC 438 1.82 (1.22–2.70) 
             
165
 Jee 2008 Korea General 
population 
M 1992 - 2006 
(10.8 yrs) 
30-95 M 770,556 BMI, ≥30 vs 
23.0–24.9 kg/m2 
CC 4,671 1.42 (1.02-1.98) 
RC 4,032 1.16 (0.77-1.74) 
F 443,273 BMI, ≥30 vs 
23.0–24.9 kg/m2 
CC 1,959 1.01 (0.72-1.42) 
RC 1,681 1.14 (0.78-1.68) 
             
223
 Song 2008 Korea General 
population 
M 1994 - 2003 
(8.8 yrs) 
40-64 F 152,772 BMI, ≥30 vs 
21.0-22.9 kg/m
2
 
CC 453 2.18 (1.43-3.33) 
RC 482 0.91 (0.55-1.52) 
  
6
5 
C
h
a
p
te
r 2
 | L
iteratu
re R
ev
iew
s 
Ref. 
Author, 
year 
Study name, 
location 
Population 
Assessment 
method
a 
Follow-up 
period 
(average 
follow-up) 
Age Sex
b 
Number 
of 
subjects 
Comparison
c 
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HR/RR (95% CI) 
187
 Wang 
2008 
Cancer 
Prevention 
Study-II 
Nutrition Cohort, 
USA 
General 
population 
S 1997 - 2005 
(7.7 yrs) 
 M 44,068 BMI, ≥35.0 vs 
18.5-24.9 kg/m
2
 
CC 402 1.93 (1.14-3.28) 
RC 142 1.38 (0.58-3.28) 
WC, ≥120 vs <95 
cm 
CC 402 2.05 (1.29-3.25) 
RC 142 1.02 (0.43-2.42) 
F 51,083 BMI, ≥35.0 vs 
18.5-24.9 kg/m
2
 
CC 314 1.40 (0.84-2.36) 
RC 93 2.67 (1.09-6.54) 
WC, ≥110 vs <85 
cm 
CC 314 1.54 (1.00-2.37) 
RC 93 2.65 (1.23-5.71) 
             
82
 Akhter 
2007 
Miyagi Cohort 
Study, Japan 
General 
population 
S 1990 - 2001 
(11 yrs) 
40-64 B 21,199 ≥25.0 vs <18.5 
kg/m
2
 
CRC 307 1.61 (0.59-4.40) 
             
160
 Adams 
2007 
NIH-AARP Diet 
& Health Study, 
USA 
Membership 
organisation 
of over 50s 
S 1995 - 2000 
(5 yrs) 
50-71 M 307,708 BMI, ≥40 vs 
18.5-<23 kg/m
2 
CC 1,676 2.39 (1.59-3.58) 
BMI, ≥35 vs 
18.5-<23 kg/m
2
 
RC 677 1.00 (0.68-1.58) 
F 209,436 BMI, ≥40 vs 
18.5-<23 kg/m
2
 
CC 769 1.49 (0.98-2.25) 
BMI, ≥35 vs 
18.5-<23 kg/m
2
 
RC 278 1.44 (0.92-2.25) 
             
232
 Driver 
2007 
Physicians’ 
Health Study, 
USA 
Physicians S 1982 - 2004 40-84 M 21,581 BMI, ≥25 vs <25 
kg/m
2
 
CC 381 1.38 (1.11-1.70) 
RC 104 1.19 (0.80-1.77) 
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233
 Lundqvist 
2007 
2 cohorts from 
Sweden and 1 
cohort from 
Finland 
Twins S 1969 - 2004 
(22.0 yrs) 
43-96 B 24,821 BMI, ≥30 vs 
18.5-<25.0 kg/m
2
 
CC 513 1.3 (0.9-1.8) 
RC 324 0.7 (0.4-1.2) 
1973 - 2004 
(28.4 yrs) 
18-47 B 43,328 BMI, ≥30 vs 
18.5-<25.0 kg/m
2
 
CC 204 1.1 (0.5-2.5) 
RC 154 0.9 (0.3-2.5) 
             
184
 Reeves 
2007 
Million Women 
Study, UK 
General 
population 
S 1996 - 2004 
(5.4 yrs) 
50-64 F 1,222,630 BMI, ≥30 vs 
22.5-24.9 kg/m
2
 
CRC 4,008 1.01 (0.94-1.09) 
             
224
 Wang 
2007 
Cancer 
Prevention 
Study-II 
Nutrition Cohort, 
USA 
General 
population 
S 1992 - 2003  F 73,842 BMI, ≥30 vs 
18.5–24.9 kg/m2 
CRC 814 1.19 (0.97-1.45) 
             
234
 Ahmed 
2006 
Atherosclerosis 
Risk in 
Communities 
Study, USA 
General 
population 
M 1987 - 2000 
(11.5 yrs) 
45-64 B 14,109 BMI, ≥35 vs <25 
kg/m
2
 
CRC 194 1.54 (0.9-2.8) 
WC, ≥102/88 vs 
<102/88 cm 
CRC 194 1.40 (1.0-1.9) 
WHR, ≥0.98 vs. 
<0.88 
CRC 194 1.67 (1.1-2.5) 
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235
 Bowers 
2006 
Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention 
Study, Finland 
Smokers M 1985 - 2002 
(14.1 yrs) 
 M 28,983 BMI, ≥30 vs 
18.5-<25 kg/m
2
 
CC 227 1.78 (1.25-2.55) 
RC 183 1.51 (0.99-2.29) 
             
170
 Larsson 
2006 
Cohort of 
Swedish Men, 
Sweden 
General 
population 
S 1997 - 2005 
(7.1 yrs) 
45-79 M 45,906 BMI, ≥30 vs <23 
kg/m
2
 
CC 309 1.60 (1.03–2.48) 
RC 190 1.44 (0.79–2.61) 
WC, ≥104 vs <88 
cm 
CC 309 1.44 (0.93–2.24) 
RC 190 1.24 (0.68–2.25) 
             
236
 Lukanova 
2006 
Northern Sweden 
Health and 
Disease Cohort, 
Sweden 
General 
population 
M 1985 - 2003 
(8.2 yrs) 
30-60 M 33,424 BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
CC 73 1.43 (0.62-3.02) 
RC 58 1.96 (0.96-3.86) 
F 35,362 
 
BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
CC 76 2.25 (1.25-3.98) 
RC 31 1.30 (0.42-3.45) 
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237
 MacInnis 
2006 
Melbourne 
Collaborative 
Cohort 
Study, Australia 
General 
population 
M 1990 - 2003 
(10.3 yrs) 
27-75 M 16,867 BMI, ≥30 vs <25 
kg/m
2
 
RC 134 1.3 (0.8-2.4) 
WC, ≥102 vs <94 
cm 
RC 134 1.4 (0.9-2.2) 
WHR, ≥0.95 vs 
<0.90 
RC 134 1.2 (0.8-1.8) 
F 24,247 BMI, ≥30 vs <25 
kg/m
2
 
RC 95 1.1 (0.7-1.9) 
WC, ≥88 vs <80 
cm 
RC 95 1.4 (0.8-2.2) 
WHR, ≥0.80 vs 
<0.75 
RC 95 1.4 (0.8-2.4) 
             
172
 MacInnis 
2006 
Melbourne 
Collaborative 
Cohort 
Study, Australia 
General 
population 
M 1990 - 2003 
(10.4 yrs) 
27-75 F 24,072 BMI, ≥30 vs <25 
kg/m
2
 
CC 212 1.0 (0.7–1.4) 
WC, ≥88 vs <80 
cm 
CC 212 1.4 (1.0–1.9) 
WHR, ≥0.80 vs 
<0.75 
CC  212 1.7 (1.1–2.4) 
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47
 Pischon 
2006 
European 
Prospective 
Investigation 
into Cancer and 
Nutrition (EPIC), 
Europe 
General 
population 
M 1992 - 2004 
(6.1 yrs) 
25-70 M 129,731 BMI, ≥29.4 vs 
<23.6 kg/m
2
 
CC 421 1.55 (1.12-2.15) 
RC 295 1.05 (0.72-1.55) 
WC, ≥103.0 vs 
<86.0 cm 
CC 421 1.39 (1.01-1.93) 
RC 295 1.27 (0.84-1.91) 
WHR, ≥0.990 vs 
<0.887 
CC 421 1.51 (1.06-2.15) 
RC 295 1.93 (1.19-3.13) 
F 238,546 BMI, ≥28.9 vs 
<21.7 kg/m
2
 
CC 563 1.06 (0.79-1.42) 
RC 291 1.06 (0.71-1.58) 
WC, ≥89.0 vs 
<70.2 cm 
CC 563 1.48 (1.08-2.03) 
RC 291 1.23 (0.81-1.86) 
WHR, ≥0.846 vs 
<0.734 
CC 563 1.52 (1.12-2.05) 
RC 291 1.20 (0.81-1.79) 
             
171
 Samanic 
2006 
Swedish 
Foundation for 
Occupational 
Safety and 
Health of the 
Construction 
Industry, Sweden 
Constructio
n workers 
M 1971 - 1999 
(19 yrs) 
18-67 M 362,552 BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
CC 1,795 1.74 (1.48-2.04) 
RC 1,362 1.36 (1.13-1.66) 
             
142
 Yeh 2006 Taiwan General 
population 
M 1990 - 2001 30-65 M 10,923 BMI, >28.6 vs 
<24.2 kg/m
2
 
CRC 68 1.98 (0.91-4.30) 
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238
 Engeland 
2005 
Norway General 
population 
M 1963 - 2001 
(23 yrs) 
20-74 M 962,901 BMI, ≥30 vs 
18.5–24.9 kg/m2 
CC 13,805 1.49 (1.39-1.60) 
RC 9,182 1.27 (1.16-1.38) 
F 1,037,077 BMI, ≥30 vs 
18.5–24.9 kg/m2 
CC 16,638 1.07 (1.02-1.12) 
RC 7,492 1.04 (0.97-1.11) 
             
239
 Otani 2005 Japan Public 
Health 
Center-based 
Prospective 
Study, Japan 
General 
population 
S 1990 - 2001 40-69 M 49,158 BMI, ≥30 vs <25 
kg/m
2
 
CC 424 1.4 (0.7-2.8) 
RC 202 1.6 (0.6-3.9) 
F 53,791 BMI, ≥30 vs <25 
kg/m
2
 
CC 229 0.5 (0.2-1.4) 
RC 131 1.3 (0.5-3.1) 
             
240
 Rapp 2005 Vorarlberg 
Health 
Monitoring and 
Promotion 
Program Study 
Cohort, Austria 
General 
population 
M 1985 - 2002 
(9.9 yrs) 
≥19 M 67,447 BMI, ≥35 vs 
18.5-24.9 kg/m
2
 
CC 260 2.48 (1.15-5.39) 
BMI, ≥30 vs 
18.5-24.9 kg/m
2
 
RC 138 1.66 (1.01-2.73) 
F 78,484 BMI, ≥35 vs 
18.5-24.9 kg/m
2
 
CC 271 0.88 (0.43-1.81) 
RC 133 0.96 (0.38-2.39) 
             
174
 Lin 2004 Women’s Health 
Study, USA 
Health 
professional
s 
S 1993 - 2003 
(8.7 yrs) 
≥45 F 37,671 BMI, ≥30 vs <23 
kg/m
2
 
CC 158 1.73 (1.05-2.85) 
RC 40 1.55 (0.64-3.77) 
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173
 MacInnis 
2004 
Melbourne 
Collaborative 
Cohort 
Study, Australia 
General 
population 
M 1990 - 2002 27-75 M 16,556 BMI, >29.2 vs 
24.8 kg/m
2
 
CC 153 1.7 (1.1-2.8) 
WC, >99.3 vs 
<87.0 cm 
CC 153 2.1 (1.3-3.5) 
WHR, >0.96 vs 
<0.88 
CC 153 2.1 (1.3-3.4) 
             
175
 Moore 
2004 
Framingham 
Study, USA 
General 
population 
M 1948 - 1999 30-54 M 1,684 BMI, ≥30 vs 
18.5-<25 kg/m
2
 
CC 71 2.0 (0.98-4.2) 
WC, ≥101.6 vs 
<83.8 cm 
CC 71 2.4 (0.99-5.7) 
F 2,080 BMI, ≥30 vs 
18.5-<25 kg/m
2
 
CC 86 1.3 (0.65-2.7) 
WC, ≥99.1 vs 
<81.3 cm 
CC 86 1.8 (0.78-4.3) 
55-79 M 1,661 BMI, ≥30 vs 
18.5-<25 kg/m
2
 
CC 69 3.7 (1.7-8.1) 
WC, ≥101.6 vs 
<83.8 cm 
CC 69 3.3 (1.3-8.8) 
F 2,141 BMI, ≥30 vs 
18.5-<25 kg/m
2
 
CC 70 1.9 (0.98-3.7) 
WC, ≥99.1 vs 
<81.3 cm 
CC 70 2.3 (0.86-6.3) 
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144
 Sanjoaquin 
2004 
Oxford 
Vegetarian 
Study, UK 
General 
population 
S 1980 - 1999 
(17 yrs) 
16-89 B 10,998 BMI, ≥25 vs <20 
kg/m
2
 
CRC 92 0.74 (0.36-1.53) 
             
78
 Wei 2004 Health 
Professionals 
Follow-up Study, 
USA 
Health 
professional
s 
S 1986 - 2000 
(13 yrs) 
40-75 M 46,632 BMI, ≥30 vs <23 
kg/m
2
 
CC 467 1.85 (1.26-2.72) 
RC 135 1.03 (0.49-2.14) 
Nurses’ Health 
Study, USA 
Nurses S 1980 - 2000 
(20 yrs) 
34-59 F 87,733 BMI, ≥30 vs <23 
kg/m
2
 
CC 672 1.28 (1.10-1.62) 
RC 204 1.56 (1.01-2.42) 
             
176
 Saydah 
2003 
CLUE II Cohort, 
USA 
General 
population 
S 1989 - 2000 ≥18 B 346‡ BMI, ≥30 vs <25 
kg/m
2
 
CC 132 1.79 (1.02-3.13) 
RC 41 1.64 (0.68-3.94) 
             
146
 Shimizu 
2003 
Takayama Study, 
Japan 
General 
population 
S 1993 - 2000 ≥35 M 13,392 BMI, ≥23.6 vs 
≤21.2 kg/m2 
CC 104 2.11 (1.26–3.53) 
RC 58 0.83 (0.42–1.64) 
F 15,659 BMI, ≥23.1 vs 
≤21.6 kg/m2 
CC 89 1.22 (0.69–2.15) 
RC 41 0.83 (0.35–1.99) 
             
177
 Terry 2002 National Breast 
Screening Study, 
Canada 
General 
population 
S 1980 - 1993 
(10.6 yrs) 
40-59 F 89, 835 BMI, ≥30 vs <25 
kg/m
2
 
CC 363 0.95 (0.67–1.34) 
RC 164 1.35 (0.87–2.07) 
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241
 Nilsen 
2001 
Norway General 
population 
M 1984 - 1996 
(10.8 yrs) 
≥20 M 36,975 ≥27.2 vs ≤23.0 
kg/m
2
 
CRC 354 1.07 (0.80–1.42) 
F 38,244 ≥27.5 vs ≤21.8 
kg/m
2
 
CRC 358 0.98 (0.71–1.34) 
             
178
 Terry 2001 Sweden General 
population 
S 1987 - 1998 
(9.6 yrs) 
40-76 F 61,463 BMI, >26.7 vs 
<22.0 kg/m
2
 
CC 291 1.21 (0.86-1.70) 
RC 159 1.32 (0.83-2.08) 
             
242
 Kaaks 
2000 
New York 
University 
Women’s Health 
Study, USA 
Women 
attending 
mammograp
hy screening 
S 1985 - 1998 35-65 F 134‡ BMI, Q5 vs Q1 CC 73 3.07 (1.12-8.41) 
             
243
 Ford 1999 National Health 
and Nutrition 
Examination 
Survey, USA 
General 
population 
M 1971 - 1992 25-74 M 5,506 BMI, ≥30 vs <22 
kg/m
2
 
CC 104 2.95 (0.99-8.74) 
F 7,914 BMI, ≥30 vs <22 
kg/m
2
 
CC 118 2.74 (1.04-7.25) 
             
179
 Robsahm 
1999 
Norway Tuberculosi
s screening 
programme 
 1963 - 1989 30-69 M 532,300 BMI, Q5 vs Q1 CC 6,397 1.39 (1.39-1.50) 
RC 4,393 1.16 (1.07-1.27) 
F 590,552 BMI, Q5 vs Q1 CC 7,620 1.07 (0.99-1.15) 
RC 3,482 1.03 (0.93-1.14) 
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244
 Schoen 
1999 
Cardiovascular 
Health Study, 
USA 
General 
population 
M 1989 - 1996 
(6.4 yrs) 
≥65 B 5,849 BMI, ≥28.5/29.6 
vs <23.9/23.2 
kg/m
2
 
CRC 102 1.4 (0.8-2.5) 
WC, 
≥104.1/101.2 vs 
<91.0/82.0 cm 
CRC 102 2.2 (1.2-4.1) 
WHR, 
≥1.01/0.96 vs 
<0.83/0.83 
CRC 102 2.6 (1.4-4.8) 
             
147
 Singh 1998 Adventist Health 
Study, USA 
Seventh-day 
Adventists 
S 1976 - 1982 
(6 yrs) 
≥25 M  BMI, >25.6 vs 
<22.5 kg/m
2
 
CC 65 2.63 (1.12-6.13) 
F  BMI, >25.6 vs 
<22.5 kg/m
2
 
CC 92 1.05 (0.63-1.75) 
             
245
 Gaard 
1997 
Norway General 
population 
M 1977 - 1991 
(11.3 yrs) 
20-54 M 31,507 BMI, ≥26.6 vs 
<21.7 kg/m
2 
CC 103 1.64 (0.92-2.92) 
RC 54 1.61 (0.76-3.44) 
F 30,666 BMI, ≥27.1 vs 
<23.0 kg/m
2
 
CC 83 1.02 (0.53-1.97) 
RC 52 0.64 (0.31-1.33) 
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180
 Martinez 
1997 
Nurses’ Health 
Study, USA 
Nurses S 1980 - 1992 
(12 yrs) 
34-59 F 89,488 BMI, ≥29 vs <21 
kg/m
2
 
CC 393 1.45 (1.02-2.07) 
WC, ≥86.4 vs 
<69.9 cm 
CC 161 1.48 (0.89-2.46) 
WHR, ≥0.83 vs 
<0.73 
CC 161 1.48 (0.88-2.49) 
             
246
 Tulinius 
1997 
Cardiovascular 
Risk Factor 
Study, Iceland 
General 
population 
M 1968-1995 33-60 M 11,366 BMI, per 1 kg/m
2 
CRC 193 1.04 (1.00-1.08) 
             
74
 Chyou 
1996 
Honolulu Heart 
Program, USA 
General 
population 
M 1965 - 1995 46-68 M 7,945 BMI, ≥25.8 vs 
<21.7 kg/m
2
 
CC 330 1.38 (1.01-1.90) 
RC 123 0.63 (0.38-1.04) 
             
247
 Thune 
1996 
Finland General 
population 
M 1972-1991 20-49 M 53,242 BMI, per 10 
kg/m
2 
CC 236 1.25 (1.01-1.53) 
RC 170 0.99 (0.60-1.63) 
F 28,274 BMI, per 10 
kg/m
2
 
CC 99 0.93 (0.57-1.52) 
RC 58 0.96 (0.51-1.82) 
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248
 Giovannuc
ci 1995 
Health 
Professionals 
Follow-up Study, 
USA 
Health 
professional
s 
S 1986 - 1992 
(5 yrs) 
40-75 M 47,723 BMI, ≥29 vs <22 
kg/m
2
 
CC 203 1.48 (0.89-2.46) 
WC, ≥109 vs <89 
cm 
CC 117 2.56 (1.33-4.96) 
WHR, ≥0.99 vs 
<0.90 
CC 117 3.41 (1.52-7.66) 
             
191
 Le 
Marchand 
1992 
Hawaii General 
population 
S 1972-1986 45-69 M 52,539 BMI, Q3 vs Q1 CC 421 1.4 (1.1-1.8) 
RC 203 0.8 (0.5-1.2) 
             
192
 Lee 1992 Harvard Alumni 
Health Study, 
USA 
University 
alumni 
S 1962 -1988  M 17,595 BMI, ≥26.0 vs 
<22.5 kg/m
2 
CC 290 1.52 (1.06-2.17) 
             
75
 Klatsky 
1988 
USA Members of 
health plan 
M 1978 - 1984  B 10,303 BMI, per 0.1 
kg/m
2
 
CC 203 1.04 (1.02-1.06) 
RC 66 1.00 (0.96-1.04) 
             
76
 Wu 1987 USA Retirement 
community 
S 1981 - 1985  M 4,141 BMI, ≥35 vs ≤31 
kg/m
2
 
CRC 58 2.40 (1.1-5.4) 
F 7,421 BMI, ≥34 vs ≤29 
kg/m
2 
CRC 68 1.19 (0.7-2.2) 
a
 S = self-reported, M = measured 
b
 M = male, F = female, B = both 
c BMI = body mass index, WC = waist circumference, WHR = waist to hip ratio 
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 CRC = colorectal cancer, CC = colon cancer, PCC = proximal colon cancer, DCC = distal colon cancer, RC = rectal cancer 
* 99% CIs 
† Case-cohort analysis 
‡ Nested case-control study 
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2.4 Smoking and Colorectal Cancer Literature Review 
 
In this section, the evidence for an association between tobacco smoking and colorectal 
cancer risk is reviewed. This association has been controversial. Many early studies did 
not find that smoking was associated with colorectal cancer risk.
249
 Recent studies have 
more consistently shown an association though the increased risk of colorectal cancer is 
fairly modest. In their 2004 monograph on tobacco smoke and the risk of cancer (based 
on the evidence available through 2002), the IARC stated that it was not possible to 
conclude that tobacco smoking is causally associated with colorectal cancer risk, mainly 
due to concerns about confounding by other risk factors.
250
 However, since that report, a 
number of prospective cohort studies have continued to support a relationship between 
smoking and colorectal cancer and, consequently, in their 2012 monograph, it was 
concluded that smoking is causally related to colorectal cancer risk.
26
 
 
Exposure to tobacco smoke is usually assessed in epidemiological studies through the 
use of questionnaires. Exposure can be defined in a number of ways. The simplest 
measure of exposure, referred to as smoking status, classifies people as never, former or 
current smokers. Other measures attempt to classify people more precisely according to 
different aspects of exposure such as smoking intensity (number of cigarettes smoked 
per day), smoking duration, pack-years of smoking or age at initiation. Time since 
cessation and age at cessation are used to try to measure how the risk differs for former 
smokers who quit smoking at different times. 
 
2.4.1 Search Strategy 
 
The IARC published reports in 2004 and 2012
26, 250
 and the U.S. Department of Health 
and Human Services (USDHHS) published reports in 2004 and 2014
29, 251
 summarising 
the evidence from prospective cohort studies for an association between smoking and 
colorectal cancer. The USDHHS searched the Medline database as well as Web of 
Science and Embase for articles published up to December 2009.
29
 Details on the 
literature search were not provided in the IARC reports though they included articles 
published in 2009.
26
 Recent meta-analyses
49, 50, 61, 226, 252
 and review articles
64
 of 
smoking and colorectal cancer risk were also searched for relevant articles. 
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To complement the articles identified by these reports and meta-analyses, PubMed was 
searched for articles reporting human studies, written in English, and published between 
1
st
 January 2008 and 31
st
 March 2015, using the MeSH terms “Colorectal Neoplasms” 
and at least one of “Tobacco Use”, “Tobacco” or “Smoking Cessation”. 350 articles 
were retrieved. 
 
Articles were selected for inclusion in this review if they (i) were based on prospective 
cohort studies (including nested case-control studies), (ii) analysed smoking status 
(separating current and former smokers), smoking duration, smoking intensity, pack-
years, age at initiation, time since cessation or age at cessation in relation to colorectal 
cancer incidence (including colorectal subsites) in the general population and (iii) 
reported risk estimates (HRs, RRs, ORs) and CIs. Analyses that reported results by 
other factors were not included. Analyses based on fewer than 30 cases were ignored. 
References of included articles were carefully examined for additional articles. 
 
This literature review excluded analyses solely focused on forms of tobacco use other 
than cigarettes (e.g. cigar or pipe smokers). However, articles generally did not provide 
detailed information on the questionnaires used and so it is not always clear how 
smokers of other forms of tobacco were defined in analyses. For example, a cigar 
smoker may be excluded from the analysis, they may be defined as a current smoker or 
they may be defined as a former smoker or never smoker based on previous cigarette 
use. 
  
Figure 2.4.1 shows a flow diagram of the literature search process, illustrating the 
number of articles identified from the different sources. Overall, 52 articles met the 
inclusion criteria for this literature review. These 52 articles were based on 38 
independent cohorts. 
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Figure 2.4.1 Flowchart of Literature Search Process for Smoking and Colorectal Cancer 
 
IARC = International Agency for Research and Cancer, USDHHS = U.S. Department of Health and 
Human Services 
 
Table 2.4.2, presented at the end of this review shows the key characteristics of the 
articles (identified in the literature search) mentioned in this review. Results are 
presented for each measure of exposure (smoking status, smoking duration, smoking 
intensity, pack-years, age at initiation, time since cessation, age at cessation) included in 
the article. Where possible, these results are presented for colorectal cancer overall and 
for men and women combined. At least one article from each cohort is included. More 
than one article from the same cohort is included if they include analyses of different 
measures of exposure. 
 
2.4.2 Smoking Status 
 
Smoking status represents the simplest form of evaluating an individuals’ smoking 
exposure; people are categorised as never, former or current smokers. Numerous 
prospective cohort studies have evaluated the relationship between smoking status and 
colorectal cancer and these studies have been summarised in meta-analyses.
49, 50, 61, 226, 
252
 Four of these meta-analyses included studies published up to 2008 and one included 
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studies published up to 2013. Though there were differences in how each meta-analysis 
was conducted, there was large agreement in results. 
 
Both former and current smokers have an increased risk of colorectal cancer. In one 
meta-analysis of 28 prospective cohort studies, the RR (95% CI) was 1.18 (1.12-1.25) 
for former smokers and 1.20 (1.10-1.30) for current smokers, compared with never 
smokers.
49
 For both former and current smokers, there was a stronger association for 
rectal cancer than for colon cancer. For former smokers, the RR (95% CI) was 1.24 
(1.11-1.37) for rectal cancer and 1.13 (1.05-1.21) for colon cancer. For current smokers, 
the RR (95% CI) was 1.36 (1.15-1.61) for rectal cancer and 1.11 (1.02-1.21) for colon 
cancer. 
 
There was also evidence for a difference in results between men and women. Male 
current smokers had an increased risk of colorectal cancer (RR, 1.38; 95% CI, 1.22-
1.56) but there was no evidence of an increased risk for female current smokers (RR, 
1.06; 95% CI, 0.95-1.18).
49
 The risk of colorectal cancer was similar for male (RR, 
1.23; 95% CI, 1.09-1.40) and female (RR, 1.18; 95% CI, 1.08-1.28) former smokers. 
 
Table 2.4.1 Results from Meta-analysis of Smoking and Colon and Rectal Cancer by 
Cheng et al.
50
 
 Colon cancer Rectal cancer 
 Former smokers Current smokers Former smokers Current smokers 
 n RR (95% CI) n RR (95% CI) n RR (95% CI) n RR (95% CI) 
Overall 21 1.16 (1.11-1.22) 23 1.09 (1.01-1.18) 19 1.20 (1.11-1.30) 20 1.24 (1.16-1.39) 
Men 7 1.18 (1.05-1.33) 8 1.09 (0.92-1.30) 7 1.23 (1.01-1.48) 8 1.36 (1.08-1.71) 
Women 7 1.19 (1.09-1.30) 8 1.08 (0.97-1.21) 7 1.27 (1.05-1.52) 8 1.16 (0.97-1.40) 
n = number of studies. 
 
The most recent meta-analysis, by Cheng et al., included the most detailed results, 
presenting estimates separately according to colorectal subsite and sex (see Table 
2.4.1).
50
 While there was a similar risk of colon and rectal cancer for former smokers, 
current smokers had a lower risk of colon cancer than rectal cancer. Male current 
smokers had a greater risk of rectal cancer than female current smokers but the risk was 
similar for men and women across the other analyses. 
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Although it seems clear that smoking is a risk factor for colorectal cancer, individual 
studies find conflicting results for former and current smokers, men and women and 
colorectal subsites. For example, the EPIC study followed over 450,000 men and 
women from ten European countries over an average of nine years, during which 2,741 
subjects were diagnosed with colorectal cancer.
253
 In the EPIC study, the evidence for 
an association between cigarette smoking was stronger for colon cancer than rectal 
cancer and stronger for former smokers than current smokers. For colon cancer, the HR 
(95% CI) was 1.21 (1.08-1.36) for former smokers and 1.13 (0.98-1.31) for current 
smokers. For rectal cancer, the HR (95% CI) was 1.10 (0.94-1.30) for former smokers 
and 0.98 (0.80-1.19) for current smokers. 
 
The Cancer Prevention Study II Nutrition Cohort included 51,365 men and 73,386 
women aged 50-74 recruited in 1992.
254
 1,962 cases of colorectal cancer were identified 
during follow-up to 2005. The risk of colorectal cancer was similar for former and 
current smokers and for men and women. For men, the HR (95% CI) was 1.26 (1.09-
1.45) for former smokers and 1.24 (0.96-1.59) for current smokers. For women, the HR 
(95% CI) was 1.19 (1.04-1.37) for former smokers and 1.30 (1.01-1.68) for current 
smokers. Analysing colon and rectal cancer separately (for men and women overall), the 
association for former smokers was similar for colon cancer (HR, 1.19; 95% CI, 1.06-
1.34) and rectal cancer (HR, 1.26; 95% CI, 1.02-1.55) whereas the association for 
current smokers was stronger for colon cancer (HR, 1.28; 95% CI, 1.04-1.57) than for 
rectal cancer (HR, 0.97; 95% CI, 0.63-1.47). 
 
In contrast, in the Singapore Chinese Health Study, former (HR, 1.45; 95% CI, 1.04-
2.01) and current smokers (HR, 1.63; 95% CI, 1.23-2.17) both had an increased risk of 
rectal cancer but there was no increased risk of colon cancer for former smokers (HR, 
0.96; 95% CI, 0.73-1.27) or current smokers (HR, 0.83; 95% CI, 0.64-1.06).
77
 
 
Parajuli et al. analysed data for 600,000 Norwegian men and women recruited from four 
different health surveys.
255, 256
 Range of follow-up was 4-33 years across the four 
surveys. 3,998 cases of colon cancer and 2,176 cases of rectal cancer were identified 
during follow-up. There was an increased risk of colon cancer for both female former 
smokers (HR, 1.16; 95% CI, 1.02-1.31) and current smokers (HR, 1.22; 95% CI, 1.10-
1.36).
255, 256
 In contrast, there was an increased risk of colon cancer for male former 
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smokers (HR, 1.14; 95% CI, 1.02-1.27) but not current smokers (HR, 1.03; 95% CI, 
0.92-1.15). For rectal cancer, results were very similar for female former (HR, 1.26; 
95% CI, 1.05-1.52) and current smokers (HR, 1.29; 95% CI, 1.10-1.51) and male 
former (HR, 1.28; 95% CI, 1.11-1.50) and current smokers (HR, 1.26; 95% CI, 1.09-
1.45). 
 
The Women’s Health Initiative identified 1,242 cases of colorectal cancer during an 
average of eight years follow-up.
257
 Current smokers had an increased risk of rectal 
cancer (HR, 1.95; 95% CI, 1.10-3.47) but not colon cancer (HR, 1.03; 95% CI, 0.77-
1.38). For former smokers, there was no clear evidence of an increased risk for colon 
(HR, 1.12; 95% CI, 0.97-1.29) or rectal cancer (HR, 1.15; 95% CI, 0.80-1.67). In a 
study of female teachers (California Teachers Study), 1,205 cases of colorectal cancer 
were diagnosed during follow-up between 1995 and 2009.
258
 There was some evidence 
that current smokers had an increased risk of colon (HR, 1.25; 95% CI, 0.94-1.66) and 
rectal cancer (HR, 1.36; 95% CI, 0.85-2.20) though the CIs were wide due to a small 
number of cases among current smokers. Former smokers seemed to have a lower risk 
of colon (HR, 1.10; 95% CI, 0.95-1.26) and rectal cancer (HR, 1.10; 95% CI, 0.86-1.42) 
than current smokers. 
  
Proximal Colon Cancer and Distal Colon Cancer 
  
Most studies that have investigated colon subsites separately support a stronger 
association for proximal colon cancer than for distal colon cancer.
253, 255, 259, 260
 For 
example, in the EPIC study, the HRs (95% CIs) for proximal colon cancer were 1.25 
(1.04-1.50) for former smokers and 1.31 (1.06-1.64) for current smokers and the HRs 
(95% CIs) for distal colon cancer were 1.13 (0.95-1.36) for former smokers and 0.91 
(0.73-1.14) for current smokers.
253
 Parajuli et al. also found that female former and 
current smokers had a greater risk of proximal colon cancer (HR, 1.22; 95% CI, 1.02-
1.45 for former smokers and HR, 1.37; 95% CI, 1.18-1.59 for current smokers) than 
distal colon cancer (HR, 1.15; 95% CI, 0.94-1.41 for former smokers and HR, 1.12; 
95% CI, 0.93-1.34 for current smokers) though results were less clear for men.
255
 
However, in the cohort of female teachers, there seemed to be an increased risk of distal 
colon cancer for former smokers (HR, 1.19; 95% CI, 0.92-1.55) and current smokers 
(HR, 1.56; 95% CI, 0.95-2.54) but evidence was weaker for proximal colon cancer (HR, 
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1.06; 95% CI, 0.90-1.25 for former smokers and HR, 1.14; 95% CI, 0.80-1.61 for 
current smokers).
258
 
 
In the most recent meta-analysis, the RRs and 95% CIs for former smokers were 1.30 
(1.15-1.48) for proximal colon cancer and 1.14 (0.97-1.33) for distal colon cancer. For 
current smokers, the results were 1.31 (1.13-1.52) for proximal colon cancer and 0.98 
(0.84-1.14) for distal colon cancer.
50
 These estimates were based on results from four 
studies. 
 
Risk for Former Smokers and Current Smokers 
 
As mentioned above, meta-analysis results find a similar risk of colorectal cancer for 
former smokers and current smokers.
49, 61, 226, 252
 Figure 2.4.2 illustrates the pattern of 
results for colorectal cancer risk for former and current smokers from different cohorts. 
Only cohorts which included results for both former and current smokers were included. 
 
The reason why former smokers have an elevated risk of colorectal cancer similar to 
that of current smokers remains unclear. It could be that former smokers have a greater 
lifetime exposure on average than current smokers at baseline. However, on average, 
former smokers will have a shorter duration of smoking than current smokers. Also, 
prospective studies have shown that people who smoke fewer cigarettes are more likely 
to quit smoking.
261-266
 Thus, it seems clear that current smokers will generally have had 
a greater exposure to tobacco smoke than former smokers. 
 
Confounding must always be considered in observational studies. Based on baseline 
data, studies find that, on average, compared to current smokers, former smokers are 
more likely to have a higher socioeconomic status, to complete more physical activity, 
to eat less red and processed meat and to attend bowel screening. Former smokers, 
however, tend to have a higher BMI than current smokers. Since BMI is associated with 
colorectal cancer risk,
56
 it is possible that the association between former smokers and 
colorectal cancer is confounded by BMI. However, many prospective cohort studies 
have adjusted for BMI and meta-analyses found no clear difference in results between 
studies that did and did not adjust for BMI.
49, 50
 Thus, it seems unlikely that the risk of 
colorectal cancer among former smokers is due to confounding by other risk factors. 
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Figure 2.4.2 Results from Prospective Cohort Studies for the Association between 
Smoking Status and Colorectal Cancer Risk 
 
Results show the comparison between current smokers or former smokers and never smokers from 
prospective cohort studies. Squares represent HRs/RRs. Bars represent 95% CIs. Black squares represent 
results for current smokers and white squares represent results for former smokers. 
 
Alternatively, the similar risks observed for former and current smokers may reflect that 
tobacco smoke promotes early colorectal carcinogenesis but has less influence on later 
stages of tumour progression, meaning that the effect of smoking persists for many 
years, even after cessation. However, current smokers would still be expected to have a 
higher risk on average since many former smokers will have a short duration of 
exposure and would not be expected to have an increased risk. 
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Other Factors Affecting the Association between Smoking and Colorectal Cancer 
 
It is also unclear why studies find rather conflicting results, for example why some 
studies find an increased risk for both former smokers and current smokers whereas 
others find an increased risk only for former smokers or a higher risk for former 
smokers. The meta-analysis by Cheng et al. did find some evidence that results may be 
affected by certain study characteristics.
50
 For example, smoking was more strongly 
associated with colon and rectal cancer among studies with fewer than 500 cases 
compared with studies with more than 500 cases. This may indicate publication bias 
though the authors reported no evidence of publication bias based on Begg’s test. There 
was also a difference in results for current smokers according to study quality score. 
The RRs (95% CIs) for the highest and lowest quality studies were 1.15 (1.05-1.27) and 
1.00 (0.89-1.12) for colon cancer and 1.34 (1.15-1.55) and 1.10 (0.97-1.25) for rectal 
cancer. However, this quality score was not described in detail and another meta-
analysis did not find different results according to study quality.
49
 There were no 
important differences in results between studies that did or did not adjust for alcohol 
intake, BMI, physical activity or family history of colorectal cancer.
49, 50
 
 
Interestingly, meta-analyses found some evidence that results for current smokers may 
depend on length of follow-up. One meta-analysis found RRs and 95% CIs of 1.08 
(0.95-1.22), 1.17 (1.08-1.29) and 1.23 (1.07-1.41) for studies with follow-up <10, 10-
<25 and ≥25 years.61 Similarly, Cheng et al. found that current smokers had a greater 
risk of colon and rectal cancer in studies with ≥10 years of follow-up than in studies 
with <10 years follow-up
50
 (although another meta-analysis did not find a difference in 
results for current smokers between studies with <12 and ≥12 years of follow-up).49 
 
That the risk of colorectal cancer among current smokers would increase with longer 
follow-up seems rather puzzling. It could be because smoking duration among current 
smokers will increase with increasing follow-up as participants age. However, this 
should not affect results since all studies adjust for age. It must also be mentioned that if 
the HR does increase with increasing follow-up, this would violate the assumptions 
required for Cox proportional hazards models.
267
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As follow-up increases, more current smokers will quit smoking and become former 
smokers. This would seem to predict a lower risk for current smokers with increasing 
follow-up. However, the higher risk could be related to weight gain among former 
smokers. Smokers tend to have a lower BMI than non-smokers and smoking cessation 
is associated with weight gain.
227, 268
 Since BMI is a major risk factor for colorectal 
cancer,
56, 157
 weight gain among former smokers may explain why the risk of colorectal 
cancer among baseline current smokers increases as more baseline current smokers quit 
smoking. However, this is not entirely clear since excess adiposity is thought to increase 
colorectal cancer risk as a result of increasing insulin resistance.
157, 185
 Although 
smoking is associated with lower BMI, smoking is also associated with insulin 
resistance. Consequently, although former smokers tend to gain weight, smoking 
cessation may actually improve insulin sensitivity.
227, 268
 
 
Another possibility is that duration of follow-up serves as a proxy for induction period. 
Giovannucci et al. hypothesised that smoking acts as an initiator of colorectal 
carcinogenesis and that an induction period of 35-40 years is required to observe an 
increased risk of colorectal cancer.
269-271
 This hypothesis was based on the fact that 
early studies of smoking and colorectal cancer did not find evidence of an association 
yet studies consistently found a strong association between cigarette smoking and 
colorectal adenomas (recognised as precursor lesions for colorectal cancer). Given that 
colorectal cancer develops over a number of decades, studies may have failed to find 
evidence for an association with colorectal cancer because they did not take into 
account this long induction period. 
 
Support for this hypothesis was provided by analyses of the Health Professionals 
Follow-up Study and the Nurses’ Health Study.269, 270 For example, men in the Health 
Professionals Follow-up Study reported the average number of cigarettes smoked at 
different ages (≤14, 15-19, 20-29, etc.).269 Total pack-years of smoking up to baseline 
was associated with an increased risk of colorectal adenoma (RR, 1.67; 95% CI, 1.25-
2.22 for ≥40 vs 0 pack-years) as well as colorectal cancer (HR, 1.45; 95% CI, 1.01-2.09 
for ≥40 vs 0 pack-years). Pack-years of smoking before age 30 was associated with the 
risk of large adenomas (≥1 cm) (RR, 2.47; 95% CI, 1.48-4.11 for ≥16 vs 0 pack-years) 
and colorectal cancer (HR, 1.66; 95% CI, 1.15-2.40 for ≥16 vs 0 pack-years) but not 
small adenomas (<1 cm) (RR, 1.19; 95% CI, 0.75-1.88 for ≥16 vs 0 pack-years). After 
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adjusting for pack-years of smoking after age 30, the association with large adenomas 
became slightly weaker (RR, 2.25; 95% CI, 1.20-4.21) whereas the association with 
colorectal cancer became stronger (HR, 2.02; 95% CI, 1.27-3.23). In contrast however, 
after adjusting for pack-years before age 30, there was only evidence of an association 
for pack-years of smoking after age 30 with small adenomas. 
 
Summary 
 
Tobacco smoking is associated with colorectal cancer. The association is similar for 
men and women and for colon and rectal cancer. The association may be stronger for 
proximal colon cancer than distal colon cancer. Former smokers have a similar risk of 
colorectal cancer to current smokers, possibly indicating an effect of smoking on early 
colorectal carcinogenesis. 
 
2.4.3 Smoking Duration 
 
Smoking status offers a very narrow picture of a person’s smoking history. If tobacco 
smoke increases the risk of colorectal cancer, it would be expected that a greater 
exposure to tobacco smoke is associated with a greater risk. One measure of tobacco 
smoke exposure is duration of smoking. Many studies have investigated the relationship 
between smoking duration and colorectal cancer risk and most find evidence that a 
longer duration is associated with a greater risk. 
 
In the Iowa Women’s Health Study, the HRs and 95% CIs for the risk of colorectal 
cancer for smoking duration 1-19, 20-39 and ≥40 years, compared to never smokers, 
were 1.17 (0.94-1.46), 1.05 (0.88-1.24) and 1.40 (1.17-1.68).
272
 In the California 
Teachers Study, there was only evidence of an increased risk of colorectal cancer for 
smokers with duration ≥40 years (HR, 1.27; 95% CI, 1.03-1.57).258 There was evidence 
for an increased risk of colorectal cancer associated with smoking more than 20 years in 
the Women’s Health Initiative though people who smoked for 20-29 years (HR, 1.36; 
95% CI, 1.12-1.66) had a higher risk than people who smoked for 30-39 or ≥40 years.257 
 
Parajuli et al. found that smoking duration was associated with colon and rectal cancer 
risk for both men and women.
255, 256
 Dose-response relationships were evident for each 
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analysis. There seemed to be an increased risk of cancer across all categories of 
smoking duration i.e. including for 1-19 years, except for the risk of colon cancer 
among men where there was an increased risk only for ≥40 years duration. 
 
Cheng et al. found that the risk of colon cancer increased by 2, 5 and 10% with an 
increase of 10, 20 and 40 years of smoking. The corresponding increases in risk for 
rectal cancer were 6, 13 and 24%.
50
 In another meta-analysis including prospective and 
retrospective studies, smoking duration was modelled as a continuous variable. The risk 
of colorectal cancer did not begin to increase until after approximately 10 years of 
smoking and reached statistical significance only after 30 years of smoking.
226
 
 
One issue with the analyses of smoking duration is that most studies consider ever 
smokers overall (i.e. former and current smokers combined) and do not analyse the 
effect of smoking duration on colorectal cancer risk separately for former smokers and 
current smokers. This may lead to rather misleading results; although some former and 
current smokers may have a similar duration of smoking up to baseline, it is plausible 
that they experience different risks of cancer since current smokers continue to add to 
their exposure during follow-up. 
 
Smoking duration was analysed separately for former and current smokers in the EPIC 
study.
253
 For former smokers, smoking less than 20 years was not associated with 
colorectal cancer risk whereas smoking 20-29 years (HR, 1.27; 95% CI, 1.10-1.47) and 
≥30 years (HR, 1.24; 95% CI, 1.07-1.44) was associated with colorectal cancer risk. 
The association between smoking duration and colorectal cancer risk was less clear for 
current smokers. There was evidence for an increased risk for 30-39 years (HR, 1.19; 
95% CI, 1.00-1.41) but not for ≥40 years (HR, 0.94; 95% CI, 0.78-1.14). 
 
In the Singapore Chinese Health Study, smoking duration was analysed separately for 
former and current smokers for rectal cancer only (there was no evidence for an 
association with colon cancer for smoking status or smoking duration).
77
 For former 
smokers, there was no increased risk of rectal cancer for duration <40 years (HR, 1.15; 
95% CI, 0.78-1.69) but there was an increased risk for former smokers with duration 
≥40 years (HR, 1.93; 95% CI, 1.20-3.09). In contrast, there was an increased risk for 
current smokers with <40 years (HR, 1.58; 95% CI, 1.09-2.29) and ≥40 years duration 
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(HR, 1.78; 95% CI, 1.27-2.50). In the Cancer Prevention Study II Nutrition Cohort, 
current smokers with 40-49 (HR, 1.32; 95% CI, 1.02-1.72) and ≥50 years duration (HR, 
1.38; 95% CI, 1.04-1.84) had an increased risk of colorectal cancer whereas there was 
no evidence of an increased risk for current smokers with <40 years duration (HR, 1.02; 
95% CI, 0.69-1.49).
254
 
 
Another potential issue when analysing smoking duration is that smokers with longer 
duration may tend to have been heavier smokers. Earlier age at onset of smoking is 
associated with nicotine dependence and heavier smoking.
273-275
 Therefore, it is possible 
that part of the increased risk for longer duration may be due to heavier smoking 
intensity. 
 
Results for smoking duration were adjusted for smoking intensity in a pooled analysis 
by Gong et al.
260
 Data were pooled from five cohort studies (including the Women’s 
Health Initiative) and three case-control studies. The analysis included a total of 6,796 
cases of colorectal cancer and 7,770 controls. Adjusting for smoking intensity (never 
smoker, <20, 20, >20 cigarettes/day), there was no evidence of an increased risk of 
colorectal cancer for ever smokers with a smoking duration <20 years whereas there 
was an increased risk for ever smokers with at least 20 years duration. The ORs (95% 
CIs) for <10, 10-20, 20-30, 30-40 and ≥40 years were 0.94 (0.78-1.13), 1.07 (0.93-
1.24), 1.29 (1.11-1.50), 1.29 (1.12-1.48) and 1.28 (1.10-1.49). 
 
Summary 
 
Smoking duration is associated with colorectal cancer risk. Studies should analyse 
smoking duration separately for former smokers and current smokers. 
 
2.4.4 Smoking Intensity 
 
Similar to smoking duration, most prospective cohort studies support a dose-response 
relationship between the number of cigarettes smoked per day and colorectal cancer 
risk. 
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The risk of colorectal cancer was associated with the number of cigarettes per day in the 
Iowa Women’s Health Study. The HRs and 95% CIs for 1-19, 20 and >20 cigarettes per 
day were 1.10 (0.94-1.29), 1.28 (1.06-1.55) and 1.32 (1.04-1.69).
272
 Parajuli et al. found 
that smoking intensity was associated with colon and rectal cancer risk for both men 
and women. The HRs and 95% CIs associated with smoking at least 20 cigarettes per 
day were 1.16 (0.97-1.28) and 1.31 (1.11-1.55) for colon and rectal cancer for men and 
1.28 (1.06-1.55) and 1.38 (1.05-1.81) for colon and rectal cancer for women.
255, 256
 In 
the Women’s Health Initiative, smoking at least 25 cigarettes per day was associated 
with a HR of 1.41 (95% CI, 1.14-1.76).
257
 
 
Similar to smoking duration, most studies analyse the association between smoking 
intensity and colorectal cancer for ever smokers. In the EPIC study, average number of 
cigarettes/day was associated with colorectal cancer risk for former smokers.
253
 The 
HRs and 95% CIs for ≤9, 10-14 and ≥15 cigarettes/day were 1.08 (0.92-1.26), 1.18 
(0.98-1.42) and 1.26 (1.08-1.47). Current smokers who smoked ≥20 cigarettes/day at 
baseline also had an increased risk of colorectal cancer (HR, 1.15; 95% CI, 0.98-1.36). 
 
Adjusting for smoking duration, Gong et al. found very similar increased risks of 
colorectal cancer for ever smokers who smoked <20, 20 and >20 cigarettes/day.
260
 The 
ORs and 95% CIs were 1.28 (1.11-1.48), 1.30 (1.09-1.55) and 1.31 (1.01-1.70). 
 
Studies have not investigated the risk of colorectal cancer according to duration and 
intensity together. For example, the risk of smoking 20 cigarettes a day will likely be 
different for someone who smoked for 10 years and someone who smoked for 40 years. 
Similarly, the risk of smoking 40 years may be different for someone who smokes 5 
cigarettes a day and someone who smokes 30 cigarettes a day. Further studies should 
categorise people by both duration and intensity. 
 
Summary 
 
Greater number of cigarettes per day is associated with a greater risk of colorectal 
cancer. More studies need to investigate the effects of duration and intensity together. 
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2.4.5 Pack-years 
 
Both smoking duration and smoking intensity are associated with colorectal cancer risk. 
Pack-years are defined as the duration of smoking multiplied by the number of 
cigarettes smoked per day divided by 20. Thus, pack-years combine smoking duration 
and intensity to provide a single measure of cumulative exposure. 
 
Pack-years were associated with colorectal cancer risk in the Iowa Women’s Health 
Study though there was only clear evidence for an increased risk for at least 40 pack-
years (HR, 1.39; 95% CI, 1.14-1.70).
272
 In the California Teachers Study, there was 
slight evidence for an increased risk of colorectal cancer for 21-30 pack-years (HR, 
1.19; 95% CI, 0.91-1.56) and stronger evidence for ≥31 pack-years (HR, 1.37; 95% CI, 
1.12-1.67).
258
 
 
Parajuli et al. found that pack-years of smoking was associated with colon cancer risk 
for men and women though the association was slightly weaker for men (HR, 1.14; 95% 
CI, 0.99-1.31 for ≥20 pack-years) than for women (HR, 1.33; 95% CI, 1.11-1.57 for ≥20 
pack-years).
255
 Pack-years of smoking was also associated with rectal cancer risk for 
both men (HR, 1.35; 95% CI, 1.14-1.58) and women (HR, 1.47; 95% CI, 1.13-1.91).
256
 
 
Thus, increasing pack-years appear to be associated with increasing risk of colorectal 
cancer, which is also supported by meta-analysis results.
49, 50, 226, 252
 However, the use of 
pack-years to represent smoking exposure has received much criticism.
276-278
 The main 
issue with pack-years is that it equates duration and intensity; for example, smoking 10 
cigarettes per day for 20 years and smoking 20 cigarettes for 10 years are both equal to 
10 pack-years. Thus, the use of pack-years assumes that both components are related to 
risk in the same way. 
 
Another issue with pack-years is that most studies only ask for very limited information 
about the number of cigarettes smoked. Most studies only ask current smokers to report 
the number of cigarettes they smoke at baseline. Calculating pack-years based on 
baseline smoking assumes that current smokers have smoked the same amount of 
cigarettes throughout the entire duration of their smoking. Former smokers are generally 
asked to report their average number of cigarettes which in theory should be sufficient 
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to provide an accurate measure of pack-years but it is not clear how accurately people 
are able to provide such information. 
 
Summary 
 
Pack-years are associated with colorectal cancer risk. Pack-years of smoking may not be 
a suitable measure of smoking exposure since it assumes that the effects of duration and 
intensity are the same. 
 
2.4.6 Age at initiation 
 
Another aspect of smoking exposure is age at initiation. People who start smoking at an 
earlier age, on average, will have a greater level of exposure than people who start 
smoking later in life. Studies do find an association between age at initiation and 
colorectal cancer risk though the evidence is not as consistent as for duration. The main 
difficulty when analysing age at initiation is that the large majority of smokers begin 
smoking during a very narrow age range. 
 
People who began smoking before age 15 had an increased risk of colorectal cancer 
(HR, 1.32; 95% CI, 1.02-1.71) compared to never smokers in the Singapore Chinese 
Health Study but there was no evidence of an increased risk after age 15 (HR, 1.07; 
95% CI, 0.90-1.27).
77
 Parajuli et al. found evidence that women who began smoking 
≤16, 17-19, 20-24 and ≥25 all had an increased risk of colon cancer though the risk was 
greatest for ≤16 (HR, 1.48; 95% CI, 1.21-1.81). The evidence was weaker for men; the 
HR (95% CI) for the risk of colon cancer for men who began smoking ≤16 was 1.15 
(0.99-1.34).
255
 For rectal cancer, both men and women who began smoking ≤19, 20-24 
and ≥25 had an increased risk. However, the risk was greatest for 20-24 for both men 
(HR, 1.35; 95% CI, 1.13-1.61) and women (HR, 1.45; 95% CI, 1.18-1.78).
256
 
 
In the EPIC study, there seemed to be an increased risk for each category of age at 
initiation for former smokers, though the greatest risk was for former smokers who 
started between ages 17-19; the HRs (95% CIs) for ≤16, 17-19 and ≥20 compared to 
never smokers were 1.12 (0.96-1.31), 1.24 (1.09-1.41) and 1.13 (0.99-1.30).
253
 The risk 
of colorectal cancer was similar for women who started before 20 (HR, 1.14; 95% CI, 
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0.97-1.33) and women who started after 20 (HR, 1.12; 95% CI, 0.95-1.31) in the 
Women’s Health Initiative.257 
 
Since the large majority of smokers begin smoking during a very narrow age range, age 
at initiation and smoking duration are very highly correlated. Hence, it is not clear 
whether age at initiation is associated with colorectal cancer risk independent of 
smoking duration since studies are unable to separate the effects of age at initiation on 
colorectal cancer risk from the effects of duration. Furthermore, it is unknown in 
general how the timing of smoking exposure may affect the risk of cancer. For example, 
does a 50 year old who starts smoking have the same risk as a 50 year old lifelong 
smoker? Hence, the effects of timing versus duration remains an important question for 
studies of smoking. 
 
One possible issue with age at initiation, besides problems with recall, is differentiating 
between starting smoking and starting smoking regularly. For example, a person may 
try their first cigarette many years before taking up smoking as a regular habit. So, 
although someone begins smoking at a very early age, they might not experience a 
greater risk because they only smoked very occasionally for a number of years. This 
will affect analyses of age at initiation as well as duration. 
 
As described in section 2.4.3, people who take up smoking at an earlier age are more 
likely to be heavy smokers and to be nicotine dependent.
273-275
 Therefore, people who 
start smoking later may have a lower risk of colorectal cancer because they are less 
dependent and tend to smoke fewer cigarettes than people who started earlier. 
 
Summary 
 
Earlier age at initiation of smoking is associated with a greater risk of colorectal cancer. 
People who start smoking earlier will generally have a longer duration of smoking and 
so the effect of age at initiation on colorectal cancer independent of smoking duration is 
not known. 
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2.4.7 Smoking Cessation 
 
The risk of colorectal cancer is similar for former and current smokers, suggesting that 
the adverse effects of smoking may persist for many years after smoking cessation. A 
number of studies have investigated how the risk of colorectal cancer differs with 
cessation at different times by analysing time since cessation and age at cessation. 
 
Time since cessation was associated with colorectal cancer risk in the Cancer 
Prevention Study II Nutrition Cohort though there was no increased risk of colorectal 
cancer for former smokers who quit at least 31 years ago.
254
 Compared to never 
smokers, the HRs and 95% CIs for former smokers who quit ≥31, 21-30, 11-20 and 1-
10 years before baseline were 1.03 (0.89-1.19), 1.28 (1.10-1.49), 1.33 (1.14-1.55) and 
1.48 (1.27-1.73). In a cohort of female teachers, smoking cessation less than 5 years ago 
was associated with an increased risk of colorectal cancer (HR, 1.44; 95% CI, 1.03-
2.01) whereas former smokers who quit at least 20 years ago did not have an increased 
risk (HR, 0.98; 95% CI, 0.83-1.14).
258
 Former smokers who quit smoking less than 20 
years ago had an increased risk of colorectal cancer in the EPIC study though the 
highest risk was actually observed for former smokers who quit 15-19 years ago (HR, 
1.34; 95% CI, 1.12-1.60).
253
 There was no clear evidence of an increased risk for former 
smokers who quit 20-24 (HR, 1.11; 95% CI, 0.91-1.35) and ≥25 years ago (HR, 1.08; 
95% CI, 0.92-1.26). 
   
Gong et al. found evidence for an increased risk of colorectal cancer for the most recent 
quitters, adjusting for pack-years of smoking.
260
 Former smokers who quit within the 
last 15 years had the highest risk of cancer (OR, 1.47; 95% CI, 1.21-1.78) compared 
with never smokers. The risk was similar to never smokers after 25-35 (OR, 1.15; 95% 
CI, 0.85-1.55) and ≥35 years since cessation (OR, 0.74; 95% CI, 0.47-1.18). 
 
Given that former smokers overall have a similar risk of colorectal cancer to current 
smokers and that time since cessation is associated with colorectal cancer risk, it is to be 
expected that the most recent quitters have a higher risk than current smokers. However, 
this result still seems surprising since recent quitters and current smokers will have a 
similar level of exposure up to baseline. One possible explanation for the higher risk 
among the most recent quitters could relate to overall health status. Former smokers 
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may quit smoking as a result of ill health whereas the fact that current smokers continue 
to smoke may be a signal of satisfactory health. 
 
Only a few studies have investigated age at cessation though they seem to agree that 
former smokers who quit smoking before age 40 are not at an increased risk of 
colorectal cancer compared to never smokers. People who quit smoking after 40 have an 
increased risk though it is not clear whether the risk increases with increasing age at 
cessation. For example, in the Cancer Prevention Study II Nutrition Cohort, HRs and 
95% CIs for quitting smoking <40, 40-49, 50-59 and ≥60 years old were 1.05 (0.91-
1.22), 1.31 (1.13-1.52), 1.44 (1.24-1.66) and 1.29 (1.08-1.54).
254
 Similarly, in the 
Women’s Health Initiative, women who quit smoking <30 (HR, 0.94; 95% CI, 0.74-
1.23) and 30-39 years old (HR, 0.86; 95% CI, 0.67-1.11) did not have an increased risk 
of colorectal whereas women who quit smoking 40-49 (HR, 1.26; 95% CI, 1.02-1.56) 
and ≥50 years old (HR, 1.28; 95% CI, 1.07-1.55) did have an increased risk.257 In the 
pooled analysis by Gong et al. (which included the Women’s Health Initiative), the ORs 
and 95% CIs for smokers who quit smoking <40, 40-50 and ≥50 years old were 1.03 
(0.79-1.34), 1.28 (0.96-1.70) and 1.31 (1.01-1.70).
260
 
 
The main difficulty when investigating smoking cessation and colorectal cancer risk is 
that the large majority of smokers begin smoking during a narrow age range. This 
means that the former smokers with the longest time since cessation will generally be 
the same smokers with the shortest smoking duration. Consequently, it is very difficult 
to disentangle the effects of duration and cessation and it is not possible to say for 
certain whether the lower risk for someone who quit smoking 30 years ago is due to the 
long time since cessation or because of the short smoking duration. 
 
It seems plausible that the association between smoking cessation and risk of colorectal 
cancer differs according to smoking intensity; former light smokers who quit recently 
may have a lower risk of colorectal cancer than former heavy smokers who quit 
recently. However, no studies have investigated the effects of smoking cessation and 
smoking intensity together and it is not known how the risk due to cessation at different 
times may differ according to the amount smoked. 
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Summary 
 
Time since cessation is associated with colorectal cancer risk. The risk of cancer for 
former smokers is comparable to the risk for never smokers after 20-30 years of 
cessation. The most recent quitters have a higher risk of colorectal cancer than current 
smokers. Age at cessation is also associated with colorectal cancer risk. Former smokers 
who quit before 40 do not appear to have an increased risk compared to never smokers. 
 
2.4.8 Effect Modifiers 
 
It is possible that the association between smoking and colorectal cancer is modified by 
the level of other risk factors. Few studies have investigated effect modifiers for 
smoking and colorectal cancer.  
 
Smoking and Alcohol Intake 
 
Alcohol intake and smoking are known to act synergistically in cancers of the upper 
aerodigestive tract
26
 though there is insufficient evidence for colorectal cancer. Both 
smoking and alcohol drinking were associated with colorectal cancer risk in the 
Singapore Chinese Health Study though there was no evidence for an interaction 
between the two risk factors.
77
 There was also no evidence for an interaction in a 
Japanese cohort study.
120
 The EPIC study reported a non-significant p-value for the 
effect modification by alcohol intake.
253
 
 
Smoking and BMI 
 
BMI represents a major risk factor for colorectal cancer.
25
 On average, smokers have a 
lower BMI than non-smokers. However, BMI is positively associated with the number 
of cigarettes smoked per day among smokers.
227, 279
 Hence, it may be important to 
consider these risk factors together when investigating colorectal cancer risk. In the 
pooled analysis by Gong et al., the OR (95% CI) comparing ever vs never smokers was 
1.14 (1.10–1.27) for people with BMI <25 kg/m2 and 1.24 (1.13–1.35) for people with 
BMI ≥25 kg/m2.260 Parajuli et al. investigated the risk for ever smokers compared to 
never smokers for different categories of BMI for rectal cancer only. The risk increased 
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with increasing BMI for men; the HR (95% CI) comparing ever smokers to never 
smokers were 1.17 (1.01-1.36) for BMI <25 kg/m
2
, 1.33 (1.15-1.54) for BMI 25-29 
kg/m
2
 and 1.53 (1.20-1.95) for BMI ≥30 kg/m2. The corresponding results for women 
were 1.18 (1.01-1.39), 1.39 (1.15-1.70) and 1.39 (1.15-1.70).
256
 There was no clear 
difference in results comparing ≥31 pack-years versus never smokers by BMI category 
in a cohort of female teachers
258
 and the EPIC study reported a non-significant p-value 
for the effect modification by BMI.
253
 
 
Summary 
 
There is insufficient evidence that the association between smoking and colorectal 
cancer is modified by alcohol intake. There is slight evidence that the effect of smoking 
on colorectal cancer risk increases with increasing BMI. 
 
2.4.9 Colorectal Adenomas 
 
Studies have also investigated the relationship between smoking and colorectal 
adenomas. Colorectal adenomas are recognised precursor lesions for most colorectal 
cancers.
19, 280
 Generally, these studies have found a much stronger association for 
colorectal adenomas than for colorectal cancer. In a meta-analysis of prospective and 
retrospective studies of smoking and colorectal adenomas through 2008, Botteri et al. 
found a pooled RR and 95% CI of 2.14 (1.86-2.46) for current smokers and 1.47 (1.29-
1.67) for former smokers.
281
 In a similar meta-analysis of smoking and colorectal cancer 
by the same authors, the corresponding RR and 95% CI was 1.07 (0.99-1.16) for current 
smokers and 1.17 (1.11-1.22) for former smokers.
226
 
 
Since the adenoma-carcinoma sequence accounts for the vast majority of colorectal 
cancers, it is unclear why there should be such a discrepancy in results for colorectal 
adenomas and colorectal cancer. Different explanations have been proposed.
282
 
 
First, the discrepancy in results may be explained by the idea that tobacco smoke acts as 
an initiator of colorectal carcinogenesis. However, even if smoking had no effect on 
later tumour progression, the effects of smoking on colorectal adenoma and cancer 
should still be similar. The only possible explanation for a lower risk of cancer than 
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adenoma would be if smoking promoted the initiation of adenomas that were less likely 
to develop into colorectal cancer. However, Botteri et al. actually found that the 
association between smoking and colorectal adenoma was stronger for “high-risk” 
adenomas than “low-risk” adenomas.281 
 
Thus, on its own, that smoking only affects early colorectal carcinogenesis is 
insufficient to explain the difference in results for adenomas and cancer. However, an 
effect of smoking mainly on early carcinogenesis implies a long induction period for 
colorectal cancer risk and perhaps the difference in results is due to studies failing to 
account for this long induction period, as hypothesised by Giovannucci et al.
269-271
 
However, as described above, most studies still find a fairly modest risk of colorectal 
cancer even for people with 30 or 40 years of smoking duration. 
 
Most studies of smoking and colorectal adenomas are retrospective case-control studies. 
Thus the higher risk of colorectal adenomas could be due to recall bias (i.e. people 
diagnosed with adenoma being more likely to recall smoking) or due to other 
differences in methodology between the two study types. However, this seems unlikely 
since the meta-analysis by Botteri et al. found a similar association between smoking 
and colorectal cancer for cohort and case-control studies.
226
 
 
Another idea put forward to explain the difference in results relates to the selection of 
controls in case-control studies.
282, 283
 Studies of colorectal adenoma are generally based 
on direct evaluation of the large bowel and so it is known that the controls are free of 
adenomas. In contrast, population-based controls are normally used in studies of 
colorectal cancer. Since these population-based controls have not undergone any kind of 
screening, a high proportion of controls will have prevalent colorectal adenomas. Thus, 
it has been argued that the inclusion of these controls with adenomas is responsible for 
the lower association observed for colorectal cancer risk.
283
 Indeed, the authors included 
results showing that the effect of smoking on colorectal cancer became stronger after 
excluding controls with adenomas. 
 
However, since smoking is associated with colorectal adenoma risk, restricting the 
control group to people free of adenomas reduces the prevalence of smoking in the 
reference group. Thus, rather than eliminating a bias of results towards the null, 
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excluding people with adenoma from the control group could be considered as 
introducing a bias of results away from the null. This idea was described in an article by 
Poole.
284
 Poole also highlighted that the effect of smoking on colorectal cancer would 
be equal to that of adenoma when there is a single pathway for colorectal cancer i.e. all 
colorectal cancers develop from adenoma. However, the effect of smoking would be 
weaker for cancer when there are multiple pathways. 
 
Summary 
 
The association between smoking and colorectal adenoma is much stronger than the 
association between smoking and colorectal cancer. Different explanations have been 
proposed though none seem to provide a sufficient explanation. The fact that the 
discrepancy in results between colorectal adenoma and colorectal cancer is not observed 
for other risk factors such as alcohol intake and adiposity
62, 63, 150, 153, 285-288
  implies that 
the discrepancy relates to how smoking influences colorectal carcinogenesis rather than 
a methodological difference between studies of adenoma and cancer. 
 
2.4.10 Molecular Subtypes 
 
Accumulating evidence indicates that smoking is strongly associated with a subtype of 
colorectal cancers characterised by high microsatellite instability (MSI), CpG island 
methylator phenotype (CIMP) positive status and positive BRAF mutation status. In the 
Iowa Women’s Health Study, the risk of these colorectal cancer subtypes for current 
smokers was approximately twice the risk for never smokers (HR, 1.99; 95% CI, 1.26-
3.14 for MSI-high cancers, HR, 1.88; 95% CI, 1.22-2.90 for CIMP-positive cancers and 
HR, 1.92; 95% CI, 1.22-3.02 for BRAF mutation-positive cancers).
272
 In contrast, there 
was no evidence of an association between smoking and microsatellite stable/MSI-low 
cancers, CIMP-negative cancers or BRAF mutation-negative cancers. 
  
The risk of these colorectal cancer subtypes was also investigated in the Health 
Professionals Follow-up Study and the Nurses’ Health Study.289 Compared to never 
smokers, current smokers had a two-fold risk of CIMP-high cancers (HR, 2.08; 95% CI, 
1.35-3.20) but no increased risk of CIMP-low cancers (HR, 1.12; HR, 0.89-1.41) and a 
two-fold risk of MSI-high cancers (HR, 2.05; 95% CI, 1.29-3.26) but no increased risk 
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of microsatellite stable cancers (HR, 1.14; 95% CI, 0.91-1.42). The results were more 
similar for BRAF mutation-positive (HR, 1.38; 95% CI, 0.84-2.25) and BRAF 
mutation-negative cancers (HR, 1.22; 95% CI, 0.98-1.52). 
 
Case-control studies also support a stronger association between smoking and these 
molecularly defined subtypes of colorectal cancer.
290-294
 Furthermore, CIMP-high, MSI-
high and BRAF mutation positive cancers occur more frequently in the proximal 
colon
52, 272, 289, 295
 which is in agreement with the stronger association observed between 
smoking and proximal colon cancer.
50
 
 
These molecular subtypes of cancer are thought to arise along a distinct pathway. Until 
recently, colorectal cancer was often thought of as a single disease, with conventional 
adenomas being the sole precursors to colorectal cancer. Indeed, the majority of 
colorectal cancers develop from adenomatous polyps via the adenoma-carcinoma 
sequence.
280
 However, it is now accepted that colorectal cancer is a heterogeneous 
disease and develops through multiple pathways.
296-299
 Approximately 30% of cancers 
are now recognised to develop along a serrated neoplasia pathway. Cancers arising from 
serrated adenomas are characterised by high MSI, CIMP positive status and positive 
BRAF mutation status. 
 
The fact that there are multiple pathways for colorectal cancer may help to explain the 
discrepancy in results for adenomas and cancer though this is not immediately clear. 
Smoking appears to be primarily associated with cancers developing along the serrated 
pathway yet serrated adenomas are actually more difficult to detect during screening.
300, 
301
 If serrated adenomas are more likely to be missed in studies of adenomas, this would 
seem to predict that smoking would be more strongly related to colorectal cancer than 
adenomas. In contrast, a stronger association for adenomas would be expected if 
smoking were primarily associated with the risk of conventional adenomas and not with 
the risk of serrated adenomas since the serrated adenomas (that are more likely to be 
missed in studies of adenoma) would “dilute” results for analyses of cancer. 
 
Some studies have investigated the risk of smoking on conventional adenomas and 
serrated adenomas separately. One study analysed data from three RCTs of 
antioxidants, calcium and aspirin.
302
 All subjects had at least one adenoma removed at 
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baseline and were followed up for the occurrence of new adenomas for up to four years. 
Out of 2,667 subjects with follow-up data, 973 had at least one conventional adenoma 
and 633 had at least one serrated adenoma. While there was an increased risk of one or 
more conventional adenomas for current smokers (RR, 1.29; 95% CI, 1.11-1.49) and 
former smokers (RR, 1.18; 95% CI, 1.05-1.32), there was a higher risk of one or more 
serrated adenomas for current smokers (RR, 2.01; 95% CI, 1.66-2.44) and former 
smokers (RR, 1.42; 95% CI, 1.20-1.68). 
 
Three case-control studies also found that smoking was more strongly associated with 
the risk of serrated adenomas than conventional adenomas.
303-305
 Comparing current to 
never smokers, the ORs and 95% CIs in the three studies for conventional adenomas 
only were 1.56 (0.99-2.44), 1.96 (1.61-2.38) and 1.8 (1.5-2.1). The ORs and 95% CIs 
for serrated adenomas only were 3.00 (1.93-4.66), 4.44 (3.47-5.67) and 4.4 (3.7-5.2). 
 
Summary 
 
The association between smoking and colorectal cancer seems to be restricted to cancers 
with high MSI, CIMP positive status and positive BRAF mutation status. These cancers 
develop from serrated adenomas which are precursors to approximately a third of 
colorectal cancers. Smoking is more strongly associated with serrated adenomas than 
conventional adenomas. These results need to be considered when trying to explain the 
discrepancy in results between colorectal adenoma and cancer. 
 
2.4.11 Mechanisms 
 
Cigarette smoke contains numerous carcinogens including polycyclic aromatic 
hydrocarbons, aromatic amines, and N-nitrosamines.
306, 307
 These carcinogens can reach 
the colorectal mucosa through the digestive system or the circulatory system.
249
 
Carcinogens from cigarette smoke form DNA adducts and subsequent mutations can 
result in the loss of normal growth control mechanisms and cancer.
306, 308
 However, not 
much is known in detail about how tobacco smoke increases colorectal cancer risk. In 
particular, smoking seems to greatly increase the risk of a subtype of colorectal cancers 
that develop along a serrated pathway yet the mechanisms for these neoplasms are not 
currently well explained in the literature. 
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2.4.12 Summary 
 
Cigarette smoking is associated with an increased risk of colorectal cancer. The risk is 
similar for men and women and smoking increases the risk of both colon and rectal 
cancer though studies find conflicting results. Smoking is more strongly related to 
proximal colon cancer than distal colon cancer. Former smokers suffer a similar level of 
risk as current smokers which may indicate that smoking mainly affects the early stages 
of colorectal carcinogenesis. Both smoking duration and smoking intensity are 
positively associated with colorectal cancer risk though it is unclear how these factors 
may interact to increase risk. It is also unclear how the risk of colorectal cancer differs 
with smoking cessation at different times. Compared to the risk of colorectal cancer, 
smoking is strongly associated to the risk of colorectal adenomas. The explanation for 
this discrepancy remains unknown but is possibly related to the stronger effects of 
smoking on a subset of cancers arising along a serrated pathway. 
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4 Table 2.4.2 Prospective Cohort Studies of Smoking and Colorectal Cancer Risk 
Ref. 
Author, 
year 
Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
309
 
 
Cross 
2014 
Prostate, Lung, 
Colorectal and 
Ovarian 
Cancer Screening 
Trial, USA 
General 
population 
1993 - 2001 55-74 B 254* CRC 255 C v N 1.51 (0.75-3.04) 
F v N 1.09 (0.72-1.65) 
>40 D v N 1.09 (0.47-2.55) 
≥30 I v N 1.11 (0.34-3.62) 
>60 PY v N 1.30 (0.38-4.42) 
>20 YSC v N 0.94 (0.59-1.48) 
            
256
 Parajuli 
2014 
The Oslo Study I 
The Norwegian 
Counties Study 
The 40 Years 
Cohort 
The CONOR 
Study, Norway 
General 
population 
1972 - 2007 
(14 yrs) 
19-67 M 299,376 RC 1,336 C v N 1.26 (1.09-1.45) 
F v N 1.28 (1.11-1.50) 
≥30 D v N 1.31 (1.09-1.59) 
≥20 I v N 1.31 (1.11-1.55) 
≥20 PY v N 1.35 (1.14-1.58) 
≤19 AI v N 1.28 (1.08-1.50) 
F 302,866 RC 840 C v N 1.29 (1.10-1.51) 
F v N 1.26 (1.05-1.52) 
≥30 D v N 1.54 (1.11-2.12) 
≥20 I v N 1.38 (1.05-1.81) 
≥20 PY v N 1.47 (1.13-1.91) 
≤19 AI v N 1.35 (1.10-1.67) 
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Ref. 
Author, 
year 
Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
310
 Hansen 
2013 
Diet, Cancer and 
Health Study, 
Denmark 
General 
population 
1995 - 2009 
(13 yrs) 
51-64 B 54,208 CRC 988 C v N 1.16 (0.96-1.39) 
F v N 1.16 (0.94-1.43) 
            
258
 Hurley 
2013 
California 
Teachers Study, 
USA 
Teachers 1995 - 2009 22-104 F 122,264 CRC 1,205 C v N 1.28 (1.00-1.63) 
F v N 1.10 (0.97-1.24) 
            
289
 Nishihara 
2013 
Health 
Professionals 
Follow-up Study 
and Nurses’ 
Health Study, 
USA 
Health 
professionals 
and nurses 
1980 - 2008 35-75 B 134,204 CRC 1,260 C v N 1.17 (0.96-1.43) 
F v N 1.18 (1.05-1.34) 
≥40 PY v N 1.28 (1.08-1.51) 
≥40 YSC v N 1.23 (0.99-1.54) 
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Ref. 
Author, 
year 
Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
255
 Parajuli 
2013 
The Oslo Study I 
The Norwegian 
Counties Study 
The 40 Years 
Cohort 
The CONOR 
Study, Norway 
General 
population 
1972 - 2007 
(14 yrs) 
19-67 M 299,376 CC 2,152 C v N 1.03 (0.92-1.15) 
F v N 1.14 (1.02-1.17) 
≥40 D v N 1.29 (1.05-1.59) 
≥20 I v N 1.16 (0.97-1.28) 
≥20 PY v N 1.14 (0.99-1.31) 
≤16 AI v N 1.15 (0.99-1.34) 
F 302,866 CC 1,846 C v N 1.22 (1.10-1.36) 
F v N 1.16 (1.02-1.31) 
≥40 D v N 1.47 (1.11-1.95) 
≥20 I v N 1.28 (1.06-1.55) 
≥20 PY v N 1.33 (1.11-1.57) 
≤16 AI v N 1.48 (1.21-1.81) 
            
311
 Doubeni 
2012 
NIH-AARP Diet 
and Health Study, 
USA 
General 
population 
1995 - 2006 50-71 B 506,488 CRC 7,676 >20 I v N (CO) 1.37 (1.22-1.53) 
>20 I v N (FO) 1.41 (1.33-1.50) 
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Author, 
year 
Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
260
 Gong 
2012 
Genetics 
and Epidemiology 
of Colorectal 
Cancer 
Consortium 
5 cohort and 3 
case-control 
studies 
 20-79 B 7,770* CRC 6,796 C v N 1.26 (1.11-1.43) 
F v N 1.18 (1.09-1.27) 
≥40 D v N 1.28 (1.10-1.49) 
>20 I v N 1.28 (1.10-1.49) 
>60 PY v N 1.37 (1.16-1.62) 
≥35 YSC v N 0.74 (0.47-1.18) 
<40 AC v N 1.03 (0.79-1.34) 
            
253
 Leufkens 
2011 
European 
Prospective 
Investigation 
into Cancer and 
Nutrition, Europe 
General 
population 
1991 - 2006 
(8.7 yrs) 
35-70 B 465,879 CRC 2,741 C v N 1.08 (0.96-1.21) 
F v N 1.17 (1.07-1.29) 
≥40 D v N (CO) 0.94 (0.78-1.14) 
≥30 D v N (FO) 1.24 (1.07-1.44) 
≥15 I v N (CO) 1.07 (0.88-1.30) 
≥15 I v N (FO) 1.26 (1.08-1.47) 
≤16 AI v N (CO) 0.95 (0.77-1.17) 
≤16 AI v N (FO) 1.12 (0.96-1.31) 
≥25 YSC v N 1.08 (0.92-1.26) 
            
312
 Nordenval
l 2011 
Sweden Construction 
workers 
1971 - 2007 
(24 yrs) 
15-82 M 200,142 CC 1,367 ≥25 D v N 1.12 (0.98-1.28) 
≥25 I v N 1.22 (0.94-1.60) 
RC 1,006 ≥25 D v N 1.18 (1.01-1.39) 
≥25 I v N 1.21 (0.88–1.66) 
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Ref. 
Author, 
year 
Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
138
 Shin 2011 National 
Health Insurance 
Corporation Study, 
Korea 
General 
population 
1996 - 2003 30-80 M 869,725 PCC 536 C v N 1.0 (0.8-1.2) 
F v N 1.0 (0.8-1.3) 
DCC 751 C v N 0.9 (0.8-1.1) 
F v N 1.4 (1.2-1.7) 
RC 1,535 C v N 1.0 (0.9-1.1) 
F v N 1.1 (1.0-1.3) 
F 395,501 PCC 236 C v N 0.7 (0.4-1.2) 
F v N 1.1 (0.5-2.6) 
DCC 225 C v N 1.1 (0.7-1.9) 
F v N 0.7 (0.2-2.4) 
RC 551 C v N 1.0 (0.7-1.4) 
F v N 0.9 (0.5-1.7) 
            
272
 Limsui 
2010 
Iowa Women’s 
Health Study, 
USA 
General 
population 
1986 - 2002 55-69 F 37,399 CRC 1,233 C v N 1.23 (1.03-1.46) 
F v N 1.16 (1.00-1.35) 
≥40 D v N 1.40 (1.17-1.68) 
>20 I v N 1.32 (1.04-1.69) 
≥40 PY v N 1.39 (1.14-1.70) 
≤30 AI v N 1.19 (1.05-1.36) 
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Author, 
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Study name, 
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Follow-up 
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(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
259
 Gram 
2009 
Norwegian 
Women and 
Cancer Study, 
Norway 
General 
population 
1996 - 2005 30-69 F 68,160 CRC 425 C v N 1.2 (0.9-1.5) 
F v N 1.3 (1.0-1.6) 
≥30 D v N 1.3 (1.0-1.6) 
≥15 I v N 1.1 (0.7-1.7) 
≥20 PY v N 1.3 (1.0-1.8) 
<20 AI v N 1.3 (1.0-1.6) 
≥20 YSC v N 1.1 (0.8-1.5) 
            
254
 Hannan 
2009 
Cancer Prevention 
Study II Nutrition 
Cohort, USA 
General 
population 
1992 - 2005 50-74 B 124,751 CRC 1,962 C v N 1.27 (1.06-1.52) 
F v N 1.23 (1.11-1.36) 
≥50 D v N (CO) 1.38 (1.04-1.84) 
≥31 YSC v N 1.03 (0.89-1.19) 
<40 AC v N 1.05 (0.91-1.22) 
            
313
 Nöthlings 
2009 
Multiethnic Cohort 
Study, USA 
General 
population 
1993 - 45-75 B 1,522* CRC 1,009 >30 PY v N 1.51 (1.17-1.95) 
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Ref. 
Author, 
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Study name, 
location 
Population 
Follow-up 
period 
(average 
follow-up) 
Age Sex
a 
Number 
of 
subjects 
Site
b Number 
of cases 
Exposure
c 
HR/RR (95% CI) 
314
 Hooker 
2008 
USA General 
population 
1963 - 1978 
(15 yrs) 
≥25 M 20,926 RC 66 C v N 3.05 (1.19-7.82) 
F v N 2.63 (0.98-7.05) 
≥40 D v N (CO) 4.40 (1.58-12.29) 
≥20 I v N (CO) 2.88 (0.98-8.48) 
≥40 PY v N (CO) 2.68 (0.97-7.44) 
<17 AI v N 3.33 (1.19-9.33) 
F 24,823 RC 54 C v N 0.93 (0.48-1.80) 
F v N 0.62 (0.19-2.08) 
≥40 D v N (CO) 1.00 (0.30-3.31) 
≥20 I v N (CO) 1.13 (0.33-3.91) 
≥40 PY v N (CO) 1.08 (0.41-2.85) 
<17 AI v N 0.83 (0.18-3.75) 
1975 - 1994 
(19 yrs) 
≥25 M 21,780 RC 77 C v N 1.80 (0.88-3.67) 
F v N 1.92 (0.98-3.78) 
≥20 I v N (CO) 2.27 (0.98-5.28) 
F 26,372 RC 77 C v N 1.57 (0.89-3.76) 
F v N 1.87 (1.02-3.45) 
≥20 I v N (CO) 2.84 (1.22-6.62) 
            
315
 Shankar 
2008 
Singapore Chinese 
Health Study, 
Singapore 
General 
population 
1993 - 2005 45-74 B 61,320 CRC 931 F v N 1.1 (0.92-1.4) 
>22 I v N (CO) 0.83 (0.56-1.2) 
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316
 Weijenber
g 2008 
Netherlands 
Cohort Study on 
Diet and Cancer, 
Netherlands 
General 
population 
1989 - 1994 
(5 yrs) 
57-72 B 4,083† 
 
CRC 648 C v N 0.81 (0.62–1.05) 
F v N 1.22 (0.97-1.53) 
>40 D v N 0.86 (0.65-1.13) 
>20 I v N 1.16 (0.89-1.52) 
>30 PY v N 1.12 (0.84-1.49) 
<17 AI v N 1.18 (0.89-1.56) 
>30 YSC v N 0.78 (0.45-1.33) 
            
317
 Akhter 
2007 
Miyagi Cohort 
Study, Japan 
General 
population 
1990 - 1997 
(7 yrs) 
40-64 M 21,695 CRC 188 C v N 1.47 (0.93-2.34) 
F v N 1.73 (1.04-2.87) 
≥40 D v N (CO) 1.59 (0.89-2.86) 
≥20 I v N (CO) 1.60 (0.99-2.58) 
≤18 AI v N (CO) 1.86 (0.97-3.58) 
            
232
 Driver 
2007 
Physicians’ Health 
Study, USA 
Physicians 1982 - 2004 
(22 yrs) 
40-84 M 21,581 CC 351 F v N 1.50 (1.19-1.89) 
≥40 I v N (CO) 1.53 (1.02-2.29) 
RC 100 F v N 1.13 (0.73-1.75) 
≥40 I v N (CO) 1.92 (1.01-3.66) 
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257
 Paskett 
2007 
Women’s Health 
Initiative, USA 
General 
population 
1993 - 2005 
(7.8 yrs) 
50-79 F 146,877 CRC 1,242 C v N 1.12 (0.86-1.46) 
F v N 1.13 (0.99-1.29) 
≥40 D v N 1.23 (0.97-1.55) 
≥25 I v N 1.41 (1.14-1.76) 
<20 AI v N 1.12 (0.95-1.31) 
≥40 YSC v N 0.93 (0.71-1.22) 
          <30 AC v N 0.94 (0.72-1.23) 
            
77
 Tsong 
2007 
Singapore Chinese 
Health Study, 
Singapore 
General 
population 
1993 - 2004 
(8.9 yrs) 
45-74 B 61,321 CRC 845 C v N 1.10 (0.92-1.32) 
F v N 1.13 (0.91-1.39) 
≥40 D v N 1.19 (0.97-1.45) 
≥13 I v N 1.18 (0.98-1.43) 
<15 AI v N 1.32 (1.02-1.71) 
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 Yun 2005 National 
Health Insurance 
Corporation Study, 
Korea 
General 
population 
1996 - 2000 
(4 yrs) 
≥30 M 733,134 CC 417 C v N 0.81 (0.63-1.05) 
F v N 1.37 (1.06-1.77) 
≥30 D v N (CO) 0.96 (0.69-1.33) 
≥30 D v N (FO) 2.08 (1.29-3.37) 
≥20 I v N (CO) 0.76 (0.51-1.15) 
RC 453 C v N 0.97 (0.76-1.24) 
F v N 1.17 (0.91-1.52) 
≥30 D v N (CO) 1.12 (0.82-1.52) 
≥30 D v N (FO) 0.61 (0.27-1.41) 
≥20 I v N (CO) 1.05 (0.74-1.50) 
            
319
 Jee 2004 Korean Cancer 
Prevention Study, 
Korea 
General 
population 
1993 - 2001 30-95 M 830,139 CC 1,633 C v N 0.8 (0.7-1.0) 
F v N 1.1 (1.0-1.3) 
            
144
 Sanjoaqui
n 2004 
Oxford Vegetarian 
Study, UK 
General 
population 
1980 - 1999 
(17 yrs) 
16-89 B 10,998 CRC 95 C v N 1.70 (0.92-3.15) 
F v N 1.80 (1.13-2.85) 
            
120
 Otani 
2003 
Japan Public 
Health Center-
based Prospective 
Study, Japan 
General 
population 
1990 - 1999 40-70 M 42,540 CRC 447 C v N 1.4 (1.1-1.8) 
F v N 1.3 (0.98-1.7) 
≥40 PY v N (CO) 1.4 (0.99-1.8) 
F 47,464 CRC 259 C v N 1.4 (0.8-2.4) 
F v N 1.3 (0.5-3.6) 
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146
 Shimizu 
2003 
Takayama Study, 
Japan 
General 
population 
1993 - 2000 
(8 yrs) 
≥36 M 13,392 CC 104 >20 PY v N 1.37 (0.81-2.32) 
RC 57 >20 PY v N 2.44 (1.12-5.30) 
F 15,659 CC 77 >10 PY v N 0.77 (0.30-1.96) 
RC 38 >10 PY v N 0.94 (0.21-4.16) 
            
320
 Wakai 
2003 
Japan 
Collaborative 
Cohort Study, 
Japan 
General 
population 
1988 - 1997 
(7.6 yrs) 
40-79 M 25,260 CC 219 C v N 1.23 (0.85-1.78) 
F v N 1.07 (0.72-1.59) 
≥40 D v N 1.07 (0.71-1.61) 
≥40 I v N 0.69 (0.33-1.43) 
≥60 PY v N 0.68 (0.34-1.37) 
<20 AI v N 1.04 (0.62-1.74) 
≥20 YSC v N 0.79 (0.41-1.52) 
RC 147 C v N 0.83 (0.55-1.26) 
F v N 0.88 (0.56-1.39) 
≥40 D v N 0.72 (0.45-1.16) 
≥40 I v N 0.80 (0.38-1.69) 
≥60 PY v N 0.78 (0.38-1.59) 
<20 AI v N 1.18 (0.69-1.99) 
≥20 YSC v N 0.53 (0.22-1.28) 
F 34,619 CC 189 C v N 1.06 (0.55-2.02) 
F v N 1.07 (0.39-2.92) 
RC 57 C v N 0.36 (0.05-2.65) 
F v N 1.05 (0.14-7.69) 
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321
 Terry 
2002 
Canadian 
National Breast 
Screening Study, 
Canada 
Trial of 
mammograph
y screening 
1980 - 1993 
(10.6 yrs) 
40-59 F 89,835 CRC 527 C v N 1.00 (0.80-1.26) 
F v N 1.15 (0.94-1.41) 
≥40 D v N 1.30 (0.68-2.47) 
≥40 I v N 0.71 (0.35-1.43) 
            
322
 Tiemersm
a 2002 
Monitoring Project 
on Cardiovascular 
Disease Risk 
Factors, 
Netherlands 
General 
population 
1987 - 1998 20-59 B 535* CRC 102 C v N 0.9 (0.5-1.7) 
F v N 1.4 (0.8-2.5) 
>25 D v N 1.2 (0.7-2.1) 
>14 I v N 1.5 (0.9-2.6) 
>15 YSC v N 1.1 (0.5-2.3) 
            
323
 Terry 
2001 
Sweden General 
population 
1967 - 1997 
(22.5 yrs) 
42-81 B 17,118 CRC 498 F v N 1.0 (0.8-1.4) 
≥21 I v N (CO) 3.1 (1.4-7.1) 
324
 Stürmer 
2000 
Physicians’ Health 
Study, USA 
Physicians 1982 - 1995 
(13 yrs) 
40-84 M 22,011 CRC 351 C v N 1.81 (1.28-2.55) 
F v N 1.49 (1.17-1.89) 
≥20 I v N (CO) 2.14 (1.45-3.14) 
≥20 I v N (FO) 1.31 (1.00-1.73) 
>40 PY v N 1.68 (1.20-2.35) 
            
325
 Knekt 
1998 
Finland General 
population 
1966 - 1994 ≥15 B 56,973 CRC 457 F v N 1.02 (0.74-1.39) 
≥15 I v N (CO) 1.04 (0.73-1.48) 
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147
 Singh 
1998 
Adventist Health 
Study, USA 
Seventh-day 
Adventists 
1976 - 1983 ≥25 B 32,051 CRC 157 C v N 1.39 (0.50-3.82) 
F v N 1.13 (0.75-1.70) 
            
326
 Kato 1997 New York 
University 
Women's Health 
Study, USA 
General 
population 
1985 - 1994 
(7.1 yrs) 
34-65 F 14,727 CRC 85 C v N 0.97 (0.53-1.77) 
F v N 0.99 (0.62-1.60) 
            
327
 Nordlund 
1997 
Sweden General 
population 
1963 - 1989 
(26 yrs) 
18-69 F 26,032 CRC 559 C v N 0.88 (0.67-1.16) 
F v N 1.16 (0.72-1.86) 
≥16 I v N (CO) 1.42 (0.77-2.60) 
≤19 AI v N (CO) 0.97 (0.49-1.92) 
            
246
 Tulinius 
1997 
Cardiovascular 
Risk Factor Study, 
Iceland 
General 
population 
1968 - 1995 33-60 F 11,580 CRC 145 F v N 1.12 (0.68-1.86) 
≥25 I v N (CO) 2.48 (0.99-6.19) 
            
74
 Chyou 
1996 
USA General 
population 
1965 - 1995 46-65 M 7,944 CC 330 C v N 1.42 (1.09-1.85) 
F v N 1.27 (0.95-1.70) 
≥31 PY v N 1.48 (1.13-1.94) 
RC 123 C v N 1.95 (1.25-3.04) 
F v N 1.31 (0.78-2.20) 
≥31 PY v N 1.92 (1.23 -2.99) 
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328
 Engeland 
1996 
Norway General 
population 
1966 - 1993 33-72 M 11,863 CC 230 C v N 1.2 (0.8-1.6) 
F v N 1.0 (0.6-1.5) 
RC 139 C v N 1.6 (1.0-2.6) 
F v N 0.8 (0.4-1.6) 
F 14,269 CC 300 C v N 1.1 (0.8-1.4) 
F v N 1.3 (0.9-2.0) 
RC 141 C v N 0.8 (0.5-1.3) 
F v N 1.3 (0.8-2.4) 
            
329
 Nyren 
1996 
Sweden Construction 
workers 
1971 - 1991 
(17.6 yrs) 
 M 134,985 CC 713 C v N 0.98 (0.82-1.17) 
F v N 1.02 (0.84-1.24) 
≥41 D v N (CO) 0.99 (0.72-1.35) 
≥21 D v N (FO) 1.08 (0.84-1.40) 
≥25 I v N 1.07 (0.63-1.82) 
RC 505 C v N 1.16 (0.94-1.44) 
F v N 1.22 (0.97-1.54) 
≥41 D v N (CO) 1.08 (0.73-1.60) 
≥21 D v N (FO) 1.06 (0.76-1.48) 
≥25 I v N 1.08 (0.58-2.03) 
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269
 Giovannu
cci 1994 
Health 
Professionals 
Follow-up Study, 
USA 
Health 
professionals 
1986 - 1990 
(4 yrs) 
40-75 M 47,935 CRC 238 C v N 1.36 (0.84-2.20) 
 
CRC 238 ≥40 PY vs N 1.45 (1.01-2.09) 
            
270
 Giovannu
cci 1994 
Nurses’ Health 
Study, USA 
Nurses 1976 - 1990 
(14 yrs) 
30-55 F 118,334 CRC 586 C v N 0.91 (0.74-1.12) 
            
75
 Klatsky 
1988 
USA General 
population 
1978 - 1984  B 10,572† CC 203 F v N 1.03 (0.74-1.43) 
≥20 I v N (CO) 1.35 (0.78-2.35) 
RC 66 F v N 1.28 (0.71-2.28) 
≥20 I v N (CO) 1.01 (0.37-2.79) 
            
76
 Wu 1987 USA Retirement 
community 
1981 - 1985  M 4,163 CRC 58 C v N 1.80 (0.6-5.2) 
>20 YSC v N 1.71 (0.8-3.6) 
F 7,456 CRC 68 C v N 1.35 (0.7-1.0) 
>20 YSC v N 1.61 (0.8-3.0) 
a 
M = male, F = female, B = both 
b
 CRC = colorectal cancer, CC = colon cancer, RC = rectal cancer, PCC = proximal colon cancer, DCC = distal colon cancer 
c 
C = current smokers, F = former smokers, N = never smokers, D = duration, I = intensity, PY = pack-years, AI = age at initiation, YSC = years since cessation, AC = age at 
cessation, CO = current smokers only, FO = former smokers only 
* Case-control analysis 
† Case-cohort analysis 
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2.5 Thesis Objectives 
 
The main aim of this thesis was to investigate the relationships between alcohol intake, 
adiposity and smoking and the risk of colorectal cancer (and colorectal cancer subsites) 
using data from UK Biobank. These literature reviews identified a number of important 
gaps in the existing literature for these relationships that this thesis will aim to answer. 
Thus, the objectives of this thesis are: 
 
i. To examine the shape of the relationship between alcohol intake and colorectal 
cancer and the possibility of a threshold at 30 g/d. 
ii. To investigate whether the relationship between alcohol intake and colorectal 
cancer differs for men and women. 
iii. To explore how the choice of different reference groups can impact on the 
results for the association between alcohol intake and colorectal cancer. 
iv. To investigate whether the level of BMI affects the relationship between alcohol 
intake and colorectal cancer. 
v. To explore reasons why BMI is more strongly related to colorectal cancer risk 
for men than for women. 
vi. To investigate how different measures of adiposity are related to colorectal 
cancer risk. 
vii. To explore reasons why former and current smokers experience a similar risk of 
colorectal cancer. 
viii. To investigate how the effects of smoking duration and smoking intensity 
increase the risk of colorectal cancer. 
ix. To investigate how the risk of colorectal cancer differs according to smoking 
cessation at different times. 
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Chapter 3 UK Biobank 
 
In this chapter, the UK Biobank cohort is described in detail including its creation, the 
recruitment of participants and the data available. At the end, characteristics of the 
cohort are presented. 
 
Since the middle of the previous century, epidemiological studies have provided vital 
evidence for the prevention of disease through environmental and lifestyle factors that 
has had a tremendous impact on public health. The role of genetics in disease has also 
been the focus of much research, particularly following the success of the Human 
Genome Project at the turn of the century.
330, 331
 However, it has been recognised for 
many years that an individual’s risk of disease depends on the complex interplay 
between lifestyle, environment and genetic factors.
332
 Therefore, a number of large, 
prospective studies including detailed information on lifestyle, environment and 
genetics have been established in recent years with the aim to improve the 
understanding of the major determinants of complex diseases and why some people 
develop certain diseases and others do not. 
 
Prospective cohort studies have a number of important advantages in comparison to 
retrospective case-control studies for the investigation of lifestyle, environment and 
genetic factors in relation to a variety of diseases.
54, 55, 333
 First of all, since the 
exposures are assessed before the onset of disease, prospective studies avoid recall bias 
where the presence of disease may affect participants’ responses. Moreover, prospective 
studies are able to investigate diseases that cannot be investigated using retrospective 
studies such as dementia or rapidly fatal conditions. Prospective studies also allow the 
investigation of a wide range of diseases whereas case-control studies by definition are 
only able to investigate a single disease. This means that prospective cohorts can be 
used to investigate the overall effects of a single exposure on multiple diseases. 
However, prospective studies require significant investment since large numbers of 
people need to be followed-up for many years in order to accumulate sufficient numbers 
of disease cases. 
 
The UK Biobank cohort was established by the Medical Research Council and the 
Wellcome Trust with the aim to investigate how the complex interplay between 
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lifestyle, environment and genetics increases the risk of a wide range of diseases.
53, 334
 
UK Biobank is a very large and detailed prospective study including over 500,000 men 
and women aged mostly 40-69 recruited between 2006 and 2010. At baseline 
participants provided detailed information on their lifestyle, health and environmental 
factors, completed physical measures and provided biological samples. Follow-up on 
health related outcomes including deaths, cancers and hospital admissions is achieved 
through linkage with national health datasets. 
 
Several other large-scale prospective cohorts have been established in recent years with 
information on lifestyle, environment and genetics including the 500,000 person China 
Kadoorie Biobank, the 500,000 person European Prospective Investigation into Cancer 
and Nutrition and the 150,000 person Mexico City Prospective Study.
335-337
 In 
comparison to these cohorts, UK Biobank aims to support a much wider range of health 
related research and includes detailed information on a wider range of exposures and 
health related outcomes. 
 
UK Biobank represents the most detailed large-scale cohort ever established and it is 
hoped that this unique combination of large size and detailed information means that 
this ambitious cohort remains a rich resource for epidemiological research for many 
years to come and is able to make a real difference to the health of future generations. 
 
3.1 Initiation 
 
The initiation of UK Biobank goes back to May 1999 when the Medical Research 
Council and the Wellcome Trust hosted a workshop to discuss the potential value of 
establishing a large prospective cohort that would be able to investigate lifestyle, 
environment and genetic factors in relation to a wide range of complex diseases.
338, 339
 
Soon after, both the Medical Research Council and the Wellcome Trust agreed in 
principle to fund the project, then known as the UK Population Biomedical Collection. 
A protocol for the cohort was developed based on wide consultation with specialist 
experts as well as public consultation. Following positive international peer review from 
12 experts, a full protocol for the project was published in February 2002. Initial 
funding of £45 million (£20 million each from the Medical Research Council and the 
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Wellcome Trust and £5 million from the Department of Health) was announced in April 
2002.
339
 
 
3.2 Pilot Studies 
 
Two pilot studies were conducted before main recruitment began. A small pilot study 
was carried out in early 2005 across six centres recruiting about 300 people. The 
principal aim of this initial pilot study was to evaluate the feasibility and suitability of 
the assessment methods and to identify areas for improvement. 
 
A more comprehensive pilot study was conducted between March and June 2006.
338, 340
 
This pilot study assessed about 4,000 people at an assessment centre in Stockport. This 
time the main aim was to assess the entire recruitment process from invitation to 
assessment to sample collection and storage at the throughput required for the main 
recruitment. These participants were included in the final UK Biobank cohort. 
 
Names and addresses of people aged 40-69 living within the vicinity of the assessment 
centre were sought from four local National Health Service primary care trusts. These 
people were sent an invitation letter with a provisional appointment plus an information 
leaflet and a pre-paid reply form. A freephone service was also available for participants 
to change their appointment or ask any questions. In total 59,383 primary invitation 
letters were sent.
340
 
 
Whilst the requested data was provided rapidly by one trust, data from another trust was 
delayed by several weeks and data from the other two trusts could not be obtained 
before the end of the pilot study. This presented a number of issues for recruitment. 
First, it meant that invitation letters were sent only three to four weeks before the 
provisional appointments instead of the proposed six to eight weeks. The delays in 
accessing contact details also meant that there was an uneven pattern of invitations 
which caused large spikes in demand for the call centre staff and increased waiting 
times which may have negatively affected participation. Furthermore, the two trusts that 
did not provide data actually covered the area immediately adjacent to the assessment 
centre which resulted in few people living within two miles being invited who may have 
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been more likely to participate. These problems highlighted the importance of 
identifying participants from national data sources to ensure smooth operation. 
 
Overall, about 4,000 participants were recruited in the pilot study, giving a response rate 
of approximately 6.7%. A higher response rate was expected for the main study since 
the response rate in the pilot study was affected by the difficulties with the primary care 
trusts. It was also found that the response rate could be improved by sending pre-visit 
reminders; the non-attendance rate was halved from 20% to 10% using pre-visit 
reminders.
340
 Also, a number of people were unable to arrange a convenient 
appointment at the end of recruitment in the pilot study which negatively affected the 
response rate; this should have impacted the response rate in the main study less since 
assessment centres were open longer. Greater promotion of UK Biobank during the 
main study should also have encouraged greater participation. 
  
A 10% random sample of people who attended the assessment centre were asked to 
complete an anonymous postal survey about the assessment visit. 65% of people 
responded.
340
 Responses showed that participants had a good understanding of what the 
study would involve and that participants found the amount of information asked and 
the length of the assessment visit acceptable (though there was a tendency to say it was 
too long and virtually no participants said it was too short). There was also a good 
understanding of what they were agreeing to by consenting to take part in the study. 
One undesirable finding was that 29% of participants mentioned “to have a health 
check” as one of the main reasons for participating in UK Biobank. Thus, following the 
pilot study, the information included in the invitation materials was revised for the main 
study. 
 
Approximately 10,000 people declined to participate in the pilot study (most people did 
not respond) using either the pre-paid response form or by phone and approximately 
70% of these people were willing to provide reasons. The most common reasons given 
were too busy (mentioned by 2,166 people), too unwell (935 people) and too far to 
travel/too inconvenient (531 people).
340
 
 
Following the pilot study, a revised protocol was assessed by the Wellcome Trust’s 
Study Design Expert Group, the independent Ethics and Governance Council, and a 
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specially convened International Review Panel.
338
 The panel concluded that “UK 
Biobank has the potential, in ways that are not currently available elsewhere, to support 
a wide range of research, particularly investigations into complex interactions of various 
exposures, including genetic and lifestyle factors in the pathways to disease and 
health”341 and unanimously recommended that full scale recruitment should begin 
without delay.
338
 In August 2006 the study was approved with £61 million funding from 
the Medical Research Council, the Wellcome Trust, the Department of Health, the 
Scottish Government and the North West Regional Development Agency.
341
 Main 
recruitment began in April 2007 and lasted over three years with the final participant 
recruited in October 2010. 
 
3.3 Main Recruitment 
 
3.3.1 Identification and Invitation 
 
In the UK virtually all members of the general population are registered with a general 
practitioner (GP) through the National Health Service (NHS). NHS records were used to 
identify people aged 40-69 years old to invite to participate in UK Biobank.
53
 The data 
made available to UK Biobank about potential participants were restricted to name, 
address, sex, date of birth, NHS number and name and address of GP.
338
 
 
People aged 40-69 years old living nearby to one of the 22 assessment centres were sent 
an invitation letter with a provisional appointment to participate in UK Biobank. 
Invitations were sent at least six to eight weeks before the provisional appointment. 
  
With the invitation letter, people also received an information leaflet which gave more 
detailed information on the purpose of UK Biobank, how people had been identified for 
invitation, what consenting to take part would mean (including being able to withdraw 
at anytime) and what the assessment visit would involve. People were advised that the 
assessment visit would last about two to three hours. People who wanted to find out 
more information were encouraged to telephone the Participant Resource Centre (PRC) 
free of charge or visit the study website. 
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To accept the provisional appointment or decline to take part people could phone the 
PRC, return the reply form using the pre-paid envelope or go to UK Biobank’s website. 
People could change the provisional appointment to a more convenient time by calling 
the PRC; most assessment centres were open Monday to Friday from 8am to 7pm and 
Saturday from 8am to 5pm. If people confirmed an appointment they were asked to 
provide a telephone number or e-mail address so that they could receive a reminder 
closer to the date. Also people who confirmed an appointment were sent written 
confirmation including a map with directions to the assessment centre and a short pre-
visit questionnaire for questions that might be more difficult to answer precisely on the 
day. 
 
3.3.2 Assessment Centres 
  
The first requirement for establishing an assessment centre was a large number of 
people aged 40-69 years old living within close proximity in order to maintain a high 
throughput of participants and reduce recruitment costs. Therefore, all assessment 
centres were generally located in large cities. It was also important that assessment 
centres were conveniently located for public transport links, nearby parking and easy 
disabled access. Figure 3.3.1 shows a map of the 22 assessment centres used for 
recruiting participants. 
 
Figure 3.3.1 Map of UK Biobank Assessment Centres  
 
Taken from www.biobank.ctsu.ox.ac.uk/crystal/ 
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The recruitment process was coordinated centrally with up to six assessment centres 
open at any time.
53
 Each assessment centre recruited around 100 participants per day 
and most assessment centres were open approximately 8-14 months. Figure 3.3.2 shows 
the timeline of recruitment for each assessment centre. 
 
Figure 3.3.2 Timelines for Recruitment by UK Biobank Assessment Centre 
 
Period of recruitment at each UK Biobank assessment centre. 
 
3.3.3 Assessment 
 
The baseline assessment consisted of a touchscreen questionnaire, a verbal interview 
with a trained member of staff and a series of physical measures. The data available 
from the baseline assessment are summarised in Table 3.3.1. A number of questions or 
measures were added during recruitment and so were available only for a subset of the 
entire cohort. 
 
Participants first provided consent to be part of UK Biobank using the touchscreen and 
a digital signature pad. Participants were given a physical copy of this consent form. 
Then participants completed the touchscreen questionnaire which included detailed 
questions on socio-demographics, lifestyle, environment and health. The touchscreen 
questionnaire was important in enabling the recruitment of a large number of 
participants at a relatively low cost since a number of participants could complete the 
questionnaire at the same time with minimal supervision from staff. It also meant 
participants could be guided through the questionnaire in order to only answer the 
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questions pertinent to them and it allowed validity checks for questions e.g. not 
accepting extreme values or asking participants if they are sure. The full touchscreen 
questionnaire can be found on the UK Biobank website (www.ukbiobank.ac.uk) and 
information on each variable can be viewed in the interactive data showcase available 
on the study website. 
 
Table 3.3.1 Data Collected at the UK Biobank Baseline Assessment
53
 
 
 
Next was the verbal interview with a member of staff designed to gain more 
information on early life factors, employment, medications and medical history. Two 
measurements of blood pressure were taken at this stage. Participants then went to the 
physical measurements station. Physical measures included height, hip circumference, 
WC, weight, bioelectrical impedance, hand grip strength, ultrasound bone densitometry 
and spirometry. The final stage of the assessment centre was to provide biological 
samples. 
 
Upon leaving the assessment centre participants were provided with some basic 
feedback on their physical measures. While it was important that feedback be kept to a 
minimum so that participants did not sign up for UK Biobank thinking it was a health 
check, it was seen as impractical and inappropriate to conceal information on physical 
measures from participants. So participants received a hard copy of some of the physical 
measurements such as blood pressure, weight, BMI and heel bone ultrasound along with 
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a simple interpretation (e.g. good/borderline/high) and information on seeking further 
advice. 
 
3.4 Response 
 
The overall response rate for UK Biobank was 5.5%.
334
 Achieving a high response rate 
was never an objective of UK Biobank; planning for recruitment was based on a 
response rate of 10%.
338
  
 
It is widely accepted that people are generally more reluctant to take part in 
epidemiological studies nowadays and response rates have been declining for a number 
of years.
342
 Furthermore, the UK Biobank assessment was particularly demanding; 
participants were asked to take three hours out of their day to take part in the study. 
 
However, although a low response rate was expected for UK Biobank, it is not clear 
why the study failed to achieve the projected 10% response or why the response rate 
was lower than that of the pilot study. 
 
Unfortunately, there is no detailed information available about the recruitment of 
participants that could possibly explain why the target response rate was not achieved. 
The pilot report did include some basic information on factors affecting confirmation 
rates (based on invitation prior to 1st May 2006 to avoid the impact of the assessment 
centre closure on confirmation rates).
340
 For example, younger people and people from 
more deprived areas were less likely to confirm an appointment. Hence, one possibility 
for the low response rate would be if these people were oversampled in the main 
recruitment. 
 
There are also other factors that may have contributed to the low response rate. For 
example, it seems that there was not much local promotion of UK Biobank during 
recruitment. Hence, the mailed invitation would likely be the first occasion when most 
people learned of the study and many people may have simply ignored it. The lack of 
promotion may have been due to constraints on resources i.e. it was more economical to 
have a low response rate and invite greater numbers of people than to increase the 
response rate by investing in promotion. 
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The original protocol mentioned that UK Biobank would recruit participants from 35 
assessment centres, each open for about six months.
338
 In reality, there were fewer 
assessment centres that were generally open much longer. Again, it is possible that it 
was decided to keep fewer centres open for longer as it was more economical than 
establishing new centres though of course this will have negatively affected response 
rates as more people living further away from the assessment centres would have to 
have been invited. 
 
Early reports suggested that UK Biobank was achieving a response rate of 
approximately 10%.
343, 344
 It is not known whether this does mean that there was a drop-
off in response rates in later assessment centres or perhaps response rates were 
calculated slightly differently. Unfortunately, there is no detailed information about 
response rates by assessment centre, although it was reported that the response rate 
achieved in Bristol was much higher than in other assessment centres.
344, 345
 Though it 
cannot be known for certain, this was thought to be related to the greater awareness of 
the benefits of cohort studies as a result of the locally-based Avon Longitudinal Study 
of Parents and Children.
346
 This is interesting because it indicates that although response 
rates for epidemiological research are declining, there may be factors that can increase 
response rates, in particular through increasing awareness of the benefits of such 
research. 
 
3.5 Representativeness 
 
The aim of all epidemiological research is to acquire knowledge that can be applied to 
improve the health of the population. To do this, some form of investigation is 
undertaken in a sample of the population and it is hoped that the evidence found can be 
generalised to the population of interest. Investigators must always think carefully about 
any potential reasons why the results found in the sample may not be generalisable to 
the larger population. Representativeness of the sample has often been thought of as a 
crucial component of generalisability but this may not be the case.
347
 
 
First of all, representativeness is vitally important in certain contexts. The validity of the 
conclusions from censuses and surveys are completely dependent on the 
representativeness of the sample used.
348
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However, cohort studies are used to investigate associations between risk factors and 
disease and are not used to describe the characteristics of a larger population. A 
distinction should first be made between representativeness and response rates. A high 
response rate obviously signifies that the recruited participants will closely resemble the 
population of interest, provided that the sample of people approached was adequately 
drawn. However, a low response rate does not necessarily signify a non-representative 
sample or cohort. A cohort with a low response rate could still be representative if each 
member of the population of interest had an equal probability of taking part. In reality 
though a low response rate generally signifies high levels of self-selection among 
participants which will result in non-representativeness. 
 
The British Doctors Study is often mentioned when talking about representativeness.
42
 
Male doctors are clearly not representative of the general population. However, the 
findings of this study on smoking and health have been considered broadly applicable to 
the general population. In fact, the non-representativeness is often considered as a 
strength of the study since it meant that smokers and non-smokers were very similar in 
most regards except for the exposure of interest. 
 
The only reason why non-representativeness may result in results that are not 
generalisable to a larger population is if the association between exposure and outcome 
was modified by a third factor which differed in prevalence between the cohort and the 
population of interest. In this case, it would be necessary to investigate the association 
according to exposure to this third factor and representativeness could actually be 
detrimental for this. For example, if an association between exposure and outcome were 
modified by ethnicity, a representative sample would likely be unable to provide 
accurate estimates of the association within different ethnic groups since there will be 
only small numbers of ethnic minorities. The most efficient thing to do from a statistical 
point of view when an association is modified by another factor, rather than recruiting a 
representative sample, would be to recruit equal numbers of people from each subgroup 
of interest. 
 
In other words, results from a representative cohort would represent the overall average 
association in the general population. However, this does not mean that this association 
is equally generalisable to everybody in the general population. Generalisation includes 
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an understanding of the full set of circumstances in which results apply and when they 
do not.
347
 For example, some hypothetical exposure could be equally harmful to men as 
it is beneficial to women but this would not mean that the exposure is safe in the general 
population. Furthermore, representativeness is not a static idea. Surveys must be 
continuously updated. If the proportion of men in the general population were to 
increase, then the hypothetical exposure would appear to be harmful. However, the 
association for men and the association for women would not change. 
 
Also, the self-selection of participants at baseline may be advantageous if it leads to a 
more motivated group of participants who are more willing to undergo further 
measures. Thus, the low response rates at baseline should be balanced against the 
response rates for follow-up measures. 
 
UK Biobank is not a representative cohort but representativeness was not a priority for 
UK Biobank and heterogeneity was emphasised over representativeness. UK Biobank is 
of a sufficient size that it will be possible to obtain reliable estimates of risk factor-
disease associations according to a number of subgroups (even though the proportions 
of people represented in these subgroups may not match those in the general 
population). 
 
3.6 Further Measurements 
 
A number of further assessments have been carried out (and more will be carried out in 
the future) in order to further enhance the UK Biobank cohort. There are two reasons for 
conducting further assessments; one is to gain information on changes in participants’ 
exposure over time and the other is to expand the amount of data available in order to 
enable an even broader scope for research. 
 
The first of these enhancements was the 24 hour recall dietary questionnaire. This web 
questionnaire asked participants about their food and drink intake during the previous 
24 hours. It included questions on about 200 commonly consumed foods and drinks and 
took about 15 minutes to complete. This questionnaire was added to the assessment 
centre towards the end of recruitment. It was later sent out to all participants 
(approximately 320,000) who provided UK Biobank with an e-mail address on four 
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separate occasions over one year between 2011-2012 in order to account for seasonal 
variation and gain a more reliable estimate of a participant’s average diet. 
Approximately 210,000 participants completed at least one questionnaire and 80,000 
participants completed at least three questionnaires. 
 
Between August 2012 and June 2013 (on average approximately five years after the 
baseline assessment), 20,000 participants were completely re-assessed at the UK 
Biobank co-ordinating centre in Stockport. The response rate for this re-assessment was 
21%.
349
 Similar re-assessments of subsets of participants are planned to be carried out 
roughly every three to five years. 
 
Starting in June 2013 participants were invited by e-mail to wear a physical activity 
monitor for a week. Participants who agreed to take part were sent a device to wear on 
their wrist continuously for seven days before returning the device to UK Biobank in a 
pre-paid envelope. The data obtained from these devices will be used to provide an 
objective measure of physical activity. Approximately 100,000 participants agreed to 
wear the physical activity monitors. 
 
The UK Biobank Imaging Study began in May 2014 and plans to conduct detailed 
imaging scans of the vital organs of 100,000 participants. The scans will include the 
brain, heart, tissue and bones. These data available on such a large number of people is 
unprecedented and will further support research into a wide range of diseases. 
 
3.7 Follow-up 
 
Follow-up data on health outcomes is achieved mainly through linkage with routinely 
available national health datasets.
53
 Data are currently available on cancer diagnoses and 
deaths for all participants as well as data on hospital in-patient episodes. Data on cancer 
diagnoses are provided to UK Biobank by the Health and Social Care Information 
Centre for participants in England and Wales and by the Information Services Division 
of NHS National Services Scotland for participants in Scotland. Data on deaths are 
provided to UK Biobank by the Health and Social Care Information Centre for 
participants in England and Wales and by the National Health Service Central Register, 
Scotland for participants in Scotland. Follow-up data are updated periodically and 
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information from further datasets will be added in the future. The follow-up data 
available on cancers and deaths used in the analyses for this thesis are described in 
further detail in section 4.5. 
 
3.8 Characteristics of UK Biobank Cohort 
 
Complete data on baseline and follow-up for cancers and deaths were available for 
502,642 participants (229,175 men and 273,467 women). Table 3.8.1 shows the dates 
each assessment centre was open and also the number of participants recruited from 
each assessment centre. 
 
Table 3.8.1 Assessment Dates and Participants by Assessment Centre 
Assessment centre Recruitment dates Participants 
Stockport 13/03/2006 - 14/06/2006 3,798 
Manchester 16/04/2007 - 22/12/2007 13,940 
Oxford 30/04/2007 - 03/11/2007 14,062 
Cardiff 08/10/2007 - 31/05/2008 17,883 
Glasgow 16/07/2007 - 19/04/2007 18,653 
Edinburgh 07/11/2007 - 07/06/2007 17,201 
Stoke 05/12/2007 - 26/07/2008 19,440 
Reading 14/05/2008 - 02/05/2009 29,421 
Bury 14/01/2008 - 20/12/2008 28,335 
Newcastle 23/01/2008 - 28/03/2009 37,009 
Leeds 27/02/2008 - 11/07/2009 44,211 
Bristol 09/07/2008 - 28/11/2009 43,017 
Barts 27/08/2008 - 29/08/2008 12,584 
Nottingham 30/07/2008- 12/09/2009 33,880 
Sheffield 05/08/2009 - 13/07/2009 30,397 
Liverpool 28/01/2009 - 01/04/2010 32,822 
Middlesborough 29/04/2009 - 06/02/2010 21,289 
Hounslow 17/06/2009 - 26/06/2010 28,880 
Croydon 24/09/2009 - 09/07/2010 27,386 
Birmingham 29/10/2009 - 21/07/2010 25,503 
Swansea 11/03/2010 - 03/07/2010 2,282 
Wrexham 16/08/2010 - 01/10/2010 649 
 
Participants were mostly aged 40-69 at baseline; the age range of the cohort was 37-73; 
2,419 participants were aged 70, seven participants were aged 71-73 and seven 
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participants were aged 37-39. The age distribution of the cohort is shown in Figure 
3.8.1. 61% of participants were aged 55 or over. 
 
Figure 3.8.1 Age Distribution of UK Biobank Participants by Sex 
 
 
94% of participants reported a white ethnic background (Table 3.8.2). The 2011 
national census found that the white ethnic group accounted for 86.0% of the 
population, decreasing from 91.3% in 2001.
350
 
 
Table 3.8.2 Ethnic Background of UK Biobank Participants 
Ethnic background Participants % 
White 472,837 94.2 
Asian 9,882 2.0 
Black 8,066 1.6 
Chinese 1,574 0.3 
Mixed 2,958 0.6 
Other ethnic group 4,560 0.9 
Do not know 217 0.0 
Prefer not to answer 1,662 0.3 
 
Participants were assigned a Townsend deprivation index score based on data from the 
2001 national census. Participants were assigned the score corresponding to the output 
area (lowest geographical area for which census data are calculated) in which their 
postcode at baseline was located. Townsend deprivation index scores from the 2001 
census for England and Wales by ward are available at census.ukdataservice.ac.uk/get-
data/related/deprivation. These data were used to calculate quintiles of Townsend 
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deprivation in the general population. The percentage of participants included in each 
quintile is shown in Figure 3.8.2. A higher Townsend score represents a higher level of 
deprivation. Thus, 42% of participants lived in areas in the lowest quintile of 
deprivation. 
 
Figure 3.8.2 Distribution of Townsend Deprivation Index Score by National Quintiles 
of Deprivation 
 
Proportion of UK Biobank participants within quintiles of Townsend deprivation index based on national 
distribution of Townsend scores. Quintile 1 represents the lowest levels of deprivation and quintile 5 
represents the highest levels of deprivation. 
 
For alcohol intake, smoking, BMI and physical activity, participants’ responses were 
compared with data from the 2008 Health Survey for England (HSE).
351
 Data from the 
2008 HSE were acquired from www.ukdataservice.ac.uk and were restricted to men and 
women aged 40-69 in order to facilitate comparisons with UK Biobank participants. 
 
Overall, participants in UK Biobank consumed more alcohol on average than people in 
the general population (Table 3.8.3 and Table 3.8.4). For example, 51.3% of male 
participants and 36.6% of female participants reported drinking at least three times a 
week in UK Biobank compared to 44.8% of men and 32.0% of women in the 2008 
HSE. Also, 2.8% of male participants and 5.9% of female participants in UK Biobank 
reported never drinking alcohol compared to 3.8% of men and 6.5% of in the 2008 
HSE. 
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Table 3.8.3 Average Alcohol Intake Frequency in UK Biobank 
 Men  Women 
Alcohol intake frequency n %  n % 
Daily or almost daily 57,914 25.3  43,878 16.1 
Three or four times a week 59,552 26.0  55,911 20.5 
Once or twice a week 59,137 25.9  70,191 25.7 
One to three times a month 20,359 8.9  35,515 13.0 
Special occasions only 16,860 7.4  41,170 15.1 
Former 8,128 3.6  9,988 3.7 
Never 6,409 2.8  15,988 5.9 
Prefer not to answer 379 0.2  378 0.1 
 
Table 3.8.4 Average Alcohol Intake Frequency in HSE 2008 
 Men  Women 
Alcohol intake frequency n %  n % 
Almost every day 641 18.5  483 11.9 
Five or six days a week 254 7.3  193 4.8 
Three or four days a week 653 18.9  622 15.3 
Once or twice a week 936 27.1  1,011 24.9 
Once or twice a month 341 9.9  487 12.0 
Once every couple of 
months 
146 4.2  352 8.7 
Once or twice a year 179 5.2  402 9.9 
Not at all in last 12 months 24 0.7  50 1.2 
Former 152 4.4  198 4.9 
Never 132 3.8  262 6.5 
Do not know/ No answer 2 0.1  1 0.0 
 
There was a much lower prevalence of cigarette smoking in UK Biobank than in HSE 
2008 (Table 3.8.5 and Table 3.8.6). There was a slight difference in definitions with 
respect to current occasional smokers though this did not account for the large 
difference in cigarette smoking prevalence. 
 
Table 3.8.5 Cigarette Smoking in UK Biobank 
 Men  Women 
Cigarette smoking n %  n % 
Current regular cigarette smoker 17,944 7.9  18,551 6.8 
Former regular cigarette smoker 62,203 27.2  55,043 20.2 
Never regular cigarette smoker 147,488 64.5  198,287 72.6 
Prefer not to answer/ Do not know 1,075 0.5  1,138 0.4 
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Table 3.8.6 Cigarette Smoking in HSE 2008 
 Men  Women 
Cigarette smoking n %  n % 
Current cigarette smoker 715 20.6  777 19.1 
Former regular cigarette smoker 1,183 34.1  1,049 25.8 
Never regular cigarette smoker 1,563 45.0  2,235 55.0 
Do not know/ No answer 10 0.3  5 0.1 
 
There was a lower proportion of men and women with BMI ≥30 kg/m2 in UK Biobank 
than in the HSE 2008 (Table 3.8.7 and Table 3.8.8). 
 
Table 3.8.7 Body Mass Index in UK Biobank 
 Men  Women 
BMI (kg/m
2
) n %  n % 
<18.5 547 0.2  2,079 0.8 
18.5 - <25 56,763 25.0  105,695 38.9 
25 - <30 112,269 49.3  99,906 36.7 
30 - <40 54,900 24.1  57,683 21.2 
≥40 3,058 1.3  6,649 2.4 
 
Table 3.8.8 Body Mass Index in HSE 2008 
 Men  Women 
BMI (kg/m
2
) n %  n % 
<18.5 10 0.3  28 0.8 
18.5 - <25 710 23.3  1,183 33.8 
25 - <30 1,384 45.5  1,243 35.5 
30 - <40 893 29.3  933 26.6 
≥40 47 1.5  118 3.4 
 
In UK Biobank, 38.2% of male participants and 34.4% of female participants reported 
doing ≥30 minutes of at least moderate activity at least five times per week. This was 
slightly higher than the proportion of men (35.5%) and women (29.9%) who reported a 
similar level of activity in the 2008 HSE. 
  
A lower proportion of men and women reported having less than fair health in UK 
Biobank than in the 2008 HSE (Table 3.8.9 and Table 3.8.10). Fewer men (34.9%) and 
women (29.4%) in UK Biobank reported having a long-standing illness than men 
(49.0%) and women (49.7%) in the 2008 HSE. 
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Table 3.8.9 Overall Health Status in UK Biobank 
 Men  Women 
Health status n %  n % 
Excellent 35,544 15.5  46,346 17.0 
Good 127,487 55.7  161,597 59.2 
Fair 52,461 22.9  52,935 19.4 
Poor 12,010 5.3  10,771 4.0 
Prefer not to answer/ Do not know 1,217 0.5  1,355 0.5 
 
Table 3.8.10 Overall Health Status in HSE 2008 
 Men  Women 
Health status n %  n % 
Very good 1,060 30.5  1,295 31.9 
Good 1,452 41.8  1,686 41.5 
Fair 689 19.9  740 18.2 
Bad 201 5.8  253 6.2 
Very bad 66 1.9  91 2.2 
Do not know 3 0.1  1 0.0 
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Chapter 4 Methods 
 
This chapter provides more detailed information on the UK Biobank dataset and the 
statistical methods used to analyse the data. The data available for each of the three risk 
factors of interest are described, including the derivation of the variables used in the 
analysis; sections on alcohol intake and smoking also include a brief discussion of 
methods for measuring and analysing these exposures in epidemiological studies. Other 
variables relevant to the analyses are also described. Then, the outcome data are 
described in detail. Lastly, the statistical methods utilised in the analysis are described. 
 
4.1 Alcohol Data 
 
4.1.1 Measuring Alcohol Intake 
 
Accurately measuring alcohol intake is a serious challenge for epidemiological studies. 
People’s patterns of consumption can be very variable and alcoholic drinks come in a 
wide range of sizes and alcoholic strengths. Studies rely on self-reported data which 
mean that people may misreport their alcohol intake. In fact, it is well known that 
estimates of total alcohol consumption from surveys greatly underestimate total alcohol 
consumption based on national sales data.
34
 In the UK, only about 60% of total alcohol 
consumption is accounted for in surveys.
352
 
 
Questionnaires 
 
There exist a number of different types of questionnaire for acquiring data on average 
alcohol intake.
353, 354
 Semi-quantitative food frequency questionnaires are commonly 
used in epidemiological studies. People are asked to report their typical intake using a 
single question which usually includes frequency categories and also quantity categories 
for more frequent drinkers, for example “never in last 12 months, less than once per 
month, 1-3 times per month, 1-2 times per week, 3-4 times per week, 5-6 times per 
week, 1-2 drinks per day, 3-4 drinks per day, 4-6 drinks per day, >6 drinks per day.” 
This kind of question is commonly used because of its simplicity but has the  
disadvantage that it confounds frequency and quantity i.e. there is no distinction 
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between someone who drinks one drink once a week and someone who drinks five 
drinks once a week. 
 
Another common method for assessing alcohol intake in epidemiological studies and 
surveys is the quantity frequency (QF) method. People are asked to report how often 
they usually drink alcohol (frequency) and then how much alcohol they usually drink on 
one of these days (quantity). The QF method is a simple measure that should be able to 
capture average alcohol intake for both regular and infrequent or occasional drinkers. 
However, the main issue with the QF method is the inability to distinguish different 
drinking patterns. 
 
Some more recent questionnaires have attempted to obtain data on patterns of drinking 
and binge drinking. For example, some questionnaires may ask people, in addition to 
the quantity frequency questions, how often they drank above a specified amount or the 
maximum amount they drank on a single day in a specified reference period. The 
graduated frequencies (GF) method attempts to obtain information on average alcohol 
intake as well as drinking patterns.
353, 355
 People are first asked how often they drink a 
large number of “standard” drinks (e.g. 12 or more). People are then asked to report 
how often they drink decreasing quantities of “standard” drinks (e.g. 8-11, 5-7, etc.). 
The advantage of graduated frequencies is that they are able to measure the variability 
of intake and in particular heavy drinking patterns. A disadvantage of the GF method is 
that it is complex and obviously more intensive for people to complete. There are also 
concerns about the administration of the method and that some people may over-report 
their intake.
356
 
 
Pattern of Drinking 
 
In recent years, there has been an increased focus on the adverse health effects of binge 
drinking and on methods to reduce binge drinking. As described above, one major 
limitation of many alcohol questionnaires is the inability to distinguish different patterns 
of alcohol intake by simply asking people to report their average intake. For many 
people alcohol intake is a variable behaviour and is characterised by a regular pattern of 
drinking interspersed with heavier drinking occasions. When reporting average alcohol 
intake, people may tend to ignore infrequent or atypical episodes of drinking and simply 
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report their “usual” intake. This could be an important reason why alcohol intake is 
underestimated by self-reported data. 
 
One study asked people to report their average alcohol intake using a simple QF method 
and also included further questions about atypical drinking and drinking during special 
occasions.
357
 Including the responses for atypical/special occasion drinking, the estimate 
for total alcohol consumption increased from 63% to 79% of total alcohol intake based 
on national sales data. Hence, it seems likely that questionnaires can better characterise 
people’s average alcohol intake by including questions on pattern of intake. However, 
there still remained a significant difference between total alcohol intake estimated by 
the questionnaire and by national sales data. 
 
It must also be mentioned that sales data are not a `gold standard’ for measuring the 
accuracy or reliability of alcohol questionnaires and it is incorrect to assume that one 
measure of alcohol intake is more accurate simply because people report a higher 
alcohol intake on average. For example, the 2004 Australian National Drug Strategy 
Household Survey compared the amount of alcohol reported using the QF method, the 
GF method and also questions on alcohol intake yesterday.
358
 Whilst the QF and GF 
methods resulted in a similar estimate for total alcohol intake (50 and 52% of total 
alcohol intake based on sales data), alcohol intake yesterday produced the highest 
estimate for total alcohol intake (57%). This makes sense since people will have less 
difficulty accurately recalling their intake from the day before. However, alcohol intake 
yesterday is clearly an inadequate measure for average alcohol intake. For example, 
alcohol intake yesterday will overestimate the number of people who are non-drinkers 
because it will not only include actual non-drinkers but also drinkers who did not 
happen to drink yesterday. 
 
Estimating Drinks 
 
Another difficulty when assessing alcohol intake is that alcoholic beverages are 
available in a wide variety of sizes and strengths. This means that a typical alcoholic 
drink can contain very different amounts of alcohol for two different individuals and 
also that the typical alcohol intake for an individual can be quite variable. 
Questionnaires do not generally ask people to provide information on size and strength 
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of alcoholic beverages. Many questionnaires define a “standard” drink and ask 
participants to report their alcohol intake in terms of “standard” drinks. However, 
people have difficulties understanding these definitions and tend to overestimate how 
much alcohol is in a “standard” drink.359 The estimates of total alcohol consumption 
from the 2004 Australian National Drug Strategy Household Survey mentioned above 
were based on “standard” drinks. People were also asked to report their alcohol intake 
yesterday using more detailed questions including options for different drink sizes and 
strengths and this method accounted for 81% of total national alcohol consumption 
based on sales data.
358
 
 
Diaries 
 
Asking participants to record their alcohol intake using diaries can avoid many of the 
issues for questionnaires. The use of diaries precludes any problems with recall, they 
automatically capture information on the pattern of intake and participants should be 
able to provide more accurate information on the actual drink size and strength. The 
main issue with diaries is that they are demanding for participants and impractical for 
long periods of time. Hence, people are normally asked to record their alcohol intake 
over a relatively short period e.g. one week. However, this week may not represent an 
individual’s typical alcohol intake over a longer period of time. 
 
4.1.2 Alcohol Reference Group 
 
The choice of reference group for analyses of alcohol intake may have important 
consequences for the results though it is not clear what the ideal choice is. There has 
been much debate about the choice of reference group for analyses of alcohol intake. 
This has generally centred around studies of coronary heart disease and overall 
mortality where studies have found evidence for a J-shaped relationship such that low or 
moderate alcohol intake is associated with the lowest level of risk.
360, 361
 
 
Non-drinkers 
 
Many early studies of alcohol and mortality that found a lower risk for light/moderate 
drinkers used non-drinkers or current abstainers (i.e. both never drinkers and former 
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drinkers combined) as the reference group. Shaper and colleagues consequently argued 
that the lower risk of mortality observed among this group compared to non-drinkers 
may be a result of including former drinkers in the reference group.
46
 Many former 
drinkers will quit drinking as a result of illness, often referred to as “sick-quitters”, and 
it is likely that these people will have an elevated risk of mortality. In fact, meta-
analyses have shown a lower protective effect of alcohol on coronary heart disease and 
mortality when restricting to results using never drinkers as the reference group.
360, 361
 
 
Furthermore, former drinkers tend to exhibit a number of characteristics associated with 
greater levels of disease and poor health.
362-364
 For example, in the British Regional 
Heart Study, former drinkers had the highest prevalence of disease, the highest 
prevalence of medication use and were most likely to report poor health status.
362
 
Former drinkers are also likely to be heavy smokers and to have a low socioeconomic 
status. Also, one prospective study found that people who developed a longstanding 
illness were much more likely to quit alcohol drinking.
365
 
 
Another issue with the use of non-drinkers as the reference group is that the proportion 
of former drinkers will vary between studies. This means that the risk of disease in the 
reference group will vary between studies because it will depend on the relative 
proportions of former drinkers and never drinkers. Despite these reasons against the use 
of non-drinkers, studies continue to use non-drinkers as the reference group, presumably 
because the questionnaire only asked about current drinking and so could not separate 
current abstainers from lifetime abstainers. 
 
Never drinkers 
 
Thus, non-drinkers should be avoided as the reference group where possible. An 
alternative is to use never drinkers or lifetime abstainers as the reference group. 
However, it has been argued that never drinkers also do not provide an ideal reference 
group.
46, 366, 367
 In many countries alcohol consumption is a widespread behaviour 
whereas lifelong abstainers represent a small proportion of the population. Hence, never 
drinkers may not represent a reliable reference group for many studies due to the small 
number of people, particularly if the outcome of interest is fairly rare. It is important 
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that different studies use the same or similar reference groups in order to facilitate the 
comparison of results between studies. 
   
There is also a concern about confounding when using never drinkers as the reference 
group.
366, 368
 Never drinkers represent a small selected group and may abstain from 
drinking for a variety of reasons. Thus, never drinkers may differ from drinkers in terms 
of a number of other health related characteristics.
363, 364, 368, 369
 In general, light or 
moderate drinking is associated with a number of favourable health related behaviours. 
 
Another potential reason against using never drinkers as the reference group is because 
of misclassification of lifelong abstainers. The U.S. National Alcohol Survey, 
conducted in 1984 with follow-ups in 1990 and 1992, found that approximately half of 
the respondents reporting never drinking in 1992 had reported some level of drinking at 
an earlier survey.
366
 The 1958 British Birth Cohort Study found a similar pattern with 
67% of people reporting never drinking at age 45 also having reported some level of 
drinking at an earlier age (16, 23, 33 or 42).
370
 In both studies however these 
participants mainly reported occasional or very light drinking at earlier timepoints. Also 
since there will be similar misclassification amongst occasional or very light drinkers,
370
 
this is not necessarily an argument against the use of never drinkers as the reference 
group but rather for improved alcohol measures. 
 
In the Health Survey for England, participants were first asked if they ever drink alcohol 
nowadays. Participants who said no were then asked whether they meant never or very 
occasionally. Remarkably, almost 40% of participants who reported not drinking 
alcohol based on the first question said they drink very occasionally.
351, 371
 This 
indicates that, rather than simply poor recall from participants, some of the 
misclassification is due to poor questionnaire design and that, in order to identify never 
drinkers, the difference between never and hardly ever should be made more explicit.
372
 
 
Light Drinkers 
 
Another option for the reference group is light or occasional drinkers. Compared with 
never drinkers, light drinkers may provide a larger, more reliable reference group and 
also a less distinct group. However, the exposure needs to be well defined when using 
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light drinkers as the reference group. For example, some light drinkers will be former 
heavy drinkers. These former heavy drinkers will likely have a higher risk of disease 
meaning that the overall risk for light drinkers depends on the proportion who used to 
be heavier drinkers (this is similar to the issue with using non-drinkers as the reference 
group). Furthermore, as described above, it is difficult to obtain accurate data on 
patterns of drinking. Hence, some light drinkers could be infrequent binge drinkers who 
also may be at an elevated risk of disease. 
  
Thus, the risk of disease for light drinkers in each study will depend on the proportion 
of former heavy drinkers and binge drinkers. However, it is important that the reference 
group be well defined so that comparisons can be made between different studies. 
Therefore, light drinkers may not be a suitable choice for the reference group in the 
absence of detailed information on lifetime exposure and patterns of drinking. 
 
4.1.3 UK Biobank Questionnaire 
 
Questions 
 
Participants answered questions on alcohol intake as part of the touchscreen 
questionnaire. All questions included in the touchscreen questionnaire can be viewed on 
the study website (www.ukbiobank.ac.uk). The structure and the wording of the alcohol 
questions can be seen in Figure 4.1.1. Participants were first asked how often they drink 
alcohol. Participants who responded “never” were asked if they previously drank 
alcohol and participants who previously drank alcohol were asked why they stopped 
drinking. 
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6 Figure 4.1.1 UK Biobank Questions on Alcohol Intake 
 
The main questions on alcohol intake answered by UK Biobank participants as part of the touchscreen questionnaire. 
*For each question on specific beverages, participants could either enter a number, say “do not know” or “prefer not to answer”. Regardless of their answers to these questions all 
participants were then asked about their drinking ten years ago.
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Participants who reported drinking “daily or almost daily”, “three or four times a week” 
or “once or twice a week” were asked to report their average weekly intake of different 
alcoholic beverages (red wine, white wine/champagne, beer/cider, spirits, fortified wine, 
other). Participants who reported drinking “one to three times a month” or “special 
occasions only” were asked to report their average monthly consumption of the same 
alcoholic beverages. Unfortunately the monthly questions were only added during 
recruitment which resulted in missing data (further explained below). 
 
Participants who reported drinking were also asked how their current drinking at 
baseline compared to ten years ago. If participants said they drank less nowadays they 
were asked why they reduced their intake. Finally, participants were also asked “When 
you drink alcohol is it usually with meals?” 
 
Missing Data 
 
Altogether, 113,903 participants reported drinking “one to three times a month” or 
“special occasions only”. According to the structure of the questionnaire these 
participants should have then reported their average monthly intake of different 
alcoholic beverages. However, 73,061 (64%) of these participants had missing data for 
each of these monthly questions. These data were missing because the monthly 
questions were only introduced during recruitment and were not included in the original 
touchscreen questionnaire. 
 
In the original questionnaire all participants who reported drinking (from “daily or 
almost daily” to “special occasions only”) were asked about their average weekly 
consumption of specific alcoholic beverages. Hence, participants who completed the 
original questionnaire and reported drinking “one to three times a month” or “special 
occasions only” answered the weekly beverage questions instead of the monthly 
beverage questions. 
  
Participants who reported drinking “one to three times a month” or “special occasions 
only” would have found it difficult to accurately report their average weekly intake and 
it is likely that many of these participants simply answered zero for each question. This 
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is presumably why the monthly questions were added (although they were a rather late 
addition) and also why the weekly data were not made available for these participants. 
 
The updated questionnaire was introduced around May-July 2009 (Figure 4.1.2). Only 
three assessment centres changed from the original to the updated questionnaire during 
recruitment. All other assessment centres either used the original questionnaire or the 
updated questionnaire throughout recruitment. The questions on other alcoholic drinks 
(both per week and per month) were also only added as part of the updated 
questionnaire so participants who answered the original questionnaire had missing data 
for other alcoholic drinks. 
 
Figure 4.1.2 Introduction of the Updated Questionnaire by Assessment Centre in UK 
Biobank 
 
Recruitment period for each assessment centre. Red indicates that the original questionnaire was used. 
Participants who answered the original questionnaire and reported drinking “one to three times a month” 
or “special occasions only” had missing data for the monthly beverage questions since these questions 
were added during recruitment. Blue indicates the use of the updated questionnaire. 
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Table 4.1.1 Frequency of Alcohol Intake in UK Biobank by Age and Sex 
 Men  Women 
 <50 yrs 50-59 yrs ≥60 yrs Total  <50 yrs 50-59 yrs ≥60 yrs Total 
Alcohol Intake 
Frequency 
n % n % n % n %  n % n % n % n % 
Daily or almost daily 9,538 17.9 18,311 25.0 30,064 29.2 57,913 25.3  8,193 12.7 15,125 16.1 20,560 17.9 43,878 16.1 
Three or four times a week 13,442 25.3 19,999 27.3 26,111 25.4 59,552 26.0  13,849 21.4 20,389 21.7 21,672 18.9 55,910 20.4 
Once or twice a week 15,767 29.6 18,926 25.9 24,441 23.8 59,134 25.8  18,211 28.2 24,609 26.2 27,368 23.9 70,188 25.7 
One to three times a month 6,169 11.6 6,300 8.6 7,890 7.7 20,359 8.9  9,808 15.2 12,127 12.9 13,580 11.8 35,515 13.0 
Special occasions only 4,197 7.9 5,002 6.8 7,660 7.5 16,859 7.4  9,021 13.9 13,363 14.2 18,786 16.4 41,170 15.1 
Never 2,056 3.9 1,705 2.3 2,646 2.6 6,407 2.8  3,463 5.4 4,710 5.0 7,815 6.8 15,988 5.9 
Former 1,791 3.4 2,659 3.6 3,677 3.6 8,127 3.6  1,918 3.0 3,446 3.7 4,623 4.0 9,987 3.7 
Missing/Prefer not to 
answer* 
255 0.5 250 0.3 319 0.3 824 0.4  230 0.4 280 0.3 321 0.3 831 0.3 
Total 53,215 100.0 73,152 100.0 102,808 100.0 229,175 100.0  64,693 100.0 94,049 100.0 114,725 100.0 273,467 100.0 
*898 people had missing data for alcohol questions, 605 said prefer not to answer to first question, 152 people said prefer not to answer for question on past drinking. 
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Responses 
 
Table 4.1.1 shows how often participants reported drinking alcohol. Participants who 
reported never drinking alcohol were split into never drinkers and former drinkers 
according to whether they reported drinking in the past. 51.3% of men reported drinking 
at least three or four times a week and 77.1% of men reported drinking at least once or 
twice a week. The corresponding figures for women were 36.5% and 62.2%. Older men 
and women were more likely to drink daily or almost daily. The proportion of former 
drinkers was similar for men (3.6%) and women (3.7%) but the proportion of never 
drinkers among women (5.9%) was more than double that among men (2.8%). 
 
4.1.4 Alcohol Analysis Variable 
 
To obtain a measure of overall consumption, grams of alcohol per day were calculated 
for each participant based on their responses to the alcoholic beverage questions. The 
grams of alcohol contained in an alcoholic drink depends on the size of the drink and 
the strength of the alcohol. The sizes and strengths used to calculate the grams of 
alcohol for each alcoholic beverage are shown in Table 4.1.2. The size of each alcoholic 
beverage was calculated using the information in the questionnaire (Figure 4.1.1). For 
example the red and white wine questions stated that an average bottle contains six 
glasses of wine. Therefore, assuming an average bottle of wine contains 750ml, the 
drink size for red and white wine was defined as 125ml. 
 
Table 4.1.2 Defintion of Grams of Alcohol for Different Alcoholic Beverages used in 
Analyses 
Alcoholic 
beverage 
Beverage 
size (ml) 
g/100ml g 
Red wine 125 9.6 12.0 
White wine 125 9.0 11.3 
Beer 568.3 3.5 19.9 
Spirits 30 30.7 9.2 
Fortified wine 62.5 15.4 9.6 
 
The alcohol strengths (g/100ml) for each alcoholic beverage were taken from the 
Oxford WebQ,
373
 an online dietary questionnaire used by UK Biobank to assess 
participants’ dietary intake. The alcohol strengths used by Oxford WebQ were based on 
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values from McCance and Widdowson’s The Compositions of Foods.58, 374 These 
g/100ml values were multiplied by the drink sizes (before dividing by 100) to obtain the 
number of grams of alcohol for each alcoholic beverage. 
 
For each participant, the grams of alcohol for each alcoholic beverage were multiplied 
by the reported number of drinks of that beverage consumed in an average week or 
month. These values were summed to give the total grams of alcohol per week or per 
month before converting to grams of alcohol per day. 
 
The questions on other alcoholic drinks were ignored when calculating grams of alcohol 
per day for two reasons. First, the questions were rather imprecise in comparison with 
the other questions on alcoholic beverages; other drinks could include a wide range of 
alcoholic beverages and the indication of the drink size was vague. Secondly, the large 
majority of participants reported zero intake for other alcoholic drinks; 99% of 
participants who answered the weekly question on other alcoholic drinks reported zero 
intake and 95% of participants who answered the monthly question reported zero intake. 
 
Alcohol intake was not defined for a number of participants. 898 participants were 
excluded because they had missing data for the first question on alcohol intake 
frequency and all following alcohol questions. 757 participants were excluded because 
they said “prefer not to answer” for the alcohol intake frequency question or for past 
alcohol intake question. 7,445 participants who said “do not know” or “prefer not to 
answer” for at least one of the alcoholic beverage questions were also excluded. 
 
2,350 participants were excluded for reporting a number of alcoholic drinks inconsistent 
with their reported alcohol intake frequency. This included participants who reported 
drinking “daily or almost daily” and less than four drinks per week, “three or four times 
a week” and less than two drinks per week, “once or twice a week” and less than one 
drink per week, and “one to three times a month” and less than one drink per month. 
Participants who reported drinking “special occasions only” were not excluded for 
reporting a low number of drinks. 
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2 Table 4.1.3 Mean Grams of Alcohol per Day Consumed by Men and Women in UK Biobank, by Alcohol Frequency  
 Men  Women 
 
Red 
wine 
White 
wine 
Beer Spirits 
Fortified 
wine 
Total  
Red 
wine 
White 
wine 
Beer Spirits 
Fortified 
wine 
Total 
Daily or almost daily 13.1 5.5 21.2 5.1 0.4 45.3  10.3 9.7 2.3 3.1 0.6 26.0 
Three or four times a week 7.1 3.0 15.0 2.4 0.2 27.6  6.3 5.6 1.8 1.8 0.4 15.8 
Once or twice a week 2.8 1.3 9.2 1.3 0.1 14.9  2.7 2.6 1.4 1.3 0.2 8.3 
One to three times a month 0.6 0.4 2.1 0.3 0.1 3.6  0.6 0.7 0.5 0.4 0.1 2.1 
Special occasions only 0.3 0.2 0.7 0.1 0.0 1.3  0.2 0.2 0.1 0.1 0.0 0.6 
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Alcohol grams per day was not calculated for 73,061 participants who reported drinking 
“one to three times a month” or “special occasions only” due to the missing data 
described above. (These missing data were imputed using multiple imputation as a form 
of sensitivity analysis for the analysis of alcohol intake and colorectal cancer (described 
in detail in section 4.6.5)). 
  
Table 4.1.3 shows the mean grams of alcohol per day reported by male and female 
drinkers for the different alcoholic beverages and overall. Results are presented by 
alcohol frequency. Within each frequency category, men reported drinking substantially 
more alcohol than women. For men the majority of alcohol was consumed in the form 
of beer and red wine and for women the majority of alcohol was consumed in the form 
of red and white wine. 
 
Categorical Analysis Variable 
 
The following categories of alcohol intake were defined: never drinkers, former 
drinkers, <5 g/d, 5-<15 g/d, 15-<30 g/d 30-<45 g/d and ≥45 g/d. These categories were 
based on those of a large pooled analysis of alcohol intake and colorectal cancer.
45
 
Participants who reported not drinking alcohol at baseline and not previously drinking 
alcohol were defined as never drinkers. Participants who reported not drinking alcohol 
at baseline and reported previously drinking alcohol were defined as former drinkers. 
Table 4.1.4 shows the number of participants in each category of the alcohol intake 
variable. 418,131 participants (217,928 men and 200,203 women) were included in this 
variable. 
 
Table 4.1.4 Alcohol Intake Variable 
 Men  Women  Overall 
Alcohol intake n %  n %  n % 
Never 6,407 3.2  15,988 7.3  22,395 5.4 
Former 8,127 4.1  9,987 4.6  18,114 4.3 
<5 g/d 17,154 8.6  46,582 21.4  63,736 15.2 
5-<15 g/d 48,041 24.0  82,547 37.9  130,588 31.2 
15-<30 g/d 57,929 28.9  46,348 21.3  104,277 24.9 
30-<45 g/d 31,748 15.9  11,758 5.4  43,506 10.4 
≥45 g/d 30,797 15.4  4,718 2.2  35,515 8.5 
Total 200,203 100.0  217,928 100.0  418,131 100.0 
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Reference Group 
 
Given the potential issues with using non-drinkers or light drinkers as the reference 
group described in section 4.1.2, never drinkers were used as the reference group in 
analyses of the categorical alcohol intake variable. The disadvantage of never drinkers 
is that they represent a small group which can result in wide CIs, particularly for 
subgroup analyses. However, in the absence of detailed information on past drinking or 
patterns of drinking, it was decided that never drinkers represented the most consistent 
and well-defined reference group. 
 
As a form of sensitivity analysis (and to provide a comparison), results were also 
calculated using a slightly different reference group which combined never drinkers and 
consistent light drinkers. Consistent light drinkers were defined as participants who 
reported drinking <5 g/d and reported drinking “about the same” or “more nowadays” 
as ten years before baseline. 27,252 participants met the definition of consistent light 
drinkers. 
 
Continuous Analysis Variable 
 
A categorical variable offers a very simple way to compare the risk of disease 
associated with different levels of exposure and therefore the interpretation of the results 
is straightforward. However, results will depend on the arbitrary choice of cut-points 
and results would suggest that the risk suddenly increases as a cut-point is crossed. In 
contrast, a continuous variable avoids the arbitrary cut-points. It also avoids the issues 
with the choice of the reference group. However, a number of different models can be 
fit to a continuous variable and it can be difficult to decide the most appropriate model. 
 
For the continuous alcohol grams per day variable, never drinkers were defined as zero 
g/d while former drinkers were excluded. Participants who reported drinking “special 
occasions only” and reported zero intake for each alcoholic beverage were also 
excluded. One g/d was added to the continuous variable to accommodate different 
analysis models (e.g. logarithmic and negative power transformations). Thus, the 
continuous variable was defined for 391,645 participants (190,006 men and 201,639 
women). 
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Alternative Variable 
 
As described above, a number of participants who reported drinking “one to three times 
a month” or “special occasions only” had missing data and so could not be included in 
the analysis variables. In the analyses of adiposity and smoking, an alternative alcohol 
variable was used in order to avoid excluding these participants. 
  
This alternative alcohol variable was similar to the original categorical variable. Never 
and former drinkers were defined as before. Also, participants who reported drinking 
“once or twice a week”, “three to four times a week” or “daily or almost daily” were 
defined by their average grams of alcohol per day as before. However, in contrast to the 
original variable, participants who reported drinking “one to three times a month” or 
“special occasions only” were not categorised by their average grams of alcohol per day 
but were included as distinct categories (Table 4.1.5). 
  
Table 4.1.5 Alternative Alcohol Intake Variable 
 Men  Women  Overall 
Alcohol intake n %  N %  n % 
Never 6,407 2.9  15,988 6.0  22,395 4.5 
Former 8,127 3.6  9,987 3.7  18,114 3.7 
Special occasions only 16,859 7.5  41,170 15.3  58,029 11.8 
One to three times a month 20,359 9.1  35,515 13.2  55,874 11.3 
<5 g/d 5,895 2.6  20,937 7.8  26,832 5.4 
5-<15 g/d 46,392 20.7  81,904 30.5  128,296 26.0 
15-<30 g/d 57,874 25.8  46,343 17.3  104,217 21.2 
30-<45 g/d 31,746 14.1  11,757 4.4  43,503 8.8 
≥45 g/d 30,794 13.7  4,718 1.8  35,503 7.2 
Total 224,453 100.0  268,319 100.0  492,772 100.0 
 
This variable was not ideal since it combined measures of average alcohol intake and 
average frequency of intake. However, only participants with a low frequency of 
alcohol intake were classified by their frequency. These participants were expected to 
have a very similar low level of average alcohol intake. For example, among 
participants with observed data, 95% of participants who reported drinking “one to three 
times a month” reported drinking less than 6.5 g/d and 95% of participants who reported 
drinking “special occasions only” reported drinking less than 3.1 g/d. Therefore, 
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including these categories should not have resulted in significant misclassification. In 
contrast, there was much more variation in average alcohol intake among participants 
who reported drinking alcohol more frequently and so it was important that these 
participants were still classified by their average alcohol intake rather than their 
frequency of intake. However, it should not have made an important difference whether 
participants who reported drinking “one to three times a month” or “special occasions 
only” were classified by their average alcohol intake or their average frequency of 
intake. In fact, among participants with complete data for alcohol intake, results for 
BMI and overall smoking status were practically identical whether adjusting for the 
original categorical variable or the alternative variable (see Table A-1 and Table A-2 in 
the appendix). 
 
An alternative approach to avoid excluding those participants with missing data from 
the analysis would be to impute the data using multiple imputation. Multiple imputation 
was used to impute these missing data in a sensitivity analysis for the relationship 
between alcohol intake and colorectal cancer (see section 4.6.5). However, it was 
decided not to use this method when considering alcohol intake as a confounder in the 
adiposity and smoking analyses. First of all, as mentioned above, the alternative 
variable was shown to give practically identical results as the original categorical 
variable among participants with complete data, suggesting that the use of this 
alternative variable throughout the adiposity and smoking analyses should produce valid 
results. 
 
Furthermore, multiple imputation has a number of limitations and is highly dependent 
on the correct specification of the imputation model.
375-377
 This can be a complex 
problem when using multiple imputation for multiple analyses with many variables and 
possible interactions between variables and a poorly specified imputation model may 
lead to biased results. 
 
Multiple imputation is also dependent on the assumption that the missing data are 
missing at random i.e. that, conditional on the observed data available in the dataset, all 
participants have an equal probability of having missing data.
375, 376
 However, if the 
probability that a participant has missing data depends on the unobserved values, then 
multiple imputation can lead to biased results. When using multiple imputation for a 
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number of analyses, a large number of analysis variables must be included in the 
imputation model. However, each of these variables will likely include some missing 
data and this reduces the amount of missing data that can be imputed (since fewer 
participants will have complete data for all variables in the imputation model). To solve 
this issue, data can be imputed for multiple analysis variables simultaneously using 
chained equations.
375
 However, if the data for any of these variables are not missing at 
random, multiple imputation can lead to biased results. 
 
4.2 Adiposity Data 
 
This section provides information on the measures of adiposity used in this thesis to 
investigate the association between adiposity and colorectal cancer. All measures of 
adiposity were completed by a trained member of staff at the baseline assessment 
centre. The following measures of adiposity were considered in this thesis: body mass 
index, waist circumference, waist to hip ratio, waist to height ratio and % body fat. 
 
Body Mass Index 
 
BMI is the most commonly used measure of adiposity in the general population. It is 
defined as the weight in kilograms divided by the square of the height in metres (kg/m
2
) 
and thus provides a very simple measure of weight adjusted for height. 
 
In UK Biobank height and weight were both measured at baseline by the assessment 
centre staff. Participants were required to stand barefoot for measurements of height and 
weight. Height was measured to the nearest centimetre and weight was measured to the 
nearest 100g. 
 
227,529 men and 272,008 women provided data on BMI. 30 men and 96 women with 
BMI <16 kg/m
2
 were excluded because these values were considered as outliers (no 
participants were excluded for a high value of BMI). BMI was defined for 227,499 men 
and 271,912 women. Figure 4.2.1 and Figure 4.2.2 show the distribution of BMI for 
men and women. 
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 Figure 4.2.1 Body Mass Index for Men 
 
Distribution of body mass index for men. 
 
Figure 4.2.2 Body Mass Index for Women 
 
Distribution of body mass index for women. 
 
Participants were classified into approximate quintiles of BMI, separately for men and 
women (Table 4.2.1). Participants were also classified into three categories of BMI 
following the WHO definitions;
159
 <25.0, 25.0-<30.0 and ≥30.0 kg/m2 (Table 4.2.2). 
(Men and women with BMI <18.5 kg/m
2
 were not defined separately as there were only 
517 men and 1,983 women with BMI <18.5 kg/m
2
). 
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Table 4.2.1 Body Mass Index Quintiles for Men and Women 
Men  Women 
BMI (kg/m
2
) Participants  BMI (kg/m
2
) Participants 
<24.45 45,428  <22.89 54,479 
24.45-<26.40 45,519  22.89-<25.04 54,314 
26.40-<28.28 43,633  25.04-<27.34 54,034 
28.28-<30.84 47,440  27.34-<30.80 54,646 
≥30.84 45,479  ≥30.80 54,439 
Total 227,499  Total 271,912 
 
Table 4.2.2 Body Mass Index Categories 
BMI (kg/m
2
) Men Women 
<25.0 57,277 107,676 
25.0-<30.0 112,265 99,905 
≥30.0 57,957 64,331 
Total 227,499 271,912 
 
Waist Circumference 
 
WC was measured to the nearest centimetre by the assessment centre staff using a tape 
measure. 228,099 men and 272,383 women provided data on WC. 408 men with a WC 
less than 70 cm and 396 women with a WC less than 60 cm were excluded because 
these values were considered as outliers (no participants were excluded for a high value 
of WC), leaving 227,691 men and 271,987 women. Figure 4.2.3 and Figure 4.2.4 show 
the distribution of WC for men and women. 
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Figure 4.2.3 Waist Circumference for Men 
 
Distribution of waist circumference for men. 
 
Figure 4.2.4 Waist Circumference for Women 
 
Distribution of waist circumference for women. 
 
Approximate sex-specific quintiles were created for the analysis of WC (Table 4.2.3). 
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Table 4.2.3 Waist Circumference Quintiles for Men and Women 
Men  Women 
WC (cm) Participants  WC (cm) Participants 
≤87 43,468  ≤74 59,183 
88-93 48,046  75-80 54,106 
94-98 44,165  81-86 51,753 
99-105 46,532  87-95 56,178 
≥106 45,480  ≥96 50,767 
Total 227,691  Total 271,987 
 
Waist to Hip Ratio 
 
Hip circumference was also measured to the nearest centimetre by assessment centre 
staff using a tape measure. WHR was calculated as the ratio between WC and hip 
circumference. 228,037 men and 272,340 women provided data on both WC and hip 
circumference. 427 men with WC less than 70 cm or hip circumference less than 80 cm 
and 405 women with WC less than 60 cm or hip circumference less than 70 cm were 
excluded (because these values were considered as outliers), leaving 227,610 men and 
271,935 women. Figure 4.2.5 and Figure 4.2.6 show the distribution of WHR for men 
and women. 
 
Figure 4.2.5 Waist to Hip Ratio for Men 
 
Distribution of waist to hip ratio for men. 
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Figure 4.2.6 Waist to Hip Ratio for Women 
 
Distribution of waist to hip ratio for women. 
 
Approximate sex-specific quintiles were created for the analysis of WHR (Table 4.2.4). 
 
Table 4.2.4 Waist to Hip Ratio Quintiles for Men and Women 
 
 
Waist to Height Ratio 
 
Waist to height ratio (WHtR) was calculated as the ratio between waist circumference 
and height (see section 4.4.1 for information on height). 227,457 men and 271,848 
women had data on both WC and height. 386 men with WC less than 70 cm and 363 
women with WC less than 60 cm were excluded, leaving 227,071 men and 271,485 
women. Figure 4.2.7and Figure 4.2.8 show the distribution of WHtR for men and 
women. 
  
Men  Women 
WHR Participants  WHR Participants 
<0.883 45,618  <0.758 55,428 
0.883-<0.918 44,701  0.758-<0.796 54,195 
0.918-<0.950 46,286  0.796-<0.832 54,229 
0.950-<0.990 45,822  0.832-<0.876 52,680 
≥0.990 45,183  ≥0.876 55,403 
Total 227,610  Total 271,935 
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Figure 4.2.7 Waist to Height Ratio for Men 
 
Distribution of waist to height ratio for men. 
 
Figure 4.2.8 Waist to Height Ratio for Women 
 
Distribution of waist to height ratio for women. 
 
Approximate sex-specific quintiles were created for the analysis of WHtR (Table 4.2.5). 
  
Chapter 4 | Methods 
164 
Table 4.2.5 Waist to Height Ratio Quintiles for Men and Women 
Men  Women 
WHtR Participants  WHtR Participants 
<0.500 44,448  <0.453 54,039 
0.500-<0.532 46,366  0.453-<0.492 54,582 
0.532-<0.562 45,120  0.492-<0.532 53,654 
0.562-<0.602 45,481  0.532-<0.586 55,040 
≥0.602 45,656  ≥0.586 54,170 
Total 227,071  Total 271,485 
 
% Body Fat 
  
% body fat of participants was measured using bioelectrical impedance. Bioelectrical 
impedance involves sending a low electrical current through the body and then 
measuring the resistance to this current. Since the current flows more easily through 
muscle which contains a high proportion of water and less easily through fat tissue, it is 
possible to estimate body fat. UK Biobank used a Tanita BC418MA body composition 
analyser to measure % body fat. Data on % body fat were available for 223,889 men 
and 268,343 women. Figure 4.2.9 and Figure 4.2.10 show the distribution of % body fat 
for men and women. 
 
Figure 4.2.9 % Body Fat for Men 
 
Distribution of % body fat for men. 
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Figure 4.2.10 % Body Fat for Women 
 
Distribution of % body fat for women. 
 
Approximate sex-specific quintiles were created for the analysis of % body fat (Table 
4.2.6). 
 
Table 4.2.6 % Body Fat Quintiles for Men and Women 
Men  Women 
% body fat Participants  % body fat Participants 
≤20.6 45,490  ≤30.8 53,980 
20.7-24.0 44,978  30.9-35.0 53,546 
24.1-26.8 44,845  35.1-38.5 53,586 
26.9-30.0 43,903  38.6-42.5 54,017 
≥30.1 44,673  ≥42.6 53,214 
Total 223,889  Total 268,343 
 
4.3 Smoking Data 
 
4.3.1 Measuring Smoking Exposure 
 
Information on tobacco use is generally obtained in epidemiological studies through the 
use of self-reported questionnaires. These questionnaires are broadly similar across 
studies. However, these questionnaires have clear limitations and there are a number of 
issues that should be kept in mind when evaluating these studies. 
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The simplest measure of tobacco exposure, included in practically all studies, is 
smoking status which classifies people as never, former or current smokers. This is 
usually accomplished with the use of one or two questions. For example, a 
questionnaire may ask people whether they currently smoke tobacco and then ask 
people who do not currently smoke tobacco whether they smoked tobacco in the past. 
 
When measuring any behaviour or exposure that can be considered socially undesirable, 
there are concerns about the accuracy of self-reported data. A systematic review of 
studies comparing measures of self-reported smoking status and cotinine (a biomarker 
of exposure to tobacco smoke) found that the self-reported data underestimated the 
prevalence of smoking in most studies.
378
 However, different studies use a wide range 
of cut-off points to define smokers and it should be recognised that biochemical 
measures of smoking can be affected by many factors including metabolism, inhalation 
and brand of cigarettes.
378
 
 
Defining participants as never, former or current smokers is clearly a rather simple 
approach and, as well as the concerns about the misclassification of participants using 
self-reported data, the smoking status variable has a number of other limitations. For 
example, current smokers will likely include both regular smokers and occasional 
smokers although these two groups will clearly have a very different level of exposure. 
Also, smoking status often does not differentiate between different forms of tobacco use 
and so will combine cigarette smokers and other smokers e.g. cigar or pipe smokers 
who may differ in terms of pattern of use as well as tobacco type. 
 
It can also be difficult to clearly differentiate between never smokers and former 
smokers when defining smoking status. For example, many people may have tried 
smoking once or twice but never smoked regularly. Using the strictest sense of the 
terms, these people are former smokers. However, given their low exposure, it seems 
inappropriate to combine these people with former regular smokers. Also, many of 
these people likely identify themselves as never smokers. Thus, a common approach in 
questionnaires is to define an upper threshold for never smokers which is often defined 
as smoking 100 times in their lifetime.
379
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Questionnaires also attempt to measure other aspects of exposure to tobacco smoke 
such as smoking intensity and smoking duration. These questions generally focus on 
cigarette use. To assess smoking intensity, current smokers are normally asked to report 
how many cigarettes they smoke per day on average and former smokers are asked to 
report how many cigarettes they used to smoke per day on average. However, self-
reports of cigarettes per day may not be very accurate. For example, there is a large 
amount of digit preference for multiples of ten when reporting the number of cigarettes 
per day. While some degree of digit preference may be expected since cigarettes are 
commonly sold in packets of ten and 20 in many countries, this does not seem to 
provide a sufficient explanation. For example, one study found that while the 
distribution of cigarettes per day reported by smokers showed large spikes for multiples 
of ten (and particularly 20), the distribution of a biochemical measure of smoking 
showed no such spikes, suggesting that the distribution of self-reported cigarettes per 
day does not reflect actual cigarette consumption.
380
 
 
Another study of smokers who were part of a cessation programme similarly showed 
large digit preference for multiples of ten when asked to report the average number of 
cigarettes they smoked per day.
381
 These people were also asked to concurrently record 
(using an electronic device) each cigarette they smoked throughout the day for a period 
of two weeks before the initiation of the programme (subjects were instructed not to 
change their smoking habits). The distribution of cigarettes per day based on the 
concurrent daily reports showed a more even spread, again suggesting that more simple 
self-report measures of cigarettes per day are limited in providing accurate data. 
 
To assess smoking duration, questionnaires ask people to report their age when they 
started smoking. In general, there is a fairly narrow range for age at initiation since the 
vast majority of smokers begin smoking before adulthood. In a U.S. survey, 88.2/99.0% 
of adults who had ever been daily cigarette smokers reported trying their first cigarette 
by the time they were 18/26 years old and 65.1/96.2% percent reported beginning daily 
smoking by 18/26 years of age.
382
 However, age at smoking initiation may not be easily 
reported. Generally, people are asked to report their age at initiation decades later 
meaning that there may be error due to difficulties with recall. Furthermore, there may 
be a number of stages from first cigarette to regular use and different people will follow 
different trajectories.
382, 383
 Former smokers are also asked to report when they quit 
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smoking. This may include some error, possibly depending on how long ago people quit 
smoking and the manner in which they converted from regular smoking to no smoking. 
 
4.3.2 UK Biobank Questionnaire 
 
Questions 
 
Participants answered questions on tobacco use as part of the touchscreen questionnaire. 
The section of the questionnaire on tobacco use was very detailed with a wide range of 
questions. The structure and wording for most of the questions on tobacco use can be 
seen in Figure 4.3.1. 
 
 
 
 
Chapter 4 | Methods 
169 
Figure 4.3.1 UK Biobank Questions on Tobacco Use 
 
The main questions on tobacco use answered by UK Biobank participants as part of the touchscreen questionnaire.
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Participants were first asked if they currently smoke tobacco. Participants who reported 
smoking tobacco on most or all days were asked what type of tobacco they mainly 
smoke. If they reported smoking cigarettes (manufactured or hand-rolled), they were 
then asked how many cigarettes they smoke on an average day. If participants reported 
smoking cigars or pipes, they were asked if they previously smoked cigarettes on most 
or all days and, if they had previously smoked cigarettes on most or all days, they were 
asked how many cigarettes they smoked on an average day. 
   
If participants reported that they do not smoke tobacco or smoke tobacco only 
occasionally, they were then asked about their past smoking. Participants who reported 
smoking on most or all days in the past were asked what type of tobacco they usually 
smoked and, if they reported smoking cigarettes (manufactured or hand-rolled), they 
were asked how many cigarettes they used to smoke on an average day. Participants 
who reported smoking occasionally in the past or having just tried once or twice were 
asked if they had ever smoked at least 100 times in their lifetime. 
 
Responses 
 
Table 4.3.1 provides a detailed description of participants’ responses to the main 
questions on tobacco use. Participants who responded “smoked occasionally” or “just 
tried once or twice” to the question on past tobacco use were defined as former 
occasional smokers. Not all subcategories sum to the higher categories due to other 
responses provided by participants, for example responding “prefer not to answer”. 
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Table 4.3.1 Tobacco Use in UK Biobank by Sex 
 Men  Women  Overall 
Smoking status n %  n %  n % 
Daily smokers 20,565 9.0  18,689 6.8  39,254 7.8 
Cigarette smoker 17,943   18,551   36,494  
Cigar/pipe smoker 2,563   105   2,668  
Occasional smoker 8,052 3.5  5,683 2.1  13,735 2.7 
Former daily smoker 2,900   2,134   5,034  
Cigarette smoker 2,576   2,127   4,703  
Cigar/pipe smoker 317   5   322  
Former occasional smoker 5,114   3,520   8,634  
Smoked ≥100 times 4,580   3,118   7,698  
Smoked <100 times 381   250   631  
Non-smoker 199,909 87.2  248,423 90.8  448,332 89.2 
Former daily smoker 62,892   53,025   115,917  
Cigarette smoker 57,917   52,838   110,755  
Cigar/pipe smoker 4,886   114   5,000  
Former occasional smoker 57,161   72,674   129,835  
Smoked ≥100 times 26,115   27,071   53,186  
Smoked <100 times 29,223   41,883   71,106  
Never smoker 79,050   121,851   200,901  
Missing/Prefer not to answer* 649 0.3  672 0.2  1,321 0.3 
Total 229,175 100.0  273,467 100.0  502,642 100.0 
*892 participants had missing data for questions on tobacco use. 429 participants reported prefer not to 
answer to question on current tobacco use. 
   
Figure 4.3.2 and Figure 4.3.3 show the age at smoking initiation reported by former and 
current smokers. 60.5% of former smokers and 51.6% of current smokers reported that 
they started smoking on most days between 15 and 18 years old. 
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Figure 4.3.2 Age at Smoking initiation by Former Smokers 
 
Age reported starting smoking on most days by former smokers. 
 
Figure 4.3.3 Age at Smoking Initiation by Current Smokers 
 
Age reported starting smoking on most days by current smokers. 
 
Figure 4.3.4 shows the age at smoking cessation reported by former smokers. The 
distribution shows a clear digit preference for multiples of five/ten. 
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Figure 4.3.4 Age at Smoking Cessation 
 
Age reported stopping smoking on most days by former smokers. 
 
Of the 120,951 participants who reported smoking on most or all days in the past, 
115,458 reported smoking cigarettes. Figure 4.3.5 shows a graph of the number of 
cigarettes smoked per day reported by these participants. 39,254 participants reported 
currently smoking tobacco on most or all days. Of these participants, 36,494 
participants reported smoking cigarettes. Figure 4.3.6 shows the distribution of the 
number of cigarettes per day reported by these participants. Both graphs showed a clear 
digit preference for multiples of five/ten. 
 
Figure 4.3.5 Number of Cigarettes Smoked per Day by Former Cigarette Smokers 
 
Number of cigarettes smoked per day reported by participants who reported smoking cigarettes most or 
all days in the past. 
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Figure 4.3.6 Number of Cigarettes Smoked per Day by Current Cigarette Smokers 
 
Number of cigarettes smoked per day reported by participants who reported smoking cigarettes most or 
all days. 
 
4.3.3 Smoking Analysis Variables 
 
Different variables were created in order to investigate the association between smoking 
and colorectal cancer. The first variable focused on overall smoking status in order to 
include as many participants as possible whereas further analysis variables focused on 
cigarette smoking since this was by far the most common form of tobacco use. 
 
Overall Smoking Status 
 
Overall smoking status was defined in order to try and analyse the range of exposures 
reported by participants. Participants were defined as follows: 
 
Never ever 
 Participants who reported currently not smoking tobacco and never smoking 
tobacco in the past. 
 
Former occasional <100  
 Participants who reported currently not smoking tobacco, reported smoking 
occasionally in the past or just tried once or twice and reported smoking less 
than 100 times. 
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Former occasional ≥100 
 Participants who reported currently not smoking tobacco, reported smoking 
occasionally in the past or just tried once or twice and reported smoking at least 
100 times. 
  
Former daily  
 Participants who reported currently not smoking tobacco and reported smoking 
on most or all days in the past. 
  
Always occasional 
 Participants who reported currently smoking tobacco occasionally and reported 
smoking occasionally in the past or just tried once or twice and reported 
smoking at least 100 times. 
 
Occasional, former daily 
 Participants who reported currently smoking tobacco occasionally and reported 
smoking on most or all days in the past. 
 
Daily smokers 
 Participants who reported currently smoking tobacco on most or all days. 
 
Overall smoking status was defined for 493,096 participants (Table 4.3.2). 
 
Table 4.3.2 Overall Smoking Status 
Overall smoking status Men Women Overall 
Never ever 79,050 121,851 200,901 
Former occasional <100 29,223 41,883 71,106 
Former occasional ≥100 26,115 27,071 53,186 
Former daily 62,892 53,025 115,917 
Always occasional 4,580 3,118 7,698 
Occasional, former daily 2,900 2,134 5,034 
Daily 20,565 18,689 39,254 
Total 225,325 267,771 493,096 
 
Since this variable included categories with relatively few participants, a further 
variable was created which combined categories in order to define participants as never 
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smokers, former smokers or current smokers. Table 4.3.3 shows how these categories 
were combined to create the new variable. 
 
Table 4.3.3 Overall Smoking Status 
Overall smoking status Never smoker Former smoker Current smoker 
Never ever 200,901   
Former occasional <100 71,106   
Former occasional ≥100  53,186  
Former daily  115,917  
Always occasional   7,698 
Occasional, former daily   5,034 
Daily   39,254 
Total 272,007 169,103 51,986 
 
Cigarette Smoking Status 
 
A further variable was created which restricted former smokers to former daily cigarette 
smokers and current smokers to current daily cigarette smokers. Participants were 
classified as never smokers, former cigarette smokers or current cigarette smokers 
according to the following criteria: 
 
Never smoker 
 Participants who reported currently not smoking tobacco and never smoking 
tobacco in the past 
OR 
 Participants who reported currently not smoking tobacco, reported smoking 
occasionally in the past or just tried once or twice and reported smoking less 
than 100 times. 
 
Former cigarette smoker 
 Participants who reported currently not smoking tobacco, reported smoking on 
most or all days in the past and reported smoking cigarettes. 
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Current cigarette smoker 
 Participants who reported currently smoking tobacco on most or all days and 
reported smoking cigarettes. 
 
Cigarette smoking status was defined for 419,256 participants (Table 4.3.4). 
 
Table 4.3.4 Cigarette Smoking Status 
Cigarette smoking status Men Women Overall 
Never smoker 108,273 163,734 272,007 
Former cigarette smoker 57,917 52,838 110,755 
Current cigarette smoker 17,943 18,551 36,494 
Total 184,133 235,123 419,256 
 
Cigarette Smoking Intensity 
  
Next, former and current cigarette smokers were categorised according to the number of 
cigarettes they reported smoking per day (Table 4.3.5). Former and current cigarette 
smokers were classified slightly differently; the greater number of former cigarette 
smokers allowed a more precise classification using more categories. 685 former 
cigarette smokers and 321 current cigarette smokers said “do not know” or “prefer not 
to answer” for the questions on number of cigarettes smoked per day and were 
excluded. 
 
Table 4.3.5 Cigarette Smoking Intensity 
Cigarette smoking intensity Participants 
Never 272,007 
Former, ≤10 27,844 
Former, 11-15 19,137 
Former, 16-20 39,331 
Former, ≥21 23,758 
Current, ≤10 12,953 
Current, 11-20 17,989 
Current, ≥21 5,231 
Total 418,250 
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Age at Cigarette Smoking Initiation 
 
Participants were also classified according to their age at initiation of smoking (Table 
4.3.6). Participants who reported smoking cigarettes currently or in the past were asked 
to report how old they were when they started smoking on most days. 552 former 
cigarette smokers and 420 current cigarette smokers responded “do not know” or 
“prefer not to answer”. 
 
Table 4.3.6 Age at Cigarette Smoking Initiation 
Cigarette smoking initiation Participants 
Never 272,007 
Former, ≤14 16,613 
Former, 15-16 36,886 
Former, 17-18 30,714 
Former, ≥19 25,990 
Current, ≤15 12,559 
Current, 16-17 9,132 
Current, ≥18 14,383 
Total 418,284 
 
Age at Cigarette Smoking Cessation 
 
Former cigarette smokers were asked to report their age when they stopped smoking on 
most days. 483 participants responded “do not know” or “prefer not to answer”. Table 
4.3.7 shows the analysis variable created. 
 
Table 4.3.7 Age at Cigarette Smoking Cessation 
Cigarette smoking cessation Participants 
Never 272,007 
≤29 24,198 
30-39 33,765 
40-49 27,843 
≥50 24,466 
Total 382,279 
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Years since Cigarette Smoking Cessation 
 
Former cigarette smokers were also classified according to the time since cessation by 
calculating the difference between age at baseline and the age they stopped smoking on 
most days (Table 4.3.8). 
 
Table 4.3.8 Years since Cigarette Smoking Cessation 
Years since cigarette smoking cessation Participants 
Never 272,007 
≤9 29,709 
10-19 25,417 
20-29 29,685 
≥30 25,461 
Total 382,279 
 
Cigarette Smoking Duration 
 
For former cigarette smokers, smoking duration was calculated as the difference 
between the reported age when participants started smoking on most days and the 
reported age when participants last smoked on most days. For current cigarette smokers, 
smoking duration was calculated as the difference between the reported age when 
participants started smoking on most days and the age at baseline. 971 former cigarette 
smokers responded “do not know” or “prefer not to answer” for at least one of age 
started smoking and age stopped smoking and 420 current cigarette smokers responded 
“do not know” or “prefer not to answer” for age started smoking. Table 4.3.9 shows the 
analysis variable for cigarette smoking duration. 
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Table 4.3.9 Cigarette Smoking Duration 
Cigarette smoking duration Participants 
Never 272,007 
Former, ≤9 16,171 
Former, 10-19 34,722 
Former, 20-29 28,978 
Former, 30-39 19,951 
Former, ≥40 9,962 
Current, ≤29 8,204 
Current, 30-39 12,750 
Current, ≥40 15,120 
Total 417,865 
 
4.4 Other Analysis Variables 
 
This section provides further information for other variables relevant to the analyses. 
 
4.4.1 Confounder Variables 
 
Analyses of alcohol intake were adjusted for BMI and overall smoking status, analyses 
of adiposity were adjusted for alcohol intake and overall smoking status and analyses of 
smoking were adjusted for alcohol intake and BMI. All analyses of men and women 
were adjusted for sex. In addition, all analysis models were adjusted for the following 
confounder variables: Townsend deprivation index, red meat intake, processed meat 
intake, family history of bowel cancer and bowel cancer screening. Analyses of alcohol 
intake and smoking were also adjusted for height. These variables were selected as 
confounders since there was strong evidence that these variables influence colorectal 
cancer risk.
19, 25, 26, 28, 384-386
 These variables are described below. 
  
Townsend Deprivation Index 
 
The Townsend deprivation index is a measure of socioeconomic status based on 
measures of unemployment, household overcrowding, non-home ownership and non-
car ownership.
387
 A higher Townsend deprivation index indicates a higher level of 
deprivation. Townsend deprivation index scores were calculated based on census output 
areas. Participants were assigned the index score for the output area in which their 
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postcode was located. 627 participants had missing data. Participants were categorised 
into approximate quintiles of deprivation; the categories were <−3.93, −3.93-<−2.76, 
−2.76-<−1.30, −1.30-<1.35 and ≥1.35. 
 
Red Meat Intake 
 
In the touchscreen questionnaire, participants were asked separate questions about their 
average intake of beef, lamb/mutton and pork. The left column of Table 4.4.1 shows the 
options available for each question. Participants could also respond “do not know” or 
“prefer not to answer”. Data were missing for 898 participants and 6,107 participants 
who responded “do not know” or “prefer not to answer” to at least one of the questions 
were excluded. The right column of Table 4.4.1 shows the values assigned to each 
response. Values from the three questions were added together and participants were 
categorised as eating red meat ≤1, >1-<3 and ≥3 times a week (Table 4.4.2). 
 
Table 4.4.1 Coding Values for Average Intake of Beef, Lamb/Mutton and Pork 
Response category 
Assigned 
number 
Never 0 
Less than once a 
week 
0.25 
Once a week 1 
2-4 times a week 3 
5-6 times a week 5.5 
Once or more daily 7 
 
Table 4.4.2 Red Meat Intake 
 Men  Women  Overall 
Red meat intake n %  n %  n % 
≤once/week 94,330 41.8  133,607 49.5  227,937 46.0 
>1-<3 times/week 73,250 32.5  83,572 31.0  156,822 31.6 
≥3 times/week 58,001 25.7  52,878 19.6  110,879 22.4 
Total 225,581 100.0  270,057 100.0  495,638 100.0 
 
Processed Meat Intake 
 
In the touchscreen questionnaire, participants were asked how often they eat processed 
meats. Options were the same as for the questions on beef, lamb/mutton and pork. 896 
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participants had missing data and 1,337 participants responded “do not know” or “prefer 
not to answer”. Participants were categorised as eating processed meat <once, once and 
>once per week (Table 4.4.3).  
 
Table 4.4.3 Processed Meat Intake 
 Men  Women  Overall 
Processed meat 
intake 
n %  n %  n % 
<once/week 61,186 26.8  138,020 50.7  199,206 39.8 
once/week 67,929 29.8  78,142 28.7  146,071 29.2 
>once/week 98,939 43.4  56,193 20.6  155,132 31.0 
Total 228,054 100.0  272,355 100.0  500,409 100.0 
 
Height 
 
Height was measured at baseline. Unfortunately, the height data were not included in 
the dataset. However, data on weight and BMI were available. Thus, height was 
calculated as the square root of weight (kg) divided by BMI (kg/m
2
): 
 
√
𝑤𝑒𝑖𝑔ℎ𝑡
𝑏𝑜𝑑𝑦 𝑚𝑎𝑠𝑠 𝑖𝑛𝑑𝑒𝑥
 
  
3,231 participants did not have data on BMI or weight and so height was defined for 
499,411 participants. 
 
Family History of Bowel Cancer 
 
Questions relating to illnesses of family members were asked in the touchscreen 
questionnaire. 7,359 participants reported being adopted and thus did not answer these 
questions. 907 participants had missing data for these questions. Participants were first 
asked if their father was still alive. If they responded other than “do not know” or 
“prefer not to answer”, they were asked to select from a list of illnesses (including 
bowel cancer) which illnesses their father had ever suffered. Participants were then 
asked the same questions with regards to their mother. Participants were also asked how 
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many brothers they have and also how many sisters they have. If they had at least one 
sibling they were asked to select the illnesses suffered by any of their siblings. 
 
Three variables were first created to identify whether there was a history of bowel 
cancer for participants’ father, mother and siblings (Table 4.4.4). 25,107 participants 
reported that their father suffered from bowel cancer. Participants who responded “do 
not know” to which illnesses their father had suffered (41,979 participants) or 
responded “do not know” to whether their father was alive (6,156 participants) were 
included as no history of bowel cancer. 319 participants responded “prefer not to 
answer” to whether their father was alive and 1,103 participants responded “prefer not 
to answer” to which illnesses their father had suffered and were excluded. 
 
Table 4.4.4 History of Bowel Cancer in Family Members 
History of bowel 
cancer 
Father Mother Siblings 
No 467,847 469,952 483,482 
Yes 25,107 23,242 9,486 
Total 492,954 493,194 492,968 
 
23,242 participants reported a history of bowel cancer for their mother. 1,095 
participants responded “do not know” to whether their mother was alive and 25,908 
participants responded “do not know” to which illnesses their mother had suffered. 
These participants were included as no history of bowel cancer. 241 participants 
responded “prefer not to answer” to whether their mother was alive and 941 participants 
responded “prefer not to answer” to which illnesses their mother had suffered and were 
excluded. 
 
9,486 participants reported that a sibling had suffered from bowel cancer. 59,382 
participants reported having no brothers and no sisters and were included as no history 
of bowel cancer. 30,402 participants responded “do not know” to which illnesses their 
siblings had suffered and were included as no history of bowel cancer. 434 participants 
responded “do not know” to both of the questions on the number of brothers and the 
number of sisters or “do not know” to one and zero to the other and were included as no 
history of bowel cancer. 869 participants responded “prefer not to answer” to which 
illnesses their siblings had suffered and were excluded. 539 participants responded 
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“prefer not to answer” to at least one of the questions on the number of brothers and 
number of sisters and did not report siblings in the other question and were excluded. 
 
Finally, participants were defined as having a family history of bowel cancer if there 
was a history of bowel cancer for at least one family member (father, mother or sibling) 
whereas participants were defined as having no family history if there was no history 
for any family member. 491,623 participants were included in this variable (Table 
4.4.5). 
 
Table 4.4.5 Family History of Bowel Cancer 
 Men  Women  Overall 
Family history of bowel cancer n %  n %  n % 
No 198,436 88.6  238,531 89.1  436,967 88.9 
Yes 25,485 11.4  29,158 10.9  54,643 11.1 
Total 223,921 100.0  267,689 100.0  491,610 100.0 
 
Bowel screening 
 
Participants were asked in the touchscreen questionnaire "Have you ever had a 
screening test for bowel (colorectal) cancer? (Please include tests for blood in the 
stool/faeces or a colonoscopy or a sigmoidoscopy)". Data were missing for 925 
participants. 8,800 participants responded “do not know” or “prefer not to answer”. 
Thus, 492,917 participants were included in the variable for bowel screening (Table 
4.4.6). 
 
Table 4.4.6 Bowel Screening 
 Men  Women  Overall 
Bowel screening n %  n %  n % 
No 149,541 67.0  187,821 69.6  337,362 68.4 
Yes 73,628 33.0  81,927 30.4  155,555 31.6 
Total 223,169 100.0  269,748 100.0  492,917 100.0 
 
The higher rate of screening among men was surprising since women have slightly 
higher rates of bowel screening uptake than men in the general population.
15, 388
 Bowel 
screening was only offered to men and women aged 60-74 though UK Biobank includes 
men and women aged 40-69 so it was possible that the greater proportion of men than 
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women reporting screening was related to the difference in age groups. However, 
comparing the proportion of men and women reporting screening by age group, men 
were more likely to report screening than women within each age group (except <45 
where the proportion of men and women reporting screening was similar) (Table 4.4.7). 
 
Table 4.4.7 All Bowel Screening Responses by Age and Sex 
 Age group 
Total 
Bowel screening (%) <45 45-49 50-54 55-59 60-64 ≥65 
Men        
Prefer not to answer 0.2 0.2 0.1 0.1 0.1 0.1 0.1 
Do not know 2.3 2.6 2.6 2.8 1.9 2.0 2.3 
No 87.8 84.0 79.9 75.6 48.2 43.9 65.4 
Yes 9.7 13.2 17.3 21.5 49.8 54.0 32.2 
        
Women        
Prefer not to answer 0.1 0.1 0.1 0.1 0.1 0.1 0.1 
Do not know 1.1 1.1 1.1 1.1 1.0 1.2 1.1 
No 89.1 85.9 81.8 78.8 50.8 46.7 68.8 
Yes 9.7 12.9 17.0 20.0 48.2 52.0 30.0 
 
4.4.2 Other Variables 
 
This section describes other variables that were not included as confounders but were 
used in the analyses e.g. for the investigation of potential effect modifiers. 
 
Physical activity 
 
Physical activity is associated with colorectal cancer risk.
25
 However, physical activity 
was not included as a confounder in the analyses presented in this thesis. Analysis 
results were very similar with and without adjustment for physical activity (results for 
alcohol intake and overall smoking status and colorectal cancer with and without 
adjustment for physical activity are shown in Table A-3 and Table A-4 in the appendix) 
(results for BMI and colon and rectal cancer with and without adjustment for physical 
activity are shown in section 6.2.6) and unfortunately physical activity could not be 
defined for a large number of participants. 
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Participants gave information on physical activity in the touchscreen questionnaire 
during the baseline assessment. Participants were asked to report the number of days in 
a typical week they walk at least ten minutes. If participants entered a number between 
one and seven, they were then asked to report the average duration of walking on a 
typical day. Similar questions were asked regarding moderate activity and vigorous 
activity. These questions are shown in Figure 4.4.1. In the pilot study, participants were 
given five categories to choose from for each question on average duration. These were 
re-coded as follows: “less than 30 mins” = 15 minutes, “30 minutes to 1 hour” = 45 
minutes, “1 to 2 hours” = 90 minutes, “2 to 4 hours” = 180 minutes and “more than 4 
hours” = 300 minutes. 
 
Figure 4.4.1 Questions on Average Physical Activity 
 
 
These questions were based on the International Physical Activity Questionnaire 
(IPAQ) short form.
389
 There exist guidelines for the scoring of these data available 
online at www.sites.google.com/site/theipaq/scoring-protocol. 
 
For each activity, the frequency was multiplied by the average duration to obtain the 
average number of minutes per week. To calculate MET-minutes per week (MET = 
metabolic equivalent), the number of minutes per week of walking, moderate activity 
and vigorous activity were multiplied by 3.3, 4.0 and 8.0 METs, respectively. 
Participants were classified into three categories (low, moderate, high) of physical 
activity according to the following definitions: 
 
Chapter 4 | Methods 
187 
Low 
 No activity or some activity is reported but less than the definition for moderate 
or high physical activity. 
 
Moderate 
 Three or more days of vigorous activity of at least 20 minutes per day 
OR 
 Five or more days of moderate activity and/or walking of at least 30 minutes per 
day 
OR 
 Five or more days of any combination of walking, moderate activity or vigorous 
activity accumulating at least 600 MET-minutes per week. 
 
High 
 Vigorous activity on at least three days and accumulating at least 1,500 MET-
minutes per week 
OR 
 Seven or more days of any combination of walking, moderate activity or 
vigorous activity accumulating at least 3,000 MET-minutes per week. 
  
Participants were excluded if they responded “do not know” or “prefer not to answer” to 
any of the questions. Participants were excluded if the sum of the walking, moderate 
activity and vigorous activity duration variables was greater than 960 minutes (16 
hours). Responses of less than ten minutes were replaced with zero and responses 
greater than 180 minutes were truncated. Thus, physical activity was defined for 
388,771 participants (Table 4.4.8). 
 
Table 4.4.8 IPAQ Physical Activity Variable 
 Men  Women  Overall 
Physical activity n %  n %  n % 
Low 35,205 18.9  36,681 18.1  71,886 18.5 
Moderate 71,372 38.3  86,571 42.7  157,943 40.6 
High 79,560 42.7  79,382 39.2  158,942 40.9 
Total 186,137 100.0  202,634 100.0  388,771 100.0 
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Unfortunately, 111,487 participants responded “do not know” or “prefer not to answer” 
to at least one of these questions and so could not be included in this variable. 
  
Therefore, an alternative physical activity variable was created which excluded fewer 
participants (by focusing on responses to the number of days only and avoiding 
excluding participants for responding “do not know” or “prefer not to answer” when 
possible). This variable classified participants into three categories of physical activity 
using the following definitions: 
 
Low 
 Fewer than three days of moderate activity and fewer than two days of vigorous 
activity. 
 
Medium 
 Three or more days of moderate activity 
OR 
 Two or more days of vigorous activity. 
 
High 
 Three or more days of vigorous activity. 
 
This variable included 464,246 participants (Table 4.4.9). 
 
Table 4.4.9 Alternative Physical Activity Variable 
 Men  Women  Overall 
Physical activity n %  n %  n % 
Low 59,750 27.8  70,160 28.1  129,910 28.0 
Medium 75,170 35.0  104,298 41.8  179,468 38.7 
High 79,838 37.2  75,030 30.1  154,868 33.4 
Total 214,758 100.0  249,488 100.0  464,246 100.0 
 
Among the 388,771 participants with data for both physical activity variables, there was 
reasonable agreement between the two variables (Table 4.4.10). For example, only 1.9% 
of participants included in the low category in the IPAQ variable were included in the 
high category in the alternative variable and only 2.5% of participants included in the 
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high category in the IPAQ variable were included in the low category in the alternative 
variable. 
 
Table 4.4.10 Comparison of Physical Activity Variables 
 Alternative variable 
IPAQ variable (%) Low Medium High Total 
Low 80.4 17.7 1.9 100.0 
Medium 32.0 58.6 9.4 100.0 
High 2.5 26.7 70.8 100.0 
 
Unfortunately, this alternative physical activity variable still resulted in the exclusion of 
37,517 participants who responded “do not know” or “prefer not to answer”. Multiple 
imputation could have been considered in order to “fill in” the physical activity values 
for these participants. However, valid multiple imputation relies on the assumption that 
the probability that a participant has missing data is independent of the true value
375
 and 
this assumption seemed questionable for physical activity data. For example, a 
participant may have responded “do not know” or “prefer not to answer” because they 
did a lot of physical activity and found it too taxing to try and answer all the questions 
accurately. Alternatively, a participant may have responded “do not know” or “prefer 
not to answer” because they did not do much physical activity but did not want to admit 
it. Hence, multiple imputation was not used for physical activity data. 
 
Another approach for dealing with missing data is to add an extra category for people 
with missing data. However, this approach would combine people with different levels 
of exposure and can produce biased results.
113, 390
 Despite this fact, this method is fairly 
commonly used in epidemiological studies.  
 
Folate 
 
To obtain further information on dietary factors, an online questionnaire was created, 
asking participants to report the food and drink consumed during the previous 24 hours. 
This was included as part of the assessment centre during the later stages of recruitment. 
Later, an invitation was sent to participants by e-mail to complete the questionnaire on 
four separate occasions. Hence, the questionnaire may have been completed by 
Chapter 4 | Methods 
190 
participants up to five times. 211,063 participants completed at least one questionnaire 
and 5,772 participants completed all five questionnaires. 
 
For each questionnaire, folate intake was calculated based on the reported consumption 
of food and drinks. The use of supplements was not included in the calculation of folate 
intake. The estimated folate intake values across the questionnaires were added and then 
divided by the number of questionnaires completed in order to obtain a single value of 
average folate intake for each participant. Figure 4.4.2 shows the distribution of average 
folate intake. Median folate intake was 288.7 µg. 
 
Figure 4.4.2 Average Folate Intake 
 
Average folate intake reported in online dietary questionnaire. 
 
Menopause 
 
Female participants were asked if they had had their menopause in the touchscreen 
questionnaire. 476 women had missing data for this question. 535 women responded 
“prefer not to answer”. 31,185 participants responded “not sure - had a hysterectomy” 
and 11,735 participants responded “not sure - other reason”. 64,092 women had not 
experienced menopause at baseline and 165,444 women had experienced menopause. 
Of these 165,444 women, 87,418 women reported never using hormone replacement 
therapy (HRT). Only pre-menopausal women and post-menopausal women who had 
never used HRT were included in this analysis variable (Table 4.4.11). 
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Table 4.4.11 Menopause Status for Women 
Menopause n % 
Pre-menopause 64,092 42.3 
Post-menopause, never HRT users 87,418 57.7 
Total 151,510 100.0 
 
4.5 Outcome Data on Cancers and Deaths 
 
4.5.1 Data Sources 
 
Outcome data on cancers and deaths are obtained via linkage with national datasets. UK 
Biobank participants are flagged in these datasets and the relevant data are sent to UK 
Biobank on a regular basis. 
 
Data on cancer diagnoses in the UK are collected from a variety of sources including 
hospital admissions, pathology laboratories, cancer screening programmes and death 
records. Cancer diagnoses in England are recorded by eight regional cancer registries 
which together form the National Cancer Registration Service (part of Public Health 
England) and cancer diagnoses in Wales are recorded by the Welsh Cancer Intelligence 
Surveillance Unit (part of Public Health Wales). These data are then submitted to the 
Office for National Statistics (ONS) and are made available to UK Biobank through the 
Health and Social Care Information Centre (with permission from the ONS). Cancer 
diagnoses in Scotland are recorded by the Scottish Cancer Registry and are provided to 
UK Biobank by the Information Services Division of NHS National Services Scotland. 
 
Maintaining national cancer registries is a complex activity and data can never be 100% 
accurate and complete. There exist a number of measures for assessing the quality and 
validity of cancer registry data though their interpretation is not straightforward.
391, 392
 
One indication for the accuracy of cancer registry data is the proportion of cases for 
which the only information available is from a death certificate, known as death 
certificate only (DCO) registrations. For these registrations, the incidence date is 
unknown and thus the date of death is used instead. Thus, a DCO registration indicates 
that the cancer could not be identified while the person was alive and a high percentage 
of DCO registrations signifies incompleteness (although a low percentage does not 
guarantee the opposite). UK cancer registries aim to have a DCO rate of less than 2%.
393
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In 2012 the English regional cancer registries migrated to a single cancer registration 
system resulting in a considerable extra workload. As a result there was a noticeable 
increase in the rates of DCO registrations (2.5% for males and 2.8% for females) though 
these figures were still extremely good.
393
 The average rates across the cancer registries 
of the UK and Ireland for 2012 were 1.1% for males and 1.3% for females. Further data 
on performance indicators of UK and Ireland cancer registries are available at 
www.ukiacr.org/kpis. 
 
Data on deaths in England and Wales are compiled by the ONS and are provided to UK 
Biobank through the Health and Social Care Information Centre. Data on deaths for 
Scotland are collected and provided to UK Biobank by the National Health Service 
Central Register, Scotland. 
 
4.5.2 Death Data 
 
For each participant who died, the following data were available: 
 
 Date of death 
 Age at death* 
 Primary cause of death (ICD-10) 
 Secondary cause(s) of death (ICD-10) 
*Age at death was calculated by UK Biobank as the difference between date of birth and date of death. 
 
Causes of death were coded according to the 10
th
 revision of the International 
Classification of Diseases (ICD-10), published by the WHO.
394
 
 
4.5.3 Cancer Data 
 
For each participant diagnosed with cancer, the following data were available (for each 
diagnosis): 
 
 Date of cancer diagnosis 
 Age at cancer diagnosis* 
 Type of cancer (ICD-10) 
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 Type of cancer (ICD-9) 
 Histology of neoplasm 
 Behaviour of neoplasm 
*Age at cancer diagnosis was calculated by UK Biobank as the difference between date of birth and date 
of cancer diagnosis. 
 
Data were available on both prevalent and incident cancer diagnoses. The type of cancer 
was coded according to the International Classification of Diseases, 9
th
 Revision (ICD-
9) or 10
th
 Revision (ICD-10). The use of the 10
th
 revision replaced the use of the 9
th
 
revision between 1995 and 1996. Thus, all incident cancers are coded according to the 
10
th
 revision. Histology and behaviour were coded according to the International 
Classification of Diseases for Oncology 3
rd
 Edition (ICD10-O-3).
9
 Neoplasms were 
coded as one of the following behaviour types: 
 
 0, Benign 
 1, Uncertain whether benign or malignant 
 2, Carcinoma in situ 
 3, Malignant, primary site 
 6, Malignant, metastatic site 
 9, Malignant, uncertain whether primary or metastatic site 
 
4.5.4 Outcome Definition 
 
Baseline assessment and follow-up data on cancers and deaths were available on 
502,642 participants. Follow-up data were complete up to 31
st
 March 2014. 
 
12 participants were excluded for erroneous follow-up data: three participants had a 
death date earlier than their assessment date, two participants had a primary cause of 
death but no death date, six participants had a date of death but no primary cause, one 
participant had a cancer diagnosis date later than the date of death. 
 
26,857 participants who had a cancer diagnosis (other than non-melanoma skin cancer) 
(ICD-10 C00 - C97 except C44, ICD-9 140-209 except 173) before recruitment were 
excluded. 3,991 participants who reported suffering from inflammatory bowel disease, 
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Crohn’s disease or ulcerative colitis were excluded because these participants may have 
a substantially elevated risk of colorectal cancer.
19
 
 
Participants were censored at the date of their first cancer diagnosis (other than non-
melanoma skin cancer) (ICD-10 C00 - C97 except C44), date of death or end of follow-
up (31
st
 March 2014), whichever came first. Participants were defined as colorectal 
cancer cases if their first cancer diagnosis was colorectal cancer (ICD-10 C18.0 - C20). 
If participants were diagnosed with colorectal cancer and another type of cancer on the 
same date they were defined as colorectal cancer cases. One participant whose first 
incident cancer diagnosis was colorectal cancer was excluded because the behaviour 
was coded as “malignant, uncertain whether primary or metastatic site”. 
  
Finally, the outcome was defined for 471,781 participants. 20,070 participants were 
censored at the date of a cancer diagnosis (including colorectal cancer) and 3,337 
participants were censored at the date of death. All other participants were censored at 
31
st
 March 2014 (end of follow-up). 
 
2,302 participants were defined as colorectal cancer cases. The definitions and the 
number of cases for colorectal, colon, proximal colon, distal colon and rectal cancer are 
shown in Table 4.5.1. Participants with diagnoses at different subsites on the same date 
were defined as cases for each analysis e.g. 21 participants had a colon cancer diagnosis 
and a rectal cancer diagnosis on the same date and were defined as cases for both the 
colon and rectal cancer analyses. 
 
Proximal colon cancer was defined as cancer located in the caecum through to the 
splenic flexure (C180.0 - C18.5) and distal colon cancer was defined as cancer located 
in the descending colon and sigmoid colon (C18.6 - C18.7). Nine participants were 
defined as cases for both proximal and distal colon cancer. 96 participants who had 
cancer classified as “overlapping lesion of colon” (C18.8) or “colon, unspecified” 
(C18.9) (and did not have a separate proximal colon cancer diagnosis) were excluded 
from the analysis of proximal colon cancer. 103 participants who had cancer classified 
as “overlapping lesion of colon” (C18.8) or “colon, unspecified” (C18.9) (and did not 
have a separate distal colon cancer diagnosis) were excluded from the analysis of distal 
colon cancer. 
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Table 4.5.1 Definitions of Colorectal Cancer and Colorectal Cancer Subsites for All Analyses 
ICD-10 
code 
Cancer type 
Number 
of cases* 
Colorectal Colon 
Proximal 
colon 
Distal colon Rectum 
C18.0 Caecum 276      
C18.1 Appendix 40      
C18.2 Ascending colon 207      
C18.3 Hepatic flexure 78      
C18.4 Transverse colon 112      
C18.5 Splenic flexure 54      
C18.6 Descending colon 97      
C18.7 Sigmoid colon 611      
C18.8 Overlapping lesion of colon 9      
C18.9 Colon, unspecified 100      
C19 Rectosigmoid junction 157      
C20 Rectum 638      
 Number of participants 2,302 1,532 751 700 791 
*Number of cases for each cancer type do not sum to total number of participants with colorectal cancer due to multiple diagnoses; 71 participants had two colorectal cancer 
diagnoses on the same date and three participants had three colorectal cancer diagnoses on the same date. 
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4.6 Statistical Methods 
 
This section describes the statistical methods used in this thesis to analyse the UK 
Biobank data. All statistical analyses were performed using Stata 13. 
 
4.6.1 Cox Proportional Hazards Models 
 
Survival analysis methods are used to analyse the time until a certain event. One 
important difference between survival data and other types of data is that the variable of 
interest (the time until the event) is not necessarily observed for all subjects i.e. not all 
subjects will experience the event during the follow-up time of the study. People who 
do not experience the event during follow-up are censored. 
 
In survival analysis, the survival function 𝑆(𝑡) is defined as the probability that an 
individual survives (i.e. does not experience the event) until at least time 𝑡. The hazard 
function ℎ(𝑡) represents the probability of an event at time 𝑡 (conditional on survival 
until 𝑡). 
 
The Cox proportional hazards model is widely used for the analysis of survival data.
267
 
The mathematical form of the Cox proportional hazards model is: 
 
log(ℎ(𝑡)) = log(ℎ0(𝑡)) + 𝛽1𝑥1 +  𝛽2𝑥2 + . . . + 𝛽𝑘𝑥𝑘 
 
where ℎ0(𝑡) represents the baseline hazard function (corresponding to an individual for 
whom all exposure variables are equal to zero) and 𝑥1 to 𝑥k are the k exposure variables. 
 
One of the main advantages of the Cox proportional hazards model over other methods 
of survival analysis is that it allows for the investigation of the effects of multiple 
variables on survival simultaneously. Also, it requires no assumptions about the form of 
the baseline hazard function. However, the key assumption of the Cox model is that the 
ratio of the hazard functions comparing different exposure groups is constant over time 
i.e. the hazards are proportional to each other over time. This is known as the 
proportional hazards assumption (investigated for the analyses in this thesis in section 
4.6.2). 
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Age was used as the underlying time variable in all analyses since the risk of colorectal 
cancer is expected to change primarily according to age whereas there should be no 
important relation between time in the study and colorectal cancer risk. Only the month 
and year of birth were available for participants so age was calculated using the 15
th
 day 
of the month as the day of birth. 
 
The proportional hazards model assumes that there are no tied survival times (since the 
time to the event is continuous). This would mean that each event would occur at a 
unique time and thus the participants at risk of the event at each event time would be 
clear. However, tied events do occur in survival data since it is only possible to measure 
time with limited precision. For this analysis the Breslow method was used for handling 
ties.
395
 When considering each individual tied event, this method assumes that all other 
participants who suffered the event at the tied time were at risk of the event at that time. 
 
Hence, Cox proportional hazard models were used in this thesis to analyse the 
associations between alcohol intake, adiposity and smoking and colorectal cancer risk, 
adjusting for other risk factors. Age was used as the underlying time variable and time 
in the study was calculated up to the date of diagnosis of colorectal cancer, the date of 
diagnosis of any other cancer (excluding non-melanoma skin cancer), the date of death 
or the end of follow-up (31
st
 March 2014). 
 
4.6.2 Proportional Hazards Assumption 
 
The use of the Cox proportional hazards model relies on the assumption that the HR is 
constant over time i.e. that the hazard functions are proportional to each other over time. 
This assumption can be assessed in a number of ways. One method is to plot -ln[-
ln(𝑆(𝑡))] against ln(𝑡) for each exposure group. These plots are usually referred to as 
“log-log” plots. If the hazard functions are proportional, then the lines representing the 
different exposure groups should be approximately parallel.
396
 
 
Figure 4.6.1 shows the log-log plot for the exposure groups defined for alcohol intake. 
Overall, the lines for the different alcohol intake exposure groups were approximately 
parallel, suggesting that there was no reason to reject the proportional hazards 
assumption for the analysis of alcohol intake. The greater variation observed at the start 
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was due to the relatively few cases in this cohort at an earlier age. Log-log plots were 
similar for BMI (Figure 4.6.2 and Figure 4.6.3) and overall smoking status (Figure 
4.6.4), and so the proportional hazards assumption was not rejected for these analyses 
either. (Separate plots are presented for men and women for BMI due to the evidence 
from the existing literature that the association between BMI and colorectal cancer 
differs for men and women (see section 2.3)). 
 
Figure 4.6.1 Log-log Plot of Alcohol Intake 
 
 
Figure 4.6.2 Log-log Plot of Body Mass Index Quintiles for Men 
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Figure 4.6.3 Log-log Plot of Body Mass Index Quintiles for Women 
 
 
Figure 4.6.4 Log-log Plot of Overall Smoking Status 
 
 
Another method for assessing the proportionality hazards assumption is using scaled 
Schoenfeld residuals. Scaled Schoenfeld residuals represent the difference between the 
observed and predicted values of the covariates at each event (calculated separately for 
each covariate).
396
 Hence, the proportional hazards assumption can be assessed by 
plotting the scaled Schoenfeld residuals against follow-up time. If the proportional 
hazards assumption is valid, there should be no systematic trend in the residuals in 
relation to time. Figure 4.6.5 - Figure 4.6.8 show the scaled Schoenfeld residuals plotted 
against follow-up time. Since there were no clear trends in the residuals against follow-
up time, the proportional hazards assumption was deemed appropriate. 
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Figure 4.6.5 Scaled Schoenfeld Residuals against Follow-up Time (Age) for Alcohol 
Intake 
 
Scaled Schoenfeld residuals over follow-up time by category of alcohol intake. Red line represents the 
fitted regression line. 
 
Figure 4.6.6 Scaled Schoenfeld Residuals against Follow-up Time (Age) for BMI 
Quintiles for Men 
 
Scaled Schoenfeld residuals over follow-up time by quintiles of BMI for men. Red line represents the 
fitted regression line. 
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Figure 4.6.7 Scaled Schoenfeld Residuals against Follow-up Time (Age) for BMI 
Quintiles for Women 
 
Scaled Schoenfeld residuals over follow-up time by quintiles of BMI for men. Red line represents the 
fitted regression line. 
 
Figure 4.6.8 Scaled Schoenfeld Residuals against Follow-up Time (Age) for Overall 
Smoking Status 
 
Scaled Schoenfeld residuals over follow-up time by category of overall smoking status. Red line 
represents the fitted regression line. 
 
4.6.3 Fractional Polynomials 
 
As mentioned in section 4.1.4, alcohol intake was considered as a continuous analysis 
variable as well as a categorical analysis variable. A continuous analysis variable may 
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be considered to be a more efficient use of the available data since it avoids the arbitrary 
cut-points used for categorical analysis variables. However, the use of continuous 
analysis variables requires an assumption to be made about the shape of the relationship 
between the variable of interest and the outcome. Continuous analysis variables are 
often modelled using linear models but the linearity assumption must always be 
evaluated. When a linear model is not suitable, the relationship can often be modelled 
using more complex polynomial models e.g. 𝑥2 or ln(𝑥). 
  
Fractional polynomial analysis was used in this thesis to evaluate the linearity 
assumption for the relationship between alcohol intake and colorectal cancer and to 
identify the “best-fitting” model.397, 398 The advantage of fractional polynomial analysis 
is that it is a very flexible method since it allows the investigation of different 
polynomial models based on a wide range of powers. 
 
In this thesis, all possible polynomial models of one (e.g. 𝑐𝑥𝑎) or two terms (e.g. 
𝑐𝑥𝑎 +  𝑑𝑥𝑏) were considered with powers from the set {-2, -1, -0.5, 0, 0.5, 1, 2, 3} 
(where 0 represents the natural logarithm). (When the same power was selected for a 
two term polynomial model, the second term was multiplied by the natural logarithm). 
From all these possible models, the one and two term polynomial models with lowest 
deviance (-2 log likelihood) were identified and a likelihood ratio test was used to 
compare these models. 
 
4.6.4 Population Attributable Fraction 
 
The population attributable fraction (PAF) is an estimate of the proportion of disease in 
a population due to exposure to a certain risk factor.
399
 In other words, it estimates the 
proportion of cases that would be prevented if no participants were exposed to the risk 
factor of interest, while the distribution of other risk factors in the population stays the 
same. Therefore, it assumes a causal association between the exposure and disease. The 
PAF is calculated as  
 
𝑃𝐴𝐹 = 𝑝𝑑
𝑅𝑅 − 1
𝑅𝑅
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Where pd is the proportion of cases exposed to the risk factor of interest and 𝑅𝑅 is the 
adjusted relative risk.
399
 
 
PAFs were estimated for a range of factors considered in this thesis: alcohol intake, 
BMI, overall smoking status, Townsend deprivation index, red meat intake, processed 
meat intake, family history of colorectal cancer and physical activity. These variables 
were all modelled together using Cox Proportional Hazards models (results were also 
adjusted for sex and colorectal screening). Following the Cox models, PAFs and 95% 
CIs were calculated using the Stata punafcc command, based on the adjusted results 
from the Cox models.
400
 
 
For alcohol intake, exposure was defined as >14 units/week, following the latest 
guidelines (grams of alcohol were divided by 7.9 to convert to units).
58, 401
 Former 
drinkers were included in the non-exposed group (≤14 units/week). Excluding the 
participants who reported drinking “one to three times a month” or “special occasions 
only” and had missing data will overestimate the exposure prevalence in the population 
(since those with missing data will be more likely to be in the non-exposed group) and 
overestimate the PAF. Among participants who reported drinking “one to three times a 
month” or “special occasions only” and had complete data, more than 99.5% of 
participants reported drinking ≤14 units per week. Therefore, to calculate the PAF for 
alcohol intake in this cohort, it was assumed that those participants with missing data 
drank ≤14 units per week and were included in the non-exposure group. 
 
Exposure for adiposity was defined as BMI ≥25 kg/m2 and exposure for smoking was 
defined as ever smoking (current smokers and former smokers). For Townsend 
deprivation index, exposure was defined as a Townsend index above the lowest quintile 
of deprivation, based on 2001 national census data (see section 3.8). Exposure for red 
meat intake and processed meat intake was >once/week. Participants were included in 
the exposure group if they did have a family history of colorectal cancer. Exposure for 
physical activity was not completing at least 150 minutes of moderate activity or 75 
minutes of vigorous activity (or an equivalent combination) per week.
402
 
 
PAF results for are shown in section 7.3. The PAF depends on the prevalence of 
exposure in the cohort. UK Biobank participants were highly self-selected which means 
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that they will likely be healthier and more likely to follow a healthy lifestyle on average 
compared to the general population. For example, there was a very low prevalence of 
current smoking among participants (although alcohol intake appeared to be slightly 
higher on average than in the general population) (see Chapter 3). Therefore, the PAF 
values presented in this thesis are likely to be biased and do not necessarily represent 
the PAF estimates for the general population. 
 
4.6.5 Multiple Imputation 
 
Missing Data and Multiple Imputation 
 
Missing data have always been a pervasive problem in epidemiological research and for 
a long time the best approach for dealing with missing data (besides not having any) 
was to ignore subjects with missing data and simply perform a complete case analysis. 
However, excluding participants with missing data results in a loss in precision and can 
lead to biased results in certain contexts.
376
 Recently, the use of statistical techniques to 
“fill in” these missing values has become more widespread as they are now easily 
available in many standard statistical software packages. 
 
The first step when dealing with missing data is to try to understand why the data are 
missing. Missing data are commonly classified into three types.
403
 Data are missing 
completely at random (MCAR) when the probability of being missing does not depend 
on any observed or missing data i.e. the probability of being missing is the same for all 
people/observations. Data are missing at random (MAR) when the probability of being 
missing depends on observed data but not on missing data (for example if younger 
people are less likely to have their blood pressure measured). Data are missing not at 
random (MNAR) when the probability depends on the values of the missing data (for 
example if people with low blood pressure are less likely to have their blood pressure 
measured). 
 
If data are MCAR, the results of a complete case analysis (ignoring people with missing 
data) will not be biased, though there may be a loss of precision. A complete case 
analysis may lead to biased results when data are MAR. For example, if younger people 
are less likely to have their blood pressure measured than older people, then the estimate 
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of mean blood pressure using only people with complete data will overestimate the true 
value of mean blood pressure in the population (given that older people tend to have a 
higher blood pressure than younger people). 
 
Multiple imputation is a common method for the handling of missing data. The 
underlying motivation for multiple imputation is fairly intuitive. A first approach for 
“filling in” missing values might be to simply replace the missing data with the mean 
value of the observed data but this would distort associations towards the null. Instead 
of filling in missing values using the mean value of the observed data, a regression 
model based on the observed data could be used to predict the missing values. Hence, 
the association between the variables in the observed data would be preserved in the 
missing data. However, the imputed values would be too precise since this method 
ignores the variation in the regression model i.e. all the imputations would lie perfectly 
on the regression line. A better approach would be to introduce random error into the 
imputations based on the residual variance from the regression model in order to 
preserve the variability in the data. However, this approach is still flawed because the 
imputed values would be treated as if they were known i.e. the uncertainty of the 
predictions would not be reflected in the final results. Multiple imputation addresses this 
problem by repeating this stochastic approach a number of times to create a number of 
different imputed datasets and then estimating the quantities of interest in each imputed 
dataset before combining these estimates to take into account the variation between 
imputations. 
  
Since multiple imputation uses the relationships among the observed data to fill in the 
missing values, valid multiple imputation relies on the assumption that the missing data 
are MAR i.e. the probability that the data are missing cannot be related to the 
unobserved values (MNAR). Otherwise, there would be no way to reliably estimate the 
missing values using only the observed data. In reality though, it is not possible to prove 
that the missing data are not MNAR using only the observed data. Hence, careful 
consideration of why data are missing is necessary when performing multiple 
imputation. 
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Missing Alcohol Intake Data in UK Biobank 
 
The missing data for alcohol intake were explained in section 4.1.3. Briefly, 73,061 
participants who reported drinking “one to three times a month” or “special occasions 
only” were not included in the alcohol grams per day variable since they had missing 
data for the questions on the average monthly intake of different alcoholic beverages. 
These data were missing because these participants completed an earlier version of the 
questionnaire that did not include these questions. Instead, these participants answered 
questions on their average weekly intake of different alcoholic beverages but these data 
were not made available. 
 
The probability that the alcohol data were missing depended on the assessment date as 
well as assessment centre since not all centres used the same questionnaire at the same 
times (Figure 4.1.2 shows when the new questionnaire was introduced at each 
assessment centre). The probability that the data were missing also depended on alcohol 
frequency since there were missing data only for participants reporting either “special 
occasions only” or “one to three times a month”. Crucially, since the data were missing 
due to a change in the questionnaire, the probability that the alcohol data were missing 
was unrelated to the values of the missing data (given alcohol frequency). Hence, 
alcohol grams per day data were MAR, conditional on assessment date, assessment 
centre and alcohol frequency. 
 
The distribution of alcohol grams per day among participants with observed alcohol 
data was very positively skewed. Figure 4.6.9 shows a histogram of the natural 
logarithm of alcohol grams per day (plus one g/d to avoid undefined values) for 
participants who reported drinking “special occasions only” and “one to three times a 
month”. The distribution of the natural logarithm of alcohol grams per day was 
approximately Normal among participants who reported “one to three times a month” 
but the distribution for “special occasions only” was not Normal, due to the large 
number of participants who reported drinking zero grams per day. 
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Figure 4.6.9 Distribution of Alcohol Intake by Alcohol Frequency for Participants 
Drinking “One to Three Times a Month” or “Special Occasions Only” 
 
Histogram of ln(alcohol grams per day + 1) by alcohol frequency for participants who reported drinking 
“one to three times a month” or “special occasions only”. 
 
Figure 4.6.10 shows the distribution of alcohol grams per day by assessment centre for 
participants who reported drinking “daily or almost daily”, “three or four times a week” 
or “once or twice a week”. The distribution of alcohol intake was similar across 
assessment centres, within alcohol frequency. The range of median alcohol intake 
across assessment centres for the three categories of alcohol frequency was 26.0-34.3, 
14.8-22.4 and 7.4-10.3 g/d. 
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Figure 4.6.10 Alcohol Intake Distribution by Alcohol Frequency and Assessment 
Centre for Participants Drinking at Least “Once or Twice a Week” 
 
Boxes show 25
th
, 50
th
 and 75
th
 percentiles of alcohol intake. Lines show the 5
th
 and 95
th
 percentiles of 
alcohol intake. Blue indicates that the assessment centre recruited participants after the change in 
questionnaire. Red indicates assessment centres which recruited participants before the change in 
questionnaire. (Bristol, Nottingham and Liverpool changed questionnaire during recruitment). 
 
There were slight differences by assessment centre. For example, within each category 
of alcohol frequency, participants from Oxford reported the lowest alcohol intake. The 
assessment centres are sorted approximately by assessment dates; hence, there seemed 
to be no trend in the amount of alcohol intake reported by assessment date, within 
alcohol frequency. Also, there seemed to be less variability between assessment centres 
with lower alcohol frequency. Figure 4.6.11 shows the distribution of alcohol grams per 
day by assessment centre for participants who reported drinking “one to three times a 
month” or “special occasions only”. 
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Figure 4.6.11 Alcohol Intake Distribution by Alcohol Frequency and Assessment 
Centre Less Than “One to Three Times a Month” 
 
Boxes show 25
th
, 50
th
 and 75
th
 percentiles of alcohol intake. Lines show the 5
th
 and 95
th
 percentiles of 
alcohol intake. 
 
Multiple Imputation Method 
 
Multiple imputation was used in this thesis to impute average alcohol intake 
(grams/day) for participants with missing data. A number of participants were excluded 
from other analysis variables as well as alcohol intake because participants responded 
“do not know” or “prefer not to answer”. Data for these variables could also have been 
imputed using multiple imputation by chained equations (MICE).
375
 However, since 
participants chose not to answer, it is plausible that these data would not be MAR and 
so multiple imputation of these data could lead to biased results. Similarly, alcohol 
intake was imputed only for participants with missing data and not for participants who 
did answer the questionnaire but were excluded e.g. for responding “do not know”. 
 
Multiple imputation can be considered in three stages.
375
 The first stage is to create 𝑚 
imputed datasets based on an imputation model which predicts missing values of a 
variable 𝑧 using data from a set of variables 𝑥1, … , 𝑥𝑛, which are complete. 
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This analysis used predictive mean matching (PMM) to impute missing values of 
alcohol grams per day. PMM is commonly used for the imputation of continuous 
variables when the Normality assumption is not met.
375, 404
 PMM begins by fitting a 
linear regression model of 𝑧 on 𝑥1, … , 𝑥𝑛 using the observed data in order to obtain 
predictions for each missing value of 𝑧. Then, for each individual with missing 𝑧, PMM 
identifies the 𝑘 individuals with the closest observed value of 𝑧 and one of these 𝑘 
values is chosen at random to replace the missing value. Hence, the distribution of 
imputed values should closely match the distribution of the observed values, conditional 
on the values of the other variables in the imputation model. 
 
The default value for 𝑘 in Stata was one. However, this would result in the same 
individual being selected for each imputation. This means there would be no uncertainty 
in the imputed values which would be equivalent to single imputation. Hence, 𝑘 was set 
to ten in this analysis.
405
 
 
In the second stage, each of these 𝑚 datasets is analysed, individually but using 
identical methods, to obtain 𝑚 estimates for the quantities of interest. The final stage is 
to combine these 𝑚 estimates using Rubin’s rules.406 If 𝑄𝑖 represents the estimate for 
the quantity of interest from the 𝑖𝑡ℎ imputed dataset and 𝑊𝑖 is the estimated variance of 
𝑄𝑖, then the combined estimate Q is 
𝑄 =
1
𝑚
 ∑ 𝑄𝑖
𝑚
𝑖=1
 
 
and the total variance of Q is 
𝑉𝑎𝑟(𝑄) = 𝑊 + (1 +
1
𝑚
) 𝐵 
 
where W is the within-imputation variance 
𝑊 =
1
𝑚
 ∑ 𝑊𝑖
𝑚
𝑖=1
 
 
and B is the between-imputation variance 
𝐵 =
1
𝑚 − 1
 ∑(𝑄𝑖 − 𝑄)
2 
𝑚
𝑖=1
. 
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Hence, the variation within and between imputations is included in the analysis. 
 
Multiple Imputation Model 
 
It is vital for valid imputation that the outcome is included in the imputation model.
407
 
Otherwise, there will be no association between alcohol intake and colorectal cancer 
among individuals with imputed data and so results using multiple imputation would be 
biased towards the null. Similarly, it is crucial that all confounder variables considered 
in analyses using imputed data are included in the imputation model. 
 
Hence, the imputation model used in this analysis included all the confounders included 
in the analysis model for alcohol intake (sex, overall smoking status, BMI, Townsend 
deprivation index, red meat intake, processed meat intake, height, family history of 
colorectal cancer and bowel screening) as well as age at baseline. The question on 
alcohol intake ten years ago was also included. For the outcome, it is recommended to 
include the event indicator variable and the Nelson-Aalen estimator of the cumulative 
hazard when using Cox proportional hazards models.
408
 Since separate analyses were 
performed for colon and rectal cancer, outcome variables for colon and rectal cancer 
were included in the imputation model. 
 
Since alcohol grams per day was strongly associated with alcohol frequency, missing 
values were imputed by alcohol frequency i.e. separate imputation models were used for 
participants who reported drinking “special occasions only” and for participants who 
reported drinking “one to three times a month”. 
 
Alcohol data for participants who reported “special occasions only” and “one to three 
times a month” were practically either completely observed or completely missing 
according to assessment date/assessment centre (see Figure 4.1.2). Thus, it was not 
possible to estimate the effect of assessment date/assessment centre on alcohol grams 
per day for the earlier centres with missing data. Hence, these variables were not 
included in the imputation model despite them being highly predictive of the missing 
alcohol data. Therefore, this analysis assumed no relationship between assessment date 
or assessment centre and alcohol intake (within alcohol frequency). Although alcohol 
grams per day did differ by assessment centre (see Figure 4.6.10), this variation is more 
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likely explained by differences in other lifestyle factors rather than differences in 
geographic location. Also, the variation was smaller among people with lower alcohol 
frequency. 
 
Table 4.6.1 Comparison of Variables for Participants with Non-missing and Missing 
Alcohol Data 
 One to three times a month  Special occasions only 
 
Non-missing 
(n = 16,401) 
Missing 
(n = 31,653) 
 
Non-missing 
(n = 17,170) 
Missing 
(n = 30,647) 
Age (mean), yrs 55.3 55.1  56.7 56.7 
Sex, % male 37.1 36.3  29.4 28.5 
Current smoker, % 9.9 10.5  10.5 12.4 
BMI, mean, kg/m
2 
28.0 28.0  28.5 28.5 
Height (mean), cm 167.6 167.2  165.6 165.3 
Townsend index, % in most deprived 
quintile 
21.7 20.0  28.3 26.3 
Red meat intake, % ≥3 times/week 17.6 19.4  18.4 20.2 
Processed meat intake % >once/week 28.8 27.6  26.4 25.9 
Family history, % 10.4 10.8  10.7 11.0 
Bowel screening, % 36.6 22.7  40.5 25.4 
Alcohol intake ten years ago, % less 
nowadays 
63.6 59.5  61.8 57.5 
Colorectal cancer cases/10,000 
person-years 
7.5 8.4  7.6 8.8 
 
Altogether, 33,571 participants had complete data for alcohol grams per day as well as 
all variables included in the imputation model. 62,300 participants had complete data 
for all variables included in the imputation model but had missing data for alcohol 
intake. Table 4.6.1 compares the characteristics of participants with non-missing and 
missing alcohol data. There were slight differences for some variables. For example, 
participants with missing alcohol data were slightly more likely to be current smokers, 
less likely to live in areas associated with highest deprivation and more likely to eat red 
meat at least 3 times a week. There was a much higher proportion of participants with a 
history of bowel screening among people with non-missing data than among people 
with missing data since national screening programmes were introduced during UK 
Biobank recruitment.
15-17
 Thus, many participants who attended earlier assessment 
centres would not have been invited to attend screening until after recruitment. 
Participants with missing alcohol data had a slightly higher number of cases per 10,000 
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person-years because these participants were recruited earlier and so followed-up until 
an older age. 
 
The number of imputations had to be decided for the analysis. There are no agreed 
guidelines for the number of imputations required. One rule of thumb is that the number 
of imputations should be at least equal to the percentage of observations with missing 
data.
375
 64.0% of participants who reported drinking “one to three times a month” and 
63.3% of participants who reported drinking “special occasions only” had missing 
alcohol intake data. Hence, this analysis created 70 imputations (the effect of the choice 
for the number of imputations on the final results was investigated in the analysis (see 
section Error! Reference source not found.)). Figure 4.6.12 and Figure 4.6.13 
compare the distribution of alcohol grams per day for participants with complete 
alcohol data with the distribution of the alcohol grams per day data in the first three 
imputations for participants with missing data. The distribution of alcohol grams per 
day in the imputations closely matched the distribution of alcohol grams per day in the 
observed data (for both “one to three times a month” and “special occasions only”).  
  
Figure 4.6.12 Distribution of Observed and Imputed Data for Alcohol Intake for “One 
to Three Times a Month” 
 
Distribution of alcohol grams per day among participants who reported drinking “one to three times a 
month” with observed data and distribution of alcohol grams per day as calculated in the first three 
imputations for participants with missing data. 
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Figure 4.6.13 Distribution of Observed and Imputed Data for Alcohol Intake for 
“Special Occasions Only” 
 
Distribution of alcohol grams per day among participants who reported drinking “special occasions only” 
with observed data and distribution of alcohol grams per day as calculated in the first three imputations 
for participants with missing data. 
 
Chapters 5, 6 and 7 present the results for the analyses of alcohol intake, adiposity and 
smoking in relation to colorectal cancer. Separate discussion sections for the three risk 
factors are included in each chapter. An overall discussion of the thesis is included in 
Chapter 8. 
 
Analyses in this thesis were complete-case analyses (except for the sensitivity analyses 
in Chapter 5 using multiple imputation), excluding participants with missing data or 
who responded “do not know” or “prefer not to answer”. A disadvantage of this 
approach is that it leads to the exclusion of many participants. An alternative approach 
is to include an additional “dummy” category for each variable for those participants 
who could not be included in the other categories. The main analyses for alcohol intake, 
BMI and overall smoking status were also performed using this alternative approach 
and results are shown in Table A-5 - Table A-7 in the appendix (compare results with 
Table 5.2.2, Table 6.1.2, Table 6.1.3 and Table 7.1.2). Results for alcohol intake and 
smoking were very similar. For BMI, there was a slight difference in results, mainly for 
colon cancer for men; the HR for the highest quintile of BMI was 1.61 in the main 
analysis and 1.53 when including “dummy” categories. 
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Chapter 5 Alcohol Intake and Colorectal 
Cancer 
 
5.1 Data Summary 
 
Before presenting the results for the analysis of alcohol intake and colorectal cancer, 
summary tables are presented to show the relationships between the main analysis 
variables and colorectal cancer by sex (Table 5.1.1 - Table 5.1.11). These tables show 
the number of cases per 10,000 person-years (C/10KPY) and therefore provide an 
absolute measure of risk for these variables. Note that these results are not adjusted for 
other variables. 
 
The absolute risk increased with each category of intake, from 7.2 C/10KPY for never 
drinkers to 16.8 C/10KPY for ≥45 g/d. However, there was no such trend for women 
where never drinkers had a higher absolute risk (8.9 C/10KPY) compared to all 
categories of current drinking. 
 
The absolute risk increased monotonically with increasing BMI for men, from 9.4 
C/10KPY for the lowest quintile to 14.5 C/10KPY for the highest quintile. Women in 
the lowest quintile of BMI did have the lowest risk (6.1 C/10KPY) but there was no 
clear trend in risk since women in the highest quintile had the next lowest level of risk 
(7.2 C/10KPY). The absolute risk for men increased from 7.2 in the lowest quintile to 
16.9 C/10KPY in the highest quintile for WC and from 7.0 to 17.2 C/10KPY for WHR 
for men. For women, the increase was from 5.6 to 8.7 C/10KPY for WC and from 5.8 to 
9.5 C/10KPY for WHR. 
 
Former smokers had the highest absolute risk for men (15.9 C/10KPY) followed by 
current smokers (11.7 C/10KPY) and then never smokers (9.3 C/10KPY). For women, 
the absolute risks for never smokers, former smokers and current smokers were 7.1, 8.9 
and 6.4 C/10KPY respectively. 
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Men who consumed more red meat and processed had a higher absolute risk of 
colorectal cancer. Men and women with a family history of bowel cancer and a history 
of bowel screening had a higher absolute risk. 
 
Also, Table 5.1.12 shows results for the association between the confounder variables 
used in the analyses and colorectal cancer risk. There was no evidence for an 
association between Townsend deprivation index and colorectal cancer. Men with a 
high intake of red meat and processed meat had an increased risk of colorectal cancer 
but evidence was less clear for women. Height was positively associated with colorectal 
cancer risk. Participants with a family history of colorectal cancer had an increased risk 
of colorectal cancer and participants with a history of bowel screening had a lower risk. 
 
Table 5.1.1 Colorectal Cancer Cases per 10,000 Person-years by Alcohol Intake and 
Sex in UK Biobank 
 Alcohol intake (grams/day) 
 Former Never <5 5-<15 15-<30 30-<45 ≥45 
Men        
Person-years 37,757 30,641 71,949 227,317 278,444 153,671 148,995 
Cases 36 22 63 243 341 219 250 
Cases/10,000 
person-years 
9.5 7.2 8.8 10.7 12.2 14.3 16.8 
        
Women        
Person-years 45,911 74,383 196,993 390,551 221,231 56,102 22,393 
Cases 44 66 135 281 160 48 10 
Cases/10,000 
person-years 
9.6 8.9 6.9 7.2 7.2 8.6 4.5 
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Table 5.1.2 Colorectal Cancer Cases per 10,000 Person-years by BMI and Sex in UK 
Biobank 
 BMI (kg/m
2
) 
 <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 
Men      
Person-years 217,112 218,711 209,047 226,974 217,554 
Cases 205 213 268 321 316 
Cases/10,000 
person-years 
9.4 9.7 12.8 14.1 14.5 
 <22.89 22.89-<25.04 25.04-<27.34 27.34-<30.80 ≥30.80 
Women      
Person-years 258,203 256,816 254,415 257,517 255,599 
Cases 157 197 216 211 183 
Cases/10,000 
person-years 
6.1 7.7 8.5 8.2 7.2 
 
Table 5.1.3 Colorectal Cancer Cases per 10,000 Person-years by WC and Sex in UK 
Biobank 
 WC (cm) 
 ≤87 88-93 94-98 99-105 ≥106 
Men      
Person-years 209,426 231,055 211,952 222,144 215,783 
Cases 151 239 270 299 364 
Cases/10,000 
person-years 
7.2 10.3 12.7 13.5 16.9 
 ≤74 75-80 81-86 87-95 ≥96 
Women      
Person-years 282,172 256,826 243,626 263,752 236,394 
Cases 158 196 198 206 206 
Cases/10,000 
person-years 
5.6 7.6 8.1 7.8 8.7 
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Table 5.1.4 Colorectal Cancer Cases per 10,000 Person-years by WHR and Sex in UK 
Biobank 
 WHR 
 <0.883 0.883-<0.918 0.918-<0.950 0.950-<0.990 ≥0.990 
Men      
Person-years 222,937 216,822 221,726 217,534 210,999 
Cases 156 193 283 329 362 
Cases/10,000 
person-years 
7.0 8.9 12.8 15.1 17.2 
 <0.758 0.758-<0.796 0.796-<0.832 0.832-<0.876 ≥0.876 
Women      
Person-years 265,802 257,807 256,930 247,422 254,583 
Cases 154 166 218 183 243 
Cases/10,000 
person-years 
5.8 6.4 8.5 7.4 9.5 
 
Table 5.1.5 Colorectal Cancer Cases per 10,000 Person-years by Overall Smoking 
Status and Sex in UK Biobank 
 Overall smoking status 
 Never smokers Former smokers Current smokers 
Men    
Person-years 524,453 418,660 135,880 
Cases 489 667 159 
Cases/10,000 person-years 9.3 15.9 11.7 
    
Women    
Person-years 777,234 372,227 113,734 
Cases 548 332 73 
Cases/10,000 person-years 7.1 8.9 6.4 
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Table 5.1.6 Colorectal Cancer Cases per 10,000 Person-years by Townsend Deprivation 
Index and Sex in UK Biobank 
 Townsend deprivation index 
 <−3.93 −3.93-<2.76 −2.76-<−1.30 −1.30-<1.35 ≥1.35 
Men      
Person-years 224,067 217,964 215,265 214,239 224,176 
Cases 278 291 255 246 262 
Cases/10,000 
person-years 
12.4 13.4 11.8 11.5 11.7 
      
Women      
Person-years 260,540 257,497 261,358 258,637 249,935 
Cases 207 209 180 196 175 
Cases/10,000 
person-years 
7.9 8.1 6.9 7.6 7.0 
 
Table 5.1.7 Colorectal Cancer Cases per 10,000 Person-years by Red Meat Intake and 
Sex in UK Biobank 
 Red meat intake 
 ≤once/week >1-<3 times/week ≥3 times/week 
Men    
Person-years 450,877 350,956 278,090 
Cases 458 451 406 
Cases/10,000 person-years 10.2 12.9 14.6 
    
Women    
Person-years 628,005 394,641 250,789 
Cases 431 337 187 
Cases/10,000 person-years 6.9 8.5 7.5 
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Table 5.1.8 Colorectal Cancer Cases per 10,000 Person-years by Processed Meat Intake 
and Sex in UK Biobank 
 Processed meat intake 
 <once/week once/week >once/week 
Men    
Person-years 293,115 326,031 472,804 
Cases 298 414 615 
Cases/10,000 person-years 10.2 12.7 13.0 
    
Women    
Person-years 652,199 368,607 263,558 
Cases 488 291 185 
Cases/10,000 person-years 7.5 7.9 7.0 
 
Table 5.1.9 Colorectal Cancer Cases per 10,000 Person-years by Height and Sex in UK 
Biobank 
 Height (cm) 
 ≤170 171-174 175-177 178-181 ≥182 
Men      
Person-years 244,989 232,454 189,344 211,185 211,423 
Cases 347 256 241 246 233 
Cases/10,000 
person-years 
14.2 11.0 12.7 11.6 11.0 
 ≤157 158-161 162-164 165-168 ≥169 
Women      
Person-years 278,345 290,895 242,209 258,815 212,285 
Cases 212 223 175 201 153 
Cases/10,000 
person-years 
7.6 7.7 7.2 7.8 7.2 
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Table 5.1.10 Colorectal Cancer Cases per 10,000 Person-years by Family History of 
Bowel Cancer and Sex in UK Biobank 
 Family history of bowel cancer 
 No Yes 
Men   
Person-years 951,540 120,555 
Cases 1,108 198 
Cases/10,000 person-years 11.6 16.4 
   
Women   
Person-years 1,126,331 136,034 
Cases 814 127 
Cases/10,000 person-years 7.2 9.3 
 
Table 5.1.11 Colorectal Cancer Cases per 10,000 Person-years by Bowel Screening and 
Sex in UK Biobank 
 Bowel screening 
 No Yes 
Men   
Person-years 748,656 319,605 
Cases 831 479 
Cases/10,000 person-years 11.1 15.0 
   
Women   
Person-years 918,481 353,633 
Cases 647 305 
Cases/10,000 person-years 7.0 8.6 
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Table 5.1.12 Confounder Variables and the Risk of Colorectal Cancer in UK Biobank 
 Overall Men Women 
 Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Sex       
Women 886 1.00     
Men 1,223 1.19 (1.04-1.36)     
       
Townsend index       
Q1 455 1.00 260 1.00 195 1.00 
Q2 468 1.06 (0.93-1.20) 272 1.09 (0.92-1.29) 196 1.02 (0.84-1.24) 
Q3 408 0.95 (0.83-1.09) 243 1.01 (0.85-1.21) 165 0.87 (0.70-1.07) 
Q4 405 1.01 (0.88-1.16) 224 1.01 (0.85-1.21) 181 1.01 (0.82-1.23) 
Q5 373 1.01 (0.88-1.16) 224 1.08 (0.90-1.30) 149 0.92 (0.74-1.15) 
       
Red meat intake       
≤once/week 821 1.00 423 1.00 398 1.00 
>1-<3 
times/week 
736 1.15 (1.04-1.27) 421 1.12 (0.97-1.28) 315 1.20 (1.03-1.39) 
≥3 times/week 552 1.14 (1.02-1.27) 379 1.20 (1.04-1.39) 173 1.02 (0.85-1.22) 
       
Processed meat 
intake 
      
<once/week 725 1.00 271 1.00 454 1.00 
Once/week 646 1.08 (0.97-1.20) 381 1.17 (1.00-1.37) 265 1.03 (0.88-1.20) 
>once/week 738 1.10 (0.99-1.23) 571 1.23 (1.06-1.43) 167 0.94 (0.78-1.12) 
       
Height (per 10 cm) 2,109 1.11 (1.04-1.19) 1,223 1.08 (0.99-1.17) 886 1.16 (1.04-1.29) 
       
Family history of 
colorectal cancer 
      
No 1,799 1.00 1,031 1.00 768 1.00 
Yes 310 1.24 (1.10-1.40) 192 1.30 (1.11-1.52) 118 1.16 (0.95-1.41) 
       
Bowel screening       
No 1,369 1.00 772 1.00 597 1.00 
Yes 740 0.87 (0.79-0.95) 451 0.87 (0.77-0.98) 289 0.87 (0.75-1.01) 
* Results adjusted for  alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), overall smoking 
status (never, former, current). 
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5.2 Results 
 
Cox proportional hazards models using age as the primary time variable were used to 
estimate the association between alcohol intake and colorectal cancer risk. Participants 
were followed-up from the date of the baseline assessment until the date of any cancer 
diagnosis, date of death or 31
st
 March 2014, whichever came first. All analyses 
presented in this section were adjusted for sex, BMI, overall smoking status, Townsend 
deprivation index, red meat intake, processed meat intake, height, family history of 
colorectal cancer and bowel screening. This analysis included a total of 367,779 
participants (177,075 men and 190,704 women) (Figure 5.2.1). 1,806 participants 
(1,108 men and 698 women) were diagnosed with colorectal cancer during a median 
follow-up of 5.07 years (range 3.50-8.05 years). 
 
Figure 5.2.1 Flowchart of Exclusions for Analysis of Alcohol Intake and Colorectal 
Cancer 
 
Flowchart of reasons for excluding participants from the analysis of alcohol intake and colorectal cancer. 
 
5.2.1 Main Results 
  
Table 5.2.1 compares characteristics of the participants included in the analysis by 
alcohol intake category and sex. Female never and former drinkers were slightly older 
than current drinkers and heavier drinkers were slightly younger than lighter drinkers. 
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Heavier drinkers as well as former drinkers were more likely to be current smokers. 
Never and former drinkers were more likely to live in areas with higher deprivation than 
current drinkers. Heavy drinkers reported the highest intakes of red meat and processed 
meat. Light drinkers had the highest rates of bowel screening for men and women. Male 
never drinkers had the lowest rates of screening whereas female heavy drinkers had the 
lowest rates. 
 
The main results for the association between alcohol intake and colorectal cancer are 
shown in Table 5.2.2. There was a noticeable difference between results adjusted for sex 
only and results adjusted for all confounder variables. Table A-8 in the appendix shows 
results adjusting for different confounder variables individually. Adjusting for smoking 
status resulted in the biggest attenuation in results. 
 
Compared to never drinkers, there was only clear evidence of an increased risk of 
colorectal cancer for participants drinking ≥45 g/d (HR, 1.33; 95% CI, 1.02-1.74) 
(Table 5.2.2). The association between alcohol intake and colorectal cancer risk was 
stronger for men than women. For men, there appeared to be evidence of an increased 
risk associated with intake ≥15 g/d; the HRs (95% CIs) were 1.48 (0.93-2.37) for 15-
<30 g/d, 1.61 (1.00-2.58) for 30-45 g/d and 1.86 (1.16-2.99) for ≥45 g/d. (CIs were wide 
due to a small number of cases in the reference group for men). In contrast, there was no 
clear evidence of an association for women. 
 
P-values for test for trend were calculated by assigning to participants in each category 
of alcohol intake the median value within their category (former drinkers were excluded 
and never drinkers were included as 0) and modelling this variable as a continuous 
variable. The p-values for the test for trend were <0.0001 overall, <0.0001 for men and 
0.7962 for women. The p-values for the test for trend were also calculated using data 
from the re-assessment. Instead of using the median value of baseline alcohol intake for 
each category, participants were assigned the median value of alcohol intake at re-
assessment (among those in the baseline category who were re-assessed). This analysis 
excluded baseline never drinkers and former drinkers. The p-values for the test for trend 
were <0.0001 overall, <0.0001 for men and 0.7608 for women. Hence, results for test 
for trend were similar when taking repeated measures into account. 
 
Chapter 5 | Alcohol Intake and Colorectal Cancer 
225 
There was no clear evidence of an increased risk of colorectal cancer for former 
drinkers compared to never drinkers (HR, 0.97; 95% CI, 0.70-1.34). Some former 
drinkers will have quit drinking as a result of ill health and it is plausible that these 
former drinkers will have an increased risk of colorectal cancer. In UK Biobank, former 
drinkers were most likely to report a long-standing illness or poor health status at 
baseline (Figure 5.2.2). 
 
Figure 5.2.2 Percentage of Participants Reporting Long-standing Illness and Poor 
Health, by Alcohol Intake 
 
Percentage of participants reporting a long-standing illness and poor health by categories of alcohol 
intake. 
 
In the touchscreen questionnaire, former drinkers were asked why they stopped drinking 
alcohol with the choice of five responses. “Illness or ill health”, “doctor’s advice” and 
“health precaution” were classified as illness related reasons and “financial reasons” and 
“other reasons” were classified as other reasons. Compared to never drinkers, the HR 
(95% CI) for colorectal cancer risk was 1.00 (0.67-1.48) for former drinkers who 
reported illness related reasons and 0.86 (0.56-1.32) for former drinkers who reported 
other reasons. 
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6 Table 5.2.1 Characteristics of UK Biobank Cohort by Alcohol Intake and Sex 
 
Alcohol intake (grams/day) 
Former Never <5 5-<15 15-<30 30-<45 ≥45 
Men        
Number of participants 6,713 5,180 14,942 42,628 51,640 28,414 27,558 
Age, mean (SD), years 56.8 (8.1) 55.8 (9.0) 56.9 (8.4) 56.8 (8.2) 56.7 (8.1) 56.7 (8.0) 56.5 (7.8) 
Overall smoking status, % current smoker 17.4 7.9 9.4 7.2 9.6 13.5 21.9 
BMI, mean (SD), kg/m
2 
28.3 (5.1) 27.8 (4.8) 27.7 (4.6) 27.4 (4.1) 27.6 (3.9) 27.9 (3.9) 28.3 (4.1) 
Townsend index, % in most deprived quintile 37.1 35.2 21.3 14.9 15.8 17.3 22.9 
Red meat intake, % ≥3 times/week 24.9 28.0 19.9 21.5 24.7 28.2 34.8 
Processed meat intake, % >once/week 38.2 35.3 39.0 39.2 42.2 47.0 54.5 
Family history, % 11.5 9.1 10.7 11.1 11.3 12.1 12.3 
Colorectal screening, % 32.5 26.5 38.0 32.4 32.5 32.7 31.0 
        
Women        
Number of participants 8,381 13,322 40,556 72,672 41,167 10,456 4,150 
Age, mean (SD), years 57.1 (7.8) 57.4 (8.3) 56.5 (8.1) 56.1 (7.9) 55.5 (7.8) 55.2 (7.6) 54.1 (7.6) 
Overall smoking status, % current smoker 13.8 5.4 6.6 6.3 10.0 16.5 25.3 
BMI, mean (SD), kg/m
2 
28.2 (6.1) 28.2 (5.9) 27.4 (5.4) 26.3 (4.6) 26.3 (4.5) 26.7 (4.6) 27.2 (4.9) 
Townsend index, % in most deprived quintile 31.1 29.1 19.5 14.5 16.2 18.6 23.3 
Red meat intake, % ≥3 times/week 17.2 19.6 17.1 19.3 21.9 24.4 28.1 
Processed meat intake, % >once/week 18.7 18.7 20.7 19.6 21.4 24.3 26.5 
Family history, % 11.7 10.1 10.5 10.9 11.2 10.9 11.7 
Colorectal screening, % 33.7 30.1 34.7 28.9 28.0 27.7 26.0 
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Table 5.2.2 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank 
 Alcohol intake (grams/day)  
 Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Overall         
Person-years 75,602 92,950 251,412 582,471 471,550 197,596 160,697  
Cases 70 79 187 499 479 248 244  
Sex adjusted HR (95% CI) 1.04 (0.76-1.44) 1.00 0.92 (0.71-1.20) 1.02 (0.81-1.30) 1.15 (0.90-1.46) 1.33 (1.03-1.72) 1.56 (1.20-2.02) <0.0001 
Multivariate HR (95% CI)* 0.97 (0.70-1.34) 1.00 0.89 (0.68-1.16) 0.96 (0.75-1.22) 1.04 (0.81-1.33) 1.16 (0.89-1.51) 1.33 (1.02-1.74) <0.0001 
         
Men         
Person-years 33,393 26,099 66,413 212,948 261,178 144,277 139,594  
Cases 30 19 59 234 328 204 234  
Multivariate HR (95% CI)* 1.07 (0.60-1.90) 1.00 1.13 (0.67-1.90) 1.35 (0.84-2.15) 1.48 (0.93-2.37) 1.61 (1.00-2.58) 1.86 (1.16-2.99) <0.0001 
         
Women         
Person-years 42,210 66,851 184,999 369,523 210,373 53,319 21,103  
Cases 40 60 128 265 151 44 10  
Multivariate HR (95% CI)* 1.04 (0.69-1.55) 1.00 0.80 (0.59-1.09) 0.81 (0.61-1.08) 0.82 (0.60-1.12) 0.97 (0.65-1.44) 0.59 (0.30-1.17) 0.7962 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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Participants who reported drinking alcohol at baseline were asked how their alcohol 
intake had changed in comparison to ten years ago. Table 5.2.3 shows the responses of 
participants by category of alcohol intake. For each category, a similar proportion of 
participants reported drinking “about the same” though the proportion reporting “less 
nowadays” decreased with increasing alcohol intake. Compared to the overall analysis, 
restricting the analysis to only those participants who reported drinking “about the 
same” as ten years ago, the HRs for each category of alcohol intake were similar except 
for ≥45 g/d which increased; the HRs (95% CIs) associated with drinking <5, 5-<15, 
15-<30, 30-<45 and ≥45 g/d were 0.90 (0.66-1.24), 0.92 (0.70-1.20), 0.96 (0.72-1.27), 
1.06 (0.76-1.46) and 1.51 (1.09-2.07). 
 
Table 5.2.3 Alcohol Intake Compared to Ten Years before Baseline 
 Alcohol intake (grams/day) 
Alcohol intake vs ten 
years ago 
<5 5-<15 15-<30 30-<45 ≥45 
n % n % n % n % n % 
Less nowadays 30,868 55.6 51,643 44.8 36,107 38.9 13,514 34.8 9,536 30.1 
About the same 21,203 38.2 44,073 38.2 34,065 36.7 14,460 37.2 12,526 39.5 
More nowadays 2,882 5.2 19,111 16.6 22,220 23.9 10,774 27.7 9,572 30.2 
Do not know 458 0.8 461 0.4 408 0.4 118 0.3 72 0.2 
Prefer not to answer 87 0.2 12 0.0 7 0.0 4 0.0 2 0.0 
 
Participants who reported drinking alcohol at baseline were also asked “when you drink 
alcohol is it usually with meals?” Participants responded “yes”, “it varies” or “no”. For 
the ease of writing, participants who responded “yes” will be referred to as “meal 
drinkers”, participants who responded “it varies” as “variable drinkers” and participants 
who responded “no” as “non-meal drinkers”. 
  
The risk of colorectal cancer was compared between the three categories. Since average 
alcohol intake differed between the categories (mean alcohol intake was 16.0, 23.3 and 
26.4 g/d for “meal drinkers”, “variable drinkers” and “non-meal drinkers”), this analysis 
was adjusted for continuous alcohol intake. Compared with “meal drinkers”, the HR 
(95% CI) was 0.95 (0.85-1.06) for “variable drinkers” and 0.96 (0.84-1.10) for “non-
meal drinkers”. 
 
Results for men also showed no evidence for differences by drinking pattern (HR, 1.00; 
95% CI, 0.86-1.15 for “variable drinkers” and HR, 1.00; 95% CI, 0.85-1.18 for “non-
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meal drinkers”) but results for women suggested that “variable drinkers” and “non-meal 
drinkers” may have a lower risk of colorectal cancer than “meal drinkers” (HR, 0.89; 
95% CI, 0.74-1.07 for “variable drinkers” and HR, 0.87; 95% CI, 0.67-1.12 for “non-
meal drinkers”). 
 
Colorectal Subsites 
 
Investigating separately the risk of colon and rectal cancer, there was still no evidence 
that alcohol intake was associated with an increased risk for women (Table 5.2.4). In 
contrast, alcohol intake seemed to be strongly associated with colon cancer risk (HR, 
1.85; 95% CI, 0.99-3.45 for ≥45 g/d) and rectal cancer risk (HR, 1.91; 95% CI, 0.92-
3.96 for ≥45 g/d) for men (though CIs were very wide). 
  
Associations with proximal and distal colon cancer were also investigated (Table 5.2.5). 
Participants drinking 30-≤45 g/d (HR, 1.66; 95% CI, 1.04-2.66) and ≥45 g/d (HR, 1.52; 
95% CI, 0.94-2.48) had an increased risk of distal colon cancer but there was no clear 
evidence of an increased risk for proximal colon cancer. 
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0 Table 5.2.4 Alcohol Intake and the Risk of Colon Cancer and Rectal Cancer in UK Biobank 
 Alcohol intake (grams/day)  
 Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Colon cancer         
Overall         
Cases 51 52 130 339 305 164 141  
HR (95% CI)* 1.12 (0.76-1.66) 1.00 0.96 (0.69-1.33) 1.04 (0.77-1.40) 1.09 (0.81-1.48) 1.32 (0.95-1.82) 1.34 (0.96-1.88) 0.0017 
Men         
Cases 20 11 39 143 192 132 136  
HR (95% CI)* 1.22 (0.58-2.55) 1.00 1.29 (0.66-2.52) 1.41 (0.76-2.61) 1.48 (0.80-2.74) 1.77 (0.95-3.29) 1.85 (0.99-3.45) 0.0020 
Women         
Cases 31 41 91 196 113 32 5  
HR (95% CI)* 1.22 (0.76-1.96) 1.00 0.87 (0.60-1.26) 0.93 (0.66-1.32) 0.98 (0.68-1.42) 1.14 (0.71-1.83) 0.48 (0.19-1.22) 0.9457 
Rectal cancer         
Overall         
Cases 20 27 60 166 176 88 104  
HR (95% CI)* 0.74 (0.41-1.32) 1.00 0.81 (0.51-1.28) 0.86 (0.57-1.29) 0.95 (0.63-1.44) 0.98 (0.63-1.54) 1.30 (0.83-2.03) 0.0024 
Men         
Cases 11 8 20 92 136 75 99  
HR (95% CI)* 0.95 (0.38-2.37) 1.00 0.91 (0.40-2.07) 1.27 (0.62-2.63) 1.49 (0.72-3.05) 1.43 (0.68-2.99) 1.91 (0.92-3.96) 0.0008 
Women         
Cases 9 19 40 74 44 13 5  
HR (95% CI)* 0.66 (0.30-1.47) 1.00 0.72 (0.41-1.24) 0.60 (0.36-1.01) 0.55 (0.31-0.97) 0.71 (0.34-1.46) 0.74 (0.27-2.02) 0.5643 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
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§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
 
Table 5.2.5 Alcohol Intake and the Risk of Proximal Colon Cancer and Distal Colon Cancer in UK Biobank 
         
 Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Proximal colon cancer         
Cases 25 22 75 180 152 61 62  
HR (95% CI)* 1.29 (0.73-2.31) 1.00 1.28 (0.79-2.06) 1.30 (0.83-2.03) 1.28 (0.81-2.02) 1.13 (0.68-1.87) 1.36 (0.82-2.27) 0.7638 
         
Distal colon cancer         
Cases 23 24 49 144 131 96 74  
HR (95% CI)* 1.09 (0.61-1.94) 1.00 0.80 (0.49-1.30) 0.95 (0.61-1.47) 1.01 (0.65-1.58) 1.66 (1.04-2.66) 1.52 (0.94-2.48) <0.0001 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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5.2.2 Continuous Alcohol Intake Variable 
 
Alcohol intake was further analysed as a continuous variable. Fractional polynomials 
were used to investigate the “best-fitting” model for the association. A linear model was 
used to model alcohol intake since there was no evidence of a non-linear relationship (p-
value for the likelihood ratio test comparing the “best-fitting” 2-degree polynomial with 
the linear model was 0.42). The HR and 95% CI associated with an increase of 10 g/d 
was 1.05 (1.03-1.07) (Table 5.2.6). (Results were presented per 10 g/d since 10 g of 
alcohol is approximately equal to a small glass of wine, half pint of beer or measure of 
spirits). Results were very similar for men but there was no evidence of an association 
for women. 
  
To investigate the effect of including never drinkers in the continuous analysis, models 
were refitted excluding never drinkers from the continuous alcohol intake variable. 
There was no evidence for a non-linear relationship and the results for an increase of 10 
g/d were very similar to the previous results (Table 5.2.6). 
 
Table 5.2.6 Continuous Alcohol Intake and the Risk of Colorectal Cancer in UK 
Biobank 
Alcohol intake (grams/day) Overall Men Women 
Overall    
Cases 1,713 1,065 648 
HR (95% CI) per 10g/d* 1.05 (1.03-1.07) 1.05 (1.03-1.07) 0.98 (0.91-1.05) 
    
Excluding never drinkers    
Cases 1,634 1,046 588 
HR (95% CI) per 10g/d* 1.05 (1.03-1.07) 1.05 (1.03-1.07) 0.99 (0.92-1.06) 
    
Excluding “extreme” values    
Cases 1,681 1,033 648 
HR (95% CI) per 10g/d* 1.06 (1.03-1.09) 1.06 (1.03-1.10) 0.99 (0.92-1.06) 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of 
colorectal screening (yes/no). 
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Since very large values of alcohol intake may impact on results (UK Biobank 
participants reported drinking up to 900 g/d), models were refitted again excluding 
participants with alcohol intake >96 g/d (the 99
th
 percentile of alcohol intake among 
drinkers). Again, there was no evidence for a non-linear relationship and results were 
very similar (Table 5.2.6). 
 
5.2.3 Alternative Reference Group 
 
24,085 participants who reported drinking <5 g/d at baseline reported drinking “about 
the same” or “more nowadays” compared to ten years before baseline (Table 5.2.3). 
These participants were defined as consistent light drinkers and were combined with 
never drinkers to form an alternative reference group. Table 5.2.7 presents the HRs and 
95% CIs for the association between alcohol intake and colorectal cancer using this 
alternative reference group. Participants who reported drinking <5 g/d at baseline and 
reported drinking “less nowadays” compared to ten years ago were classified separately 
(<5 (reduced)). 
 
The HRs using never drinkers and consistent light drinkers as the reference group were 
slightly higher than those using only never drinkers (Figure 5.2.3). CIs were narrower 
due to the larger number of cases included in the new reference group. Consequently, in 
contrast to overall results using never drinkers as the reference group, overall results 
using the alternative reference group did show evidence of an increased risk for 
participants drinking 30-<45 g/d and slight evidence of an increased risk for participants 
drinking 15-<30 g/d. 
 
HRs for men decreased slightly when including consistent light drinkers in the reference 
group, for example the HR associated with drinking 30-<45 g/d decreased from 1.61 to 
1.54 and the HR associated with drinking ≥45 g/d decreased from 1.86 to 1.79. For 
women, there remained no evidence for an association. 
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Figure 5.2.3 Comparison of Association between Alcohol Intake and Colorectal Cancer 
Using Different Reference Groups 
 
Blue diamonds represent HRs using never drinkers as the reference group. Red diamonds represent HRs 
using never drinkers and consistent light drinkers combined as the reference group. Error bars represent 
95% CIs. 
 
Table 5.2.8 presents the results for the association between alcohol intake and colon and 
rectal cancer using the alternative reference group. HRs for the association with colon 
cancer were very similar using the alternative reference group (Figure 5.2.4). However, 
there was a decrease in the HRs for men using the alternative reference group. 
  
In contrast to the overall results using never drinkers as the reference group, there was 
evidence for an association between alcohol intake and rectal cancer risk when 
including consistent light drinkers in the reference group (Table 5.2.8 and Figure 5.2.5). 
The HRs for the association between alcohol intake and rectal cancer increased for men 
and thus there was evidence that drinking above 15 g/d is associated with an increased 
risk of rectal cancer compared to the alternative reference group. 
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Table 5.2.7 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank (Alternative Reference Group) 
 Alcohol intake (grams/day)  
 Former 
Never /  
<5 (consistent) 
<5 (reduced) 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Overall         
Cases 70 160 103 499 479 248 244  
HR (95% CI)* 1.04 (0.78-1.38) 1.00 0.96 (0.75-1.23) 1.03 (0.86-1.24) 1.11 (0.92-1.34) 1.25 (1.01-1.54) 1.43 (1.15-1.77) <0.0001 
         
Men         
Cases 30 41 36 234 328 204 234  
HR (95% CI)* 1.03 (0.64-1.65) 1.00 1.10 (0.70-1.72) 1.29 (0.93-1.81) 1.43 (1.03-1.98) 1.54 (1.10-2.17) 1.79 (1.28-2.51) <0.0001 
         
Women         
Cases 40 119 67 265 151 44 10  
HR (95% CI)* 1.18 (0.82-1.69) 1.00 0.92 (0.68-1.25) 0.92 (0.74-1.15) 0.94 (0.73-1.20) 1.10 (0.77-1.57) 0.68 (0.35-1.30) 0.8463 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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6 Table 5.2.8 Alcohol Intake and the Risk of Colon Cancer and Rectal Cancer in UK Biobank (Alternative Reference Group) 
         
 Former 
Never /  
<5 (consistent) 
<5 (reduced) 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Colon cancer         
Overall         
Cases 51 111 68 339 305 164 141  
HR (95% CI)* 1.13 (0.81-1.59) 1.00 0.93 (0.69-1.26) 1.05 (0.84-1.30) 1.11 (0.88-1.39) 1.33 (1.03-1.71) 1.36 (1.04-1.77) 0.0015 
Men         
Cases 20 27 22 143 192 132 136  
HR (95% CI)* 1.03 (0.57-1.84) 1.00 1.01 (0.57-1.78) 1.18 (0.78-1.79) 1.25 (0.83-1.87) 1.48 (0.98-2.26) 1.55 (1.02-2.37) 0.0019 
Women         
Cases 31 84 46 196 113 32 5  
HR (95% CI)* 1.32 (0.87-1.99) 1.00 0.91 (0.64-1.31) 1.01 (0.78-1.31) 1.06 (0.79-1.42) 1.23 (0.81-1.86) 0.52 (0.21-1.28) 0.8881 
Rectal cancer         
Overall         
Cases 20 50 37 166 176 88 104  
HR (95% CI)* 0.88 (0.52-1.48) 1.00 1.07 (0.70-1.65) 1.02 (0.74-1.41) 1.14 (0.82-1.57) 1.17 (0.81-1.69) 1.55 (1.08-2.23) 0.0024 
Men         
Cases 11 14 14 92 136 75 99  
HR (95% CI)* 1.14 (0.51-2.52) 1.00 1.28 (0.61-2.68) 1.52 (0.86-2.67) 1.78 (1.02-3.09) 1.71 (0.96-3.05) 2.28 (1.29-4.04) 0.0008 
Women         
Cases 9 36 23 74 40 13 5  
HR (95% CI)* 0.83 (0.40-1.74) 1.00 0.99 (0.59-1.68) 0.76 (0.50-1.14) 0.70 (0.44-1.11) 0.90 (0.47-1.72) 0.94 (0.36-2.43) 0.5660 
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*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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Figure 5.2.4 Comparison of Association between Alcohol Intake and Colon Cancer 
Using Different Reference Groups 
 
Blue diamonds represent HRs using never drinkers as the reference group. Red diamonds represent HRs 
using never drinkers and consistent light drinkers combined as the reference group. Error bars represent 
95% CIs. 
 
Figure 5.2.5 Comparison of Association between Alcohol Intake and Rectal Cancer 
Using Different Reference Groups 
 
Blue diamonds represent HRs using never drinkers as the reference group. Red diamonds represent HRs 
using never drinkers and consistent light drinkers combined as the reference group. Error bars represent 
95% CIs. 
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5.2.4 Effect Modifiers 
 
Alcohol intake was modelled as a continuous variable when investigating the potential 
effect of other variables on the association between alcohol intake and colorectal cancer 
risk in order to maximise statistical power (former drinkers were not included). 
 
Table 5.2.9 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank by Other 
Variables 
 Alcohol intake (per 10 g/d) P-interaction 
BMI (kg/m
2
)   
<25   
Cases 459  
HR (95% CI)*† 1.03 (0.98-1.08)  
25-<30   
Cases 815  
HR (95% CI)*† 1.05 (1.02-1.09)  
≥30   
Cases 439  
HR (95% CI)*† 1.05 (1.02-1.08) 0.5153 
   
Smoking status   
Never   
Cases 763  
HR (95% CI)*‡ 1.05 (1.02-1.08)  
Ever   
Cases 950  
HR (95% CI)*‡ 1.04 (1.02-1.07) 0.9875 
   
Folate intake (µg)   
<289.43   
Cases 285  
HR (95% CI)*†‡ 1.03 (0.97-1.09)  
≥289.43   
Cases 318  
HR (95% CI)*†‡ 1.02 (0.97-1.08) 0.6647 
*Adjusted for sex, Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 times/week), 
processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) 
and history of colorectal screening (yes/no). 
† Adjusted for overall smoking status (never, former, current). 
‡ Adjusted for BMI (<25, 25-<30, ≥30 kg/m2). 
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Results did not show clear evidence that the association between alcohol intake and 
colorectal cancer differed by BMI category (Table 5.2.9). The HR (95% CI) associated 
with a 10 g/d increase was 1.03 (0.98-1.08) for BMI <25 kg/m
2
, 1.05 (1.02-1.09) for 
BMI 25-<30 kg/m
2
 and 1.05 (1.02-1.08) for BMI ≥30 kg/m2. There was also no 
evidence that the association differed for never smokers (HR, 1.05; 95% CI, 1.02-1.08) 
and for ever smokers (HR, 1.04; 95% CI, 1.02-1.07). 
 
The association between alcohol intake and colorectal cancer was investigated 
according to average folate intake as measured by the online 24 hour recall dietary 
questionnaire. 167,941 participants included in this analysis also had data on average 
folate intake. Median folate intake among these participants was 289.4 µg. There was 
no clear evidence that the association between alcohol intake and colorectal cancer 
differed for participants with above or below median folate intake. 
 
5.2.5 Multiple Imputation 
 
Multiple imputation was used to impute missing alcohol grams per day data for 
participants who reported drinking “one to three times a month” and “special occasions 
only”. 16,472 participants who reported drinking “one to three times a month” had 
complete data for alcohol grams per day as well as all confounder variables. In contrast, 
31,653 participants who reported drinking “one to three times a month” had complete 
data for all confounder variables but had missing data for alcohol grams per day. Of the 
participants who reported drinking “special occasions only” and who had complete data 
for all confounder variables, 17,557 had complete alcohol grams per day data and 
30,647 participants had missing data. 
 
Thus, alcohol grams per day data were imputed for those participants with missing data 
using multiple imputation. Missing data were imputed separately for participants who 
reported drinking “one to three times a month” and “special occasions only”. Following 
multiple imputation, this analysis included 430,079 participants (197,289 men and 
232,790 women) and 2,103 cases of colorectal cancer (1,221 cases for men and 882 
cases for women). 
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Results for the association between alcohol intake and colorectal cancer, colon cancer 
and rectal cancer are shown in Table 5.2.10, for the entire cohort and men and women 
separately. Results were very similar to the results of the complete case analysis (Table 
5.2.2 and Table 5.2.4). The most notable difference was the increase for the HR for 
colorectal cancer associated with <5 g/d for men from 1.13 to 1.20. 
 
This analysis was based on 70 imputations. Figure 5.2.6 shows that there was very little 
change in the HRs for <5 and 5-<15 g/d when restricting the analysis to different 
numbers of imputations. Thus, results were unlikely to change with more imputations. 
 
Figure 5.2.6 Association between Alcohol Intake and Colorectal Cancer by Number of 
Imputations 
 
HR calculated using different numbers of imputations. Blue dots show the HR for the risk of colorectal 
cancer associated with <5 g/d and red dots show the HR associated with 5-<15 g/d as calculated based on 
different numbers of imputations. 
 
It was also decided to repeat the analysis with the alternative reference group using the 
imputed data. All participants (including those with missing alcohol grams per day data) 
were asked how their alcohol drinking compared to ten years ago. As before, 
participants who drank <5 g/d and reported drinking “about the same” or “more 
nowadays” compared to ten years before baseline were combined with never drinkers to 
form the reference group. Results for colorectal cancer, colon cancer and rectal cancer 
are shown in Table 5.2.11.  
  
HRs for colorectal cancer (overall and for men and women) were similar to HRs in the 
complete case analysis using the alternative reference group (Table 5.2.7). CIs were 
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narrower in this analysis due to more cases being included in the reference group. As a 
result, there was now slight evidence of an increased risk including for men drinking 5-
<15 g/d (HR, 1.30; 95% CI, 0.98-1.71). 
 
HRs were also similar to the complete case analysis results for colon and rectal cancer 
(Table 5.2.8). While alcohol intake was associated with colon cancer (HR, 1.64; 95% 
CI, 1.15-2.33 for ≥45 g/d) and rectal cancer risk (HR, 2.09; 95% CI, 1.33-3.29 for ≥45 
g/d) for men, there remained no clear evidence of an association for women. 
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Table 5.2.10 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank using Multiple Imputation 
 Alcohol intake (grams/day)  
HR (95% CI)* Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Colorectal cancer         
Overall 0.98 (0.71-1.35) 1.00 0.94 (0.74-1.20) 0.98 (0.77-1.24) 1.05 (0.82-1.34) 1.19 (0.91-1.54) 1.36 (1.05-1.78) <0.0001 
Men 1.08 (0.61-1.92) 1.00 1.20 (0.74-1.95) 1.37 (0.86-2.20) 1.51 (0.95-2.40) 1.63 (1.02-2.63) 1.90 (1.18-3.05) <0.0001 
Women 1.04 (0.69-1.55) 1.00 0.85 (0.64-1.12) 0.81 (0.61-1.08) 0.82 (0.61-1.12) 0.97 (0.65-1.45) 0.60 (0.30-1.18) 0.6540 
         
Colon cancer         
Overall 1.13 (0.76-1.66) 1.00 1.02 (0.76-1.37) 1.04 (0.77-1.40) 1.09 (0.81-1.48) 1.32 (0.96-1.82) 1.35 (0.97-1.89) 0.0015 
Men 1.23 (0.59-2.57) 1.00 1.36 (0.73-2.54) 1.41 (0.76-2.62) 1.49 (0.81-2.75) 1.78 (0.96-3.31) 1.87 (1.00-3.47) 0.0012 
Women 1.21 (0.76-1.94) 1.00 0.93 (0.66-1.30) 0.93 (0.66-1.31) 0.97 (0.67-1.40) 1.13 (0.70-1.81) 0.48 (0.19-1.21) 0.8661 
         
Rectal cancer         
Overall 0.75 (0.42-1.34) 1.00 0.82 (0.54-1.25) 0.89 (0.59-1.35) 0.99 (0.65-1.50) 1.03 (0.66-1.60) 1.37 (0.88-2.13) 0.0004 
Men 0.96 (0.39-2.40) 1.00 1.02 (0.48-2.17) 1.33 (0.64-2.75) 1.54 (0.75-3.15) 1.48 (0.71-3.09) 1.97 (0.95-4.09) 0.0001 
Women 0.68 (0.31-1.51) 1.00 0.70 (0.42-1.16) 0.62 (0.37-1.04) 0.57 (0.32-1.00) 0.73 (0.36-1.52) 0.77 (0.28-2.10) 0.6292 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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4
4 Table 5.2.11 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank (Alternative Reference Group) using Multiple Imputation 
 Alcohol intake (grams/day)  
HR (95% CI)* Former 
Never /  
<5 (consistent) 
<5 (reduced) 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Colorectal cancer         
Overall 0.99 (0.76-1.30) 1.00 0.93 (0.78-1.11) 1.00 (0.86-1.16) 1.07 (0.92-1.25) 1.21 (1.01-1.45) 1.39 (1.15-1.67) <0.0001 
Men 1.02 (0.66-1.58) 1.00 1.20 (0.88-1.65) 1.30 (0.98-1.71) 1.42 (1.09-1.86) 1.55 (1.17-2.04) 1.80 (1.36-2.37) <0.0001 
Women 1.11 (0.79-1.56) 1.00 0.84 (0.68-1.04) 0.87 (0.72-1.05) 0.88 (0.71-1.09) 1.04 (0.75-1.45) 0.64 (0.34-1.21) 0.6540 
         
Colon cancer         
Overall 1.08 (0.79-1.47) 1.00 0.94 (0.77-1.16) 1.00 (0.83-1.20) 1.05 (0.87-1.27) 1.26 (1.01-1.58) 1.30 (1.02-1.64) 0.0014 
Men 1.08 (0.63-1.84) 1.00 1.27 (0.86-1.88) 1.24 (0.88-1.76) 1.31 (0.93-1.83) 1.56 (1.10-2.22) 1.64 (1.15-2.33) 0.0012 
Women 1.20 (0.81-1.77) 1.00 0.84 (0.66-1.08) 0.92 (0.74-1.15) 0.96 (0.75-1.24) 1.11 (0.75-1.64) 0.47 (0.19-1.15) 0.8778 
         
Rectal cancer         
Overall 0.85 (0.52-1.39) 1.00 0.93 (0.68-1.27) 1.01 (0.77-1.33) 1.12 (0.85-1.47) 1.17 (0.85-1.60) 1.55 (1.14-2.12) 0.0004 
Men 1.02 (0.50-2.09) 1.00 1.15 (0.67-1.96) 1.41 (0.89-2.23) 1.63 (1.05-2.52) 1.57 (0.99-2.50) 2.09 (1.33-3.29) 0.0001 
Women 0.85 (0.42-1.71) 1.00 0.84 (0.57-1.24) 0.78 (0.55-1.10) 0.71 (0.47-1.08) 0.92 (0.50-1.70) 0.97 (0.38-2.43) 0.6300 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded for this analysis). 
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5.3 Discussion 
 
5.3.1 Alcohol Intake and Colorectal Cancer 
 
Though the relationship between alcohol intake and colorectal cancer has been 
investigated in a number of prospective cohort studies,
26, 56, 63
 few studies have analysed 
alcohol intake with a similar level of precision as this analysis of UK Biobank data. 
Among the more detailed studies, there seems to be a suggestion that only alcohol 
intake above a certain threshold increases the risk of colorectal cancer.
45, 69, 70
 A recent 
review of studies (published between 2008 and 2014) investigating alcohol intake and 
colorectal cancer concluded that alcohol intake below 30 g/d was not associated with an 
increased risk of colorectal cancer.
409
 Overall results from this analysis of UK Biobank 
only found clear evidence of an increased risk for participants drinking ≥45 g/d. 
However, this analysis also found important differences in results between men and 
women. 
 
5.3.2 Sex 
 
Alcohol intake was strongly associated with colorectal cancer risk for men in this study. 
There did not appear to be a threshold for the effects of alcohol intake on colorectal 
cancer risk; compared to never drinkers, there was slight evidence of an increased risk 
for men drinking 5-<15 g/d when using the alternative reference group. Furthermore, 
the association for men appeared to be much stronger than in other studies of men in 
Western populations. For example, the HR (95% CI) comparing ≥45 g/d vs non-
drinkers in the Western pooled analysis was 1.41 (1.11-1.79) and the HR (95% CI) 
comparing ≥45 g/d vs never drinkers in this analysis was 1.86 (1.16-2.99).45 CIs were 
much wider in this analysis but results were similar (with narrower CIs) when using the 
alternative reference group and the multiple imputed data. In contrast to results for men, 
there was no evidence of an association between alcohol intake and colorectal cancer 
for women. 
 
The WCRF classified alcohol intake as a cause of colorectal cancer for men but only as 
a probable cause for women.
56
 Furthermore, meta-analysis results supported a stronger 
association for men than women.
63
 However, it is likely that this is because women on 
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average have a lower alcohol intake and so there are fewer studies with results for heavy 
alcohol intake among women. For example, the most recent meta-analysis identified 20 
studies (both case-control and cohort studies) reporting results for heavy intake (≥50 
g/d) for men but only four studies for women.
63
 
 
Compared with meta-analyses, individual studies provide more reliable evidence for 
investigating a differential effect of alcohol intake on colorectal cancer risk according to 
sex since they are able to use the same categories of alcohol intake for both men and 
women. Overall, individual studies seem to support a similar association between 
alcohol intake and colorectal cancer risk for both men and women.
45, 65, 66, 69
 For 
example, in the pooled analysis by Cho et al., the HR (95% CI) comparing ≥45 g/d with 
non-drinkers was 1.41 (1.11-1.79) for men and 1.41 (0.98-2.02) for women.
45
 However, 
the Canadian National Breast Screening Study (HR, 1.02; 95% CI, 0.72-1.44 for ≥30 
g/d vs non-drinkers) and the Iowa Women’s Health Study (HR, 1.00; 95% CI, 0.71-1.40 
for ≥30 g/d vs non-drinkers) (both included in Cho et al.) both failed to find evidence of 
an association for women.
67, 68
 
 
It is not clear why this analysis found evidence of an association only for men when 
other studies found evidence for both men and women. There were a relatively small 
number of colorectal cancer cases among women drinking ≥30 g/d in this study. 
However, there seemed to be a clear difference in results for men and women, even for 
15-<30 g/d. 
 
One possible explanation could be due to different patterns of consumption among men 
and women. Men are more likely to binge drink than women.
35
 Thus, if heavy episodes 
of alcohol consumption were particularly associated with colorectal cancer risk, the 
association between alcohol intake and colorectal cancer would be stronger for men. 
That men are more likely to binge drink than women also means that men would be 
more likely to underestimate their average alcohol intake
357
 which would also lead to a 
stronger association for men than women. However, while this explanation may be 
plausible, it does not explain why other studies do not generally find a stronger 
association for men. 
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Men and women also differ in terms of alcoholic beverages consumed which could lead 
to different results if different beverages are not similarly related to colorectal cancer 
risk. Hence, a further analysis was performed analysing alcohol intake from wine, beer 
and spirits separately (Table 5.3.1). Results for each beverage type were adjusted for 
alcohol intake from the other two beverage types. Former drinkers were excluded from 
the analysis. While beer intake was associated with colorectal cancer risk there appeared 
to be no association between wine intake and colorectal cancer risk (results were similar 
when restricted to men (data not shown)). Hence, it is possible that the different results 
for men and women for the association between total alcohol intake and colorectal 
cancer are due to the fact that men tend to drink more beer whereas women tend to 
drink more wine. 
 
Table 5.3.1 Intake of Different Alcoholic Beverages and the Risk of Colorectal Cancer 
in UK Biobank 
Alcohol 
intake (g/d) 
Wine intake  Beer intake  Spirits intake 
Cases HR (95% CI)*  Cases HR (95% CI)*  Cases HR (95% CI)* 
0 399 1.00  775 1.00  1,072 1.00 
>0-<5 306 0.98 (0.84-1.15)  200 0.96 (0.81-1.12)  357 0.90 (0.80-1.02) 
5-<15 604 1.04 (0.91-1.18)  368 1.02 (0.88-1.17)  234 1.12 (0.97-1.29) 
15-<30 290 1.04 (0.89-1.21)  204 1.21 (1.02-1.45)  49 1.09 (0.81-1.45) 
30-<45 98 1.14 (0.91-1.43)  87 1.38 (1.08-1.75)  17 0.94 (0.58-1.52) 
≥45 39 1.04 (0.74-1.45)  102 1.61 (1.28-2.03)  7 1.03 (0.49-2.17) 
P-trend§  0.3173   <0.0001   0.6334 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, 
current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 times/week), 
processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer 
(yes/no) and history of colorectal screening (yes/no). Results for wine adjusted for intake of 
beer and spirits (0, >0-<5, 5-<15, 15-<30, 30-<45, ≥45 g/d), results for beer adjusted for intake 
of wine and spirits (0, >0-<5, 5-<15, 15-<30, 30-<45, ≥45 g/d) and results for spirits adjusted 
for intake of beer and wine (0, >0-<5, 5-<15, 15-<30, 30-<45, ≥45 g/d). Former drinkers were 
excluded from this analysis. 
§ P-values for test for trend were calculated by assigning participants the median value of their 
category of wine/beer/spirits intake and this variable was modelled as a continuous variable. 
 
An analysis of the Norfolk participants of the EPIC study found that people who drank 
≥7 units/week of wine had a decreased risk of colorectal cancer compared to people 
who drank no wine (HR, 0.61; 95% CI, 0.40–0.94).83 A Danish study also found slight 
evidence that wine intake decreased the risk of colon cancer (HR, 0.5; 95% CI, 0.2-1.0 
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for ≥14 vs 0 glasses of wine/week) and also that the risk of rectal cancer for people 
drinking ≥14 drinks per week was higher if they did not drink any wine.73 Both of these 
studies cited evidence that resveratrol, found in red wine, may be protective against 
cancer. However, this is controversial since it is doubtful that resveratrol is present in 
wine at sufficient levels to reduce cancer risk.
410
 Furthermore, most other studies have 
not found evidence for different associations by alcoholic beverage.
45, 65, 69, 70, 80
 For 
example, the association between alcohol intake and rectal cancer was similar for 
women who drank wine exclusively and for women who drank other alcoholic drinks in 
the Million Women Study.
70
 
 
5.3.3 Continuous Alcohol Intake Variable 
 
Alcohol intake was also analysed as a continuous variable. A continuous variable does 
not require the creation of arbitrary cut-points such as for a categorical variable and so 
can be considered a more efficient use of the available data. It also avoids the need to 
explicitly define a reference group which can be a controversial decision for analyses of 
alcohol intake. However, results using a continuous variable are dependent on the 
choice of the analysis model. 
 
Alcohol intake was modelled as a linear variable in this analysis since there was no 
evidence for a non-linear relationship using fractional polynomial analysis. Overall, 
each additional 10 g/d of alcohol was associated with a 5% increased risk of colorectal 
cancer. Results were similar when excluding never drinkers and excluding “extreme” 
levels of intake. Analysing alcohol intake as a continuous variable separately for men 
and women, there was no evidence for an association for women. 
 
5.3.4 Colorectal Cancer Subsites 
 
This analysis found that alcohol intake was associated with an increased risk of both 
colon cancer and rectal cancer for men though results were slightly different when using 
different reference groups. Using never drinkers as the reference group, there seemed to 
be a similar association for colon cancer and rectal cancer. However, using never 
drinkers and consistent light drinkers as the reference group, alcohol intake was more 
strongly associated with rectal cancer than colon cancer. 
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Other studies have found differing results for the associations with colon cancer and 
rectal cancer. Alcohol intake was associated with both colon and rectal cancer in the 
Western and Japanese pooled analyses with no clear differences in results.
45, 71
  The 
EPIC cohort found that alcohol intake was more strongly associated with rectal cancer 
risk than colon cancer risk and the Million Women Study found that alcohol intake was 
only associated with rectal cancer risk.
69, 70
 The Singapore Chinese Health Study found 
a stronger association between alcohol intake and colon cancer than rectal cancer and 
the Health Professionals Follow-up Study found evidence only for an association with 
colon cancer and not rectal cancer.
77, 78
 
 
Overall, there is convincing evidence that alcohol intake increases the risk of both colon 
and rectal cancer and the evidence seems to indicate a slightly stronger association for 
rectal cancer.
60-62
 For example, one meta-analysis found that the pooled RRs (95% CIs) 
associated with moderate drinking (12.6-49.9 g/d) were 1.15 (1.06-1.24) for colon 
cancer and 1.23 (1.13-1.35) for rectal cancer and that the pooled RRs (95% CIs) 
associated with heavy drinking (≥50 g/d) were 1.43 (1.23-1.67) for colon cancer and 
1.59 (1.18-2.15) for rectal cancer.
62
 
 
The current analysis found that drinking ≥30 g/d was associated with an increased risk 
of distal colon cancer compared to never drinkers while alcohol intake was not 
associated with proximal colon cancer. Few studies have investigated the association 
between alcohol intake and proximal colon cancer and distal colon cancer though these 
studies seem to agree that alcohol intake is more strongly associated with the risk of 
distal colon cancer.
45, 65, 69, 80, 82
 
 
5.3.5 Reference Group 
 
Non-drinkers 
 
Many studies of alcohol intake and colorectal cancer have used non-drinkers as the 
reference group. The use of non-drinkers as the reference group has been argued 
against, particularly for studies of mortality and heart disease, since a number of former 
drinkers will have quit drinking due to illness.
46, 367
 In UK Biobank, former drinkers 
were most likely to report a long-standing illness or poor health status. Furthermore, 
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prospective studies have shown that people reporting long standing illness or poor 
health are more likely to quit drinking alcohol.
365, 411
 
 
However, the choice of reference group has not been given much discussion in studies 
of alcohol intake and colorectal cancer. Most studies have used non-drinkers as the 
reference group. This is presumably because many questionnaires only asked about 
baseline alcohol intake and did not include questions on past drinking. The Western 
pooled analysis did find that results were similar whether including or excluding former 
drinkers from the reference group (though it was only possible to identify people who 
had quit drinking in the previous five or ten years).
45
 
 
Only a few studies have actually reported results comparing the risk of colorectal cancer 
between former drinkers and never drinkers; one Japanese study
82
 did not find an 
increased risk of colorectal cancer for former drinkers (HR, 1.08; 95% CI, 0.64-1.85) 
though another Japanese study
143
 found an increased risk of colon cancer (HR, 2.01; 
95% CI, 1.09-3.68) but not rectal cancer (HR, 1.25; 95% CI, 0.66-2.38) for former 
drinkers. The EPIC cohort did not include results but reported that former drinkers had a 
similar risk to never drinkers.
69
 
 
In UK Biobank, there was no evidence that former drinkers had an increased risk of 
colorectal cancer compared with never drinkers (overall or for men and women 
separately). Furthermore, results did not suggest that the risk of colorectal cancer 
differed for former drinkers who quit for “illness related reasons” or for “other reasons”. 
 
Consequently, results using non-drinkers instead of never drinkers as the reference 
group were similar to the main results for the association between alcohol intake and 
colorectal cancer. The HRs (95% CIs) comparing <5, 5-<15, 15-<30, 30-<45 and ≥45 
g/d with non-drinkers for men were 1.08 (0.74-1.58), 1.29 (0.95-1.76), 1.43 (1.05-1.93), 
1.54 (1.12-2.11) and 1.79 (1.31-2.44). The corresponding results for women were 0.79 
(0.61-1.03), 0.80 (0.63-1.01), 0.81 (0.62-1.05), 0.95 (0.66-1.37) and 0.59 (0.30-1.13). 
Therefore, there was no evidence in this study that the association between alcohol 
intake and colorectal cancer may be underestimated in studies using non-drinkers as the 
reference group. 
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Never Drinkers 
 
Never drinkers were used as the reference group in this analysis since they represent a 
consistent, well-defined group; while the risk of colorectal cancer for non-drinkers in 
each study will depend on the relative proportions of never drinkers and former 
drinkers, the risk for never drinkers should be reasonably consistent across studies. 
However, the main issue with using never drinkers as the reference group is that they 
represent a relatively small group which results in wide CIs. 
 
The choice of never drinkers as the reference group has also been criticised because of 
the high levels of misclassification of never drinkers.
366
 For example, one U.S. survey 
of alcohol intake found that approximately half of the people who reported being never 
drinkers in a 1992 survey had previously reported drinking in the 1984 or 1990 
survey.
366
 A British study also found that 67% of people who reported being never 
drinkers at age 45 previously reported some level of drinking at age 16, 23, 33 or 42.
370
 
However, in both these studies, these participants had mainly reported very light or 
occasional drinking in the past. 
 
20,346 UK Biobank participants were completely re-assessed between 2012 and 2013, a 
mean of 4.4 years (range 2.1-7.0 years) after the baseline assessment. 710 participants 
reported being never drinkers at re-assessment. 532 of these participants reported being 
never drinkers at baseline, meaning that 25.1% of participants reporting never drinking 
at re-assessment had previously reported drinking. However, similar to the studies 
mentioned above, most of these participants reported a low level of drinking; 7.8% 
reported being former drinkers, 15.6% reported drinking “special occasions only” and 
1.4% reported drinking “one to three times a month”. Although this does not exactly 
represent the proportion of never drinkers at baseline who may be misclassified, it does 
suggest that there should not have been a large amount of misclassification and so this 
should not have had a large impact on results. 
 
Light Drinkers 
 
A further choice for the reference group when analysing alcohol intake is light drinkers. 
For example, the EPIC cohort used alcohol drinkers drinking <5 g/d as the reference 
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group and the Million Women Study used alcohol drinkers drinking ≤2 drinks/week.69, 
70
 However, similar to non-drinkers, light drinkers represent a heterogeneous group. For 
example, some light drinkers will be former heavy drinkers and some light drinkers may 
be binge drinkers. Hence, the risk of colorectal cancer among light drinkers will depend 
on the relative proportions of people with different past exposures or different patterns 
of drinking. Furthermore, while some people quit drinking entirely as a result of illness, 
other people who suffer from illness will simply reduce their intake and become light or 
occasional drinkers.
365
 
 
Alternative Reference Group 
 
To further evaluate the impact of the choice of the reference group on the association 
between alcohol intake and colorectal cancer, it was also decided to investigate results 
using an alternative reference group. Ideally, it would have been possible to identify 
participants who had forever been at most light or occasional drinkers and had never 
been binge drinkers. These participants would represent a larger group than never 
drinkers on their own but would still represent a well-defined group who should 
experience the lowest risk of colorectal cancer. Furthermore, it would reduce concerns 
about the misclassification of never drinkers and hardly ever drinkers. Unfortunately, 
UK Biobank did not include sufficiently detailed information on the pattern of drinking 
or the lifetime exposure to alcohol intake. 
 
Participants in UK Biobank were asked about how their drinking compared to ten years 
before baseline and thus consistent light drinkers were defined as participants who 
reported drinking <5 g/d at baseline and reported drinking “about the same” or “more 
nowadays” compared to ten years before baseline. Using never drinkers and consistent 
light drinkers combined as the reference group, the HRs for men for the association 
between alcohol intake and colorectal cancer were slightly lower to those using never 
drinkers as the reference group. However, since the CIs were narrower, the evidence for 
an increased risk was slightly stronger and there was even slight evidence of an 
increased risk for men drinking 5-<15 g/d. The HRs decreased for the association with 
colon cancer using the alternative reference group though there was still evidence for an 
association between alcohol intake and colon cancer risk. In contrast, the HRs increased 
for rectal cancer and there was clearer evidence of an increased risk for men drinking 
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≥15 g/d. There remained no evidence of an association for women between alcohol 
intake and colorectal, colon or rectal cancer. 
 
5.3.6 Pattern of Drinking 
 
The pattern of drinking may be important when considering the association between 
alcohol intake and colorectal cancer risk. For example, it was shown that the protective 
effects of moderate alcohol drinking for coronary heart disease were absent among 
people with irregular heavy drinking occasions (>60 g per occasion at least monthly).
412
 
However, no studies have presented detailed analyses on the pattern of drinking and the 
risk of colorectal cancer. 
 
UK Biobank did not include detailed questions about patterns of drinking or binge 
drinking. However, participants were asked “when you drink alcohol is it usually with 
meals?” In an analysis of a small Italian study which asked a similar question, people 
who reported drinking outside of meals had a much higher risk of death compared to 
people who reported drinking with meals, adjusting for total alcohol intake.
413
 
 
In the current analysis, participants were classified as meal drinkers, variable drinkers 
and non-meal drinkers. It was expected that variable drinkers and non-meal drinkers 
would be most likely to have heavy episodes of drinking. Therefore, if heavy episodes 
of drinking carried a greater risk of colorectal cancer compared to more consistent 
intake, these participants would be expected to have the highest risk. Furthermore, 
variable drinkers and non-meal drinkers may be expected to have a greater risk of 
colorectal cancer since they will be more likely to underestimate their average alcohol 
intake as a result of their irregular drinking pattern. 
 
Results comparing variable drinkers and non-meal drinkers with meal drinkers 
(adjusting for total alcohol intake) did not show an increased risk of colorectal cancer. It 
is not clear why non-meal drinkers did not have a higher risk but it may be related to the 
crudeness of the question as a measure of binge drinking. Interestingly, results were 
similar when not adjusting for total alcohol intake despite the fact that variable drinkers 
and non-meal drinkers had a higher alcohol intake on average than meal drinkers (data 
not shown). 
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5.3.7 Effect Modifiers 
 
Body Mass Index 
 
The Western pooled analysis by Cho et al. was the first study to provide evidence that 
the association between alcohol intake and colorectal cancer risk may be modified by 
BMI.
45
 Cho et al. found that alcohol intake was strongly associated with colorectal 
cancer risk for people with low BMI but there was no association for people with high 
BMI. The HR (95% CI) associated with ≥30 g/d vs non-drinkers was 1.84 (1.27-2.67) 
for BMI <22 kg/m
2
, 1.23 (0.91-1.65) for BMI 22-<25kg/m
2
 and 1.08 (0.88-1.33) for 
BMI ≥25 kg/m2. 
 
The effect modification by BMI was also investigated by Mizoue et al. in the Japanese 
pooled analysis.
71
 Similar to the Western pooled analysis, alcohol intake had a stronger 
effect on colorectal cancer risk among men with low BMI though there was evidence 
that alcohol intake was associated with colorectal cancer within each category of BMI; 
the HR (95% CI) associated with drinking ≥69 g/d compared with non-drinkers was 
3.25 (21.2-4.99) for BMI <22 kg/m
2
, 2.12 (1.57-2.87) for BMI 22-<25kg/m
2
 and 1.83 
(1.26-2.67) for BMI ≥25 kg/m2. A stronger effect of alcohol intake on colorectal cancer 
risk for people with lower BMI may also contribute to the stronger association observed 
for Japanese men compared to Western men. 
 
However, results from this analysis of UK Biobank did not find a stronger association 
between alcohol intake and colorectal cancer risk among people with lower BMI. There 
is scarce evidence from other epidemiological studies though one case-control study 
actually found that alcohol intake increased the risk of colorectal cancer for obese 
subjects (BMI ≥30 kg/m2) but there was no association for non-obese subjects.84 Hence, 
more studies should investigate the possible interaction between alcohol intake and 
BMI. 
 
Smoking 
 
Alcohol intake and tobacco smoking are both known risk factors for colorectal cancer 
and it is plausible that alcohol intake and tobacco smoking have a synergistic effect on 
Chapter 5 | Alcohol Intake and Colorectal Cancer 
255 
cancer risk, such that the combined effect of both exposures is superior to the sum of the 
individual exposures. For example, there is evidence that alcohol intake and tobacco 
smoking have a synergistic effect on the risk of cancers of the upper aerodigestive 
tract.
26
 There is not much existing evidence for a synergistic effect in relation to 
colorectal cancer. 
 
In UK Biobank, although the evidence for an interaction was not clear, results did 
suggest a stronger association for ever smokers than for never smokers. Results from 
other studies also seem to show a stronger association between alcohol intake and 
colorectal cancer for current and former smokers.
45, 69, 77
 For example, the HRs (95% 
CIs) comparing 30 g/d with non-drinking in the Western pooled analysis were 1.17 
(0.84-1.63) for never smokers, 1.26 (1.00-1.58) for former smokers and 1.42 (1.11-1.83) 
for current smokers.
45
 In the EPIC study, the HR (95% CI) associated with an increase 
of 15 g/d was higher for current smokers (HR, 1.23; 95% CI, 1.12-1.36) than for never 
smokers (HR, 1.15; 95% CI, 1.03-1.28) or former smokers (HR, 1.11; 95% CI, 0.97-
1.28).
69
 
 
Folate 
 
The final effect modifier considered in this analysis was folate intake. Alcohol is known 
to inhibit folate metabolism and folate intake may be associated with a lower colorectal 
cancer risk.
85, 88, 89
 Thus, the adverse effects of alcohol on folate are thought to be a 
potential mechanism for how alcohol increases an individual’s risk of colorectal 
cancer.
414
 This would predict a stronger association between alcohol intake and 
colorectal cancer among people with a lower folate intake. Unfortunately, data on 
average folate intake was available only for a subset of participants in UK Biobank and 
there was no clear evidence of a difference in the association for participants with below 
or above median folate intake. 
 
Overall, the existing evidence for an interaction between alcohol intake and folate 
intake for colorectal cancer is unclear. Although results from the EPIC study did 
support a stronger association between alcohol intake and colorectal cancer for people 
with lower folate intake,
69
 results from the Western and Japanese pooled analyses did 
not find evidence that the association differed by folate intake.
45, 71
 Results from studies 
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of folate intake and colorectal cancer also find inconsistent results for an interaction 
with alcohol intake.
90, 91, 93, 117
 
 
5.3.8 Multiple Imputation 
 
Results for the association between alcohol intake and colorectal cancer using multiple 
imputation were generally very similar to the results among participants with complete 
data. This was expected since only participants who reported drinking “one to three 
times a month” or “special occasions only” had missing alcohol grams per day data in 
this dataset. 
 
There was a notable increase for the HR for the risk of colorectal cancer associated with 
<5 g/d for men. Hence, this seems to suggest that, among male participants who 
reported drinking “one to three times a month” or “special occasions only”, men with 
missing data had a greater risk of colorectal cancer than men with complete data. This 
could possibly be explained if men with missing data tended to drink more alcohol than 
men with complete data, so that the imputed values for alcohol intake underestimated 
their “actual” values of intake. Since men with missing data were recruited earlier than 
participants with complete data, this could happen if average alcohol intake decreased in 
the general population during recruitment. In fact, there does seem to have been a slight 
decrease in alcohol intake in the general population between 2006 and 2010 (beginning 
and end of recruitment).
35
 However, these differences were small and it seems likely 
that changes in alcohol intake during recruitment will have been partly captured by 
alcohol frequency, meaning that differences within participants reporting “one to three 
times a month” or “special occasions only” should have been very minor. 
 
Participants with missing data were recruited earlier and so had a longer period of 
follow-up on average than participants with complete data. Therefore, there was a much 
higher proportion of cases of colorectal cancer among participants with missing data. 
However, this should not have impacted on results since the Cox proportional hazards 
model accounts for different follow-up time between participants. 
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5.3.9 Summary 
 
This analysis found that alcohol intake was strongly associated with colorectal cancer 
risk for men. However, this analysis did not find evidence of an association for women. 
Alcohol intake was associated with both colon cancer and rectal cancer risk but was 
more strongly associated to distal colon cancer than proximal colon cancer risk. Never 
drinkers were used as the reference group in this analysis. Results using non-drinkers as 
the reference group were similar to results using never drinkers as the reference group. 
This analysis was not able to identify any effect modifiers for the association between 
alcohol intake and colorectal cancer. Results using multiple imputation for participants 
with missing alcohol data were similar to results of the complete case analysis. 
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Chapter 6 Adiposity and Colorectal Cancer 
 
6.1 Results 
 
To assess the relationship between adiposity and colorectal cancer risk, data on BMI, 
WC and WHR were used. Analyses were restricted to participants with available data 
on BMI, WC and WHR. Thus, the analysis of adiposity and colorectal cancer included 
197,443 men and 233,575 women (Figure 6.1.1). Data were analysed using Cox 
proportional hazards models using age as the underlying time variable. Participants 
were followed-up from the date of the baseline assessment until the date of any cancer 
diagnosis, the date of death or the end of follow-up (31
st
 March 2014), whichever came 
first. Participants were followed up for a median 5.18 years (range 3.50-8.05 years). 
1,219 men and 884 women were diagnosed with colorectal cancer. All analyses were 
adjusted for alcohol intake, overall smoking status, Townsend deprivation index, red 
meat intake, processed meat intake, family history of colorectal cancer and bowel 
screening. Analyses of WC and WHR were additionally adjusted for height. Results are 
not presented for colorectal cancer or for men and women overall as there is consistent 
evidence that the association differs by colorectal subsite and sex.
150, 152, 153
 
 
Figure 6.1.1 Flowchart of Exclusions for Analysis of Adiposity and Colorectal Cancer 
 
Flowchart of reasons for excluding participants from the analysis of adiposity and colorectal cancer. 
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6.1.1 Body Mass Index 
 
Table 6.1.1 shows some basic characteristics of the analysis cohort by sex-specific 
quintiles of BMI. Men with higher BMI were more likely to be heavy drinkers. Men and 
women with the lowest BMI were most likely to be current smokers. Men and women 
with the highest BMI were more likely to live in areas with higher deprivation. Men and 
women with higher BMI reported higher intakes of red meat and processed meat. 
 
Quintiles of BMI for men showed a strong association with the risk of colon cancer 
(Table 6.1.2). Compared to men in the lowest quintile of BMI, the HRs (95% CIs) were 
1.52 (1.19-1.95) for men in the fourth quintile and 1.63 (1.27-2.09) for men in the 
highest quintile. However, there was no clear evidence for an association between 
quintiles of BMI and the risk of rectal cancer (HR, 1.13; 95% CI, 0.84-1.51 for fifth vs 
first quintile). Table A-9 - Table A-12 in the appendix show the effects of adjusting for 
different confounders on results. 
 
Compared to women with the lowest BMI, there was no evidence that women with the 
highest BMI had an increased risk of colon cancer (HR, 1.07; 95% CI, 0.82-1.39) or 
rectal cancer (HR, 0.88; 95% CI, 0.56-1.40) (Table 6.1.3). However, there was slight 
evidence that women in the second quintile of BMI had an increased risk of rectal 
cancer compared to women in the first quintile (HR, 1.41; 95% CI, 0.94-2.12). 
 
BMI categories based on the WHO definitions of overweight (≥25 kg/m2) and obesity 
(≥30 kg/m2) were also considered. Compared to men with BM <25 kg/m2, men with 
BMI 25-<30 and ≥30 kg/m2 had an increased risk of colon cancer but evidence was 
weaker for an increased risk of rectal cancer. While there was no evidence of an 
increased risk of colon cancer for women with BMI ≥30 kg/m2, there was slight 
evidence that women with BMI ≥30 kg/m2 had a decreased risk of rectal cancer 
compared to women with BMI <25 kg/m
2
. (Restricting the reference group to 18.5-<25 
kg/m
2
, results for colon cancer and rectal cancer for men and women were very similar 
(results not shown)). 
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0 Table 6.1.1 Characteristics of UK Biobank Cohort by Sex Specific BMI Quintiles and Sex 
 BMI (kg/m
2
) 
Men <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 
Number of participants 39,155 39,890 38,170 41,200 39,028 
Age, mean (SD), years 56.0 (8.4) 56.6 (8.2) 56.7 (8.2) 56.9 (8.1) 56.7 (7.9) 
Alcohol intake, % ≥45 g/d 10.9 12.5 14.1 15.9 16.2 
Overall smoking status, % current smoker 15.2 11.8 11.2 11.1 11.1 
Townsend index, % in most deprived quintile 20.3 17.0 17.1 18.9 23.8 
Red meat intake, % ≥3 times/week 21.7 23.0 24.8 27.1 30.7 
Processed meat intake, % >once/week 39.9 40.4 42.1 44.3 49.5 
Family history, % 10.5 11.2 11.3 11.8 12.0 
Colorectal screening, % 30.6 31.5 32.3 32.4 31.8 
      
Women <22.89 22.89-<25.04 25.04-<27.34 27.34-<30.80 ≥30.80 
Number of participants 47,150 47,203 46,458 46,751 46,013 
Age, mean (SD), years 54.5 (8.2) 55.8 (8.0) 56.6 (7.9) 57.1 (7.9) 56.5 (7.8) 
Alcohol intake, % ≥45 g/d 1.6 1.7 1.9 2.0 1.8 
Overall smoking status, % current smoker
 
9.8 8.5 8.5 8.5 8.1 
Townsend index, % in most deprived quintile 17.1 15.5 16.8 19.4 26.2 
Red meat intake, % ≥3 times/week 15.5 18.0 19.6 21.5 23.0 
Processed meat intake, % >once/week 16.7 18.4 19.8 21.8 26.0 
Family history, % 10.2 10.7 11.2 11.0 11.2 
Colorectal screening, % 26.6 28.3 29.9 30.6 29.9 
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Table 6.1.2 BMI and the Risk of Colon Cancer and Rectal Cancer for Men in UK Biobank 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)* HR (95% CI)†  Cases HR (95% CI)* HR (95% CI)† 
<24.45 197,756 99 1.00 1.00  83 1.00 1.00 
24.45-<26.40 201,583 118 1.11 (0.85-1.45) 1.06 (0.81-1.39)  81 0.91 (0.67-1.24) 0.89 (0.65-1.21) 
26.40-<28.28 192,524 159 1.56 (1.21-2.00) 1.46 (1.13-1.87)  98 1.15 (0.86-1.54) 1.09 (0.81-1.47) 
28.28-<30.84 207,592 184 1.67 (1.30-2.13) 1.52 (1.19-1.95)  113 1.23 (0.92-1.63) 1.14 (0.86-1.52) 
≥30.84 196,336 186 1.81 (1.42-2.32) 1.63 (1.27-2.09)  106 1.23 (0.93-1.65) 1.13 (0.84-1.51) 
P-trend§   <0.0001 <0.0001   0.0377 0.1628 
         
<25 250,280 137 1.00 1.00  99 1.00 1.00 
25-<30 494,608 372 1.30 (1.07-1.58) 1.22 (1.00-1.49)  249 1.22 (0.96-1.53) 1.16 (0.92-1.46) 
≥30 250,903 237 1.66 (1.34-2.05) 1.50 (1.21-1.85)  133 1.29 (0.99-1.67) 1.19 (0.91-1.55) 
P-trend§   <0.0001 0.0002   0.0706 0.2461 
* Results not adjusted for confounders. 
† Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status 
(never, former, current), Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), family history of colorectal 
cancer (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable. 
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2 Table 6.1.3 BMI and the Risk of Colon Cancer and Rectal Cancer for Women in UK Biobank 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)* HR (95% CI)†  Cases HR (95% CI)* HR (95% CI)† 
<22.89 239,626 106 1.00 1.00  38 1.00 1.00 
22.89-<25.04 239,747 134 1.15 (0.89-1.49) 1.15 (0.89-1.48)  59 1.44 (0.96-2.16) 1.41 (0.94-2.12) 
25.04-<27.34 235,738 137 1.13 (0.88-1.46) 1.13 (0.87-1.45)  60 1.42 (0.95-2.14) 1.38 (0.92-2.08) 
27.34-<30.80 237,556 143 1.14 (0.88-1.46) 1.13 (0.88-1.45)  53 1.22 (0.80-1.85) 1.17 (0.77-1.78) 
≥30.80 232,894 127 1.08 (0.84-1.40) 1.07 (0.82-1.39)  39 0.94 (0.60-1.47) 0.88 (0.56-1.40) 
P-trend   0.7827 0.8433   0.2995 0.1921 
         
<25 474,532 237 1.00 1.00  97 1.00 1.00 
25-<30 435,007 257 1.05 (0.88-1.26) 1.05 (0.88-1.25)  105 1.07 (0.81-1.42) 1.05 (0.79-1.38) 
≥30 276,021 153 1.01 (0.83-1.24) 1.01 (0.82-1.24)  47 0.77 (0.54-1.09) 0.73 (0.51-1.04) 
P-trend   0.8827 0.9410   0.1617 0.0981 
* Results not adjusted for confounders. 
† Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status 
(never, former, current), Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), family history of colorectal 
cancer (yes/no).  
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It is important to consider the potential for reverse causation for the association between 
adiposity and colorectal cancer i.e. participants’ adiposity at baseline could be 
influenced by undiagnosed colorectal cancer. This would mean that the association 
between adiposity and colorectal cancer would change over follow-up time. To 
investigate this possibility, BMI was modelled as a time varying coefficient i.e. a 
product term for BMI and follow-up time was included in the Cox proportional hazards 
model (BMI was modelled as a continuous variable). If the association did vary with 
time, the coefficient for this term would be non-zero. The p-values, testing the null 
hypothesis that this term was zero versus the two-sided alternative, were 0.460 for men 
and 0.032 for women for the association with colon cancer and 0.714 for men and 0.917 
for women for the association with rectal cancer. For colon cancer for women, the HR 
associated with the product term (between BMI and time) was extremely close to 1 
(1.000007). Therefore, although the p-value was statistically significant (at the 5% 
significance level), it is unlikely that there was important reverse causation for these 
results. 
 
In the touchscreen questionnaire, participants were asked whether their weight had 
changed compared to one year ago. 61.5% of men and 50.6% of women reported that 
they weighed about the same as one year ago. The analysis for the association between 
BMI and colorectal cancer risk was repeated among these participants (Table 6.1.4). 
Results were fairly similar for men; there was clear evidence for an association between 
BMI and colon cancer risk but the evidence for an association with rectal cancer risk 
was less clear. For women, there was still no clear evidence for an association with 
colon cancer and the increased risk of rectal cancer for women in the second BMI 
quintile appeared to be even greater in this analysis. 
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Table 6.1.4 BMI and the Risk of Colon Cancer and Rectal Cancer in UK Biobank for 
Participants with No Weight Change from One Year Ago 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)*  Cases HR (95% CI)* 
Men       
<24.45 153,944 79 1.00  62 1.00 
24.45-<26.40 139,530 79 0.98 (0.72-1.34)  57 0.93 (0.65-1.33) 
26.40-<28.28 119,317 101 1.41 (1.05-1.89)  57 1.06 (0.73-1.52) 
28.28-<30.84 113,053 99 1.40 (1.04-1.88)  65 1.23 (0.87-1.75) 
≥30.84 86,849 82 1.52 (1.11-2.08)  51 1.27 (0.87-1.86) 
P-trend   0.0011   0.0809 
       
Women       
<22.89 172,664 79 1.00  30 1.00 
22.89-<25.04 141,846 86 1.19 (0.88-1.62)  46 1.67 (1.05-2.65) 
25.04-<27.34 111,759 68 1.12 (0.81-1.56)  28 1.21 (0.72-2.04) 
27.34-<30.80 93,745 61 1.15 (0.82-1.61)  27 1.33 (0.78-2.25) 
≥30.80 79,141 53 1.24 (0.87-1.77)  14 0.82 (0.43-1.57) 
P-trend   0.3146   0.3973 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
 
BMI was strongly associated with the risk of proximal colon cancer for men (HR, 1.75; 
95% CI, 1.24-2.49 for highest vs lowest quintiles) (Table 6.1.5). There was also slight 
evidence for an increased risk of distal colon cancer though the association appeared to 
be weaker (HR, 1.41; 95% CI, 0.97-2.05 for highest vs lowest quintile). For women, 
there was no evidence for an association between BMI and proximal colon cancer or 
distal colon cancer (though women in the second BMI quintile appeared to have an 
increased risk of distal colon cancer). 
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Table 6.1.5 BMI and the Risk of Proximal Colon Cancer and Distal Colon Cancer in 
UK Biobank 
 Proximal colon cancer  Distal colon cancer 
BMI (kg/m
2
) Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
<24.45 51 1.00  44 1.00 
24.45-<26.40 52 0.96 (0.65-1.41)  62 1.19 (0.81-1.75) 
26.40-<28.28 73 1.40 (0.98-2.01)  76 1.44 (0.99-2.09) 
28.28-<30.84 98 1.74 (1.23-2.44)  82 1.37 (0.95-1.98) 
≥30.84 91 1.75 (1.24-2.49)  82 1.41 (0.97-2.05) 
P-trend  <0.0001   0.0797 
      
Women      
<22.89 55 1.00  40 1.00 
22.89-<25.04 60 0.98 (0.68-1.41)  63 1.43 (0.96-2.13) 
25.04-<27.34 72 1.13 (0.79-1.61)  62 1.35 (0.91-2.01) 
27.34-<30.80 71 1.08 (0.76-1.54)  67 1.38 (0.93-2.06) 
≥30.80 59 0.99 (0.68-1.44)  58 1.25 (0.83-1.89) 
P-trend  0.9938   0.5925 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no) 
and height (continuous). 
 
6.1.2 Waist Circumference and Waist to Hip Ratio 
 
While BMI is the most common measure of adiposity in the general population, WC 
and WHR are also used to assess adiposity. Table 6.1.6 shows the correlation 
coefficients between the three adiposity measures for men and women. WC was highly 
correlated with BMI (0.88 for men and women) and WHR (0.79 for men and 0.74 for 
women) for both men and women. The correlations between BMI and WHR were 
weaker (0.59 for men and 0.46 for women). 
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Table 6.1.6 Correlation between BMI, WC and WHR 
Correlation coefficients BMI WC WHR 
Men    
BMI 1.00   
WC 0.88 1.00  
WHR 0.59 0.79 1.00 
    
Women    
BMI 1.00   
WC 0.88 1.00  
WHR 0.46 0.74 1.00 
 
Table 6.1.7 WC and the Risk of Colon Cancer and Rectal Cancer in UK Biobank 
  Colon cancer  Rectal cancer 
WC (cm) Person-years Cases HR (95% CI)*  Cases HR (95% CI)* 
Men       
≤87 191,786 76 1.00  60 1.00 
88-93 212,882 127 1.31 (0.98-1.74)  97 1.29 (0.94-1.78) 
94-98 195,031 157 1.63 (1.23-2.14)  99 1.35 (0.97-1.86) 
99-105 202,313 171 1.60 (1.21-2.10)  114 1.41 (1.03-1.93) 
≥106 193,779 215 2.02 (1.54-2.64)  111 1.39 (1.01-1.92) 
P-trend   <0.0001   0.0687 
       
Women       
≤74 263,697 108 1.00  44 1.00 
75-80 239,409 128 1.17 (0.91-1.52)  56 1.26 (0.85-1.87) 
81-86 225,830 136 1.23 (0.95-1.59)  47 1.05 (0.69-1.59) 
87-95 242,507 141 1.14 (0.89-1.47)  52 1.04 (0.69-1.56) 
≥96 214,117 134 1.25 (0.96-1.62)  50 1.12 (0.74-1.70) 
P-trend   0.1540   0.8357 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no), history of colorectal screening (yes/no) and 
height (continuous). 
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Table 6.1.8 WHR and the Risk of Colon Cancer and Rectal Cancer in UK Biobank 
  Colon cancer  Rectal cancer 
WHR Person-years Cases HR (95% CI)*  Cases HR (95% CI)* 
Men       
<0.883 206,085 84 1.00  61 1.00 
0.883-<0.918 200,001 104 1.10 (0.82-1.46)  77 1.12 (0.80-1.57) 
0.918-<0.950 203,347 162 1.52 (1.17-1.98)  108 1.41 (1.03-1.93) 
0.950-<0.990 198,071 181 1.61 (1.24-2.09)  116 1.44 (1.05-1.97) 
≥0.990 188,287 215 1.87 (1.44-2.42)  119 1.45 (1.06-1.99) 
P-trend   <0.0001   0.0091 
       
Women       
<0.758 249,292 109 1.00  38 1.00 
0.758-<0.796 240,077 107 0.93 (0.71-1.22)  49 1.25 (0.82-1.92) 
0.796-<0.832 238,261 144 1.19 (0.92-1.53)  60 1.47 (0.98-2.22) 
0.832-<0.876 227,351 130 1.08 (0.83-1.39)  42 1.04 (0.67-1.62) 
≥0.876 230,578 157 1.22 (0.95-1.57)  60 1.41 (0.93-2.14) 
P-trend   0.0750   0.3243 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no), history of colorectal screening (yes/no) and 
height (continuous). 
 
There was a strong association between WC and colon cancer risk for men (Table 
6.1.7). There was also evidence of an association between WC and rectal cancer risk for 
men. The HRs (95% CIs) comparing the highest and lowest quintiles of WC were 2.02 
(1.54-2.64) for colon cancer and 1.39 (1.01-1.92) for rectal cancer. The association 
between WC and colon cancer risk appeared to be weaker for women than for men 
though there was still slight evidence of an increased risk of colon cancer for women in 
the highest WC quintile (HR, 1.25; 95% CI, 0.96-1.62). There was no clear evidence for 
an association between WC and rectal cancer risk for women. 
 
Results for WHR showed a similar pattern to results for WC (Table 6.1.8). WHR was 
associated with the risk of colon cancer (HR, 1.87; 95% CI, 1.44-2.42 for highest vs 
lowest quintile) and rectal cancer (HR, 1.45; 95% CI, 1.06-1.99 for highest vs lowest 
quintile) for men. There was slight evidence of an increased risk of colon cancer for 
women in the highest quintile of WHR (HR, 1.22; 95% CI, 0.95-1.57). In contrast to 
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results for WC, women in the highest quintile of WHR also appeared to have an 
increased risk of rectal cancer (HR, 1.41; 95% CI, 0.93-2.14). 
 
Table 6.1.9 and Table 6.1.10 show the associations between WC and WHR and 
proximal and distal colon cancer for men and women. WC and WHR were both 
strongly associated with proximal colon cancer risk for men; the HRs (95% CIs) 
associated with the highest quintile compared with the lowest quintile were 2.53 (1.70-
3.78) for WC and 2.19 (1.49-3.24) for WHR. Men in the highest quintiles of WC and 
WHR also had an increased risk of distal colon cancer though the association was 
weaker than for proximal colon cancer. Women in the highest quintiles of WC and 
WHR had an increased risk of proximal colon cancer but not distal colon cancer. 
 
Table 6.1.9 WC and the Risk of Proximal Colon Cancer and Distal Colon Cancer in UK 
Biobank 
 Proximal colon cancer  Distal colon cancer 
WC (cm) Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
≤87 33 1.00  39 1.00 
88-≤93 60 1.49 (0.98-2.29)  61 1.16 (0.77-1.73) 
94-≤98 81 2.07 (1.38-3.11)  71 1.33 (0.90-1.97) 
99-≤105 86 2.02 (1.35-3.04)  80 1.32 (0.89-1.94) 
≥106 105 2.53 (1.70-3.78)  95 1.53 (1.04-2.24) 
P-trend  <0.0001   0.0190 
      
Women      
≤74 47 1.00  47 1.00 
75-≤80 63 1.32 (0.90-1.92)  56 1.18 (0.80-1.74) 
81-≤86 69 1.42 (0.98-2.06)  63 1.31 (0.90-1.92) 
87-≤95 72 1.33 (0.92-1.93)  65 1.20 (0.82-1.76) 
≥96 66 1.45 (0.99-2.13)  59 1.23 (0.83-1.82) 
P-trend  0.0923   0.3989 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no) 
and height (continuous). 
  
Chapter 6 | Adiposity and Colorectal Cancer 
269 
Table 6.1.10 WHR and the Risk of Proximal Colon Cancer and Distal Colon Cancer in 
UK Biobank 
 Proximal colon cancer  Distal colon cancer 
WHR Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
<0.883 36 1.00  44 1.00 
0.883-<0.918 54 1.39 (0.91-2.11)  46 0.88 (0.58-1.33) 
0.918-<0.950 87 2.03 (1.38-3.01)  67 1.11 (0.76-1.62) 
0.950-<0.990 90 2.03 (1.37-3.00)  82 1.25 (0.87-1.82) 
≥0.990 98 2.19 (1.49-3.24)  107 1.56 (1.09-2.23) 
P-trend  <0.0001   0.0009 
      
Women      
<0.758 46 1.00  50 1.00 
0.758-<0.796 55 1.13 (0.77-1.68)  42 0.80 (0.53-1.20) 
0.796-<0.832 65 1.27 (0.87-1.85)  74 1.32 (0.92-1.90) 
0.832-<0.876 67 1.31 (0.90-1.92)  59 1.05 (0.72-1.55) 
≥0.876 84 1.56 (1.08-2.26)  65 1.08 (0.74-1.58) 
P-trend  0.0132   0.4442 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no) 
and height (continuous). 
 
Next, analyses were performed which modelled quintiles of BMI and WC 
simultaneously (Table 6.1.11) and quintiles of BMI and WHR simultaneously (Table 
6.1.12). For men, there was no longer an association between BMI and colon cancer 
risk or rectal cancer risk when including WC or WHR in the analysis model. In contrast, 
results for WC and WHR were similar for colon and rectal cancer risk with and without 
BMI though results were slightly attenuated for colon cancer. 
 
For women, there was still no evidence that BMI was associated with colon cancer or 
rectal cancer risk. Results were also similar for WC and WHR after including BMI in 
the analysis model though there was now slight evidence of an increased risk of rectal 
cancer for women in the highest quintile of WC as well as women in the highest quintile 
of WHR. 
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Table 6.1.11 BMI and WC and the Risk of Colon Cancer and Rectal Cancer in UK 
Biobank 
 Colon cancer  Rectal cancer 
 Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
BMI      
<24.45 99 1.00  83 1.00 
24.45-<26.40 118 0.92 (0.69-1.24)  81 0.76 (0.54-1.07) 
26.40-<28.28 159 1.17 (0.85-1.60)  98 0.88 (0.61-1.28) 
28.28-<30.84 184 1.14 (0.80-1.61)  113 0.90 (0.60-1.36) 
≥30.84 186 1.07 (0.72-1.60)  106 0.90 (0.55-1.46) 
P-trend  0.7720   0.8007 
WC      
≤87 76 1.00  60 1.00 
88-≤93 127 1.27 (0.93-1.73)  97 1.40 (0.98-1.98) 
94-≤98 157 1.50 (1.07-2.11)  99 1.46 (0.98-2.18) 
99-≤105 171 1.42 (0.98-2.06)  114 1.49 (0.96-2.32) 
≥106 215 1.83 (1.20-2.78)  111 1.45 (0.86-2.42) 
P-trend  0.0040   0.2086 
      
Women      
BMI      
<22.89 106 1.00  38 1.00 
22.89-<25.04 134 1.06 (0.80-1.40)  59 1.39 (0.89-2.17) 
25.04-<27.34 137 0.99 (0.72-1.35)  60 1.35 (0.81-2.23) 
27.34-<30.80 143 0.94 (0.66-1.35)  53 1.02 (0.57-1.83) 
≥30.80 127 0.81 (0.53-1.24)  39 0.59 (0.29-1.21) 
P-trend  0.2111   0.0420 
WC      
≤74 108 1.00  44 1.00 
75-≤80 128 1.17 (0.89-1.56)  56 1.13 (0.73-1.75) 
81-≤86 136 1.27 (0.92-1.73)  47 0.97 (0.59-1.60) 
87-≤95 141 1.24 (0.87-1.77)  52 1.14 (0.65-1.98) 
≥96 134 1.50 (0.98-2.29)  50 1.79 (0.92-3.49) 
P-trend  0.0731   0.0824 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no), history of colorectal screening (yes/no) and 
height (continuous). BMI results were adjusted for WC (quintiles) and WC results were adjusted for BMI 
(quintiles). 
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Table 6.1.12 BMI and WHR and the Risk of Colon Cancer and Rectal Cancer in UK 
Biobank 
 Colon cancer  Rectal cancer 
 Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
BMI      
<24.45 99 1.00  83 1.00 
24.45-<26.40 118 0.98 (0.74-1.29)  81 0.81 (0.59-1.11) 
26.40-<28.28 159 1.26 (0.96-1.65)  98 0.95 (0.69-1.30) 
28.28-<30.84 184 1.25 (0.95-1.64)  113 0.95 (0.69-1.31) 
≥30.84 186 1.27 (0.95-1.69)  106 0.91 (0.66-1.29) 
P-trend  0.0652   0.9321 
WHR      
<0.883 84 1.00  61 1.00 
0.883-<0.918 104 1.03 (0.77-1.39)  77 1.15 (0.81-1.62) 
0.918-<0.950 162 1.39 (1.05-1.84)  108 1.44 (1.03-2.02) 
0.950-<0.990 181 1.41 (1.06-1.89)  116 1.46 (1.03-2.07) 
≥0.990 215 1.58 (1.17-2.14)  119 1.47 (1.02-2.13) 
P-trend  0.0002   0.0270 
      
Women      
BMI      
<22.89 106 1.00  38 1.00 
22.89-<25.04 134 1.12 (0.87-1.45)  59 1.36 (0.90-2.06) 
25.04-<27.34 137 1.08 (0.85-1.40)  60 1.31 (0.86-1.99) 
27.34-<30.80 143 1.06 (0.81-1.38)  53 1.08 (0.69-1.68) 
≥30.80 127 0.98 (0.74-1.31)  39 0.80 (0.49-1.31) 
P-trend  0.6321   0.0815 
WHR      
<0.758 109 1.00  38 1.00 
0.758-<0.796 107 0.93 (0.71-1.22)  49 1.25 (0.81-1.92) 
0.796-<0.832 144 1.18 (0.91-1.53)  60 1.49 (0.98-2.26) 
0.832-<0.876 130 1.08 (0.82-1.41)  42 1.08 (0.68-1.72) 
≥0.876 157 1.24 (0.94-1.63)  60 1.57 (1.00-2.46) 
P-trend  0.0574   0.0763 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no), history of colorectal screening (yes/no) and 
height (continuous). BMI results were adjusted for WHR (quintiles) and WHR results were adjusted for 
BMI (quintiles). 
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6.1.3 Waist to Height Ratio 
 
Waist to height ratio was also analysed for men and women (Table 6.1.13). WHtR was 
strongly associated with colon cancer risk for men (HR, 1.97; 95% CI, 1.50-2.59 for 
highest vs lowest quintile) while the association with rectal cancer was less clear. There 
was slight evidence that women with greater WHtR had a higher risk of colon cancer; 
however, for rectal cancer, women in the second (HR, 1.82; 95% CI, 1.19-2.78) and 
third quintiles (HR, 1.58; 95% CI, 1.02-2.48) of WHtR had a particularly increased risk. 
  
Table 6.1.13 Waist to Height Ratio and the Risk of Colon Cancer and Rectal Cancer in 
UK Biobank  
 Colon cancer  Rectal cancer 
WHtR Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
<0.500 75 1.00  32 1.00 
0.500-<0.532 118 1.31 (0.98-1.75)  64 1.11 (0.89-1.54) 
0.532-<0.562 167 1.74 (1.32-2.29)  57 1.36 (0.99-1.86) 
0.562-<0.602 182 1.78 (1.36-2.35)  47 1.25 (0.91-1.72) 
≥0.602 204 1.97 (1.50-2.59)  49 1.31 (0.95-1.80) 
P-trend  <0.0001   0.0996 
      
Women      
<0.453 93 1.00  63 1.00 
0.453-<0.492 129 1.22 (0.93-1.60)  84 1.82 (1.19-2.78) 
0.492-<0.532 136 1.24 (0.95-1.62)  110 1.58 (1.02-2.45) 
0.532-<0.586 148 1.27 (0.97-1.66)  108 1.24 (0.79-1.97) 
≥0.586 141 1.28 (0.97-1.68)  116 1.35 (0.85-2.14) 
P-trend  0.2465   0.6647 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
 
6.1.4 Percent Body Fat 
 
194,277 men and 230,531 women additionally had data on percent body fat, as 
measured by bioelectrical impedance. Percent body fat was strongly correlated with 
BMI; correlation coefficients were 0.80 for men and 0.85 for women. Table 6.1.14 
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shows the results for the association between quintiles of percent body fat and colorectal 
cancer for men and women. Percent body fat was associated with colon cancer risk for 
men (HR, 1.59; 95% CI, 1.23-2.05 for highest vs lowest quintile) but not women (HR, 
0.98; 95% CI, 0.76-1.27 for highest vs lowest quintile). There was no clear evidence for 
an association between percent body fat and rectal cancer for men or women. 
 
Table 6.1.14 Percent Body Fat and the Risk of Colon Cancer and Rectal Cancer in UK 
Biobank  
 Colon cancer  Rectal cancer 
Body fat (%) Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
≤20.6 90 1.00  73 1.00 
20.7-24.0 115 1.11 (0.84-1.46)  81 0.98 (0.71-1.34) 
24.1-26.8 149 1.31 (1.00-1.70)  97 1.08 (0.80-1.47) 
26.9-30.0 169 1.41 (1.09-1.83)  110 1.17 (0.87-1.59) 
≥30.1 209 1.59 (1.23-2.05)  109 1.07 (0.79-1.45) 
P-trend  <0.0001   0.4120 
      
Women      
≤30.8 115 1.00  39 1.00 
30.9-35.0 115 0.87 (0.67-1.13)  58 1.31 (0.87-1.97) 
35.1-38.5 133 0.95 (0.74-1.22)  57 1.22 (0.81-1.84) 
38.6-42.5 142 0.97 (0.76-1.25)  45 0.93 (0.60-1.43) 
≥42.6 138 0.98 (0.76-1.27)  45 0.94 (0.61-1.46) 
P-trend  0.8184   0.3394 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
 
6.1.5 Effect Modifiers 
 
Physical Activity 
 
187,797 men and 215,976 women also had available data for physical activity (using the 
alternative physical activity variable). The association between BMI, WC and WHR and 
colon cancer was investigated across different levels of physical activity, modelling 
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BMI, WC and WHR as continuous variables in order to maximize statistical power 
(Table 6.1.15). 
 
Table 6.1.15 BMI, WC, WHR and the Risk of Colon Cancer by Physical Activity 
 Low physical activity 
Medium physical 
activity 
High physical activity 
 Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
BMI (per 5 kg/m
2
)       
Men 202 1.06 (0.91-1.24) 292 1.31 (1.15-1.49) 205 1.29 (1.09-1.52) 
 P-interaction = 0.0684 
Women 175 0.95 (0.82-1.10) 256 1.05 (0.93-1.19) 160 0.97 (0.81-1.16) 
 P-interaction = 0.3600 
       
WC (per 10 cm)       
Men 202 1.11 (0.99-1.25) 292 1.24 (1.12-1.37) 205 1.27 (1.12-1.44) 
 P-interaction = 0.2139 
Women 175 1.11 (0.99-1.25) 256 1.06 (0.95-1.17) 160 1.00 (0.87-1.15) 
 P-interaction = 0.5899 
       
WHR (per 0.1)       
Men 202 1.26 (1.01-1.57) 292 1.30 (1.08-1.57) 205 1.54 (1.24-1.91) 
 P-interaction = 0.4857 
Women 175 1.46 (1.19-1.79) 256 1.04 (0.87-1.25) 160 1.02 (0.81-1.30) 
 P-interaction = 0.0567 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
 
BMI was associated with the risk of colon cancer among men who reported medium 
physical activity (HR, 1.31; 95% CI, 1.15-1.49 per 5 kg/m
2
) and high physical activity 
(HR, 1.29; 95% CI, 1.09-1.52 per 5 kg/m
2
) but there was no association for men 
reporting low physical activity (HR, 1.06; 95% CI, 0.91-1.24 per 5 kg/m
2
). Results for 
WC for men were similar though there was slight evidence for an association for men 
reporting low physical activity (HR, 1.11; 95% CI, 0.99-1.25 per 10 cm). WHR was 
associated with the risk of colon cancer within each category of physical activity though 
the association was strongest for men who reported high physical activity (HR, 1.54; 
95% CI, 1.24-1.91 per 0.1). 
 
Chapter 6 | Adiposity and Colorectal Cancer 
275 
BMI was not associated with colon cancer risk for women reporting low, medium or 
high physical activity. For WC and WHR, there was an association only for women 
reporting low physical activity; the HR (95% CI) was 1.11 (0.99-1.25) for WC and 1.46 
(1.19-1.79) for WHR. 
 
Menopause 
 
57,957 women reported being pre-menopausal at baseline and 73,719 women reported 
being post-menopausal at baseline and never having used HRT. Analysing the 
associations between BMI, WC and WHR and colon cancer risk separately for pre-
menopausal women and post-menopausal women who had never taken HRT, there was 
no clear evidence for an association for either group of women (Table 6.1.16). 
 
Table 6.1.16 BMI, WC, WHR and the Risk of Colon Cancer by Menopause Status 
 Pre-menopause  Post-menopause 
 Cases HR (95% CI)*  Cases HR (95% CI)* 
BMI (per 5 kg/m
2
) 75 0.92 (0.72-1.16)  224 1.02 (0.89-1.16) 
 P-interaction = 0.3938 
      
WC (per 10 cm) 75 0.94 (0.78-1.15)  224 1.08 (0.97-1.20) 
 P-interaction = 0.2242 
      
WHR (per 0.1) 75 1.00 (0.70-1.41)  224 1.13 (0.94-1.37) 
 P-interaction = 0.4711 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
Results for WC and WHR additionally adjusted for height (continuous). 
 
6.2 Discussion 
 
6.2.1 Body Mass Index 
 
BMI was clearly associated with colon cancer risk for men but there was no strong 
evidence for an association with rectal cancer risk. For women, there was no evidence 
of an association between BMI and colon cancer risk. Surprisingly, compared to women 
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with BMI <25 kg/m
2, women with BMI ≥30 kg/m2 seemed to have a decreased risk of 
rectal cancer. Analysing BMI quintiles, it seemed that the decreased risk observed was 
explained by the fact that women with BMI 22.89-<25.04 kg/m
2
 had an increased risk 
of rectal cancer compared to women with BMI <22.89 kg/m
2
. However, it remains 
unclear why there would be an increased risk of rectal cancer for women with BMI 
22.89-<25.04 kg/m
2
 but not for women with BMI ≥30.80 kg/m2. 
 
Numerous studies have previously investigated the association between BMI and colon 
and rectal cancer. Overall, studies have shown that the association is stronger for men 
than women and is stronger for colon cancer than rectal cancer.
150, 152, 153
 For example, a 
recent meta-analysis, pooling results from the highest vs lowest comparisons, found that 
the pooled RRs (95% CIs) were 1.55 (1.47-1.63) for colon cancer and 1.24 (1.11-1.38) 
for rectal cancer for men. For women, the RRs (95% CIs) were 1.23 (1.10-1.37) for 
colon cancer and 1.07 (1.01-1.14) for rectal cancer.
150
 
 
Hence, results from UK Biobank were in broad agreement with results from meta-
analyses, showing a strong association between BMI and colon cancer risk for men. It is 
not clear why this analysis of UK Biobank did not find evidence for an association 
between BMI and colon cancer for women or for an association between BMI and rectal 
cancer for men or women. However, individual cohorts do find slightly different results 
and other cohorts have also found similar results to this analysis. 
 
For example, the EPIC cohort also found evidence of an association between BMI and 
colon cancer only for men and no evidence of an association between BMI and rectal 
cancer for men or women. The HRs (95% CIs) comparing the highest and lowest 
quintiles of BMI were 1.55 (1.12-2.15) for men and 1.06 (0.79-1.42) for women for 
colon cancer and 1.05 (0.72-1.55) for men and 1.06 (0.71-1.58) for women for rectal 
cancer.
47
 The NIH-AARP Diet and Health Study also found evidence for a strong 
association between BMI and colon cancer for men but no evidence for an association 
with rectal cancer. However, there was evidence that BMI was associated with colon 
and rectal cancer for women.
160
 
 
The associations between BMI and proximal colon cancer and distal colon cancer were 
also investigated. For men, BMI was strongly associated with proximal colon cancer 
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risk and there was slight evidence of an increased risk of distal colon cancer for men in 
the highest BMI quintile. For women, there was no clear evidence for an association 
between BMI and proximal colon cancer or distal colon cancer. 
  
In contrast to these results, evidence from other cohort studies indicates a stronger 
association between BMI and distal colon cancer.
150, 151, 153
 One meta-analysis which 
pooled results comparing the highest and lowest categories of BMI from 16 cohort 
studies found a pooled RR (95% CI) of 1.24 (1.08-1.42) for proximal colon cancer and 
1.59 (1.34-1.89) for distal colon cancer.
151
 
 
A strength of the current analysis, compared to many other studies of BMI and 
colorectal cancer, was that height and weight were measured at the baseline assessment. 
Many other studies have relied on self-reported height and weight. However, since 
people tend to underestimate their weight as well as overestimate their height,
48
 self-
reported data results in BMI being underestimated for many participants. Consequently, 
studies using self-reported height and weight data will tend to overestimate the 
association between BMI and colorectal cancer, as found in meta-analyses.
152-154
 
 
The precise mechanisms linking adiposity to colorectal cancer are unclear. However, 
insulin resistance likely plays an important role in colorectal carcinogenesis.
157, 158, 185
 
This is supported by studies that found that people with type 2 diabetes have an 
increased risk of colorectal cancer.
415, 416
 Furthermore, adipose tissue is not simply an 
inert tissue that stores fat; it also produces various hormones, growth factors and 
cytokines known as adipokines which may increase the risk of colorectal cancer.
157, 158, 
185
 
 
While this analysis found evidence for an association between BMI and colon cancer 
for men, there was no evidence that BMI was associated with colon cancer risk for 
women. Although other studies have found an association between BMI and colorectal 
cancer for women, it is clear that BMI is more strongly associated with colorectal 
cancer risk for men than for women. The reason for this difference remains unknown. 
 
One hypothesis for the difference for men and women is related to the different body 
compositions of men and women.
47
 The proportion of body fat and the way body fat is 
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distributed differs between men and women.
417
 Overall, women tend to store greater 
levels of body fat than men. However, there are two types of body fat: subcutaneous 
body fat and visceral body fat.
418
 Subcutaneous fat is stored just beneath the skin 
whereas visceral fat is stored within the abdominal cavity. Women tend to store more 
fat in the thighs and buttocks whereas men store more abdominal fat. Hence, women 
tend to have greater levels of subcutaneous fat and men tend to have greater levels of 
visceral fat.
185, 417
 Visceral fat is more metabolically active than subcutaneous fat and 
secretes greater numbers of cytokines and hormones.
185, 229
 Also, visceral fat is 
associated with a greater risk of insulin resistance.
418, 419
 
 
BMI is a crude measure of body weight adjusted for height and is unable to account for 
how body fat is distributed throughout the body. Thus, the stronger association between 
BMI and colorectal cancer observed for men may be because BMI is more closely 
related with visceral adiposity for men than for women. Hence, measures of abdominal 
adiposity such as WC and WHR may represent more precise predictors of colorectal 
cancer risk for both men and women. 
 
Results from the EPIC cohort provided strong evidence for this hypothesis.
47
 While 
BMI was associated with colon cancer risk only for men and not for women, WC and 
WHR were associated with colon cancer risk for both sexes. The HRs (95% CIs) 
associated with the highest vs lowest quintile of WC were 1.39 (1.01-1.93) for men and 
1.48 (1.08-2.03) for women and the HRs (95% CIs) associated with the highest vs 
lowest quintile of WHR were 1.51 (1.06-2.15) for men and 1.52 (1.12-2.05) for women. 
Furthermore, after adjusting for body weight as well as height, the associations for 
women remained whereas the associations for men were attenuated, indicating that WC 
and WHR provided information about colon cancer risk beyond BMI for women. 
 
6.2.2 Waist Circumference and Waist to Hip Ratio 
 
For men, this analysis found that, similar to BMI, WC and WHR were strongly 
associated with colon cancer risk. For women, while there was no association between 
BMI and colon cancer, there was slight evidence for an association between WC and 
WHR and colon cancer risk. Thus, this seemed to suggest that WC and WHR were 
better predictors of colon cancer risk than BMI for women, in agreement with results 
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from the EPIC study. Also, modelling BMI and WC/WHR together in this analysis, the 
associations with WC and WHR for men remained while there was no longer an 
association between BMI and colon cancer, suggesting that WC and WHR provided 
better measures of colon cancer risk than BMI for men. 
 
However, in contrast to the EPIC study, the association between WC/WHR and colon 
cancer risk still appeared to be much weaker for women than for men. Hence, results in 
this analysis did not seem to support the hypothesis described above to explain the 
differences in the association between BMI and colon cancer risk for men and women. 
 
Other studies have also investigated the associations between BMI, WC and WHR and 
colon cancer risk for men and women. For example, in the NIH-AARP Diet and Health 
Study, BMI, WC and WHR were each associated with colon cancer risk for men; HRs 
(95% CIs) comparing highest and lowest quintiles were 1.42 (1.1-1.68) for BMI, 1.45 
(1.16-1.82) for WC and 1.29 (1.10-1.52) for WHR.
186
 In contrast, there was no evidence 
for an association for women with any of these adiposity measures; HRs (95% CIs) 
were 0.96 (0.74-1.23) for BMI, 0.90 (0.63-1.27) for WC and 0.90 (0.70-1.15) for WHR. 
Further adjusting for BMI, results for WC and WHR were slightly attenuated for men 
while there was still no evidence for an association for women. Analysis of the 
Shanghai Men’s Health Study and the Shanghai Women’s Health Study also found that 
BMI, WC and WHR were each strongly associated with colon cancer risk for men but 
not for women.
164
 
 
One cohort of U.S. men and women found that both BMI and WC were strongly 
associated with colon cancer risk for men (HR, 1.93; 95% CI, 1.14-3.28 for ≥35.0 vs 
18.5-24.9 kg⁄m2 and HR, 2.05; 95% CI, 1.29-2.35 for ≥120 vs <95 cm).187 For women, 
there also seemed to be a similar increased risk of colon cancer for both BMI and WC 
(HR, 1.40; 95% CI, 0.84-2.36 for ≥35.0 vs 18.5-24.9 kg⁄m2 and HR, 1.54; 95% CI, 1.00-
2.37 for ≥110 vs <85 cm). Results were also presented for BMI and WC mutually 
adjusted for one another for men and women and results were clearly attenuated for 
BMI but not for WC. 
 
While BMI was associated with colon cancer risk only for men and not for women in 
the Melbourne Collaborative Cohort Study, WC and WHR were associated with colon 
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cancer risk for both men and women (though the associations were slightly stronger for 
men).
172, 173
 In the Iowa Women’s Health Study, there were similar associations with 
colon cancer risk for BMI (HR, 1.29; 95% CI, 1.10-1.51), WC (HR, 1.32; 95% CI, 1.11-
1.56) and WHR (HR, 1.28; 95% CI, 1.08-1.50), comparing highest and lowest 
quartiles.
188
 
 
Thus, all studies found strong associations between BMI, WC and WHR and colon 
cancer risk for men. Furthermore, studies that found positive associations between 
WC/WHR and colon cancer risk and further adjusted for BMI generally found that WC 
and WHR were still associated with colon cancer risk, indicating that WC and WHR 
may be more directly associated with colon cancer risk. 
 
Results were less clear for women. Some studies did show an association between WC 
and WHR but these studies gave conflicting results about whether WC/WHR were more 
strongly associated with colon cancer risk than BMI. Furthermore, results from these 
studies still showed that the association between WC/WHR and colon cancer was 
weaker for women than for men. Hence, it seems unlikely that the difference in the 
association between BMI and colon cancer risk between men and women is due to the 
difference in body composition between men and women. 
 
Visceral Abdominal Adiposity 
 
However, it should be pointed out that while WC and WHR measure total abdominal 
fat, they do not differentiate between subcutaneous abdominal fat and visceral 
abdominal fat. WC is strongly correlated with total abdominal fat for both men and 
women. In contrast, WC is only moderately correlated with visceral abdominal fat 
though this correlation is stronger for men than for women.
420
 In other words, the 
difference in results between men and women for measures of abdominal adiposity may 
be due to the fact that WC and WHR are not strong predictors of visceral fat. 
 
Some case-control studies have actually measured visceral fat using computed 
tomography and found that visceral fat is associated with colorectal adenoma risk
421-425
 
and colorectal cancer risk.
426
 Furthermore, visceral fat was associated with colorectal 
adenoma risk for both men and women.
421-423
 Hence, it is possible that the stronger 
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associations between BMI/WC/WHR and colorectal cancer risk observed for men than 
women are due to how closely these measures represent visceral adiposity for men and 
women. Larger prospective studies will be required to investigate these relationships in 
greater detail and confirm the role of visceral fat for colorectal cancer risk. 
 
6.2.3 Waist to Height Ratio 
 
WHtR is another measure of adiposity that has received attention recently.
427
 Recent 
research indicates that WHtR is a better predictor of cardiovascular risk factors 
including hypertension and type 2 diabetes than BMI.
428, 429
 However, so far no studies 
have investigated WHtR and colorectal cancer risk. 
 
WHtR is a measure of abdominal adiposity, similar to WC and WHR. WHtR was 
strongly correlated with WC in UK Biobank (correlation coefficient was 0.94 for men 
and 0.97 for women) and results were very similar for WC and for WHtR. WHtR was 
strongly associated with colon cancer risk for men whereas the association appeared to 
be weaker for women. There was slight evidence for an association with rectal cancer 
for men. However, one difference in the results for WHtR was that there was a large 
increased risk of rectal cancer for women in the second and third quintiles of WHtR, 
compared to women in the lowest quintile, but not for women with greater WHtR. 
 
6.2.4 Percent Body Fat 
 
Percent body fat, measured by bioelectrical impedance represents another method for 
assessing adiposity. Compared to other measures of adiposity that rely on data that can 
be recorded easily and cheaply, bioelectrical impedance analysis is more costly and so it 
is less widely used to assess adiposity. 
 
One other cohort, the Melbourne Collaborative Cohort Study, previously investigated 
the relationship between body fat as measured by bioelectrical impedance and colorectal 
cancer risk.
172, 173, 237
 For colon cancer, the HR (95% CI) associated with highest vs 
lowest tertile of percent body fat was 1.2 (0.9-1.6) for women. Results for percent body 
fat for men were not presented for colon cancer (though fat mass was associated with 
colon cancer risk for men). The HRs (95% CIs) comparing the highest and lowest 
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tertiles of percent body fat for rectal cancer risk were 1.5 (1.0-2.3) for men and 1.3 (0.8-
2.2) for women. 
 
In UK Biobank, percent body fat was strongly associated with colon cancer risk for men 
but not women and was not associated with rectal cancer risk for men or women. 
Hence, results for percent body fat were similar to results for BMI which was not 
surprising since percent body fat and BMI were highly correlated in this cohort. 
 
6.2.5 Menopause 
 
Another potential reason for the difference in results between men and women is due to 
the changes brought about by menopause among women. Studies have found a stronger 
association between BMI and colorectal cancer among pre-menopausal women than 
among post-menopausal women.
177, 184
 For example, the Million Women Study found 
that the HR (95% CI) associated with a 10 kg/m
2
 increase for colorectal cancer risk was 
1.61 (1.05-2.48) for pre-menopausal women and 0.99 (0.88-1.12) for post-menopausal 
women who had never used HRT.
184
 Meta-analysis results also support a stronger 
association between BMI and colorectal cancer for pre-menopausal women (RR, 1.20; 
95% CI, 1.03-1.32 per 5 kg/m
2
 increase) than post-menopausal women (RR, 1.09; 95% 
CI, 1.00-1.19).
152
 
 
HRT use is associated with a lower risk of colorectal cancer.
64, 207, 216
 Hence, oestrogen 
may have a protective effect for colorectal cancer. Menopause is associated with a 
decline in oestrogen levels. After menopause, adipose tissue becomes a major source of 
oestrogen and BMI is correlated with oestrogen levels in postmenopausal women.
222
 
Thus, it is hypothesised that the association between BMI and colorectal cancer is 
weaker among post-menopausal women since the adverse effects of greater adiposity 
are off-set by the beneficial effects of greater adiposity on oestrogen levels.
177, 206
 
 
This analysis did not find any clear evidence that the association between BMI, WC or 
WHR and colon cancer risk differed among pre-menopausal women and post-
menopausal women who had never used HRT. However, this cohort included a 
relatively small number of pre-menopausal women and there were relatively few cases 
of colon cancer among these women. Thus, the fact that this analysis did not find an 
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association among pre-menopausal women does not provide strong evidence that 
adiposity is not associated with colon cancer risk among these women. 
 
However, other studies also cast doubt on a stronger association for pre-menopausal 
women. One study found that BMI was associated with colon cancer risk for post-
menopausal women (HR, 1.76; 95% CI, 1.13-2.74 for ≥30 vs 18.5-22.9 kg⁄m2) but not 
pre-menopausal women (HR, 0.79; 95% CI, 0.30-2.10).
169
 A large prospective analysis 
of primary care data including 2.9 million women did not find different associations 
between BMI and colon or rectal cancer by menopause status.
161
 Two other studies of 
post-menopausal women found a strong association between BMI and colorectal and 
colon cancer risk
188, 223
 and the NIH-AARP Diet and Health Study found that BMI was 
associated with colon cancer risk for women aged 50-62 and 63-66 though there was no 
association for women aged 67-71 at baseline.
160
 
 
Hence, there is no consistent evidence that adiposity is more strongly associated with 
colon cancer risk for post-menopausal women. Interestingly, after menopause, as 
oestrogen levels fall, women tend to gain weight and in particular to gain visceral fat.
417, 
430
 Since visceral fat is thought to be of particular importance for colorectal cancer 
risk,
157
 this may actually suggest that there should be a stronger relation between 
adiposity and colorectal cancer among post-menopausal women. 
 
6.2.6 Physical Activity 
 
Confounder 
 
Physical activity is strongly related to adiposity and physical activity is related to the 
risk of colon cancer.
25, 151, 225
 Hence, physical activity represents an important 
confounder for analyses of adiposity and colorectal cancer. However, the analyses for 
the association between adiposity and colorectal cancer risk presented in this thesis were 
not adjusted for physical activity. 
 
Physical activity was not included as a confounder in the analysis models as there was 
no evidence that results for the association between adiposity and colorectal cancer were 
strongly affected by the inclusion of physical activity and also because the inclusion of 
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physical activity would have led to the exclusion of a large number of participants (who 
responded “do not know” or “prefer not to answer” to at least one of the questions on 
physical activity) (see section 4.4.2). Table 6.2.1 shows results for the association 
between BMI and colorectal cancer with and without adjustment for physical activity 
(using the IPAQ physical activity variable), restricted to 164,406 men and 177,187 
women with complete data for all variables. 
 
One possible solution would have been to have imputed the physical activity data for 
those participants who were excluded using multiple imputation. However, since the 
data were missing as a result of participants choosing not to respond, the assumption 
that the data were missing at random was questionable and thus multiple imputation 
may have led to biased results.
375
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Table 6.2.1 BMI and the Risk of Colon Cancer and Rectal Cancer in UK Biobank with and without Adjustment for Physical Activity 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)* HR (95% CI)†  Cases HR (95% CI)* HR (95% CI)† 
Men         
<24.45 167,759 83 1.00 1.00  69 1.00 1.00 
24.45-<26.40 170,793 93 1.02 (0.76-1.37) 1.01 (0.75-1.36)  70 0.92 (0.66-1.28) 0.92 (0.66-1.29) 
26.40-<28.28 161,390 140 1.58 (1.20-2.07) 1.56 (1.19-2.06)  81 1.10 (0.79-1.52) 1.11 (0.80-1.53) 
28.28-<30.84 171,793 148 1.54 (1.17-2.01) 1.51 (1.15-1.99)  96 1.20 (0.88-1.64) 1.22 (0.89-1.67) 
≥30.84 157,964 142 1.62 (1.23-2.13) 1.57 (1.19-2.07)  70 0.96 (0.68-1.34) 1.00 (0.71-1.40) 
P-trend   <0.0001 0.0001   0.7830 0.5920 
         
Women         
<22.89 190,701 81 1.00 1.00  24 1.00 1.00 
22.89-<25.04 188,452 97 1.11 (0.82-1.49) 1.10 (0.82-1.48)  41 1.60 (0.97-2.66) 1.60 (0.97-2.65) 
25.04-<27.34 180,201 104 1.17 (0.88-1.57) 1.17 (0.87-1.56)  45 1.77 (1.07-2.91) 1.77 (1.07-2.91) 
27.34-<30.80 176,003 106 1.19 (0.89-1.60) 1.18 (0.88-1.58)  44 1.73 (1.04-2.86) 1.72 (1.04-2.85) 
≥30.80 164,121 87 1.10 (0.81-1.50) 1.08 (0.79-1.48)  27 1.16 (0.66-2.04) 1.15 (0.65-2.03) 
P-trend   0.5661 0.6600   0.8999 0.9329 
* Adjusted for alcohol intake (never, former, special occasions only, one to three times a month, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, 
former, current), Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), family history of colorectal cancer 
(yes/no), history of colorectal screening (yes/no) and height (continuous). 
† Also adjusted for IPAQ physical activity (low, moderate, high). 
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However, since there exists convincing evidence for a relationship between physical 
activity and colon cancer risk,
25, 151, 225
 it is unclear why there was no difference in 
results for BMI in this analysis. It could have been because self-reported physical 
activity is a very limited measure of physical activity and includes significant 
measurement error.
431, 432
 For example, the adherence to physical activity 
recommendations in a representative sample of the U.S. population was substantially 
lower using accelerometer measured activity compared to self-reported activity.
433
 
Therefore, it is possible that adjustment for physical activity did not affect the 
association between BMI and colorectal cancer as a result of measurement error for 
physical activity. Yet, physical activity did appear to be inversely associated with colon 
cancer risk in the analysis models, particularly for men (data not shown). 
 
Also, results from a meta-analysis of BMI and colorectal cancer indicated that the 
association between BMI and colorectal cancer was actually stronger among studies that 
adjusted for physical activity.
152
 Hence, the relationship between BMI and physical 
activity for colorectal cancer risk may not be as straightforward as it seems. 
 
Effect Modifier 
 
Physical activity was also considered as a potential effect modifier for the association 
between adiposity and colon cancer risk in this thesis. For this analysis, an alternative 
physical activity variable was used since it excluded fewer participants (see section 
4.4.2). A stronger association between adiposity and colorectal cancer among people 
with a low level of physical activity may be hypothesised since physical activity may 
counteract some of the harmful effects of adiposity e.g. by increasing insulin 
sensitivity.
434, 435
 
 
This analysis found that WC and WHR were associated with colon cancer risk among 
women who reported low physical activity but not among women reporting medium or 
high physical activity. In contrast, BMI, WC and WHR were more strongly associated 
with colon cancer for men reporting medium and high physical activity than for men 
reporting low physical activity. 
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Few other studies have presented results for an interaction between adiposity and 
physical activity and these studies do not provide convincing evidence that the 
association between adiposity and colorectal cancer is modified by physical activity. 
One study analysed men according to categories of BMI and physical activity.
170
 
Compared with men with high BMI and low physical activity, men with low BMI and 
high physical activity had a lower risk of colorectal cancer (HR, 0.42; 95% CI, 0.22-
0.78), however, there was no evidence for an interaction. A similar analysis was 
performed in the Netherlands Cohort Study using categories of trouser size and physical 
activity and there was also no clear evidence for an interaction.
168
 
 
6.2.7 Summary 
 
BMI was strongly associated with colon cancer risk for men but not for women. There 
was no clear evidence of an association between BMI and rectal cancer risk for men or 
women. One hypothesis for the stronger relationship between BMI and colorectal 
cancer for men than for women is that it is due to the different body compositions for 
men and women i.e. BMI is more closely related to abdominal or visceral adiposity for 
men than for women. However, the results from this analysis for WC and WHR did not 
support this hypothesis since, although there was evidence that WC and WHR were 
associated with colon cancer risk for women, the associations between WC/WHR and 
colon cancer were still much stronger for men than for women. Modelling BMI and 
WC/WHR together, the associations for WC/WHR remained while there was no longer 
an association between BMI and colon cancer risk, suggesting that measures of 
abdominal adiposity may be more directly associated with colon cancer risk. Adiposity 
was more strongly related to the risk of proximal colon cancer than distal colon cancer. 
There was some evidence that the associations between adiposity and colon cancer risk 
differed according to the level of physical activity though results differed for men and 
women. This analysis was not able to find evidence for different associations according 
to menopause status among women. 
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Chapter 7 Smoking and Colorectal Cancer 
 
7.1 Results 
 
The analysis of the association between smoking and colorectal cancer included 
431,755 participants (197,800 men and 233,955 women) (Figure 7.1.1). Data were 
analysed using Cox proportional hazards models using age as the underlying time 
variable. Participants were followed-up from the date of the baseline assessment until 
the date of any cancer diagnosis, the date of death or the end of follow-up (31
st
 March 
2014), whichever came first. Participants were followed up for a median 5.18 years 
(range 3.50-8.05 years). During follow-up, 2,109 participants (1,223 men and 886 
women) were diagnosed with colorectal cancer. All analyses were adjusted for sex, 
alcohol intake, BMI, Townsend deprivation index, red meat intake, processed meat 
intake, height, family history of colorectal cancer and bowel screening. 
  
Figure 7.1.1 Flowchart of Exclusions for Analysis of Smoking and Colorectal Cancer 
 
Flowchart of reasons for excluding participants from the analysis of smoking and colorectal cancer. 
 
7.1.1 Main Results 
 
Table 7.1.1 shows the characteristics of the analysis cohort by category of overall 
smoking status and by sex. Participants with a greater smoking exposure were more 
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likely to drink ≥45 grams of alcohol per day and to live in the most deprived areas. 
Also, participants with a greater smoking exposure ate more red meat and processed 
meat. Former daily smokers had the highest rates of bowel cancer screening for men 
and women. Daily smokers had the lowest rates of screening for men and always 
occasional smokers had the lowest rates for women.  
 
Compared to never ever smokers, former daily smokers had an increased risk of 
colorectal cancer (HR, 1.20; 95% CI, 1.08-1.34) (Table 7.1.2). In contrast, there was no 
clear evidence of an increased risk for other categories of smoking, including daily 
smokers (HR, 1.09; 95% CI, 0.92-1.30). Results for former daily and daily smokers 
were similar for men and women. However, there was slight evidence that women but 
not men who smoked occasionally in the past (more than 100 times) and no longer 
smoked at baseline had an increased risk of colorectal cancer (HR, 1.19; 95% CI, 0.95-
1.48). Also, men who smoked fewer than 100 times in the past had a lower risk of 
colorectal cancer than never ever smokers (HR, 0.77; 95% CI, 0.62-0.97). 
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0 Table 7.1.1 Characteristics of UK Biobank Cohort by Overall Smoking Status and Sex 
 Never Former occ <100 Former occ ≥100 Former daily Always occ Occ, former daily Daily 
Men        
Number of participants 70,071 26,238 23,158 54,439 4,030 2,494 17,370 
Age, mean (SD), years 55.5 (8.2) 54.9 (8.3) 57.4 (8.0) 59.2 (7.4) 54.2 (8.3) 55.0 (8.5) 55.0 (8.2) 
Alcohol intake, % ≥45 g/d 8.5 8.3 12.7 19.2 21.0 20.7 27.0 
BMI, mean (SD), kg/m
2 
27.6 (4.2) 27.1 (4.0) 27.7 (4.0) 28.7 (4.2) 28.0 (4.1) 27.8 (4.2) 27.1 (4.4) 
Townsend index, % in most deprived quintile 16.9 14.8 16.5 19.5 25.3 28.8 37.9 
Red meat intake, % ≥3 times/week 23.8 22.4 24.1 27.1 26.5 29.1 33.0 
Processed meat intake, % >once/week 40.8 43.3 39.3 44.2 41.7 46.7 55.1 
Family history, % 10.8 10.3 11.9 12.5 11.7 10.5 11.3 
Colorectal screening, % 28.9 29.0 34.3 38.2 27.1 28.3 24.7 
        
Women        
Number of participants 107,086 37,073 23,885 45,582 2,731 1,789 15,809 
Age, mean (SD), years 55.9 (8.1) 55.8 (8.1) 56.6 (7.9) 57.5 (7.6) 52.8 (8.0) 54.3 (8.3) 54.3 (7.9) 
Alcohol intake, % ≥45 g/d 0.7 1.2 1.7 3.2 3.6 4.6 5.5 
BMI, mean (SD), kg/m
2 
27.0 (5.2) 26.5 (5.0) 26.8 (5.0) 27.8 (5.3) 26.5 (4.9) 27.0 (5.2) 26.8 (5.3) 
Townsend index, % in most deprived quintile 16.7 14.2 16.7 22.0 25.2 31.2 37.3 
Red meat intake, % ≥3 times/week 19.5 18.7 18.4 19.7 17.1 19.3 22.8 
Processed meat intake, % >once/week 19.8 21.7 17.9 20.8 17.3 21.0 26.2 
Family history, % 10.5 10.8 11.4 11.6 9.6 10.8 10.6 
Colorectal screening, % 27.8 29.2 30.8 33.4 21.2 25.4 23.8 
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Table 7.1.2 Overall Smoking Status and Cigarette Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
 
Overall 
 
Men 
 
Women 
Person-
years 
Cases HR (95% CI)* HR (95% CI)† 
Person-
years 
Cases HR (95% CI)† 
Person-
years 
Cases HR (95% CI)† 
Overall smoking status             
Never ever 900,144 742 1.00 1.00  355,705 360 1.00  544,438 382 1.00 
Former occasional <100 321,017 231 0.89 (0.76-1.03) 0.88 (0.76-1.02)  132,953 100 0.77 (0.62-0.97)  188,064 131 1.00 (0.82-1.22) 
Former occasional ≥100 236,639 247 1.10 (0.95-1.27) 1.07 (0.93-1.24)  116,252 143 0.99 (0.82-1.21)  120,388 104 1.19 (0.95-1.48) 
Former daily 502,821 682 1.28 (1.15-1.42) 1.20 (1.08-1.34)  272,029 478 1.19 (1.04-1.38)  230,792 204 1.16 (0.97-1.39) 
Always occasional 34,336 27 1.00 (0.68-1.47) 0.93 (0.63-1.37)  20,518 21 0.98 (0.63-1.52)  13,818 6 0.76 (0.34-1.71) 
Occasional, former daily 21,754 22 1.20 (0.79-1.84) 1.13 (0.74-1.72)  12,634 15 1.08 (0.64-1.81)  9,120 7 1.22 (0.58-2.59) 
Daily 168,328 158 1.17 (0.98-1.39) 1.09 (0.92-1.30)  87,464 106 1.12 (0.90-1.40)  80,863 52 1.04 (0.77-1.40) 
             
Overall smoking status             
Never smokers 1,221,160 973 1.00 1.00  488,658 460 1.00  732,503 513 1.00 
Former smokers 739,460 929 1.26 (1.15-1.38) 1.20 (1.09-1.32)  388,280 621 1.21 (1.07-1.37)  351,180 308 1.17 (1.01-1.36) 
Current smokers 224,418 207 1.18 (1.02-1.37) 1.10 (0.95-1.29)  120,617 142 1.16 (0.95-1.41)  103,801 65 1.02 (0.78-1.33) 
             
Cigarette smoking status             
Never smokers 1,221,160 973 1.00 1.00  488,658 460 1.00  732,503 513 1.00 
Former cigarette smokers 481,055 648 1.34 (1.21-1.48) 1.27 (1.14-1.41)  250,996 445 1.32 (1.15-1.51)  230,059 203 1.16 (0.98-1.38) 
Current cigarette smokers 156,268 134 1.15 (0.96-1.37) 1.09 (0.91-1.32)  75,995 82 1.14 (0.89-1.45)  80,273 52 1.05 (0.79-1.41) 
* Adjusted for sex only. 
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2 † Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 
kg/m
2
), Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal 
cancer (yes/no) and history of colorectal screening (yes/no). 
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The relationship between smoking and colorectal cancer was next evaluated using a 
simpler variable that combined the groups of the first variable. Both male (HR, 1.21; 
95% CI, 1.07-1.37) and female former smokers (HR, 1.17; 95% CI, 1.01-1.36) had an 
increased risk of colorectal cancer compared to never smokers. There was slight 
evidence of an increased risk for male current smokers (HR, 1.16; 95% CI, 0.95-1.41) 
but not for female current smokers (HR, 1.02; 95% CI, 0.78-1.33). Table A-13 in the 
appendix shows the effects of adjusting for different confounders on results. 
 
Next, the relationship between cigarette smoking status and colorectal cancer was 
evaluated. Results were similar to the previous variable for men and women except 
male former cigarette smokers had a slightly higher risk of colorectal cancer than male 
former smokers (HR, 1.32; 95% CI, 1.15-1.51). 
 
Thus, former cigarette smokers had a greater risk of colorectal cancer than current 
cigarette smokers. This could be related to differences in health status between the two 
groups. For example, former cigarette smokers may have had greater levels of illness 
whereas the fact that current cigarette smokers continued to smoke could indicate that 
they were generally in good health and relatively free of major illnesses. However, the 
proportion of participants reporting a long-standing illness was similar among former 
and current cigarette smokers while approximately twice as many current cigarette 
smokers reported poor health as former cigarette smokers (Figure 7.1.2). 
 
Figure 7.1.2 Participants Reporting Long-standing Illness and Poor Health, by Cigarette 
Smoking Status and Sex 
 
 
Former cigarette smokers were also asked to provide reasons why they quit smoking. 
Participants could select all options that applied from “illness or ill health”, “doctor’s 
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advice”, health precaution”, “financial reasons” or could select “none of the above”. 
Compared with never smokers, the HR (95% CI) was 1.22 (1.09-1.38) for former 
cigarette smokers who selected at least one of the illness related reasons (first three 
options) and 1.37 (1.16-1.60) for former cigarette smokers who selected other reasons. 
 
Table 7.1.3 Cigarette Smoking Status and the Risk of Colon Cancer and Rectal Cancer 
in UK Biobank 
 Cigarette smoking status 
 Never Former Current 
Colon cancer    
Overall    
Cases 658 415 80 
HR (95% CI)* 1.00 1.22 (1.08-1.39) 1.00 (0.79-1.27) 
Men    
Cases 274 276 40 
HR (95% CI)* 1.00 1.36 (1.14-1.62) 0.96 (0.68-1.35) 
Women    
Cases 384 139 40 
HR (95% CI)* 1.00 1.03 (0.85-1.26) 1.08 (0.77-1.51) 
Rectal cancer    
Overall    
Cases 323 242 54 
HR (95% CI)* 1.00 1.38 (1.16-1.65) 1.23 (0.91-1.66) 
Men    
Cases 188 175 42 
HR (95% CI)* 1.00 1.29 (1.04-1.60) 1.36 (0.96-1.93) 
Women    
Cases 135 67 12 
HR (95% CI)* 1.00 1.57 (1.16-2.14) 0.93 (0.51-1.70) 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
Next, the associations between cigarette smoking and colon and rectal cancer were 
investigated (Table 7.1.3). Male former cigarette smokers had an increased risk of colon 
cancer (HR, 1.36; 95% CI, 1.14-1.62) but there was no evidence of an increased risk for 
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male current cigarette smokers (HR, 0.96; 95% CI, 0.68-1.35). There was no evidence 
of an increased risk of colon cancer for former or current cigarette smokers for women. 
 
For rectal cancer, both former (HR, 1.29; 95% CI, 1.04-1.60) and current cigarette 
smokers (HR, 1.36; 95% CI, 0.96-1.93) had an increased risk for men. Female former 
cigarette smokers had a particularly high risk of rectal cancer (HR, 1.57; 95% CI, 1.16-
2.14) but there was no evidence of an increased risk for female current cigarette 
smokers (HR, 0.93; 95% CI, 0.51-1.70). 
 
Analysing proximal and distal colon cancer, there was only clear evidence of an 
increased risk of distal colon cancer for former cigarette smokers (HR, 1.44; 95% CI, 
1.20-1.74) (Table 7.1.4). 
 
Table 7.1.4 Cigarette Smoking Status and the Risk of Proximal Colon Cancer and 
Distal Colon Cancer in UK Biobank 
 Cigarette smoking status 
 Never Former Current 
Proximal colon cancer    
Cases 333 178 45 
HR (95% CI)* 1.00 1.06 (0.87-1.28) 1.23 (0.89-1.69) 
    
Distal colon cancer    
Cases 281 216 31 
HR (95% CI)* 1.00 1.44 (1.20-1.74) 0.83 (0.57-1.21) 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
7.1.2 Smoking Duration and Intensity 
 
The effects of smoking duration and smoking intensity on colorectal cancer risk were 
also investigated for former and current cigarette smokers. Compared to never smokers, 
former cigarette smokers with ≥40 years of duration had the highest risk of colorectal 
cancer (HR, 1.65; 95% CI, 1.33-2.05) (Table 7.1.5). Former cigarette smokers with ≥40 
years of duration also had an increased risk of both colon and rectal cancer. Results 
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seemed to indicate a dose-response relationship between smoking duration and rectal 
cancer but results were less clear for colon cancer since there was an increased risk for 
participants who smoked ≤9 years (HR, 1.32; 95% CI, 1.01-1.74).  
 
Table 7.1.5 Smoking Duration and the Risk of Colorectal Cancer in UK Biobank 
Smoking duration 
(years) 
Colorectal cancer Colon cancer Rectal cancer 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never smoker 973 1.00 658 1.00 323 1.00 
Former cigarette 
smoker 
      
≤9 81 1.26 (1.00-1.58) 56 1.32 (1.01-1.74) 26 1.17 (0.78-1.74) 
10-19 184 1.20 (1.02-1.41) 116 1.15 (0.94-1.40) 70 1.32 (1.01-1.72) 
20-29 150 1.14 (0.96-1.36) 91 1.05 (0.84-1.32) 61 1.35 (1.02-1.79) 
30-39 128 1.30 (1.08-1.57) 80 1.23 (0.97-1.56) 50 1.48 (1.09-2.02) 
≥40 97 1.65 (1.33-2.05) 67 1.70 (1.31-2.20) 31 1.58 (1.08-2.32) 
P-trend  0.0510  0.1286  0.2063 
Current cigarette 
smoker 
      
≤29 10 0.77 (0.41-1.45) 4 0.47 (0.17-1.27) 6 1.31 (0.57-3.01) 
30-39 33 1.01 (0.71-1.44) 17 0.84 (0.51-1.37) 16 1.26 (0.75-2.11) 
≥40 90 1.18 (0.95-1.48) 58 1.15 (0.87-1.52) 32 1.22 (0.84-1.77) 
P-trend  0.1235  0.3446  0.1880 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
There was also slight evidence that current cigarette smokers with duration ≥40 years 
had an increased risk of colorectal cancer (HR, 1.18; 95% CI, 0.95-1.48) though the risk 
was lower than for former cigarette smokers with duration ≥40 years. 
 
Former cigarette smokers who smoked 11-15, 16-20 and ≥21 cigarettes per day had an 
increased risk of colorectal cancer (Table 7.1.6). These participants also had an 
increased risk of colon and rectal cancer risk. However, while participants who smoked 
≥21 cigarettes per day had the highest risk of colon cancer (HR, 1.44; 95% CI, 1.17-
1.78), participants who smoked 11-15 cigarettes per day had the highest risk of rectal 
cancer (HR, 1.68; 95% CI, 1.23-2.29). 
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Current cigarette smokers who smoked ≥21 cigarettes per day had a high risk of rectal 
cancer though the CI was wide (HR, 1.81; 95% CI, 1.05-3.13). There was no evidence 
of an association for colon cancer. 
 
Table 7.1.6 Smoking Intensity and the Risk of Colorectal Cancer in UK Biobank 
 
Colorectal cancer Colon cancer Rectal cancer 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never smoker 973 1.00 658 1.00 323 1.00 
Former cigarette 
smoker 
      
≤10 122 1.05 (0.87-1.27) 76 0.96 (0.76-1.22) 47 1.24 (0.91-1.70) 
11-15 118 1.43 (1.18-1.73) 74 1.34 (1.05-1.71) 47 1.68 (1.23-2.29) 
16-20 229 1.26 (1.08-1.46) 146 1.21 (1.01-1.46) 84 1.33 (1.04-1.71) 
≥21 174 1.39 (1.17-1.65) 116 1.44 (1.17-1.78) 60 1.33 (1.00-1.78) 
P-trend  0.1735  0.0592  0.7969 
Current cigarette 
smoker 
      
≤10 42 1.04 (0.76-1.42) 29 1.08 (0.74-1.57) 13 0.94 (0.54-1.65) 
11-20 63 1.03 (0.79-1.33) 37 0.93 (0.67-1.30) 26 1.18 (0.79-1.78) 
≥21 28 1.42 (0.97-2.09) 14 1.16 (0.68-1.99) 14 1.81 (1.05-3.13) 
P-trend  0.0658  0.4615  0.0455 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
Among former cigarette smokers, the effects of smoking duration and smoking intensity 
were analysed together (Table 7.1.7). Participants with the greatest level of exposure 
(participants who smoked ≥16 cigarettes per day for ≥40 years) had the highest risk of 
colorectal cancer compared to never smokers (HR, 1.72; 95% CI, 1.33-2.21). 
 
There were some slight differences for colon and rectal cancer. Participants who 
smoked ≤15 or ≥16 cigarettes per day for ≥40 years both had a similar increased risk of 
colon cancer. However, for rectal cancer, there was only evidence of an increased risk 
for participants who smoked ≥16 cigarettes per day. There seemed to be a greater risk of 
rectal cancer for participants who smoked ≤15 cigarettes per day than for participants 
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who smoked ≥16 cigarettes per day among participants who smoked for ≤29 years. This 
pattern was reversed for participants who smoked for ≥30 years. 
 
There was also slight evidence of an increased risk of colon cancer (HR, 1.41; 95% CI, 
0.98-2.03) and rectal cancer (HR, 1.53; 95% CI, 0.94-2.49) for former cigarette smokers 
with the lowest level of exposure (participants who smoked ≤15 cigarettes per day for 
≤9 years) compared to never smokers. 
 
Table 7.1.7 Smoking Duration and Smoking Intensity for Former Cigarette Smokers 
and the Risk of Colorectal Cancer in UK Biobank 
Smoking duration 
and smoking 
intensity 
Colorectal cancer Colon cancer Rectal cancer 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never Smoker 973 1.00 658 1.00 323 1.00 
≤9 yrs, ≤15 cigs/d 48 1.46 (1.09-1.95) 31 1.41 (0.98-2.03) 17 1.53 (0.94-2.49) 
≤9 yrs, ≥16 cigs/d 31 1.00 (0.70-1.44) 24 1.20 (0.80-1.80) 7 0.64 (0.30-1.35) 
10-19 yrs, ≤15 cigs/d 70 1.11 (0.87-1.42) 40 0.94 (0.68-1.30) 32 1.53 (1.06-2.20) 
10-19 yrs, ≥16 cigs/d 114 1.27 (1.04-1.55) 76 1.30 (1.02-1.66) 38 1.19 (0.85-1.68) 
20-29 yrs, ≤15 cigs/d 51 1.08 (0.82-1.44) 28 0.88 (0.60-1.28) 24 1.54 (1.02-2.34) 
20-29 yrs, ≥16 cigs/d 99 1.18 (0.96-1.46) 63 1.15 (0.88-1.50) 37 1.26 (0.89-1.79) 
30-39 yrs, ≤15 cigs/d 37 1.07 (0.77-1.49) 25 1.07 (0.72-1.60) 12 1.05 (0.59-1.88) 
30-39 yrs, ≥16 cigs/d 91 1.42 (1.14-1.77) 55 1.31 (0.99-1.74) 38 1.69 (1.20-2.40) 
≥40 yrs, ≤15 cigs/d 29 1.53 (1.05-2.22) 23 1.75 (1.15-2.66) 7 1.17 (0.55-2.48) 
≥40 yrs, ≥16 cigs/d 68 1.72 (1.33-2.21) 44 1.70 (1.23-2.30) 24 1.78 (1.16-2.73) 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
7.1.3 Smoking Initiation 
 
Age at smoking initiation was also investigated for former and current cigarette smokers 
(Table 7.1.8). For former cigarette smokers, there were no clear trends in results, for 
colon cancer or rectal cancer risk. Former cigarette smokers with the earliest age at 
initiation (≤14 years) did have the highest risk of colon cancer (HR, 1.41; 95% CI, 1.08-
1.82) however there was an increased risk for participants who started smoking at age 
Chapter 7 | Smoking and Colorectal Cancer 
299 
≥19 years (HR, 1.27; 95% CI, 1.03-1.57) while there was no increased risk for 
participants who started at age 17-18 years (HR, 1.01; 95% CI, 0.81-1.25). Results for 
rectal cancer showed an approximately similar level of risk for each category of age at 
initiation. 
 
For current cigarette smokers, there was no evidence of an association between age at 
smoking and colon cancer risk but participants who started smoking ≤15 and 16-17 
years seemed to have an increased risk of rectal cancer. 
 
Table 7.1.8 Smoking Initiation and the Risk of Colorectal Cancer in UK Biobank 
Smoking initiation 
(years) 
Colorectal cancer Colon cancer Rectal cancer 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never smoker 973 1.00 658 1.00 323 1.00 
Former cigarette 
smoker 
      
≤14 104 1.41 (1.14-1.73) 66 1.41 (1.08-1.82) 38 1.40 (0.99-1.98) 
15-16 230 1.32 (1.14-1.53) 148 1.30 (1.08-1.56) 86 1.41 (1.10-1.81) 
17-18 158 1.10 (0.93-1.31) 96 1.01 (0.81-1.25) 64 1.32 (1.00-1.74) 
≥19 152 1.29 (1.09-1.54) 102 1.27 (1.03-1.57) 52 1.37 (1.02-1.84) 
P-trend  0.4940  0.5284  0.8182 
Current cigarette 
smoker 
      
≤15 46 1.09 (0.81-1.48) 24 0.90 (0.60-1.36) 22 1.40 (0.90-2.18) 
16-17 33 1.07 (0.76-1.52) 15 0.76 (0.45-1.27) 18 1.62 (1.00-2.62) 
≥18 54 1.11 (0.84-1.46) 40 1.23 (0.89-1.70) 14 0.84 (0.49-1.44) 
P-trend  0.8537  0.3238  0.1202 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
7.1.4 Smoking Cessation 
 
Participants who quit smoking after age 50 had an increased risk of colon cancer (HR, 
1.43; 95% CI, 1.18-1.68) and rectal cancer (HR, 1.39; 95% CI, 1.05-1.85) (Table 7.1.9). 
However, for rectal cancer, participants who quit smoking 40-49 had the highest risk 
compared to never smokers (HR, 1.67; 95% CI, 1.28-2.17). Participants who quit 
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smoking before 30 also appeared to have an increased risk of colon and rectal cancer 
compared to never smokers. 
 
Results for years since cessation did seem to show clearer trends for the risk of colon 
cancer and rectal cancer. The HRs (95% CIs) for participants who quit smoking ≤9 
years before baseline were 1.45 (1.17-1.78) for colon cancer and 1.53 (1.15-2.04). 
Participants who quit at least 30 years before baseline still appeared to have an 
increased risk of rectal cancer compared to never smokers (HR, 1.24; 95% CI, 0.94-
1.65). 
 
Table 7.1.9 Smoking Cessation and the Risk of Colorectal Cancer in UK Biobank 
 Colorectal cancer Colon cancer Rectal cancer 
 Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Age at cessation 
(yrs) 
      
Never smoker 973 1.00 658 1.00 323 1.00 
≤29 126 1.27 (1.05-1.53) 80 1.23 (0.97-1.49) 47 1.35 (0.99-1.84) 
30-39 169 1.12 (0.95-1.33) 113 1.14 (0.93-1.36) 58 1.12 (0.84-1.49) 
40-49 158 1.25 (1.05-1.49) 89 1.06 (0.85-1.36) 72 1.67 (1.28-2.17) 
≥50 190 1.41 (1.20-1.66) 130 1.43 (1.18-1.68) 62 1.39 (1.05-1.85) 
P-trend  0.1144  0.1738  0.3819 
Years since 
cessation 
      
Never smoker 973 1.00 658 1.00 323 1.00 
≤9 162 1.46 (1.23-1.73) 107 1.45 (1.17-1.78) 58 1.53 (1.15-2.04) 
10-19 136 1.26 (1.05-1.51) 82 1.14 (0.90-1.44) 54 1.47 (1.09-1.97) 
20-29 174 1.21 (1.03-1.43) 112 1.18 (0.96-1.45) 64 1.30 (0.98-1.71) 
≥30 171 1.15 (0.97-1.35) 111 1.12 (0.91-1.38) 63 1.24 (0.94-1.65) 
P-trend  0.0174  0.0452  0.1829 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
Analysing years since cessation and smoking intensity together, participants who quit 
smoking ≤9 years before baseline and smoked ≥16 cigarettes per day had an increased 
risk of colon cancer (HR, 1.51; 95% CI, 1.17-1.95) (Table 7.1.10). Participants who 
smoked ≥16 cigarettes per day and quit 20-29 years before baseline also had an 
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increased risk but evidence for an increased risk was less clear for those who quit 10-19 
years before baseline. Among participants who smoked ≤15 cigarettes per day, there 
was an increased risk of colon cancer only for those who quit ≤9 years before baseline. 
 
For rectal cancer, participants who smoked ≥16 cigarettes per day had an increased risk 
if they quit smoking ≤9 (HR, 1.80; 95% CI, 1.30-2.49) or 10-19 years before baseline 
(HR, 1.58; 95% CI, 1.12-2.23). However, among participants who smoked ≤15 
cigarettes per day, there was an increased risk only for participants who quit 20-29 or 
≥30 years before baseline. 
 
Table 7.1.10 Smoking Cessation and Smoking Intensity and the Risk of Colorectal 
Cancer in UK Biobank 
Years since 
cessation and 
smoking intensity 
Colorectal cancer Colon cancer Rectal cancer 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never Smoker 973 1.00 658 1.00 323 1.00 
≤9 yrs, ≥16 cigs/d 111 1.59 (1.30-1.95) 69 1.51 (1.17-1.95) 44 1.80 (1.30-2.49) 
≤9 yrs, ≤15 cigs/d 51 1.25 (0.94-1.65) 38 1.36 (0.98-1.89) 14 1.04 (0.61-1.78) 
10-19 yrs, ≥16 cigs/d 92 1.34 (1.08-1.67) 54 1.20 (0.90-1.59) 38 1.58 (1.12-2.23) 
10-19 yrs, ≤15 cigs/d 44 1.14 (0.84-1.54) 28 1.06 (0.73-1.56) 16 1.25 (0.76-2.08) 
20-29 yrs, ≥16 cigs/d 113 1.25 (1.03-1.53) 79 1.35 (1.06-1.71) 35 1.10 (0.77-1.57) 
20-29 yrs, ≤15 cigs/d 61 1.17 (0.90-1.51) 33 0.94 (0.66-1.33) 29 1.66 (1.13-2.43) 
≥30 yrs, ≥16 cigs/d 87 1.06 (0.85-1.33) 60 1.12 (0.85-1.47) 27 0.95 (0.63-1.42) 
≥30 yrs, ≤15 cigs/d 82 1.24 (0.99-1.56) 50 1.12 (0.84-1.50) 34 1.55 (1.08-2.22) 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
 
7.1.5 Effect Modifiers 
 
Finally, the relationship between cigarette smoking status and colorectal cancer risk was 
investigated according to different levels of BMI (Table 7.1.11). Within each category 
of BMI, former cigarette smokers had an increased risk of colorectal cancer compared 
to never smokers. Current cigarette smokers had an increased risk compared to never 
smokers only among participants with BMI <25 kg/m
2
 (HR, 1.38; 95% CI, 1.02-1.87). 
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Table 7.1.11 Cigarette Smoking Status and the Risk of Colorectal Cancer in UK 
Biobank by Body Mass Index 
 Cigarette smoking status  
BMI Never Former Current P-interaction 
<25 kg/m
2 
    
Cases 305 121 56  
HR (95% CI)* 1.00 1.22 (0.98-1.52) 1.38 (1.02-1.87)  
25-<30 kg/m
2
     
Cases 432 314 52  
HR (95% CI)* 1.00 1.31 (1.12-1.53) 1.02 (0.76-1.37)  
≥30 kg/m2     
Cases 236 213 26  
HR (95% CI)* 1.00 1.20 (0.99-1.46) 0.87 (0.58-1.32) 0.3538 
*Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), Townsend deprivation index (quintiles), red meat intake 
(1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of 
colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
 
7.2 Discussion 
 
7.2.1 Smoking Status and Colorectal Cancer 
 
Tobacco smoking and cigarette smoking were associated with colorectal cancer risk in 
this analysis. The detail of the baseline questionnaire meant that different categories of 
tobacco exposure could be assessed in this analysis. Most analyses of tobacco smoking 
simply classify individuals as never, former or current smokers and thus combine 
slightly different levels of exposure without much consideration due to the limitations 
of the questionnaire. However, the current analysis was able to analyse exposure to 
tobacco smoke more precisely. 
 
For example, compared to never ever smokers, participants who had smoked 
occasionally in the past or just tried smoking once or twice and had smoked less than 
100 times did not have an increased risk of colorectal cancer, as expected. The question 
on smoking 100 times is often used to define a threshold of exposure for never smoking, 
given that many people will have tried smoking but will have a very low level of 
exposure.
379
 Thus, in all further analyses in this section, these participants were 
combined with never ever smokers to form the reference group never smokers. 
Chapter 7 | Smoking and Colorectal Cancer 
303 
Both male and female former daily smokers had an increased risk of colorectal cancer 
compared to never ever smokers. However, evidence was weaker for an increased risk 
for daily smokers. Results were unclear for participants who were occasional smokers at 
baseline due to the relatively small number of cases among these participants. Also, 
there was very slight evidence that women who had smoked occasionally in the past and 
had smoked more than 100 times had an increased risk of colorectal cancer, despite the 
fact that these participants were never regular smokers. 
 
Next, some of these categories were combined to create a simpler smoking status 
variable (never smokers, former smokers, current smokers), comparable to other 
analyses. Also, to provide further comparison, a further variable was created which 
focused on cigarette smoking status and restricted former smokers to former daily 
cigarette smokers and current smokers to current daily cigarette smokers. 
 
Results for overall smoking status and cigarette smoking status were fairly similar. For 
women, there was a similar increased risk of colorectal cancer for former smokers and 
former cigarette smokers. There was no evidence of an increased risk for current 
smokers or current cigarette smokers. Results for current smokers and current cigarette 
smokers were also similar for men. However, there was a slight difference between 
former smokers and former cigarette smokers with a slightly greater risk of colorectal 
cancer for former cigarette smokers. Other studies should obtain more detailed 
information on smoking exposure and also provide more information for how analysis 
variables were derived. 
 
Thus, this analysis found clear evidence that former cigarette smokers had an increased 
risk of colorectal cancer but not current cigarette smokers. Overall, it seems clear from 
existing studies that both former and current smokers have an increased risk of 
colorectal cancer. For example, a recent meta-analysis found that the pooled RR (95% 
CI) was 1.20 (1.10-1.30) for current smokers and 1.18 (1.12-1.25) for former smokers.
49
 
 
It is not clear why current cigarette smokers did not appear to have an increased risk of 
colorectal cancer in this study. Individual studies have found contrasting results for 
former and current smokers. For example, former smokers (HR, 1.17; 95% CI, 1.07-
1.29) also had a greater risk of colorectal cancer than current smokers (HR, 1.08; 95% 
Chapter 7 | Smoking and Colorectal Cancer 
304 
CI, 0.96-1.21) in the EPIC study.
253
 However, the Cancer Prevention Study II Nutrition 
Cohort found a similar risk of colorectal cancer for former smokers (HR, 1.23; 95% CI, 
1.11-1.36) and current smokers (HR, 1.27; 95% CI, 1.06-1.52)
254
 and current smokers 
(HR, 1.28; 95% CI, 1.00-1.63) had a greater risk of colorectal cancer than former 
smokers (HR, 1.10; 95% CI, 0.97-1.24) in a cohort of female teachers.
258
 
 
One possible explanation for the conflicting results is because of the varying definitions 
of smoking status between studies. Many epidemiological studies include only very 
basic questions on smoking exposure and smoking status is a fairly crude measure. For 
example, many studies will likely define both occasional and regular smokers as current 
smokers. 
 
However, although varying definitions of smoking status may contribute to conflicting 
results between studies, it remains unclear why this study found a greater risk of 
colorectal cancer for former cigarette smokers than for current cigarette smokers despite 
the more precise definition of this variable. 
 
7.2.2 Colorectal Cancer Subsites 
 
Colon and Rectal Cancer 
 
The relationships between cigarette smoking status and colon and rectal cancer risk 
were also investigated in this study. Results were slightly different for men and women. 
Male former cigarette smokers had an increased risk of colon cancer but there was no 
evidence of an increased risk for male current cigarette smokers. Male former cigarette 
smokers and male current cigarette smokers appeared to have a similar increased risk of 
rectal cancer. There was no evidence that female former cigarette smokers or current 
cigarette smokers had an increased risk of colon cancer while female former cigarette 
smokers had a particularly increased risk of rectal cancer. 
 
Overall, evidence from prospective cohort studies supports a relationship between 
smoking and both colon and rectal cancer risk though smoking seems to be slightly 
more strongly related to rectal cancer risk.
49, 50
 For example, in the most recent meta-
analysis, the pooled RRs (95% CIs) for former smokers were 1.20 (1.11-1.30) for rectal 
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cancer and 1.16 (1.11-1.22) for colon cancer and the pooled RRs (95% CIs) for current 
smokers were 1.24 (1.16-1.39) for rectal cancer and 1.09 (1.01-1.18) for colon cancer.
50
 
Thus, similar to results for men in this analysis, former and current smokers have a 
similar risk of rectal cancer while former smokers have a greater risk of colon cancer 
than current smokers. 
 
Parajuli et al. also presented results for colon and rectal cancer for men and women.
255, 
256
 Similar to the results for UK Biobank, male former smokers (HR, 1.28; 95% CI, 
1.11-1.50) and current smokers (HR, 1.26; 95% CI, 1.09-1.45) had a similar increased 
risk of rectal cancer. Also, male former smokers had an increased risk of colon cancer 
(HR, 1.14; 95% CI, 1.02-1.27) but male current smokers did not have an increased risk 
(HR, 1.03; 95% CI, 0.92-1.15). However, results differed to UK Biobank for women. 
Parajuli et al. found an increased risk of colon cancer for both female former smokers 
(HR, 1.16; 95% CI, 1.02-1.31) and current smokers (HR, 1.22; 95% CI, 1.10-1.36) and 
an increased risk of rectal cancer for both female former smokers (HR, 1.26; 95% CI, 
1.05-1.52) and current smokers (HR, 1.29; 95% CI, 1.10-1.51). 
 
Other studies have also found slightly different results. For example, in the EPIC study, 
both former and current smokers appeared to have a greater risk of colon cancer than 
rectal cancer and former smokers appeared to have a greater risk than current smokers 
for both colon cancer and rectal cancer.
253
 The HRs (95% CIs) were 1.21 (1.08-1.36) for 
former smokers and 1.13 (0.98-1.31) for current smokers for colon cancer and 1.10 
(0.94-1.30) for former smokers and 0.98 (0.80-1.19) for current smokers for rectal 
cancer. While both former smokers and current smokers in the Cancer Prevention Study 
II Nutrition Cohort had an increased risk of colon cancer (HR, 1.19; 95% CI, 1.06-1.34 
for former smokers and HR, 1.28; 95% CI, 1.04-1.57 for current smokers), only former 
smokers had an increased risk of rectal cancer (HR, 1.26; 95% CI, 1.02-1.55 for former 
smokers and HR, 0.97; 95% CI, 0.63-1.47 for current smokers).
254
 
 
Proximal and Distal Colon Cancer 
 
This analysis also investigated the relationships between cigarette smoking status and 
proximal colon cancer and distal colon cancer risk. Former cigarette smokers had an 
increased risk of distal colon cancer but not proximal colon cancer. It was unclear 
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whether current cigarette smokers had an increased risk of proximal colon cancer or 
distal colon cancer. Few studies have investigated the risk of proximal and distal colon 
cancer. The meta-analysis by Cheng et al. suggested that smoking is more strongly 
related to proximal colon cancer risk though results were based on only four studies.
50
 
 
7.2.3 Smoking Duration and Intensity 
 
Smoking Duration 
 
Overall, studies generally find a positive association between smoking duration and 
colorectal cancer risk.
26, 29, 49, 226
 However, most studies of smoking and colorectal 
cancer have combined former and current smokers when analysing smoking duration. 
This may lead to misleading results since current smokers will continue to add to their 
exposure during follow-up whereas the number of years since cessation will increase for 
former smokers. Also, the distributions of smoking duration are very different for 
former and current smokers e.g. very few current smokers will have a duration less than 
ten years. 
 
Smoking duration was associated with colorectal cancer risk for former cigarette 
smokers in UK Biobank. Former cigarette smokers with ≥40 years duration had the 
highest risk of colorectal cancer. Compared to never smokers, there was evidence of an 
increased risk for all former cigarette smokers, including those with ≤9 years duration. 
Current cigarette smokers with ≥40 years duration also had an increased risk of 
colorectal cancer but the risk was much more moderate compared to the risk for former 
cigarette smokers with ≥40 years duration (in fact, results for current cigarette smokers 
with ≥40 years duration were similar to results for former cigarette smokers with ≤9 
years duration). 
 
The EPIC study also investigated smoking duration separately for former and current 
smokers.
253
 However, there were no clear trends for former or current smokers. 
Compared to never smokers, former smokers who smoked 20-29 and ≥30 years both 
had an increased risk of colon cancer but so did former smokers who smoked ≤9 years. 
For rectal cancer, only former smokers who smoked 20-29 years had an increased risk 
and there was no evidence of an increased risk for former smokers who smoked ≥30 
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years. There was no evidence that current smokers with ≥40 years duration had an 
increased risk of colon cancer or rectal cancer. 
 
In contrast to results from the EPIC study, the Cancer Prevention Study II Nutrition 
Cohort found an increased risk of colorectal cancer for current smokers who smoked 
40-49 (HR, 1.32; 95% CI, 1.02-1.72) and ≥50 years (HR, 1.38; 95% CI, 1.04-1.84). 
There was no increased risk for current smokers with <40 years duration (HR, 1.02; 
95% CI, 0.69-1.49).
254
 
 
Smoking Intensity 
 
Again, existing studies do show a positive association between smoking intensity and 
colorectal cancer risk.
26, 29, 49, 226
 Similar to analyses of smoking duration, it may be 
important to analyse smoking intensity separately for former and current smokers since 
current smokers continue to accumulate exposure during follow-up. Another reason is 
that smoking intensity normally represents two slightly different measures for former 
and current smokers in most studies; while current smokers are asked to report how 
many cigarettes they currently smoke per day, former smokers are asked to report the 
average number of cigarettes they smoked per day in the past. 
 
Former cigarette smokers who smoked 11-15, 16-20 and ≥21 cigarettes per day each 
had an increased risk of colon cancer and rectal cancer compared to never smokers in 
UK Biobank. However, while smoking ≥21 cigarettes per day carried the highest risk of 
colon cancer, smoking 11-15 cigarettes per day was associated with a higher risk of 
rectal cancer than smoking 16-20 or ≥21 cigarettes per day. Current cigarette smokers 
who smoked ≥21 cigarettes per day appeared to have a particularly high risk of rectal 
cancer (though the CI was wide) but there was no evidence of an increased risk of colon 
cancer. 
 
The EPIC study also found that smoking intensity was associated with colon and rectal 
cancer risk for former smokers.
253
 Former smokers who smoked 10-14 (HR, 1.30; 95% 
CI, 1.04-1.63) and ≥15 cigarettes per day (HR, 1.25; 95% CI, 1.03-1.53) both had an 
increased risk of colon cancer while only former smokers who smoked ≥15 cigarettes 
per day had an increased risk of rectal cancer (HR, 1.26; 95% CI, 0.98-1.61). In contrast 
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to UK Biobank results for current smokers, there was only evidence of an increased risk 
of colon cancer for current smokers smoking ≥20 cigarettes per day (HR, 1.20; 95% CI, 
0.97-1.50). 
 
The Physicians’ Health Study also analysed smoking intensity separately for former and 
current smokers and found a much higher risk of colorectal cancer for current smokers 
who smoked ≥20 cigarettes per day (HR, 2.14; 95% CI, 1.45-3.14) than for former 
smokers who smoked cigarettes ≥20 per day (HR, 1.31; 95% CI, 1.00-1.73) (though CIs 
were quite wide).
324
 In a cohort of Japanese men, the HR (95% CI) for current smokers 
smoking ≥20 cigarettes per day was 1.60 (0.99-2.58).317 
 
Smoking Duration and Intensity 
 
Studies of smoking and colorectal cancer have not investigated the effects of smoking 
duration and smoking intensity together. It is important to consider smoking duration 
and intensity together because the effects of smoking duration on colorectal cancer risk 
may be affected by smoking intensity and vice versa. For example, individuals who start 
smoking earlier will tend to have a longer duration than individuals who start later but 
they may also have a greater nicotine dependence and thus be heavier smokers.
273-275
 
Also, individuals who smoke fewer cigarettes are more likely to quit smoking and 
therefore will have a shorter smoking duration on average.
261-266
 Furthermore, it is 
plausible that people with a long duration of heavy smoking will have a particularly 
elevated risk of colorectal cancer (yet this is ignored in most studies). 
 
A number of studies have analysed the relationship between pack-years of smoking, 
which combines smoking duration and smoking intensity, and colorectal cancer. 
However, the pack-years variable is flawed and has received much criticism.
276, 277
 The 
main issue with pack-years is that it confounds smoking duration and smoking intensity 
when it seems clear that these two aspects do not affect cancer risk in the same way. 
 
Pack-years is also flawed due to the limitations of measuring smoking duration and 
smoking intensity. Pack-years is intended to be a measure of lifetime exposure. Yet 
current smokers are generally only asked to report their current smoking intensity. Thus, 
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it is necessary to assume that current smokers have always smoked this number of 
cigarettes, including when people report starting smoking at very young ages. 
 
This analysis investigated the joint effects of smoking duration and smoking intensity 
among former cigarette smokers (current smokers were not included because of the 
relatively small number of cases). Former cigarette smokers who smoked for ≥40 years 
and smoked ≤15 or ≥16 cigarettes per day both had an increased risk of colorectal 
cancer compared to never smokers though there was a greater risk for participants who 
smoked ≥16 cigarettes per day. There was also evidence that participants who smoked 
≥16 cigarettes per day for 10-39 years had an increased risk of colorectal cancer but 
there was no evidence of an increased risk for participants who smoked ≤15 cigarettes 
per day. 
 
Thus, results from this analysis found that the association between smoking duration 
and colorectal cancer differed according to smoking intensity (and vice versa). Hence, 
more studies should try to classify people by both smoking duration and smoking 
intensity in order to better classify the additional risks due to smoking exposure. 
Surprisingly, this analysis also found an increased risk of colorectal cancer for former 
cigarette smokers with the lowest exposure. In fact, these participants appeared to have 
an approximately similar risk as participants who smoked ≥16 cigarettes per day for 30-
39 years or ≤15 cigarettes per day for ≥40 years. Possible reasons for such an increased 
risk among these participants are unclear. 
 
7.2.4 Smoking Initiation 
 
There were no clear trends in the results for age at smoking initiation and colon cancer 
and rectal cancer risk in this analysis. For example, although former cigarette smokers 
with the earliest age at initiation (≤14) had the highest risk of colon cancer, there was 
also an increased risk for former cigarette smokers who started smoking ≥19 but not for 
former cigarette smokers who started smoking 17-18. For rectal cancer, there was a 
similar increased risk for each category of age at initiation. There was slight evidence 
that current cigarette smokers who began smoking ≤15 or 16-17 had an increased risk of 
rectal cancer but there was no evidence for an association between age at initiation and 
colon cancer risk. 
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Other studies also do not find clear trends for the relationship between smoking 
initiation and colorectal cancer. For example, in the EPIC study, there was an increased 
risk of colon cancer for former smokers who began smoking 17-19 or ≥20 but not for 
former smokers who began ≤16.253 However, for rectal cancer, only former smokers 
who began smoking ≤16 appeared to have an increased risk. There was no clear 
association for current smokers. 
 
Parajuli et al. investigated age at smoking initiation for men and women and found a 
clear trend for the associations with colon cancer but evidence for a trend was less clear 
for rectal cancer.
255, 256
 Also, the Women’s Health Initiative found a similar risk of 
colorectal cancer for women who started smoking before and after age 20.
257
 
 
7.2.5 Smoking Cessation 
 
Age at Cessation 
 
Age at cessation and years since cessation were both considered in this analysis to 
investigate the effects of smoking cessation at different times on colorectal cancer risk. 
Participants who quit ≥50 years old had an increased risk of both colon and rectal 
cancer. However, there also seemed to be an increased risk of colon and rectal cancer 
for participants who quit ≤29 years old. 
 
Few other studies have investigated age at cessation but results seem to indicate that 
there is an increased risk of colorectal cancer compared to never smokers only for 
former smokers who quit smoking ≥40 years old.254, 257, 260 For example, the HRs (95% 
CIs) in the Cancer Prevention Study II Nutrition Cohort were 1.05 (0.91-1.22), 1.31 
(1.13-1.52), 1.44 (1.24-1.66) and 1.29 (1.08-1.54) for quitting smoking <40, 40-49, 50-
59 and ≥60 years old.254 Thus, it was slightly surprising that former smokers who quit 
≤29 years old in UK Biobank appeared to have an increased risk of colorectal cancer 
compared with never smokers. 
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Years since Cessation 
 
In contrast to the results for age at cessation, there were clearer trends for the 
associations between years since cessation and colon and rectal cancer. Interestingly, 
participants who quit smoking ≥30 years ago appeared to still have an increased risk of 
rectal cancer (but not colon cancer) compared to never smokers. 
 
There was a clear trend between years since cessation and colorectal cancer risk in the 
Cancer Prevention Study II Nutrition Cohort with no evidence of an increased risk for 
former smokers who quit more than 30 years before baseline; the HRs (95% CIs) for 
≥31, 21-30, 11-20 and 1-10 years since cessation were 1.03 (0.89-1.19), 1.28 (1.10-
1.49), 1.33 (1.14-1.55) and 1.48 (1.27-1.73).
254
 In the pooled analysis by Gong et al., 
there was evidence of an increased risk of colorectal cancer for former smokers who 
quit 0-15 and 15-25 years ago but not for former smokers who quit 25-35 or ≥35 years 
ago. 
260
 
  
The EPIC study did not find a clear relationship between years since smoking cessation 
and the risk of colon cancer or rectal cancer.
253
 For example, although there was no 
evidence of an increased risk of colon or rectal cancer for former smokers who quit 20-
24 or ≥25 years ago, former smokers who quit 15-19 years ago had the highest risk of 
colon cancer (HR, 1.36; 95% CI, 1.09-1.70) and rectal cancer (HR, 1.30; 95% CI, 0.96-
1.76). 
 
Years since Cessation and Smoking Intensity 
 
This analysis also investigated the combined effects of years since cessation and 
smoking intensity. Participants with the highest exposure (quit smoking ≤9 years before 
baseline and smoked ≥16 cigarettes per day) had the greatest risk of colon and rectal 
cancer. However, there were slightly different patterns of results for colon and rectal 
cancer. Participants who smoked ≥16 cigarettes per day seemed to have an increased 
risk of colon cancer if they quit ≤29 years before baseline and participants who smoked 
≤15 cigarettes per day seemed to have an increased risk of colon cancer only if they quit 
≤9 years before baseline. For rectal cancer, while there was an increased risk for 
participants who smoked ≥16 cigarettes per day and quit ≤19 years before baseline, 
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among participants who smoked ≤15 cigarettes per day, there was only an increased risk 
for participants who quit ≥20 years before baseline. Similar to the analysis of smoking 
duration and intensity, it is unclear why former cigarette smokers with supposedly the 
lowest exposure should have an increased risk of rectal cancer compared to never 
smokers. 
 
7.2.6 Smoking and Body Mass Index 
 
On average, smokers have a lower BMI than non-smokers, likely as a result of the 
effects of smoking on metabolism as well as suppressing appetite.
227
 However, heavy 
smokers also tend to have a higher BMI than light smokers and non-smokers, most 
likely due to a clustering of negative behaviours (e.g. low physical activity, poor diet 
and high alcohol intake).
227
 Since BMI represents a major risk factor for colorectal 
cancer, it may be important to consider the effects of smoking and BMI together. 
 
This analysis found a fairly similar increased risk for former cigarette smokers within 
each category of BMI, compared to never smokers. However, there was a clear 
difference for current cigarette smokers as there was an increased risk only for current 
cigarette smokers with BMI <25 kg/m
2
. Furthermore, within participants with BMI <25 
kg/m
2
, current cigarette smokers seemed to have a higher risk of colorectal cancer than 
former cigarette smokers. 
 
One possible explanation for a higher risk for current cigarette smokers with lower BMI 
than for current cigarette smokers with higher BMI could be related to insulin 
resistance. Higher insulin resistance is thought to be an important factor linking BMI 
and colorectal cancer risk.
157, 185
 Although smoking is associated with a lower BMI, 
smoking may actually increase insulin resistance.
227
 Thus, compared to never smokers 
with a lower BMI, current cigarette smokers with a lower BMI may be at an increased 
risk of colorectal cancer due to the direct negative effects of smoking as well as the 
indirect effects through insulin resistance. In contrast, never smokers with a higher BMI 
will have an increased insulin resistance and so the effects of current smoking on insulin 
resistance may be less important. 
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Only a few studies have previously presented results for smoking and BMI. A cohort of 
female teachers found no clear difference in results comparing ≥31 pack-years with 
never smokers for women with BMI <25 kg/m
2
, 25-29 kg/m
2
 and BMI ≥30 kg/m2.258 
Results from the pooled analysis by Gong et al. supported a stronger effect of smoking 
on colorectal cancer risk for people with higher BMI and Parajuli et al. also supported a 
stronger effect of smoking on rectal cancer risk for people with higher BMI.
256, 260
 
However, both of these analyses compared ever vs never smokers which makes results 
more difficult to interpret since former smokers tend to gain weight after cessation.
227
 
 
7.2.7 Former and Current Smokers 
 
Perhaps the biggest remaining question about the relationship between smoking and 
colorectal cancer is why former smokers appear to have a similar (or even greater) risk 
than current smokers. Yet, surprisingly, there is very little discussion about these results 
in most studies of smoking and colorectal cancer. 
 
One possible explanation why current smokers do not have a greater risk than former 
smokers could be because of confounding. However, this seems unlikely since although 
former cigarette smokers had a slightly higher BMI than current cigarette smokers on 
average in UK Biobank, current cigarette smokers had a higher intake of alcohol and 
red and processed meat, were more likely to live in areas of high deprivation and were 
less likely to have undergone bowel cancer screening. Another possible explanation 
could be that a number of former smokers have a particularly elevated risk of colorectal 
cancer because they quit smoking as a result of ill health. In contrast, the fact that 
current smokers continue to smoke could be considered a marker of reasonable health. 
However, current cigarette smokers reported the highest levels of poor health in this 
cohort. Furthermore, results for former cigarette smokers did not appear to differ 
according to reasons for quitting smoking (though this question was very crude). 
 
The similar risks for former and current smokers may possibly be related to the long 
induction period for the effects of smoking on colorectal cancer hypothesised by 
Giovannucci et al., meaning that the effects of smoking persist for many years, even 
after cessation.
50, 249, 252, 269
 
 
Chapter 7 | Smoking and Colorectal Cancer 
314 
Though smoking is only associated with a moderately increased risk of colorectal 
cancer, smoking has been shown to be strongly related to the risk of colorectal 
adenomas. Meta-analyses by Botteri et al. found that the pooled RR (95% CI) for 
current vs never smokers was 2.14 (1.86-2.46) for colorectal adenomas and 1.07 (0.99-
1.16) for colorectal cancer.
226, 281
 Since colorectal adenomas are precursors to the 
majority of colorectal cancers,
19, 280
 the risk of cancer would be expected to be at least as 
large as the risk for adenomas.
282
 Thus, to explain this discrepancy, Giovannucci et al. 
hypothesised that smoking mainly affects the early stages of colorectal carcinogenesis 
and that an induction period of 30-40 years is required to observe an increased risk of 
cancer.  
 
First of all, it is not clear that this hypothesis does explain the greater risk of colorectal 
adenomas than colorectal cancer. In UK Biobank, there was still only a modest 
increased risk for current smokers with more than 40 years duration. More pertinently, a 
long induction period does not seem to explain why current smokers do not have a 
greater risk of colorectal cancer than former smokers. 
 
Even if smoking mainly affects earlier stages of colorectal carcinogenesis, current 
smokers should still be expected to have a greater risk of colorectal cancer. Both former 
and current smokers will have started smoking at a similar age (median age at initiation 
in UK Biobank was 17 for former cigarette smokers and 16 for current cigarette 
smokers). However, while current smokers will have continued to accumulate a number 
of decades of smoking, a number of former smokers will have quit relatively early and 
so would be expected to have a low risk of colorectal cancer. In other words, current 
smokers should always be expected to have a greater level of exposure than former 
smokers. The only way this could be offset is if former smokers tended to be much 
heavier smokers than current smokers though this seems unlikely since heavier smokers 
are less likely to quit smoking.
261-263
 
 
Furthermore, a long induction period does not explain why the most recent quitters had 
a much higher risk of colorectal cancer than current smokers in UK Biobank despite 
having a similar level of exposure up to baseline, or why former smokers with ≥40 years 
duration had a much higher risk than current smokers with ≥40 years duration. 
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Protective Effect? 
 
So why do former and current smokers have a similar risk of colorectal cancer? And 
why do current smokers not have a similar risk to recent quitters? A similar risk for 
former and current smokers could be explained if, although smoking promoted early 
colorectal carcinogenesis, smoking also had some protective effect during later stages of 
carcinogenesis. Individuals with ulcerative colitis are at a substantially increased risk of 
colorectal cancer
19, 436, 437
 and it has been found that smoking reduces the risk of 
ulcerative colitis.
438, 439
 Hence, it may be plausible that current smoking does have some 
protective effect on colorectal cancer risk. 
 
This hypothesis would explain why current smokers do not have a greater risk than 
former smokers and also why the most recent former smokers have the highest risk of 
colorectal cancer. While recent quitters and current smokers have a similar exposure up 
to baseline, the harmful effects of smoking on early carcinogenesis could be offset for 
current smokers if active smoking offered some form of protection against late stages of 
carcinogenesis. Furthermore, this hypothesis would also explain why smoking is more 
strongly related to the risk of colorectal adenomas than colorectal cancer. 
 
This hypothesis could also explain why results from meta-analyses suggest that the risk 
of colorectal cancer for current smokers increases with longer follow-up.
50, 61
 This result 
is surprising since more current smokers will become former smokers with longer 
follow-up. However, if current smoking offered some form of protection against 
colorectal cancer, it could make sense that the risk increased as more current smokers 
stopped smoking. 
 
7.2.8 Summary 
 
In conclusion, this analysis found that smoking increases the risk of colorectal cancer 
risk. While there was an increased risk for former cigarette smokers, it was not clear 
whether current cigarette smokers in UK Biobank had an increased risk of colorectal 
cancer. Only male former cigarette smokers had an increased risk of colon cancer. For 
rectal cancer, there was an increased risk for male former and current cigarette smokers 
and female former cigarette smokers. There seemed to be dose-response relationships 
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for smoking duration and years since smoking cessation though results were less clear 
for smoking intensity, initiation and age at cessation. Former cigarette smokers with the 
shortest duration or longest time since cessation still seemed to have a higher risk of 
colorectal cancer than never smokers. Results for analyses combining smoking intensity 
and smoking duration/years since cessation were unclear since there seemed to be an 
increased risk for participants with the lowest level of exposure. Despite no evidence for 
an increased risk overall, current cigarette smokers with BMI <25 kg/m
2
 did seem to 
have an increased risk of colorectal cancer compared to never smokers with BMI <25 
kg/m
2
. It is unclear why former cigarette smokers had a higher risk of colorectal cancer 
than current cigarette smokers or why former cigarette smokers with ≥40 years duration 
had a much higher risk than current cigarette smokers with ≥40 years duration. 
 
7.3 Population Attributable Fractions 
 
Table 7.3.1 shows the population attributable fraction estimates (presented as 
percentages) and 95% CIs for different risk factors, overall and for men and women 
separately. 378,263 participants (178,468 men and 199,795 women) were included in 
this analysis and there were 1,833 cases (1,096 men and 737 women). 
 
Table 7.3.1 Population Attributable Fractions for Different Risk Factors in UK Biobank 
 PAF (%) (95% CI) 
Exposure Overall Men Women 
Alcohol intake, >14 units/week 6.62 (2.44, 10.61) 12.69 (5.89, 19.01) -0.39 (-4.46, 3.52) 
BMI, ≥25 kg/m2 9.82 (2.65, 16.46) 16.43 (5.74, 25.91) 3.54 (-6.03, 12.25) 
Smoking, ever smoker 7.95 (3.22, 12.46) 9.79 (2.71, 16.36) 5.09 (-1.05, 10.86) 
Townsend index, >lowest quintile -2.86 (-8.01, 2.04) -0.67 (-7.29, 5.54) -6.12 (-14.51, 1.67) 
Red meat intake, >once/week 8.68 (3.18, 13.87) 11.10 (3.35, 18.22) 5.69 (-2.17, 12.95) 
Processed meat intake, >once/week 2.48 (-0.94, 5.79) 6.52 (1.10, 11.64) -2.12 (-5.64, 1.27) 
Family history, yes 3.52 (1.61, 5.39) 4.29 (1.74, 6.78) 2.34 (-0.54, 5.15) 
Physical activity, <75/150 mins 
moderate/vigorous activity/week 
0.69 (-2.87, 4.12) -0.81 (-5.41, 3.60) 2.68 (-3.03, 8.08) 
 
For alcohol intake, it was estimated that 6.62% of cases were due to alcohol intake >14 
units/week i.e. 6.62% of cases in this cohort could have been avoided if all participants 
drank ≤14 units/week. Estimates were very different for men and women since there 
was no evidence that alcohol intake was associated with colorectal cancer for women in 
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this cohort; the PAF estimate was 12.69 for men and -0.39 for women. It was estimated 
that 9.82% of cases were attributable to participants having BMI ≥25 kg/m2 (16.43% for 
men and 3.54% for women) and that 7.95% of cases were attributable to participants 
being ever smokers (9.79% for men and 5.09% for women). 
 
8.68% of cases could have been avoided if participants reduced their intake of red meat 
to ≤once/week and reducing processed meat intake to ≤once/week was estimated to 
reduce the number of cases for men (6.52%) but not for women (-2.12%). 3.52% of 
cases were attributable to family history of colorectal cancer. 
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Chapter 8 Discussion 
 
This thesis investigated the relationship between three classic lifestyle risk factors and 
colorectal cancer. Alcohol intake, adiposity and smoking represent three of the most 
important modifiable risk factors for a wide range of NCDs, that are currently the 
leading cause of death worldwide.
3
 Yet these diseases are often the result of unhealthy 
lifestyles and are largely preventable. For example, it is predicted that one in two people 
in the UK born after 1960 will be diagnosed with cancer in their lifetime.
7
 However, 
based on existing evidence, it is also predicted that approximately 40% of cancers are 
attributable to lifestyle factors.
30
 Therefore, research to improve our understanding of 
how these risk factors contribute to disease is highly important. 
 
The main objectives for this thesis were described in section 2.5. The findings for these 
objectives are summarised below, separately for alcohol intake, adiposity and smoking.  
 
8.1 Alcohol Intake and Colorectal Cancer 
 
Results from different studies have found evidence for a threshold for the association 
between alcohol intake and colorectal cancer with an increased risk only for people 
drinking at least approximately 30 g/d.
45, 65, 66, 69, 70, 409
 In contrast, this thesis found a 
dose-response relationship between alcohol intake and colorectal cancer risk for men 
with evidence of an increased risk including for men drinking 5-<15 g/d (when using 
the alternative reference group and multiple imputed data). Furthermore, fractional 
polynomial analysis did not find evidence for a non-linear relationship between alcohol 
intake and colorectal cancer. Hence, results from this thesis did not support a threshold 
for alcohol intake and suggest that any alcohol intake should be minimised to prevent 
colorectal cancer, at least for men. 
 
In contrast to the results for men, this thesis did not find evidence for an association 
between alcohol intake and colorectal cancer for women (whether analysing alcohol 
intake as a categorical or continuous variable). It was unclear why this thesis found an 
association for men but not for women, particularly when other studies have not found 
evidence for a stronger association for men.
45, 65, 66, 69
 One possible explanation could be 
because men and women tend to prefer different alcoholic beverages and there was 
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evidence that beer intake but not wine intake was associated with colorectal cancer risk 
in UK Biobank. However, it is not clear if this provides a valid explanation since most 
other studies do not find differences according to alcoholic beverages.
45, 65, 69, 70
 Also, it 
may not be surprising that these studies do not find differences by alcoholic beverages 
since they do not find evidence for different associations for men and women despite 
their different preferences for alcoholic beverages. 
 
Few studies have investigated the association between alcohol intake and colorectal 
cancer using different reference groups despite the fact that the choice of reference 
group is a controversial issue in analyses of alcohol intake.
46
 Given the detail available 
in this cohort, it was possible to investigate different choices of reference group and it 
was hypothesised that the association between alcohol intake and colorectal cancer 
could be underestimated in many studies that used non-drinkers as the reference group 
since former drinkers would likely have an increased risk of colorectal cancer compared 
to never drinkers. This could potentially explain differences in results between studies 
e.g. why this thesis seemed to find a stronger association between alcohol intake and 
colorectal cancer for men than other studies of men conducted in Western populations 
or why there was no evidence of a threshold for men. However, former drinkers did not 
have an increased risk of colorectal cancer in this study compared to never drinkers and 
results were similar using never drinkers or non-drinkers as the reference group. 
 
The main disadvantage of using never drinkers as the reference group is that they 
represent a small group and so include a relatively small number of cases of colorectal 
cancer which leads to wide CIs. Therefore, the association between alcohol intake and 
colorectal cancer was also investigated using an alternative reference group which 
combined never drinkers and select light drinkers who reported not reducing their 
drinking since ten years before baseline. (Ideally, it would have been possible to 
identify participants who had never been heavy drinkers and who had never been binge 
drinkers but the data available on past drinking and pattern of drinking were limited.) 
Results for men using this alternative reference group were fairly similar to results using 
never drinkers as the reference group; the HRs were slightly attenuated though there 
was still a clear trend between alcohol intake and colorectal cancer risk. For women, 
there was still no evidence for an association. 
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This thesis did not find a clear difference in the association between alcohol intake and 
colorectal cancer risk by BMI. Hence, these results were not in agreement with results 
from the Western pooled analysis and the Japanese pooled analysis which showed a 
stronger association between alcohol intake and colorectal cancer for people with lower 
BMI.
45, 71
 Future studies should investigate the relationship between alcohol intake and 
colorectal cancer by BMI. 
 
8.2 Adiposity and Colorectal Cancer 
 
This thesis found a strong association between BMI and colon cancer risk for men but 
no association for women. There was no clear evidence for an association with rectal 
cancer risk for men or women. Numerous other studies have also found that BMI is 
more strongly associated with both colon cancer risk and rectal cancer risk for men than 
for women.
150
 However, the reasons for this difference remain unclear. One hypothesis 
for the difference is due to the different body compositions of men and women. Visceral 
fat, which is stored abdominally, may be particularly important for colorectal cancer 
risk and the different associations for men and women may be because BMI is more 
strongly correlated with abdominal fat for men than for women.
47, 185
 
 
However, results from this thesis did not appear to support this hypothesis. Although 
there was slight evidence that WC and WHR were associated with colon cancer risk for 
women, WC and WHR were still much more strongly related to colon cancer risk for 
men than for women. Other studies investigating BMI, WC and/or WHR also did not 
support the hypothesis that the difference was due to different body compositions.
164, 172, 
173, 186-188
 Hence, it seems that the different body compositions for men and women do 
not explain the difference in associations, at least based on the evidence for WC and 
WHR. However, these abdominal measures of adiposity still do not represent precise 
measures of visceral fat
420
 and hence the different body compositions of men and 
women may still contribute to the different associations for men and women. 
 
The other possible reason investigated in this thesis for the different associations in men 
and women was because of the effects of menopause on oestrogen levels which may be 
protective against colorectal cancer. Meta-analysis results do indicate that the 
association between BMI and colorectal cancer is stronger for pre-menopausal women 
Chapter 8 | Discussion 
321 
than post-menopausal women.
152
 However, this thesis found no evidence of an 
association for pre-menopausal women or for post-menopausal women who were never 
HRT users. Not many studies have included results by menopause status but there are 
other studies that also do not support a stronger association for pre-menopausal women 
than for post-menopausal women.
161, 169
 Thus, further research is required to understand 
how menopause and oestrogen may influence the association between BMI and 
colorectal cancer. 
 
Although results for BMI, WC and WHR in this thesis did not appear to explain the 
discrepancy between men and women for the association between BMI and colon 
cancer risk, results did seem to suggest that WC and WHR may be more directly 
associated with colon cancer risk than BMI. First of all, WC and WHR seemed to be 
associated with colon cancer risk for women whereas there was no association for BMI. 
Furthermore, when modelling BMI and WC or WHR simultaneously, the associations 
for WC and WHR remained while the associations for BMI were severely attenuated. 
Also, other studies found similar results when adjusting analyses of WC/WHR for 
BMI.
47, 186, 187
 
 
8.3 Smoking and Colorectal Cancer 
 
Compared to never smokers in UK Biobank, former cigarette smokers had an increased 
risk of colorectal cancer but there was no increased risk for current cigarette smokers. 
Other studies have also shown a slightly greater risk for former smokers than current 
smokers.
226, 252
 However, the similar risks for former and current smokers are rarely 
discussed in studies of smoking and colorectal cancer and the reasons why current 
smokers do not have a greater risk are unclear. This thesis tried to consider different 
possible explanations. For example, it seems unlikely that results were due to 
confounding since results in this thesis were adjusted for a number of confounders 
associated with colorectal cancer. 
 
Another reason could be related to the overall health status of former and current 
smokers i.e. quitting smoking may be related to higher levels of disease whereas current 
smokers, since they continue to smoke, may find themselves in reasonable health. 
However, there was no evidence in this thesis to support this idea since former cigarette 
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smokers did not report higher levels of long-standing illness or poor health and also 
former cigarette smokers who quit for illness related reasons did not appear to have a 
greater risk than former cigarette smokers who quit for other reasons. 
   
Finally, another reason considered was because the effects of smoking may persist for 
many years.
50, 252
 However, this does not explain why current cigarette smokers with 40 
years duration appeared to have a much lower risk of colorectal cancer than former 
cigarette smokers with a similar duration in this analysis. Thus, the reason why current 
smokers do not have a greater risk of colorectal cancer than former smokers remains an 
important unanswered question for future studies. 
 
This thesis also investigated the effects of smoking duration and smoking intensity on 
the risk of colorectal cancer and, in particular, tried to investigate how these measures 
interact for colorectal cancer risk. Results did suggest that former cigarette smokers 
with the highest exposure i.e. the longest duration and heaviest intensity had the greatest 
risk of colorectal cancer. However, the overall pattern of risk was not very clear and 
former cigarette smokers with the lowest exposure also appeared to have a particularly 
high risk of colorectal cancer. 
 
Results for age at cessation were not clear in this analysis. While there seemed to be no 
increased risk for former cigarette smokers who quit smoking 30-39 years old, former 
cigarette smokers who quit ≤29 years old did appear to have an increased risk of 
colorectal cancer. This was in contrast to results from other studies which did not find 
an increased risk for former smokers who quit before 40 years old.
254, 257, 260
 The pattern 
of results was slightly clearer when investigating years since cessation. However, there 
was still evidence that former cigarette smokers who quit at least 30 years ago had a 
slightly increased risk of colorectal cancer compared to never smokers though other 
studies seem to indicate that former smokers with the longest time since cessation no 
longer had an increased risk.
253, 254, 260
 
 
8.4 Strengths and Limitations 
 
The analyses carried out in this thesis had a number of strengths and limitations. First of 
all, UK Biobank was a prospective cohort study, meaning that participants were asked 
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to provide data on risk factors before being followed-up using health records to discover 
which participants suffered particular diseases. This is very important when attempting 
to draw causal inferences from epidemiological studies since the outcome may 
influence participants’ recall of exposure (known as recall bias) in retrospective studies, 
leading to biased results.
54, 55
 
 
Very few other studies combine such a large number of participants with detailed 
information on a wide range of health and lifestyle factors. This meant that this thesis 
was able to investigate the associations between these risk factors and colorectal cancer 
in greater detail than many other studies. For example, in contrast to many existing 
studies of alcohol intake and colorectal cancer which have used non-drinkers as the 
reference group, this thesis was able to separately identify never and former drinkers 
and therefore compare results using different reference groups. Also, the questions on 
smoking in UK Biobank were very detailed in comparison to many other studies which 
often include only very basic questions in order to identify current smokers and separate 
never smokers from former smokers. 
 
Since UK Biobank included detailed information on health and lifestyle, it was possible 
to adjust for a number of confounders known to be important for colorectal cancer risk, 
thus reducing the possibility that the associations observed between the risk factors of 
interest and the outcome were due to confounding by other factors. Analyses in this 
thesis, however, did not adjust for physical activity, despite the fact that physical 
activity is associated with colon cancer and so represents an important confounder, 
25, 225
 
due to a large number of participants who chose not to answer the questions on physical 
activity. However, results with and without adjustment for physical activity were found 
to be very similar (for participants with complete data on physical activity), suggesting 
that the exclusion of physical activity from analysis models did not have a large effect 
on results. 
 
Establishing a cohort study with a wide range of information on a large number of 
participants can be very expensive and time-consuming. It can also take many years 
before sufficient numbers of cases accumulate. Routinely collected data (e.g. from 
general practitioners or from hospital admissions) are increasingly being used in 
epidemiological research as they allow easy access to data on a very large number of 
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people who have often been followed-up for many years. However, since these data are 
generally collected for purposes other than epidemiological research, the use of routine 
data for epidemiological research has important limitations.
440, 441
 For example, the data 
available from routine sources can be very limited and important information may not 
be available (e.g. it may not include data on a number of important confounders). 
Furthermore, it is not always clear exactly how data are generated and there may be 
important variation in coding between different individuals/organisations. 
 
While UK Biobank did include detailed information on alcohol intake, adiposity and 
smoking, these data also had certain limitations. For example, there was no detailed 
information about alcohol intake, adiposity or smoking throughout life. Furthermore, 
the use of questionnaires may not provide an accurate picture of people’s average 
exposure since questionnaires generally include fairly basic questions which are often 
poor measures of the exposure of interest. For example, questionnaires on alcohol 
intake generally ask people to report their average alcohol intake. However, when 
answering such questions, people tend to ignore atypical or occasional drinking 
episodes, which is one reason why alcohol intake is underestimated using self-reported 
data.
357
 Another example is the large amount of digit preference for multiples of ten 
when participants are asked to report the average number of cigarettes they smoke per 
day.
380, 381
  
 
A strength of these analyses was that the adiposity variables were measured at baseline. 
This was important because relying on self-reported height and weight is known to 
underestimate BMI which can lead to biased results.
48
 However, analyses of alcohol 
intake and smoking relied on self-reported data which meant that alcohol intake and 
smoking prevalence may have been underestimated in UK Biobank.
352, 378
 
 
UK Biobank included only a small proportion of current cigarette smokers which 
limited the analyses that could be carried out among these participants. For example, it 
was difficult to evaluate the effects of smoking duration and smoking intensity among 
current cigarette smokers. In 2008, 21% of men and 20% of women in England reported 
smoking.
442
 In UK Biobank, only 12.5% of men and 8.9% of women reported smoking 
(either daily or occasionally). Assuming that a representative sample of the population 
was invited to participate in UK Biobank, this suggests that smokers were much less 
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likely to participate than non-smokers. Previous studies have also demonstrated that 
smokers are less likely to take part in surveys and epidemiologic studies.
443-445
 
 
The low response rate achieved by UK Biobank meant that participants were highly 
self-selected and therefore unlikely to be representative of the greater population. High 
levels of self-selection may lead to the inclusion of fewer people with unhealthy 
lifestyle behaviours or ill health and this may be a concern for the validity of the results 
in this thesis. On average, compared to the general population, UK Biobank participants 
lived in areas with less deprivation, were more likely to have a healthy lifestyle (though 
they were more likely to be heavy alcohol drinkers) and were less likely to have poor 
health (see Chapter 3). Representativeness is not necessarily an important issue for the 
investigation of associations in cohort studies i.e. the proportion of smokers is 
unimportant when investigating how smoking relates to the outcome of interest. 
However, the self-selection of participants may still be a concern for results if, for 
example, there were major differences between participating and non-participating 
smokers. 
 
Another limitation of this analysis was that a large number of participants had missing 
data on alcohol intake due to changes to the alcohol questions during recruitment. In a 
sensitivity analysis, multiple imputation was used to impute alcohol intake values for 
these participants. Overall, results using multiple imputation were very similar to the 
complete case results. This was not surprising since only participants who reported 
drinking “one to three times a month” or “special occasions only” had missing data. 
Thus, the only major difference was in the estimate of the HR associated with alcohol 
intake <5 g/d. These results were presented as a sensitivity analysis since among 
participants who reported drinking “one to three times a month” or “special occasions 
only”, the majority actually had missing data. 
 
Instead of using multiple imputation in the analyses of adiposity and smoking, it was 
decided to use an alternative analysis variable to adjust for alcohol intake in the analysis 
models. Using multiple imputation for multiple analyses requires a much more complex 
imputation model and can potentially lead to biased results if this imputation model is 
not correctly specified.
375
 Furthermore, this imputation model would need to include a 
large number of variables which would reduce the number of participants with complete 
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data on all independent variables in the imputation model. This issue is normally 
resolved by imputing data for more variables however this can lead to biased results if 
missing data are not missing at random, which may be likely when participants choose 
not to answer.
376
 Thus, given these limitations of multiple imputation and given that the 
alternative analysis variable was shown to give practically identical results as the 
original grams per day variable (among participants with complete data), it was decided 
to use the alternative variable for analyses of adiposity and smoking. Furthermore, 
based on the imputation model used for the sensitivity analysis, it was possible to 
calculate basic results for BMI and overall smoking status using the imputed alcohol 
intake values and these results showed no important differences to the results presented 
in this thesis (see Table A-14 and Table A-15 in the appendix). 
 
Follow-up data on cancers and deaths are periodically updated as UK Biobank receives 
data from the cancer and death registries. This presented a challenge for this thesis since 
results (and consequently conclusions) could change significantly as further data were 
made available. This was made more difficult as there were significant delays in these 
follow-up data becoming available which impeded the progress of analyses. Ultimately, 
the analyses in this thesis were able to use follow-up data complete up to the end of 
March 2014. However, these data only became available in May 2016 and prior to this 
complete outcome data were only available up to the end of December 2012. 
 
Also, UK Biobank remains a fairly young cohort in terms of follow-up; median follow-
up in these analyses was approximately 5 years. With longer follow-up, more 
participants will be diagnosed with colorectal cancer and the associations investigated in 
this thesis can be evaluated with greater precision. 
 
Bowel screening programmes in England, Scotland and Wales were introduced during 
recruitment of UK Biobank which may have impacted on results found in this thesis. 
First of all, it will have resulted in “misclassification” of a number of participants with 
respect to bowel screening since participants’ responses will have depended on whether 
they had been invited yet; many participants who reported not having bowel screening 
at baseline may have been screened shortly after. 
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The introduction of bowel cancer screening programmes may also lead to an increase in 
colorectal cancer incidence in the short term through the increased detection of 
prevalent cases.
13, 22
 This should not impact on the associations between risk factors and 
colorectal cancer if all participants are equally likely to accept the screening invitation. 
However, people who follow healthy lifestyle behaviours may be more likely to 
undergo screening than people with unhealthy lifestyles.
446
 This would result in a 
greater increase of colorectal cancer incidence among people following a healthy 
lifestyle relative to people with an unhealthy lifestyle, making the incidence rates in the 
two groups more similar, at least in the short term. 
 
A large number of analyses were presented in this thesis. The issue with performing 
large numbers of statistical tests is that the probability of finding a statistically 
significant result is greatly increased. Therefore, some of the results presented in this 
thesis may simply be due to chance and so results should be treated with a certain 
amount of caution. However, many of the results in this thesis are in agreement with 
results from other studies which provides some external validity to these results. 
 
8.5 Further Research 
 
UK Biobank included information on a wide range of exposures at the baseline 
assessment. Since baseline, UK Biobank has continued to broaden this information with 
further data on participants and some of these data could be used in future analyses. For 
example, approximately 20,000 participants were completely re-assessed between 2012 
and 2013. The purpose of this re-assessment was in order to adjust analyses for 
regression dilution.
53, 447
 During follow-up, participants’ level of exposure to different 
risk factors will change and as a result the association between baseline exposure and 
disease risk generally underestimates the association between “usual” exposure and 
disease risk.
447
 However, this can be addressed using data on changes in exposure in a 
subset of participants. These data were not used to adjust for regression dilution in this 
study since there was not sufficient follow-up data in relation to when the re-assessment 
was carried out. Participants were re-assessed approximately five years after the 
baseline assessment on average and it is recommended that the re-assessment should 
take place at approximately the midpoint of follow-up (i.e. approximately ten years of 
follow-up are required before these data can be used to adjust for regression dilution).
447
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UK Biobank is also completing MRI imaging scans of 100,000 participants.
53
 This will 
allow precise measures of fat distribution throughout the body including visceral fat. 
Understanding why certain measures of adiposity are more strongly related to colorectal 
cancer than others and why these measures tend to be more strongly related to colorectal 
cancer for men than for women remain important questions. Fat distribution may be 
important for understanding how adiposity relates to colorectal cancer risk yet previous 
prospective studies have not been able to acquire imaging data on a large number of 
participants. 
 
Genetic data will also soon be available for the entire UK Biobank cohort. The 
investigation of how genetic factors interact with lifestyle and environmental factors to 
cause disease was an important aim of UK Biobank.
53
 These data could potentially be 
used to understand how an individual’s genotype interacts with lifestyle factors to 
modify the risk of colorectal cancer and thus to improve understanding of the 
mechanisms relating lifestyle factors to colorectal cancer. 
 
It may also be possible to obtain genetic data on colorectal cancers for UK Biobank 
participants in the future in order to classify tumours by molecular subtypes. These data 
could be important to improve the understanding of how smoking increases the risk of 
colorectal cancer since smoking appears to be strongly related to a particular molecular 
subtype of colorectal cancer.
272, 289
 These data may also help to shed light on why 
smoking is more strongly related to colorectal adenomas than colorectal cancer.
296, 297
 
 
There are also a number of other important remaining research questions that cannot be 
investigated using the UK Biobank cohort. For example, the relationship between 
alcohol intake and colorectal cancer may depend on the pattern of alcohol intake. There 
is evidence that the effect of alcohol intake on coronary heart disease depends on the 
pattern of alcohol intake i.e. binge drinking was associated with a greater risk compared 
to more regular intake.
412
 However, no existing studies of alcohol intake and colorectal 
cancer have included detailed information on pattern of drinking. Therefore, future 
studies should include questions on the pattern of alcohol intake. 
 
Another important research question is how exposure to alcohol intake, adiposity and 
smoking throughout life influence an individual’s risk of colorectal cancer. Information 
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on exposure throughout life may be particularly important since there is a long 
induction period for colorectal cancer yet most cohort studies assess exposure only 
during late adulthood. Thus, few studies have analysed exposure throughout the lifetime 
in relation to colorectal cancer. Some studies have investigated the relationship between 
early adulthood BMI and colorectal cancer though these studies generally relied on 
participant’s recall to evaluate past BMI which may be not be very accurate.195 
However, acquiring exposure data on participants periodically from early adulthood 
would represent a significant cost and significant numbers of disease cases would not 
accumulate for many years. Most cohort studies focus on recruiting participants in mid-
late age (e.g. 40-70 years old) so that a large number of cases can accumulate in a 
relatively short period of time but that only a small number of participants will have 
already suffered major illnesses. It is possible that future cohort studies will use online 
questionnaires to recruit people and to obtain information on exposures at multiple 
times in life at a much lower cost. 
 
Further research could also be carried out to evaluate different methods for capturing 
data on exposure. Self-reported measures are commonly used in epidemiological 
studies. Such measures are known to have limitations and tend to underestimate actual 
exposure yet most cohort studies continue to use very similar questionnaires.
48, 353, 378
 
For example, including questions on atypical alcohol intake may improve the accuracy 
of alcohol intake questionnaires.
357
 The use of diaries may provide a method for 
obtaining more detailed information on exposure and could possibly become more 
widespread since they could be easily completed online by participants at different 
times. Also, other methods may be developed that are able to reliably measure exposure 
indirectly e.g. transdermal alcohol sensors (which measure the amount of alcohol that is 
excreted through the skin via perspiration)
448, 449
 which could possibly be employed in 
large epidemiological studies in a similar way to physical activity monitors. 
 
8.6 Awareness of the Effects of Lifestyle on Cancer 
 
This thesis clearly showed that alcohol intake, adiposity and smoking are all associated 
with the risk of colorectal cancer. Furthermore there is convincing evidence that these 
risk factors are associated with multiple forms of cancer.
26, 450, 451
 Hence, a significant 
proportion of cancers could be prevented by reducing exposure to these risk factors in 
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the general population.
30
 However, despite this potential for prevention, the awareness 
of the relationship between lifestyle and cancer is alarmingly low (except for 
smoking).
452, 453
 For example, a survey commissioned by Cancer Research UK found 
that only a third of people identified “drinking alcohol frequently” as a risk factor for 
cancer.
452
 Also, a survey by the WCRF found that 41% of people were unaware that 
being overweight increases the risk of cancer.
453
 Therefore, awareness of the effects of 
lifestyle on cancer should be promoted. 
 
8.7 Public Health and the Prevention of NCDs 
 
The prevention of NCDs represents a major public health challenge.
3, 39, 454
 The WHO 
aims to achieve a 25% relative reduction worldwide in overall mortality from major 
NCDs (cardiovascular diseases, cancer, diabetes and chronic respiratory diseases) by 
2025.
3
 Alcohol intake, adiposity and smoking are all important modifiable risk factors 
for a wide range of NCDs.
3, 39
 Hence, there is an urgent need to reduce the prevalence of 
these risk factors in the general population in order to prevent these diseases. 
 
A key role of public health is to provide information. There have been numerous public 
health messages promoting healthy lifestyles in an attempt to modify people’s 
behaviour but it seems that public health messages alone are largely ineffective at 
influencing behaviour. One reason may be due to the numerous conflicting messages 
about lifestyle and health regularly observed in the media. For example, there are many 
conflicting stories about the effects of alcohol on health.
455
 It sometimes seems as 
though there are just as many stories reporting that alcohol prevents cancer than stories 
reporting that alcohol causes cancer.
456-458
 These mixed messages clearly cause 
confusion and may cause people to become sceptical about epidemiological research 
and public health messages. Researchers themselves are to blame in some circumstances 
since press releases are generally written with the intention of maximising interest in 
their research (and so researchers may choose to highlight conflicting results). However, 
in other instances, it seems that a story is intentionally misinterpreted in order to create 
a more exciting headline before later publishing a criticism of such interpretation.
459, 460
 
 
The position of public health in modifying people’s behaviour presents a critical ethical 
issue, namely whose responsibility is it that people lead a healthy lifestyle?
461
 The role 
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of public health is to promote health and healthy living in the population. Most people 
would agree that this includes a duty to provide accurate information on risk factors for 
health so that people can make informed decisions about their own lifestyle. However, 
what is the responsibility of public health if the public are informed of the risks and 
choose not to modify their behaviour? A libertarian view would suggest that the 
government has no further role beyond providing information since people should be 
allowed to make their own decisions about how they live. Furthermore, governments 
are generally wary of introducing more intrusive measures to modify behaviour lest 
they be accused of “nannying” and interfering excessively with an individual’s personal 
choice. 
 
However, these unhealthy lifestyle behaviours represent a substantial cost to the 
NHS.
462-464
 Furthermore, there is an increasing understanding that, rather than being 
simply the result of informed decision making, our lifestyle choices are influenced by 
numerous factors in our environment that lie outside of our control.
461, 465
 Therefore, in 
order to prevent NCDs, public health institutions will need to introduce a wide range of 
measures in order to create environments that promote healthy lifestyles (for example 
by controlling the promotion, availability and pricing of unhealthy products).
466-468
 For 
example, the prevalence of smoking has decreased in Great Britain and many other 
countries as a result of public health interventions including increased tax and bans on 
advertising.
44, 469
 
 
To conclude, alcohol intake, adiposity and smoking contribute significantly to the 
global burden of NCDs, including colorectal cancer, and represent a substantial cost to 
health services. Reducing the prevalence of these risk factors in the general population 
is a vital challenge for public health and will require the introduction and evaluation of 
comprehensive interventions. 
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Table A-1 BMI and the Risk of Colon Cancer and Rectal Cancer in UK Biobank (Adjusting for Different Alcohol Intake Variables) 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)*† HR (95% CI)*‡  Cases HR (95% CI)*† HR (95% CI)*‡ 
Men         
<24.45 175,939 92 1.00 1.00  76 1.00 1.00 
24.45-<26.40 181,554 106 1.02 (0.77-1.35) 1.02 (0.77-1.35)  75 0.88 (0.64-1.22) 0.88 (0.64-1.22) 
26.40-<28.28 172,880 148 1.45 (1.11-1.88) 1.44 (1.11-1.88)  91 1.09 (0.80-1.48) 1.09 (0.80-1.48) 
28.28-<30.84 184,678 162 1.44 (1.11-1.86) 1.43 (1.11-1.85)  106 1.15 (0.86-1.55) 1.15 (0.85-1.55) 
≥30.84 167,417 163 1.59 (1.23-2.06) 1.59 (1.22-2.06)  91 1.08 (0.79-1.47) 1.07 (0.79-1.46) 
P-trend§   0.0002 0.0002   0.3133 0.3362 
Women         
<22.89 200,985 86 1.00 1.00  31 1.00 1.00 
22.89-<25.04 199,338 109 1.17 (0.88-1.55) 1.17 (0.88-1.55)  46 1.34 (0.85-2.11) 1.34 (0.85-2.12) 
25.04-<27.34 191,320 112 1.18 (0.89-1.57) 1.18 (0.89-1.57)  52 1.49 (0.95-2.33) 1.49 (0.95-2.33) 
27.34-<30.80 186,810 110 1.15 (0.87-1.53) 1.16 (0.87-1.54)  39 1.10 (0.68-1.76) 1.10 (0.68-1.77) 
≥30.80 168,356 91 1.12 (0.83-1.51) 1.12 (0.83-1.51)  31 0.98 (0.59-1.62) 0.98 (0.59-1.62) 
P-trend§   0.9472 0.9313   0.5048 0.5080 
* Adjusted for smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
† Adjusted for original categorical alcohol intake variable. 
‡ Adjusted for alternative alcohol intake variable.  
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable.
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Table A-2 Overall Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
(Adjusting for Different Alcohol Intake Variables) 
Overall smoking status Person-years Cases HR (95% CI)*† HR (95% CI)*‡ 
Overall     
Never 1,003,205 800 1.00 1.00 
Former 645,088 833 1.22 (1.10-1.35) 1.22 (1.10-1.35) 
Current 183,986 173 1.10 (0.93-1.31) 1.10 (0.93-1.31) 
Men     
Never 426,639 407 1.00 1.00 
Former 352,938 577 1.19 (1.01-1.40) 1.19 (1.01-1.40) 
Current 104,324 124 1.03 (0.76-1.39) 1.03 (0.76-1.40) 
Women     
Never 576,565 393 1.00 1.00 
Former 292,150 256 1.23 (1.08-1.41) 1.23 (1.08-1.40) 
Current 79,662 49 1.15 (0.93-1.41) 1.14 (0.93-1.41) 
* Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation index (quintiles), red meat 
intake (≤1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), height (continuous), family 
history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
† Adjusted for original categorical alcohol intake variable. 
‡ Adjusted for alternative alcohol intake variable. 
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4 Table A-3 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank (with and without Adjustment for Physical Activity) 
         
 Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Overall         
Person-years 56,229 64,886 192,833 466,255 388,954 165,797 134,186  
Cases 43 65 131 387 384 197 206  
HR (95% CI)* 0.68 (0.46-1.01) 1.00 0.70 (0.52-0.94) 0.79 (0.61-1.04) 0.86 (0.65-1.12) 0.94 (0.70-1.25) 1.14 (0.85-1.53) 0.0001 
HR (95% CI)*† 0.68 (0.46-1.01) 1.00 0.70 (0.52-0.94) 0.79 (0.61-1.04) 0.86 (0.66-1.13) 0.94 (0.70-1.26) 1.14 (0.85-1.53) 0.0001 
         
Men         
Person-years 26,318 19,725 54,445 179,318 221,105 122,596 116,921  
Cases 18 15 47 196 265 165 196  
HR (95% CI)* 0.80 (0.40-1.60) 1.00 1.07 (0.60-1.92) 1.31 (0.77-2.22) 1.39 (0.82-2.35) 1.51 (0.88-2.57) 1.83 (1.08-3.12) <0.0001 
HR (95% CI)*† 0.80 (0.40-1.60) 1.00 1.07 (0.60-1.92) 1.31 (0.77-2.22) 1.39 (0.82-2.35) 1.51 (0.88-2.57) 1.84 (1.08-3.12) <0.0001 
         
Women         
Person-years 29,911 45,161 138,388 286,937 167,849 43,201 17,264  
Cases 25 50 84 191 119 32 10  
HR (95% CI)* 0.74 (0.46-1.21) 1.00 0.57 (0.40-0.82) 0.61 (0.44-0.84) 0.65 (0.46-0.92) 0.69 (0.44-1.09) 0.57 (0.29-1.15) 0.8837 
HR (95% CI)*† 0.74 (0.46-1.21) 1.00 0.57 (0.40-0.82) 0.61 (0.44-0.84) 0.66 (0.47-0.93) 0.69 (0.44-1.09) 0.58 (0.29-1.15) 0.8877 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
† Also adjusted for IPAQ physical activity (low, moderate, high). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous 
variable (former drinkers were excluded). 
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Table A-4 Overall Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
(with and without Adjustment for Physical Activity) 
Overall smoking status Person-years Cases HR (95% CI)* HR (95% CI)*† 
Overall     
Never 966,603 767 1.00 1.00 
Former 594,287 719 1.16 (1.05-1.30) 1.16 (1.05-1.30) 
Current 171,148 151 1.06 (0.89-1.27) 1.06 (0.88-1.27) 
Men     
Never 412,608 399 1.00 1.00 
Former 322,807 485 1.11 (0.97-1.28) 1.12 (0.97-1.28) 
Current 95,702 106 1.05 (0.84-1.31) 1.05 (0.84-1.31) 
Women     
Never 553,995 368 1.00 1.00 
Former 271,480 234 1.23 (1.04-1.46) 1.23 (1.04-1.46) 
Current 75,446 45 1.05 (0.77-1.44) 1.05 (0.77-1.44) 
† Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
† Also adjusted for IPAQ physical activity (low, moderate, high).  
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Table A-5 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank (Including Missing Categories for Confounder Variables) 
 Alcohol intake (grams/day)  
 Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Overall         
Person-years 83,544 104,815 268,576 617,013 498,902 209,384 170,994  
Cases 80 88 198 522 500 266 260  
HR (95% CI)* 1.00 (0.74-1.36) 1.00 0.89 (0.69-1.15) 0.95 (0.76-1.20) 1.04 (0.82-1.31) 1.20 (0.93-1.54) 1.36 (1.05-1.75) <0.0001 
         
Men         
Person-years 37,689 30,541 71,829 226,972 277,961 153,383 148,632  
Cases 36 22 63 241 341 218 250  
HR (95% CI)* 1.12 (0.66-1.91) 1.00 1.11 (0.68-1.81) 1.29 (0.83-2.01) 1.45 (0.94-2.24) 1.62 (1.04-2.52) 1.87 (1.20-2.92) <0.0001 
         
Women         
Person-years 45,855 74,274 196,746 390,041 220,941 56,000 22,363  
Cases 44 66 135 281 159 48 10  
HR (95% CI)* 1.05 (0.71-1.54) 1.00 0.80 (0.59-1.08) 0.81 (0.62-1.07) 0.83 (0.61-1.11) 1.00 (0.68-1.47) 0.56 (0.28-1.09) 0.7858 
*Adjusted for sex, BMI (<25, 25-<30, ≥30 kg/m2), overall smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (≤1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (quintiles), family history of colorectal cancer (yes/no) and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous variable 
(former drinkers were excluded). 
 
 
Appendix 
337 
Table A-6 BMI and the Risk of Colon Cancer and Rectal Cancer in UK Biobank 
(Including Missing Categories for Confounder Variables) 
  Colon cancer  Rectal cancer 
BMI (kg/m
2
) Person-years Cases HR (95% CI)*  Cases HR (95% CI)* 
Men       
<24.45 215,916 113 1.00  91 1.00 
24.45-<26.40 217,825 128 1.02 (0.79-1.31)  85 0.86 (0.64-1.15) 
26.40-<28.28 208,260 168 1.35 (1.06-1.71)  100 1.03 (0.77-1.37) 
28.28-<30.84 225,906 204 1.46 (1.16-1.84)  118 1.10 (0.83-1.45) 
≥30.84 216,640 203 1.51 (1.20-1.91)  115 1.13 (0.85-1.50) 
P-trend§   <0.0001   0.1140 
       
Women       
<22.89 256,367 115 1.00  43 1.00 
22.89-<25.04 255,419 139 1.09 (0.85-1.40)  63 1.32 (0.90-1.95) 
25.04-<27.34 252,802 153 1.14 (0.90-1.46)  67 1.35 (0.92-1.98) 
27.34-<30.80 256,081 156 1.10 (0.86-1.41)  55 1.05 (0.70-1.57) 
≥30.80 254,237 142 1.05 (0.81-1.35)  42 0.81 (0.53-1.26) 
P-trend§   0.9483   0.1841 
* Results adjusted for alcohol intake (never, former, special occasions only, one to three times a month, 
<5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), overall smoking status (never, former, current), 
Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 
1, >1 time/week), family history of colorectal cancer (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category 
of BMI and this variable was modelled as a continuous variable.  
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Table A-7 Overall Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
(Including Missing Categories for Confounder Variables) 
 Overall smoking status 
 Never Former Current 
Overall    
Person-years 1,296,524 787,565 248,495 
Cases 1,034 998 231 
HR (95% CI)* 1.00 1.20 (1.10-1.32) 1.11 (0.96-1.29) 
    
Men    
Person-years 523,076 417,467 135,486 
Cases 487 666 158 
HR (95% CI)* 1.00 1.22 (1.08-1.37) 1.16 (0.97-1.40) 
    
Women    
Person-years 773,448 370,098 113,009 
Cases 547 332 73 
HR (95% CI)* 1.00 1.18 (1.02-1.36) 1.03 (0.80-1.32) 
* Adjusted for sex, alcohol intake (never, former, special occasions only, one to three times a month, <5 
g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation 
index (quintiles), red meat intake (1, >1-<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), 
height (continuous), family history of colorectal cancer (yes/no) and history of colorectal screening 
(yes/no). 
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Table A-8 Alcohol Intake and the Risk of Colorectal Cancer in UK Biobank with Adjustment for Different Confounders 
 Alcohol intake (grams/day)  
Confounder adjustment Former Never <5 5-<15 15-<30 30-<45 ≥45 P-trend§ 
Cases 70 79 187 499 479 248 244  
Sex 1.04 (0.76-1.44) 1.00 0.92 (0.71-1.20) 1.02 (0.81-1.30) 1.15 (0.90-1.46) 1.33 (1.03-1.72) 1.56 (1.20-2.02) <0.0001 
         
Sex, BMI 1.04 (0.76-1.44) 1.00 0.93 (0.72-1.21) 1.05 (0.82-1.33) 1.17 (0.92-1.48) 1.34 (1.03-1.73) 1.56 (1.20-2.03) <0.0001 
         
Sex, overall smoking status 0.97 (0.70-1.34) 1.00 0.89 (0.69-1.16) 0.98 (0.77-1.24) 1.07 (0.84-1.36) 1.22 (0.94-1.58) 1.42 (1.09-1.85) <0.0001 
         
Sex, Townsend index 1.04 (0.76-1.44) 1.00 0.92 (0.71-1.20) 1.03 (0.81-1.30) 1.15 (0.90-1.46) 1.33 (1.02-1.72) 1.56 (1.20-2.02) <0.0001 
         
Sex, red meat intake 1.04 (0.75-1.44) 1.00 0.92 (0.71-1.20) 1.01 (0.80-1.28) 1.13 (0.88-1.43) 1.29 (1.00-1.68) 1.51 (1.16-1.96) <0.0001 
         
Sex, processed meat intake 1.04 (0.76-1.44) 1.00 0.92 (0.71-1.20) 1.02 (0.80-1.29) 1.13 (0.89-1.44) 1.30 (1.01-1.69) 1.52 (1.17-1.97) <0.0001 
         
Sex, height 1.03 (0.75-1.42) 1.00 0.91 (0.70-1.18) 1.00 (0.79-1.27) 1.12 (0.88-1.42) 1.29 (1.00-1.68) 1.52 (1.17-1.98) <0.0001 
         
Sex, family history of 
colorectal cancer 
1.04 (0.75-1.43) 1.00 0.92 (0.71-1.20) 1.02 (0.81-1.30) 1.14 (0.90-1.46) 1.32 (1.02-1.71) 1.55 (1.19-2.01) <0.0001 
         
Sex, bowel screening 1.05 (0.76-1.45) 1.00 0.94 (0.72-1.22) 1.03 (0.81-1.30) 1.15 (0.91-1.47) 1.33 (1.03-1.73) 1.56 (1.20-2.03) <0.0001 
§ P-values for test for trend were calculated by assigning participants the median value of their category of alcohol intake and this variable was modelled as a continuous variable 
(former drinkers were excluded). 
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0 Table A-9 BMI and the Risk of Colon Cancer for Men in UK Biobank with Adjustment for Different Confounders 
 BMI (kg/m
2
)  
Confounder adjustment <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 P-trend§ 
Cases 99 118 159 184 186  
None 1.00 1.11 (0.85-1.45) 1.56 (1.21-2.00) 1.67 (1.30-2.13) 1.81 (1.42-2.32) <0.0001 
       
Alcohol intake 1.00 1.09 (0.83-1.42) 1.51 (1.18-1.94) 1.61 (1.26-2.05) 1.76 (1.38-2.25) <0.0001 
       
Overall smoking status 1.00 1.09 (0.84-1.43) 1.52 (1.18-1.95) 1.61 (1.26-2.06) 1.73 (1.36-2.22) <0.0001 
       
Townsend index 1.00 1.11 (0.85-1.45) 1.56 (1.21-2.00) 1.66 (1.30-2.12) 1.81 (1.42-2.32) <0.0001 
       
Red meat intake 1.00 1.10 (0.84-1.44) 1.53 (1.19-1.97) 1.62 (1.27-2.08) 1.75 (1.37-2.23) <0.0001 
       
Processed meat intake 1.00 1.10 (0.85-1.44) 1.54 (1.20-1.98) 1.64 (1.29-2.10) 1.78 (1.39-2.27) <0.0001 
       
Family history of colorectal 
cancer 
1.00 1.11 (0.85-1.45) 1.56 (1.21-1.99) 1.66 (1.30-2.11) 1.80 (1.41-2.30) <0.0001 
       
Bowel screening 1.00 1.11 (0.85-1.45) 1.56 (1.21-2.00) 1.67 (1.30-2.13) 1.81 (1.42-2.32) <0.0001 
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable. 
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Table A-10 BMI and the Risk of Colon Cancer for Women in UK Biobank with Adjustment for Different Confounders 
 BMI (kg/m
2
)  
Confounder adjustment <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 P-trend§ 
Cases 106 134 137 143 127  
None 1.00 1.15 (0.89-1.49) 1.13 (0.88-1.46) 1.14 (0.88-1.46) 1.08 (0.84-1.40) 0.7827 
       
Alcohol intake 1.00 1.15 (0.89-1.49) 1.13 (0.88-1.46) 1.14 (0.88-1.46) 1.08 (0.83-1.40) 0.8015 
       
Overall smoking status 1.00 1.15 (0.89-1.48) 1.13 (0.88-1.46) 1.13 (0.88-1.46) 1.08 (0.83-1.40) 0.8073 
       
Townsend index 1.00 1.15 (0.89-1.49) 1.13 (0.88-1.46) 1.14 (0.88-1.46) 1.08 (0.83-1.40) 0.7876 
       
Red meat intake 1.00 1.15 (0.89-1.48) 1.13 (0.87-1.45) 1.13 (0.88-1.46) 1.08 (0.83-1.39) 0.8162 
       
Processed meat intake 1.00 1.15 (0.89-1.49) 1.14 (0.88-1.47) 1.14 (0.89-1.47) 1.09 (0.84-1.41) 0.7447 
       
Family history of colorectal 
cancer 
1.00 1.15 (0.89-1.49) 1.13 (0.88-1.46) 1.14 (0.88-1.46) 1.08 (0.83-1.40) 0.7900 
       
Bowel screening 1.00 1.15 (0.89-1.49) 1.13 (0.88-1.46) 1.14 (0.88-1.46) 1.08 (0.84-1.40) 0.7838 
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable. 
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2 Table A-11 BMI and the Risk of Rectal Cancer for Men in UK Biobank with Adjustment for Different Confounders 
 BMI (kg/m
2
)  
Confounder adjustment <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 P-trend§ 
Cases 83 81 98 113 106  
None 1.00 0.91 (0.67-1.24) 1.15 (0.86-1.54) 1.23 (0.92-1.63) 1.23 (0.93-1.65) 0.0377 
       
Alcohol intake 1.00 0.89 (0.66-1.21) 1.11 (0.83-1.48) 1.17 (0.88-1.56) 1.19 (0.89-1.59) 0.0668 
       
Overall smoking status 1.00 0.91 (0.67-1.24) 1.14 (0.85-1.53) 1.21 (0.91-1.60) 1.20 (0.90-1.61) 0.0638 
       
Townsend index 1.00 0.92 (0.67-1.25) 1.15 (0.86-1.55) 1.23 (0.93-1.63) 1.23 (0.92-1.64) 0.0410 
       
Red meat intake 1.00 0.91 (0.67-1.24) 1.14 (0.85-1.53) 1.21 (0.91-1.61) 1.21 (0.91-1.62) 0.0542 
       
Processed meat intake 1.00 0.91 (0.67-1.23) 1.13 (0.85-1.52) 1.20 (0.90-1.59) 1.18 (0.88-1.57) 0.0862 
       
Family history of colorectal 
cancer 
1.00 0.91 (0.67-1.24) 1.15 (0.86-1.54) 1.22 (0.92-1.63) 1.23 (0.92-1.64) 0.0395 
       
Bowel screening 1.00 0.91 (0.67-1.24) 1.15 (0.86-1.54) 1.23 (0.93-1.63) 1.23 (0.93-1.65) 0.0376 
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable. 
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Table A-12 BMI and the Risk of Rectal Cancer for Women in UK Biobank with Adjustment for Different Confounders 
 BMI (kg/m
2
)  
Confounder adjustment <24.45 24.45-<26.40 26.40-<28.28 28.28-<30.84 ≥30.84 P-trend§ 
Cases 38 59 60 53 39  
None 1.00 1.44 (0.96-2.16) 1.42 (0.95-2.14) 1.22 (0.80-1.85) 0.94 (0.60-1.47) 0.2995 
       
Alcohol intake 1.00 1.45 (0.96-2.17) 1.42 (0.95-2.14) 1.21 (0.79-1.84) 0.92 (0.59-1.45) 0.2533 
       
Overall smoking status 1.00 1.42 (0.94-2.13) 1.40 (0.93-2.10) 1.19 (0.78-1.81) 0.91 (0.58-1.43) 0.2327 
       
Townsend index 1.00 1.44 (0.95-2.16) 1.43 (0.95-2.14) 1.23 (0.81-1.87) 0.96 (0.61-1.51) 0.3682 
       
Red meat intake 1.00 1.43 (0.95-2.16) 1.42 (0.94-2.13) 1.21 (0.80-1.84) 0.94 (0.60-1.47) 0.2880 
       
Processed meat intake 1.00 1.44 (0.96-2.17) 1.42 (0.95-2.14) 1.22 (0.80-1.85) 0.94 (0.60-1.48) 0.3005 
       
Family history of colorectal 
cancer 
1.00 1.44 (0.96-2.17) 1.42 (0.95-2.14) 1.22 (0.80-1.85) 0.94 (0.60-1.48) 0.3013 
       
Bowel screening 1.00 1.44 (0.95-2.16) 1.42 (0.94-2.13) 1.21 (0.80-1.84) 0.94 (0.60-1.47) 0.2995 
§ P-values for test for trend were calculated by assigning participants the median value of their category of BMI and this variable was modelled as a continuous variable.  
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Table A-13 Overall Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
with Adjustment for Different Confounders 
 Overall smoking status 
Confounder adjustment Never Former Current 
Cases 973 929 207 
Sex 1.00 1.26 (1.15-1.38) 1.18 (1.02-1.37) 
    
Sex, alcohol intake 1.00 1.21 (1.10-1.33) 1.11 (0.95-1.30) 
    
Sex, BMI 1.00 1.25 (1.14-1.37) 1.18 (1.02-1.37) 
    
Sex, Townsend index 1.00 1.26 (1.15-1.39) 1.18 (1.02-1.38) 
    
Sex, red meat intake 1.00 1.26 (1.15-1.38) 1.17 (1.00-1.36) 
    
Sex, processed meat 
intake 
1.00 1.26 (1.15-1.38) 1.17 (1.00-1.36) 
    
Sex, height 1.00 1.26 (1.15-1.38) 1.19 (1.02-1.38) 
    
Sex, family history of 
colorectal cancer 
1.00 1.26 (1.15-1.38) 1.18 (1.01-1.37) 
    
Sex, bowel screening 1.00 1.27 (1.16-1.39) 1.18 (1.01-1.37) 
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Table A-14 BMI and the Risk of Colon Cancer and Rectal Cancer in UK Biobank 
(Using Multiply Imputed Alcohol Intake Data) 
 Colon cancer  Rectal cancer 
BMI (kg/m
2
) Cases HR (95% CI)*  Cases HR (95% CI)* 
Men      
<25 138 1.00  101 1.00 
25-<30 371 1.22 (1.00-1.48)  249 1.15 (0.91-1.45) 
≥30 237 1.50 (1.21-1.86)  133 1.18 (0.91-1.54) 
P-trend§  0.0001   0.1368 
Women      
<25 238 1.00  97 1.00 
25-<30 254 1.04 (0.87-1.24)  105 1.05 (0.80-1.39) 
≥30 152 1.01 (0.82-1.24)  48 0.76 (0.53-1.08) 
P-trend§  0.9444   0.2483 
* Results adjusted for alcohol intake (never, former, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), 
smoking status (never, former, current), Townsend deprivation index (quintiles), red meat intake (1, >1-
<3, ≥3 times/week), processed meat (<1, 1, >1 time/week), family history of colorectal cancer (yes/no) 
and history of colorectal screening (yes/no). 
§ P-values for test for trend were calculated by assigning participants the median value of their category 
of BMI and this variable was modelled as a continuous variable. 
 
Table A-15 Overall Smoking Status and the Risk of Colorectal Cancer in UK Biobank 
(Using Multiply Imputed Alcohol Intake Data) 
 Overall Men Women 
Overall 
smoking status 
Cases HR (95% CI)* Cases HR (95% CI)* Cases HR (95% CI)* 
Never 972 1.00 460 1.00 512 1.00 
Former 926 1.19 (1.09-1.31) 620 1.21 (1.06-1.37) 306 1.16 (1.00-1.35) 
Current 205 1.10 (0.94-1.28) 141 1.16 (0.95-1.40) 64 1.01 (0.77-1.32) 
* Adjusted for sex, alcohol intake (never, former, <5 g/d, 5-<15 g/d, 15-<30 g/d, 30-<45 g/d, ≥45 g/d), 
BMI (<25, 25-<30, ≥30 kg/m2), Townsend deprivation index (quintiles), red meat intake (1, >1-<3, ≥3 
times/week), processed meat (<1, 1, >1 time/week), height (continuous), family history of colorectal 
cancer (yes/no) and history of colorectal screening (yes/no). 
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